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4 
Abstract 
 
 
Cancer-related pain is a major clinical problem. The World Health Organisation recommends 
morphine first-line for moderate to severe cancer-related pain, however several other strong 
opioids are available.  There is wide inter-individual variation in morphine response, in terms 
of analgesic efficacy and side effects.  Switching to an alternative opioid such as oxycodone 
has become common clinical practice to improve outcomes.   There has been growing interest 
in potential genetic factors behind such differences in clinical response.  This thesis aimed to 
compare the overall response rates of morphine and oxycodone, explore the effects of opioid 
switching in non-responders, and to redefine opioid response phenotypes to allow predictive 
modelling. 
 
Data from two opioid response studies is presented: the first a prospective observational 
study of morphine in cancer-related pain (n=298), the second a large open-label randomised 
controlled trial of oral morphine versus oral oxycodone in cancer-related pain (n=200).  
Single nucleotide polymorphisms from 15 candidate genes were tested using sequence 
specific primer polymerase chain reaction.  Principal Component Analysis (PCA) was used to 
mathematically define opioid response phenotypes. Multivariate regression analysis of 
Component scores was used to build predictive models from genetic and clinical variables. 
 
There was no difference between the response rates of oral morphine and oral oxycodone 
when used first-line in cancer-related pain.  Analgesia and adverse reaction profiles were 
similar. Switching from morphine to oxycodone and vice versa improved outcomes in the 
majority of non-responders.  Opioid response appears to have three main domains identified 
by PCA in the two studies: analgesic response, upper gastrointestinal adverse reactions and 
central adverse reactions.  Morphine and oxycodone although had similar response 
phenotypes had different clinical and genetic factors contributing to each, suggesting 
different mechanisms.   Future work includes collaboration to enable larger studies to be 
conducted and to investigate the potential role of metabolites in oxycodone response. 
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1 General Introduction 
1.1 Cancer-related Pain 
One third of the UK population receive a diagnosis of cancer within their lifetime.  In 2006 
alone there were 154,162 cancer-related deaths 1.  Given that 80% of cancer patients 
experience severe pain in the final year of life, cancer-related pain represents a significant 
and ongoing problem 2.   Cancer-related pain can be caused directly by the cancer itself, and 
indirectly from subsequent debility or as a consequence of treatment.  With improving 
therapies increasing life-expectancy, achieving pain relief must be a priority in both cancer 
survivors as well as cancer patients. 
 
Good pain relief can be achieved for the majority of patients by employing the World Health 
Organisation (WHO) analgesic ladder 3.   This process however takes up valuable time if 
dose titration is slow or difficult due to unwanted side effects and/or unresponsive pain.   The 
clinical practice of opioid switching has improved clinical outcomes over time 4, however 
currently there is no way to know which drug or drug combination a patient will respond best 
to.  Research by the Palliative Medicine Research Department at the Royal Marsden Hospital 
(RMH) and Imperial College, London and others has aimed to identify clinical and genetic 
factors predictive of opioid response, the ultimate goal being to translate this work into a 
clinical tool to personalise prescribing thus enabling rapid, safe and effective symptom 
control. This thesis explores the relative roles of two commonly used strong opioids 
morphine and oxycodone.   
 
1.2 Opioid Response in Cancer-related Pain 
The WHO has published a three step “analgesic ladder” to guide the management of cancer-
related pain in adults (Figure 1.1) 5.  The ladder involves: step 1 non-opioid analgesics, step 2 
“weak” opioids and step 3 “strong” opioids, in combination with adjuvant drugs all titrated to 
meet the individual needs of the patient, according to the pathophysiology and severity of the 
pain. Field testing of these guidelines has demonstrated that 70%–90% of cancer patients’ 
pain can be controlled by using this approach 6.   
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Figure 1.1  WHO Analgesic Ladder 
 
 
1.2.1 First-line Strong Opioid 
The WHO recommends morphine to be the first-line strong opioid of choice, based mainly on 
expert opinion and worldwide availability 5.  There are several other strong opioids available 
including oxycodone, hydromorphone and fentanyl.  Oxycodone is currently used second-line 
in many centres throughout the UK.   It has been suggested that morphine and oxycodone 
differ in analgesic properties and side effect profiles (33,35).   Morphine and oxycodone are 
both μ-opioid receptor agonists and produce effective analgesia in cancer pain 7.  Morphine 
and oxycodone however display different pharmacokinetic and pharmacodynamic properties 
in terms of oral bioavailability, metabolism and activity of metabolites. Their differential 
activity at other types of opioid receptors has also been debated 8-10.   
 
1.2.2 Morphine 
Morphine is a naturally occurring alkaloid derived from the opium poppy, Papaver 
Somniferum, which has been cultivated for medicinal purposes for thousands of years. 
Morphine is still used today in the treatment of acute and chronic pain conditions.  It is 
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available in a variety of oral (immediate and modified release) and parenteral preparations 
(http://bnf.org). 
 
1.2.2.1 Morphine Pharmacokinetics and Pharmacodynamics 
Oral morphine undergoes significant first pass metabolism with bioavailability between 19 
and 47% 11. Approximately 90% of morphine is metabolised with the remaining 10% being 
excreted unchanged by the kidneys. The liver is the main site of morphine metabolism but 
extrahepatic sites include the gastrointestinal tract and kidney 12, 13.  The hepatic isoenzyme 
UDP-glucuronosyltransferase (UGT) 2B7 is primarily responsible for morphine metabolism. 
Levels of UGT expression vary widely within the population 14.  Genetic variation however 
has not been linked with inter-individual variation in plasma morphine and metabolite 
concentrations or overall response to morphine 15. Morphine is contraindicated in moderate to 
severe renal failure as the accumulation of morphine’s main metabolites is toxic. It is also 
contraindicated in severe hepatic failure.   
 
The main metabolites of morphine: morphine-3-glucuronide (M3G) and morphine-6-
glucuronide (M6G), account for approximately 50% and 10% of metabolites respectively 11. 
M3G binds poorly to opioid receptors and although it lacks analgesic properties it has several 
neuroexcitatory effects and may be responsible for hyperalgesia, allodynia and myoclonic 
jerks 16.  The effects of M3G are thought to be mediated primarily by non-opioid receptors 
such as the N-Methyl-D-Aspartic Acid (NMDA) receptor 17, 18. Unlike M3G, M6G has been 
shown to have analgesic qualities and has been used as an analgesic agent in its own right. In-
vitro and animal studies suggest that M6G is more potent than its parent morphine due to 
higher efficiency of receptor activation 19. It has also been suggested that M6G has a different 
adverse reaction profile to morphine with significantly less respiratory depression and 
perhaps less nausea and vomiting compared to morphine in post-operative pain studies 20, 21. 
Variation between the balance of morphine and its main metabolites M3G and M6G is 
thought be another source of inter-individual variation in response to morphine.  
 
Morphine produces analgesia through activation of µ-opioid receptors within the CNS and to 
a lesser extent within the PNS. Morphine’s affinity to the µ-opioid receptors is 20-30 times 
greater than its affinity to κ-opioid receptors and nearly 100 times greater compared to δ-
opioid receptors 22.   
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The most common adverse reactions to morphine are gastrointestinal (nausea, vomiting and 
constipation) and central (drowsiness, confusion and hallucinations).  Suspected adverse 
reactions to morphine are presented from the summary of product characteristics in Table 1.4 
by Medical Dictionary for Regulatory Activities (MedDRA) System Order Classification. 
 
Table 1.1   Comparison of Morphine and Oxycodone Adverse Reactions 
    Morphine Oxycodone 
System Order Classification 
Common 
(≥1%) 
Uncommon 
(≤1%)  
Not known 
 
Common 
(≥1%) 
Uncommon 
(≤1%)   
Cardiac disorders   
 
    
 
 
Palpitations   X     
 
 
Bradycardia   
 
X   
 
 
Tachycardia   
 
X   
 
 
Supraventricular tachycardia   
 
    X 
Ear and labyrinth disorders   
 
    
 
 
Vertigo   X     X 
Eye disorders   
 
    
 
 
Visual disturbance   X     X 
 
Miosis   
 
X   X 
Gastrointestinal disorders   
 
    
 
 
Nausea X 
 
  X 
 
 
Abdominal pain X 
 
  X 
 
 
Constipation X 
 
  X 
 
 
Dry mouth X 
 
  X 
 
 
Vomiting X 
 
  X 
 
 
Dyspepsia   X   X 
 
 
Diarrhoea   
 
  X 
 
 
Ileus   X     X 
 
Taste perversion   X     X 
 
Dysphagia   
 
    X 
 
Eructation   
 
    X 
 
Flatulence   
 
    X 
 
Gastritis   
 
    X 
General disorders and 
administration site conditions   
 
    
 
 
Asthenic conditions X 
 
  X 
 
 
Chills   
 
  X 
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    Morphine Oxycodone 
System Order Classification 
Common 
(≥1%) 
Uncommon 
(≤1%)  
Not known 
 
Common 
(≥1%) 
Uncommon 
(≤1%)   
 
Malaise   X     X 
 
Peripheral Oedema   X     X 
 
Drug tolerance   
 
X   X 
 
Drug withdrawal syndrome   
 
X   X 
 
Oedema   
 
    X 
 
Thirst   
 
    X 
 
Pyrexia   
 
    X 
Hepatobiliary disorders   
 
    
 
 
Increased hepatic enzymes   X     X 
 
Biliary pain   
 
X   X 
 
Exacerbations of pancreatitis   
 
X   
 Immune system disorders   
 
    
 
 
Allergic reaction   
 
X   
 
 
Anaphylactic reaction   
 
X   X 
 
Hypersensitivity   
 
    X 
Infections and infestations   
 
    
 Metabolism and nutrition disorders   
 
    
 
 
Anorexia X 
 
    X 
 
Dehydration   
 
    X 
Musculoskeletal and connective 
tissue disorders   
 
    
 
 
Muscular rigidity   
 
    X 
Nervous system disorders   
 
    
 
 
Dizziness X 
 
  X 
 
 
Headache X 
 
  X 
 
 
Involuntary muscle contractions X 
 
    X 
 
Somnolence X 
 
  X 
 
 
Sedation   
 
  X 
 
 
Convulsions   X     X 
 
Hypertonia   X     X 
 
Paraesthesia   X     X 
 
Syncope   X     X 
 
Myoclonus   X     
 
 
Hyperalgesia   
 
X   
 
 
Amnesia   
 
    X 
 
Tremor   
 
    X 
 
Hypoaesthesia   
 
    X 
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    Morphine Oxycodone 
System Order Classification 
Common 
(≥1%) 
Uncommon 
(≤1%)  
Not known 
 
Common 
(≥1%) 
Uncommon 
(≤1%)   
 
Hypotonia   
 
    
 
 
Speech disorder   
 
    
 Psychiatric disorders   
 
    
 
 
Confusion X 
 
  X 
 
 
Insomnia X 
 
  X 
 
 
Thinking disturbance   
 
X X 
 
 
Anxiety   
 
  X 
 
 
Nervousness   
 
  X 
 
 
Abnormal dreams   
 
  X 
 
 
Agitation   X     X 
 
Euphoria   X     X 
 
Hallucination   X     X 
 
Mood altered   X     X 
 
Drug dependence   
 
X   X 
 
Dysphoria   
 
X   X 
 
Affect lability   
 
    X 
 
Depression   
 
    X 
 
Disorientation   
 
    X 
 
Restlessness   
 
    X 
Renal and urinary disorders   
 
    
 
 
Urinary retention   X     X 
 
Ureteric spasm   
 
X   X 
Reproductive system and breast 
disorders   
 
    
 
 
Amenorrhoea   
 
X   X 
 
Decrease libido   
 
X   X 
 
Erectile dysfunction   
 
X   X 
Respiratory, thoracic and 
mediastinal disorders   
 
    
 
 
Bronchospasm   X   X 
 
 
Cough decreased   
 
X X 
 
 
Dyspnoea   
 
  X 
 
 
Pulmonary oedema   X     
 
 
Respiratory depression   X     X 
 
Hiccups   
 
    X 
Skin and subcutaneous tissue 
disorders   
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    Morphine Oxycodone 
System Order Classification 
Common 
(≥1%) 
Uncommon 
(≤1%)  
Not known 
 
Common 
(≥1%) 
Uncommon 
(≤1%)   
 
Hyperhidrosis X 
 
  X 
 
 
Rash X 
 
  X 
 
 
Urticaria   X     X 
 
Pruritus   
 
  X 
 
 
Dry skin   
 
    X 
 
Exfoliative dermatitis   
 
    X 
Vascular disorder   
 
    
 
 
Facial flushing   X     X 
 
Hypotension   X     X 
 
Hypertension   
 
X   
 
 
Orthostatic hypotension   
 
    X 
 
Vasodilation         X 
Adverse reactions listed on Summary of Product Characteristic for morphine and oxycodone immediate release 
preparations (www.medicines.org.uk) 
 
 
1.2.3 Oxycodone 
Oxycodone is a semi-synthetic derivative of the naturally occurring alkaloid, thebaine.  It  
was developed in Germany in 1916 23. 
 
1.2.3.1 Pharmacokinetics and Pharmacodynamics of Oxycodone 
Oral oxycodone is well absorbed from the GI tract and has an oral bioavailability of between 
60 and 87%.  Elimination of oxycodone is mainly by metabolism in the liver and excretion 
via the kidneys. Oxycodone is extensively metabolised by liver cytochrome p450 (CYP) 
isoenzymes, however approximately 10% is excreted unchanged in the urine.  CYP3A4 N-
demethylates the majority of oxycodone to noroxycodone, whereas as CYP2D6 O-
demethylates a much smaller percentage to oxymorphone (10%).  Oxycodone is 
contraindicated in patients with moderate to severe hepatic impairment and severe renal 
impairment.   
 
Oxycodone binds selectively to μ-opioid receptors with greater affinity than κ- or δ-opioid 
receptors. The main metabolites of oxycodone: noroxycodone and oxymorphone, also show 
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selectivity for μ- over κ-opioid receptors, and demonstrate affinities for the μ-opioid that are 
4-fold lower and 40-fold higher than oxycodone respectively 24.  The potential activity of the 
main metabolites of oxycodone has been debated. Noroxycodone is generally accepted to be 
inactive in contrast to oxymorphone which has been suggested to have a greater analgesic 
potency than oxycodone 25, 26.  In view of this there has been much debate about whether 
variation in CYP2D6 metabolism either through drug inhibition and/or genetic variation 
within the human population significantly alter the clinical efficacy of oxycodone 27-29.  
 
In animal studies, the concentration of oxycodone achieved in the rat brain is higher than that 
achieved with morphine for the same unbound plasma concentration, despite being similarly 
hydrophilic.  It is suggested that the passage of oxycodone through the blood brain barrier is 
actively aided by an as yet undefined active transporter 30.  Furthermore studies also in the rat 
showed that unlike morphine, oxycodone is not a substrate for p-glycoprotein which actively 
exports drugs across the blood brain barrier 31. 
 
There has been much controversy over a possible role for κ-opioid receptors in oxycodone 
analgesia.  Studies by one group in Sprague-Dawley rats using the intracerebroventricular 
and intrathecal routes have shown that the κ-opioid receptor selective antagonist 
norbinaltorphimine (nor-BNI) produces marked attenuation of the antinociceptive effects of 
oxycodone but not those of morphine 9, 32.  The authors conclude that the intrinsic 
antinociceptive effects of oxycodone and morphine are mediated by distinctly different 
opioid receptor populations, namely the κ2B -opioid receptor in oxycodone in contrast to the 
µ-opioid receptor for morphine 32.  There is much opposition to this hypothesis as other 
studies show that the oxycodone is µ-opioid receptor selective, produces similar behaviour as 
other µ-opioid receptor agonists and that the existence of  κ-opioid receptor subtypes is 
unconfirmed 10, 24.   
 
The most common adverse reactions to oxycodone are GI (nausea, vomiting and 
constipation) and central (drowsiness, confusion and hallucinations).  Suspected adverse 
reactions to oxycodone from the summary of product characteristics are compared to those of 
morphine in Table 1.4. 
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1.2.3.2 A Comparison of Morphine and Oxycodone in Cancer-related Pain 
A recent systematic review of oxycodone in the management of cancer pain concluded that 
there was no significant difference between the efficacy or tolerability of oxycodone and 
other strong opioids such as morphine 33.  There is however growing evidence from opioid 
switching studies that there is wide variation in morphine and oxycodone responses at the 
individual level.  Reasons for this may include: 
• Although morphine and oxycodone are selective µ-opioid receptor agonists, morphine 
has a greater affinity. 
• Morphine and oxycodone have different bioavailability, 19-47% versus 60-87%.   
• Morphine and oxycodone have different pathways of metabolism, UGT and CYP450 
respectively. 
• Morphine and oxycodone have different metabolites, each with different properties. 
• Morphine and oxycodone have different passages across the blood brain barrier 
 
1.2.4 Inter-individual Variation in Response to Opioids 
There is wide inter-individual variation in clinical response to morphine when used for 
cancer-related pain.  Broadly speaking patients can be divided into morphine “responders” 
and “non-responders”.  Morphine responders achieve good analgesia and experience little or 
no adverse effects.  Morphine non-responders however can present in three different 
scenarios: good analgesia but intolerable adverse reactions; poor analgesia and intolerable 
adverse reactions and poor analgesia despite dose titration with no adverse reactions.  
Currently there is no way to identify to which group an individual patient will belong prior to 
drug administration.  The same scenarios are commonly observed in clinical practice with 
oxycodone use. 
 
1.2.5 Opioid Switching 
Clinical failure of opioid treatment may be due to inadequate analgesia, intolerable side 
effects or a combination of both 34.  In practice, when a patient fails to respond to a first-line 
strong opioid, they are often “switched” to an alternative strong opioid.  The term opioid 
switching is often used interchangeably with the term “opioid rotation” however there is an 
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important distinction between the two terms. Opioid switching refers to the practice of 
switching from one strong opioid to another with the aim of achieving a better clinical 
outcome, when there is either inadequate analgesia, intolerable side effects or both.  Opioid 
rotation however encompasses not only opioid switching but is also used when the change of 
strong opioid is made on the basis of patient or prescribing physician preference and when 
the route of administration is changed but not the type of opioid.   
 
Systematic reviews on opioid switching have been published which examine the evidence 
behind its use in clinical practice. In 2004 a Cochrane review concluded that most, albeit low 
level, evidence suggests that opioid switching is a useful therapeutic manoeuvre that 
improves pain management 4.  Mercadante et al in 2006 quantified its utility stating that more 
than 50% of patients with chronic pain and a poor response to first-line opioid gained clinical 
improvement with opioid switching 35.   The conclusion of an updated systematic review this 
year was that more high quality evidence in the form of RCTs are required to establish the 
true effectiveness of this clinical practice 36. 
 
Previous work in the RMH Palliative Medicine Research Department has evaluated the 
strategy of opioid switching in first retrospective and then prospective studies 37, 38.  The 
Prospective Morphine Study was the first prospective case-control study of opioid switching 
and is the corner stone on which the opioid response work presented in this thesis is based 15, 
39. Clinical, biochemical, haematological, immunological and genetic factors have so far been 
explored with the aim of building a model to predict who will need to switch from morphine 
as first-line opioid to an alternative opioid 37, 40-42.   
 
1.2.6 Opioid Dose Conversion in Opioid Switching 
To reach a successful conclusion in opioid switching the correct dose of the second-line 
opioid must be found.  The “equianalgesic” conversion ratios presented in reference material 
are merely guidelines to the relative potencies of different opioids and are often taken from 
studies not designed for the purpose 43.  Importantly they do not take into account individual 
patient factors which may contribute to effect, such as previous opioid therapy, opioid 
tolerance and disease status.  Equianalgesic dose ratios vary between studies however most 
agree that on average the dose conversion ratio for oral morphine: oral oxycodone lies 
between 1:1 and 1:2, although the direction of conversion may make a difference 44, 45.   
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Tolerance to opioids is defined as the need to increase the dose of drug administered to 
produce the same pharmacologic effect.  All µ-opioid receptor agonists such as morphine and 
oxycodone are associated with tolerance following repeated usage and exhibit cross tolerance 
to one another, although the degree of cross tolerance varies substantially.  Tolerance to both 
an opioid’s analgesic effects and adverse reactions may however develop although not 
necessarily simultaneously.  Incomplete cross tolerance is a mechanism which is utilised to 
restore analgesic sensitivity in highly tolerant patients by switching one strong opioid to 
another.  In these circumstances analgesia may be restored by the second strong opioid at 
doses substantially below the predicted equivalent dose 46.  In some cases however the dose 
of the second opioid may need to be substantially titrated up to achieve the desired effect.  In 
one study of opioid switching from morphine to oxycodone the median dose ratio of 
morphine: oxycodone was 1.7 with a broad range from 0.25 – 12 40. 
 
Dose conversion decisions when switching opioids should take into consideration the reason 
for switch, such as uncontrolled pain and/or adverse reactions, and the type of opioid used. 
Use of a conservative dose ratio together with a potential dose reduction of the equi-analgesic 
dose by 25-50%, followed by subsequent careful individualised dose titration is 
recommended 43, 45. 
 
1.2.7 Genetics 
DNA holds the genetic code, and may be divided into functional unit called genes which each 
code for a specific protein, for example a receptor or transporter.  The DNA code is expressed 
by variable sequences of four nucleotides: adenine (A), thymine (T), guanine (G) and 
cytosine (C). Each gene has coding regions, exons and non-coding regions, introns.  The 
promoter region is located upstream and is influential in gene expression.  The untranslated 
region which may either be up- (5’UTR) or downstream (3’UTR) undergoes transcription but 
not translation. The synthesis of a protein from its DNA blueprint requires a series of steps.  
Firstly the code is transcribed from DNA to messenger RNA (mRNA) which is then 
translated into a corresponding amino acid chain and ultimately forms the final protein. 
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1.2.8 Mechanisms of Inter-individual Variation 
1.2.8.1 Genetic Variation 
Each individual has a unique genetic code.  Variation in the DNA sequence between 
individuals may be due to a number of mechanisms including SNPs, insertions/deletions and 
variable number tandem repeats (VNTR). The most common type of genetic variation is the 
SNP, when one nucleotide is substituted for another. Different variants are known as alleles.  
In the majority of cases there are two alleles: the common, major allele and the variant, minor 
allele.   
 
SNPs may or may not have functional consequences depending on where they are within the 
gene sequence.  If a SNP occurs within the promoter sequence then it may create or abolish a 
transcription factor binding site and influence the expression of the gene.  If the SNP falls 
within an exon, the coding portion of the gene, it may influence the amino acid sequence of 
the resultant protein and therefore change the protein structure or function.  Alternatively if 
the SNP occurs with an intron/exon boundary then mRNA processing may be affected 
resulting in splice variants. 
 
Completion of the human genome sequence has resulted in millions of SNPs being identified. 
Each SNP has been allocated a unique identifying number, often known as an rs (reference 
SNP) number. SNPs may also be referred to by different names, often describing their 
location and any resultant amino acid change.  
 
1.2.8.2 RNA Variation 
A single gene can result in a number of different protein products, primarily through RNA 
post-transcriptional modification. Splicing refers to the process whereby intronic material is 
removed and the remaining exons joined together to form mRNA.  Alternative splicing 
results in the inclusion of different exons and exon combinations in the final protein which 
can confer different functionality. 
 
The existence of multiple µ-opioid receptor subtypes from alternative splicing has been found 
both from animal studies and human studies 47-50.  These subtypes have been hypothesised to 
contribute to incomplete cross tolerance or differential actions that are observed between the 
various strong opioids 46. With regards to pain perception a SNP in OPRM, rs563649, has 
  
 
 
   
41 
been associated with differential translation of splice variants of µ-opioid receptor and altered 
pain response (135).  
 
1.2.8.3 Protein Variation 
Interactions between different proteins may also produce variation.  In the case of receptors, 
dimerisation to form either homo- or heterodimers can occur, each form having different 
functions such as altered ligand binding and receptor trafficking.  This phenomenon has been 
demonstrated with the classical opioid receptors and other g-protein coupled receptors 51-53. 
The potential for opioid receptor dimerisation therefore adds further scope to inter-individual 
variation in opioid response.  
 
1.2.9 Population-based Genetic Studies 
There have been two main approaches to population-based genetic association studies: 
candidate gene studies and more recently genome-wide association (GWA) studies.  GWA 
arrays can type as many as one million SNPs across the genome to provide the highest 
possible coverage of common genetic variation.  Associations generated from GWA studies 
may not have any direct causal relevance and are more likely to be in linkage disequilibrium 
(LD) with underlying causative variants.  Candidate gene studies tend to focus on a smaller 
but denser set of SNPs in genes which are hypothesised to have biological relevance to the 
condition being studied.  The SNPs selected invariably are of higher density and include 
functional SNPs which may have direct causal consequence.  This thesis uses the candidate 
gene approach to assess potential associations between opioid response and variation in genes 
contributing to opioid pharmacogenomics and overall pain susceptibility.   
 
1.2.10 Candidate Genes 
1.2.10.1 Opioid Pharmacogenomics 
Pharmacogenomics is the study of how genetic variation may influence the pharmacokinetic 
and pharmacodynamic profile of a drug and thereby impact on an individual’s response.  It is 
central to the idea of personalised medicine where the right drug is prescribed to the right 
individual at the right dose at the right time, far removed from the one drug fits all approach 
in current medicine.   
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One of the best characterised phenomena in opioid pharmacogenomics is the effect of genetic 
variation in CYP2D6 on codeine metabolism and efficacy. Codeine, a weak opioid, is 
metabolised to morphine by CYP2D6.  The CYP2D6 gene is located on chromosome 22q13.1 
and is part of the 2D cluster together with the pseudogenes CYP2D8P and CYP2D7.  Over 70 
CYP2D6 alleles have been described which directly affect the final protein including both 
SNPs, deletions, insertions, and copy number variation 54.  The sum effect of variation on 
phenotype has been classified into four major groups: poor metabolisers, intermediate 
metabolisers, extensive metabolisers and ultrarapid metabolisers.  Up to 10% of Caucasians 
are poor metabolisers and experience little analgesia from codeine 55. At the other end of the 
spectrum 3% of Caucasians are ultra-rapid metabolisers and have a higher incidence of 
codeine related adverse reactions 56. There are case reports of fatal neonatal opioid toxicity in 
children who are breastfed by CYP2D6 ultra-rapid metabolising mother who have ingested 
codeine 57.  Recent data suggest that CYP2D6 phenotype also plays a role in response to 
tramadol and possibly oxycodone 29, 58.  
 
Morphine pharmacogenomics has previously been studied in the RMH Palliative Medicine 
Research Department using the candidate gene approach (Table 1.5) and more recently 
genome wide analysis 59, 60.   
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Table 1.2   Morphine Pharmacogenomics Candidate Genes 
Gene symbol 
    
Gene Description 
 
Pharmacodynamics 
 
 OPRM1 Μ-opioid receptor 1 Target receptor 
 OPRK1 κ-opioid receptor 1 Target receptor 
 OPRD1 δ-opioid receptor 1 Target receptor 
 ARRB2 β-arrestin Target receptor recycling 
 STAT6 Signal transducer and activator of transcription 6 Transcription factor (target receptor) 
    Pharmacokinetics  
 ABCB1 P-glycoprotein Transmembrane drug transporter protein 
 UGT2B7 UDP glucuronosyltransferase 2 family, polypeptide B7 Drug metabolic enzyme 
 HNF1A Hepatic nuclear factor 1α Transcription factor (metabolic enzyme) 
 OCT Octamer-binding transcription factor 1 Transcription factor (metabolic enzyme) 
 DCOH Dimerization Cofactor of HNF1α Transcription factor dimerisation 
cofactor 
     Pharmacogenomic candidate genes from the theses of Dr Joy Ross 39 and Dr Dag Rutter 15 
        
 
OPRM, the μ-opioid receptor gene the most studied in opioid pharmacogenomics.  A non-
synonymous exonic SNP, OPRM rs1799971 (A118G), has been reported in several studies to 
be associated with pain and opioid response 61-64, however these findings have not been 
replicated by our group.  The multidrug resistance gene (ABCB1) encodes p-glycoprotein, a 
membrane transporter important in regulating drugs across the blood-brain barrier.  SNPs in 
ABCB1 have been associated with central side effects of morphine 42.  Polymorphisms in the 
STAT6 and β-arrestin genes have also been implicated in response to morphine/switching by 
our group 41. STAT6 is a transcription factor involved in cytokine induced up-regulation of μ-
opioid receptor expression 65. β-arrestin is an intercellular protein which is involved in μ-
opioid receptor inactivation and internalisation 66.    
 
1.2.10.2 Pain Susceptibility Genes 
Inter-individual response to opioids may be influenced by variation in the susceptibility or 
perception of pain, and may therefore involve many more candidate genes from pain 
signalling and modulatory pathways.  Twin studies in experimental pain have suggested that 
up to 60% of variability in response to painful stimuli is genetically mediated 67, 68.  Table 1.6 
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shows the pain susceptibility genes that have been investigated by the RMH Palliative 
Medicine Research Department 15, 39, 59, 60. 
 
In cancer pain, SNPs in cytokine genes (IL8, IL6 and TNF) have been associated with pain 
severity and morphine dose 69, 70.   Pro-inflammatory cytokines and microglial activation are 
thought to play an important role in the pathophysiology of neuropathic pain 71.  Expression 
of key genes that contribute to the excitability of neurons such as ion channels (e.g. α2δ 
calcium channel subunit) and neuropeptides, and genes that are involved in the immune 
response and activation of microglia are consistently reported as being up-regulated in animal 
models of neuropathic pain 72, 73.   
 
Protections from central adverse reactions to morphine have been associated with 
polymorphisms in the catechol-O-methyltransferase (COMT) gene which encodes an enzyme 
responsible for catecholamine metabolism 42. 
 
1.2.11 Opioids and the Immune Response 
The hypothesis that opioids have immune-modulatory properties was first proposed in the 
nineteenth century.  Since then a battery of animal and in vitro experimental work has been 
conducted which provides evidence that opioid have immunosuppressive actions both on 
innate and adaptive immunity. 
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Table 1.3  Pain Susceptibility Candidate Genes 
Gene symbol 
    
Gene Description 
 
Cytokines 
 
 *TNF Tumour Necrosis Factor α Pro-inflammatory cytokine 
 *IL6 Interleukin 6 Pro-inflammatory cytokine 
 *IL8 Interleukin 8 Pro-inflammatory cytokine 
 *IL10 Interleukin 10 Anti-inflammatory cytokine 
    Receptors  
 ADORA1 Adenosine A1 receptor Inhibition of neurotransmission 
 ADRA2A α-2a-adrenergic receptor Inhibition of neurotransmission 
 *CCKBR Cholecystokinin B Receptor Neuropeptide receptor  
 GRIN1 N-methyl-D-aspartate receptor   1 Excitatory neurotransmitter receptor 
 GRIN2A N-methyl-D-aspartate receptor 2A Excitatory neurotransmitter receptor 
 MC1R Melanocortin 1 receptor Hormone receptor 
    Ion channels, transporters or related proteins  
 TRPV1 Transient receptor potential cation channel V1 Sensory transducer 
 *TRPV4 Transient receptor potential cation channel V4 Sensory transducer  
 CSEN Downstream regulatory element antagonistic 
modulator/Kv channel interacting protein 3 
Regulator of endogenous opioid production 
 SCL6A4 Serotonin transporter Neurotransmitter transporter 
    Enzymes  
 ALOX12 Arachidonate 12-lipoxygenase Biosynthesis of signalling messenger 
 COMT Catechol-O-methyl transferase Metabolic enzyme (catecholamines) 
 GCH1 GTP cyclohydrolase 1 Biosynthesis of cofactor to neurotransmitter 
synthesis 
    Growth factors  
 BDNF Brain-derived neurotrophic  factor Nerve growth factor 
    
 *Candidate genes added as part of this thesis to departmental pain plate 
 Other pain susceptibility genes appear in the theses of Dr Joy Ross39, Dr Sophy Gretton60 and Dr Joanne Droney 59 
 
 
1.2.11.1 Interaction of the Immune and Nervous Systems 
Pain is one of the hallmarks of the inflammatory response.  Granulocytes and monocytes are 
attracted to sites of injury and inflammation and once activated contribute to the release of 
pro-inflammatory mediators which add to generation and maintenance of pain. These 
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immune cells may also produce and secrete endogenous opioids at sites of inflammation act 
on peripheral neural opioid receptors to attenuate inflammatory pain 74. 
 
1.2.11.2 Mechanism of Action 
The immunosuppressive action of opioids has been proposed to be either direct via opioid 
receptors on white blood cells, or indirect via the hypothalamic-pituitary-adrenal (HPA) axis. 
There is conflicting evidence on the expression of the classical opioid receptors on white cell 
subsets 75-77.  It has previously been hypothesised that expression of neurotransmitter 
receptors and opioid receptors on peripheral blood lymphocytes (PBL) mirrors that which is 
seen in the brain.  PBL could therefore potentially be studied as models or peripheral markers 
of changes in expression of these molecules over time 76.  
 
1.2.11.3 Immunosuppressive Effects of Opioids 
Reported immunosuppressive effects of morphine include suppression of phagocytosis, 
modulation of cytokine secretion, reduction of antibody production and modulation of T cell 
differentiation 78.   The consequences of these changes are hypothesised to be wide-ranging 
from increased susceptibility to infection and the enhancement of malignant processes.  
Susceptibility to and severity of infection has been the most widely studied consequences of 
opioid induced immunosuppression in animal models.  In general there have been three main 
models: new infectious challenge to an animal after chronic opioid exposure, opioid initiation 
in an infected animal and acute withdrawal of opioid in an opioid tolerant infected animal.  
Morphine has been shown to have deleterious effects across all of these models which have 
tested a wide range of microorganisms including: bacteria, mycobacteria, protozoans, yeast 
and viruses 79.  It has also been suggested that some opioids are less likely to induce 
immunosuppression than others 80, 81.   
 
In humans Anand et al conducted a large placebo controlled study of the use of pre-emptive 
continuous morphine in premature infants requiring mechanical ventilation compared to as 
required use.  They found no difference in the primary outcomes of death, intra-ventricular 
haemorrhage and periventricular leukomalacia 82.  Rates of infection were not commented 
upon in the adverse event reporting.  The short and long-term effects of opioid administration 
still remain largely unknown in the clinical setting, however the potential immunosuppressive 
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qualities of chronic exogenous opioid administration may theoretically have an impact on 
incidence and severity of infection, cancer progression and ultimately survival.  
Immunosuppression however in cancer patients is common and multi-factorial and it is 
unclear whether any additional immunosuppressive effects of exogenous opioids are 
clinically meaningful 83. 
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1.3 Aims and Hypotheses 
1.3.1 Hypotheses 
• There is a difference in the first-line response rates of oral morphine and oxycodone 
in the treatment of moderate to severe cancer-related pain. 
• There is a difference in the analgesic response, as measured by a reduction in pain 
scores, between oral morphine and oxycodone. 
• There is a difference in the adverse reaction profiles of oral morphine and oxycodone. 
• Inter-individual variation in analgesic response and adverse reactions to oral morphine 
and oxycodone are associated with genetic variation. 
 
1.3.2 Aims 
• To complete the Morphine versus Oxycodone RCT for Cancer-related Pain. 
• To develop a new clinical trial management system for use in the Morphine versus 
Oxycodone RCT for Cancer-related Pain. 
• To determine whether there is a difference in response rate between oral morphine 
and oral oxycodone when used first-line in cancer-related pain. 
• To determine whether there is a difference in pain relief or adverse reactions between 
oral morphine and oral oxycodone when used first-line in cancer-related pain. 
• To explore the practice of opioid switching in first-line opioid non-responders. 
• To define morphine and oxycodone response phenotypes uses Principal Component 
Analysis. 
• To develop assays for new candidate genes in pain and opioid response using samples 
from the Prospective Morphine Study 
• To second-set genetic results from earlier work in the Prospective Morphine Study in 
the Morphine versus Oxycodone RCT for Cancer-related Pain. 
• To perform an exploratory pilot study of global gene expression of peripheral blood 
leukocytes from patients undergoing opioid treatment over time. 
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2 Methods: Clinical Trials in Opioid Response 
2.1 Introduction 
This Chapter describes two clinical opioid response studies: the Prospective Morphine Study 
and the Morphine versus Oxycodone Randomised Controlled Trial for Cancer-related Pain.  
Both studies were well established within the Royal Marsden Palliative Medicine Research 
Department when I joined the team.   
 
The Prospective Morphine Study has been described in detail in prior theses 15, 39, 60.  Briefly, 
it is an observation study of response to morphine in cancer-related pain and identified 
morphine “responders” and “non-responders” who required switching to an alternative 
opioid.  In this project I have used the DNA samples and data from the Prospective Morphine 
Study in order to develop and test my own assays for six new candidate pain genes and to 
explore the concept of morphine response using Principal Component Analysis (PCA).   
 
The Morphine versus Oxycodone RCT for Cancer-related Pain was originally designed by Dr 
Sophy Gretton with subsequent amendments made by Dr Joanne Droney and myself.  Dr 
Sophy Gretton completed an interim analysis of the results for the first 100 participants in her 
thesis 60.  There were 92/200 patients still to recruit to the Morphine versus Oxycodone RCT 
when I took over as the lead Clinical Research Fellow for the study. 
 
My involvement in the Morphine versus Oxycodone RCT for Cancer-related Pain included: 
• Clinical 
o Patient screening, recruitment and follow-up 
o Biological sample collection, storage and processing 
o Supervision of research nurses 
o Pharmacovigilance 
• Data management 
o Development of a new Clinical Trial Management System: InForm 
o Data entry into InForm 
o Data monitoring of InForm 
o Validation of InForm against previous Excel database 
• Research governance  
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o Liaison with and writing annual reports for: Data Monitoring Committee, 
Research Ethics Committee, RMH Research and Development Department, 
and MHRA. 
• Genetics 
o Genotyping of all patients for 12 candidate genes 
o Completion of genotyping for the second 100 patients for three genes (OPRM, 
OPRK, OPRD) 
• Gene expression 
o RT-PCR and Microarray 
• Analysis 
o Final analysis for primary outcome and preliminary analysis for secondary 
outcomes 
 
 
2.2 Prospective Morphine Study 
2.2.1 Study Population 
Patients over the age of 18 with moderate to severe cancer pain uncontrolled by weak opioids 
and clinically requiring a strong opioid were deemed eligible for the study. 
 
2.2.2 Study Design 
This was a prospective observational study of patients undergoing morphine treatment for 
cancer pain.  Patients were grouped according to clinical response into “morphine 
responders” or “morphine non-responders”.  Time Point A was at entry to the study 
(baseline) and Time Point B was when patients had been on oral morphine for at least one 
month or when switched to an alternative opioid or when morphine was stopped.  If a patient 
had already been on morphine for ≥ one month when recruited to the study then Time Points 
A and B were done together. 
 
The study was sponsored by the Royal Marsden NHS Foundation Trust.  Ethical approval 
was granted by the Surrey Borders Research Ethics Committee. 
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2.2.3 Inclusion Criteria 
• Patients over the age of 18 and under the age of 78 years. 
• Diagnosis of cancer. 
• Patients already on morphine or patients whose pain is not controlled by maximum 
doses of step 2 analgesia (according to WHO guidelines) and who are due to start 
morphine. 
• Able to give written informed consent  
• Capable of completing the study  
• Willing to undergo genetic screening  
 
2.2.4 Exclusion Criteria 
• Pain that was predominantly neuropathic or incident in nature.  
• Renal impairment (serum creatinine >1.5 times the upper limit of normal). 
 
2.2.5 Study Procedures 
Patients were commenced (or continued) on regular oral morphine and titrated according to 
response.  Appropriate breakthrough medication was provided throughout the study as per 
normal practice and all co-analgesics were continued.  Dose titration of morphine was 
continued until effective pain relief was achieved +/- acceptable adverse reactions.   Patients 
intolerant of morphine either because of inadequate analgesia and/or intolerable adverse 
reactions were switched to an alternative strong opioid. 
 
2.2.6 Adverse Reactions and Pharmacovigilance 
Common, well known adverse reactions such as nausea, vomiting and constipation were 
treated as per local symptom control guidelines.  If adverse reactions were not resolved by 
maximal standard management or slow titration/dose reduction patients were switched to an 
alternative opioid.  Adverse events and adverse reactions were recorded as per protocol and 
GCP 84. 
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2.2.7 Study Assessments 
Pain and side effect scores were collected.  Pain was assessed by the mBPI.  Patients rated 
pain on an 11-point Likert scale, 0 = no pain, 10 = worst possible pain imaginable, for four 
descriptors: pain at its worst, pain at its least, average pain and pain right now.  A percentage 
rating of pain relief was also conducted from 0% relief to 100% total relief.  Morphine side 
effects were measured on 4-point Likert scales: Grade 0 “not at all”, Grade 1 “a little”, Grade 
2 “quite a bit”, Grade 3 “very much”.  Tables 3.2 and 3.3 list the assessment and sample 
schedules for the Prospective Morphine Study.  Examples of questionnaires are available in 
Appendix A. 
 
Table 3.1  Prospective Morphine Study: Assessment Schedule 
 Time Point 
Item A B 
Consent X  
Demographics X  
Modified Brief Pain Inventory (mBPI) X X 
Toxicity score X X 
Opioid dosage  X X 
Concurrent medication X X 
Constipation assessment X X 
Urinary metabonomics X X 
Criteria for switching  X 
 
Table 3.2  Prospective Morphine Study: Sample Schedule 
  Time Point 
Sample  A B 
Blood    
  Haematology (FBC) 1 x 3ml EDTA X X 
  Biochemistry (U&E, LFTs, Ca) 1 x 4.5ml Lithium Heparin PST II X X 
  Immunology (Lymphocyte subsets) 1 x 3ml EDTA X X 
  Genetics 3 x 3ml EDTA X  
Urine 1 x 10ml X X 
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2.2.8 Evaluation of Outcome 
2.2.8.1 Primary Outcome  
The primary outcome of the study was the response to morphine  
• A “good” response to morphine was defined as: time on morphine ≥ one month with 
no change to an alternate opioid and toxicity scores of Grade 3 in no more than two 
symptoms.  
•  “Poor” response to morphine was be defined as: time on morphine < one month with 
change to an alternative opioid or toxicity scores of Grade 3 in two or more 
symptoms. 
 
2.2.8.2 Secondary Outcomes 
• Morphine toxicity.  
• Morphine dose.  
• Continued treatment on morphine / requirement for an alternative opioid.  
 
2.2.9 Analytical Strategy 
2.2.9.1 Data Mining 
Knowledge Studio (Angoss Software) was used for data mining.  Significant associations 
found on data mining were explored using conventional statistics (SPSS version 17.0).  
2.2.9.2 Principal Component Analysis 
PCA was conducted using clinical response variables of pain and adverse reaction scores 
(SPSS version 17.0).   Component scores were calculated with the regression method.  An 
oblique method of rotation (direct oblimin) was used as morphine response Components may 
be related.  All Components with eigenvalues >1 were retained. 
2.2.9.3 Regression Modelling 
PCA Component scores were used as dependant variables.  Univariate relationships were 
quantified between dependent variables and demographic criteria, tumour diagnoses, 
biochemical and haematological variables, time on morphine, 24 hour dose of morphine, time 
to death and genetic information.  Statistically significant variables were re-evaluated 
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together using multivariate linear regression models.  A stepwise backwards methodology 
was used, with variables retained only if significant (P < 0.05) or marginal (0.05 < P < 0.1).   
 
 
2.3 Morphine versus Oxycodone RCT in Cancer-related Pain 
2.3.1 Study Population 
Patients over the age of 18 with moderate to severe cancer pain uncontrolled by weak opioids 
and clinically requiring a strong opioid were deemed eligible for the study. 
 
2.3.2 Primary Objectives 
The primary objective of the study was to compare the response rates of morphine and 
oxycodone when used as first-line strong opioids in the treatment of moderate to severe 
cancer pain. 
 
2.3.3 Study Design 
The study was a single centre, open-label RCT.  Patients were randomised to morphine or 
oxycodone and titrated to response.  If patients did not respond to first-line opioid due to 
uncontrolled pain or adverse reactions they were switched to the alternate opioid.  Figure 3.1 
shows the study schema.  Table 3.3 describes the study time-points.    
 
The study was sponsored by the Royal Marsden NHS Foundation Trust.  Ethical approval 
was granted by the Surrey Borders Research Ethics Committee. 
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Figure 3.1  Morphine versus Oxycodone RCT Schema 
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Screen  Randomise 
>200% 
dose? 
 
>200% 
dose? 
Response? 
 
Response? 
↑Dose 
(E) 
End (F)       
1 year 
 
yes 
yes 
yes 
 
yes 
no 
no 
no 
Oxycodone 
(A or C) 
Morphine 
(A or C) 
Stable 
(B or D) 
Stable 
(B or D) 
 
Titration Monthly follow-up 
End  
(F) 
Switched 
already? 
yes 
no 
no 
  
 
 
   
56 
Table 3.3 Morphine versus Oxycodone RCT: Description of Time Points 
Time Point Description 
A Baseline. 
B When the patient was stabilised on first-line opioid. 
C If patients did not respond to the first-line opioid and required switching to the 
alternative arm of the study. 
D When the patient was stabilised on second-line opioid 
E If a patients’ analgesic requirements increased by 200% of their initial stable dose 
of opioid. 
F If patients did not respond to the second-line opioid and fit the criteria to exit 
from the study. 
 
2.3.4 Inclusion Criteria 
• Age 18 years or over. 
• Clinical or histological diagnosis of cancer. 
• Pain not controlled on weak opioid analgesics, clinically requiring a strong opioid. 
• Able to give written informed consent. 
• Willing to undergo genetic screening. 
 
2.3.5 Exclusion Criteria 
• Renal failure (1.5x upper limit of normal).   
• Current regular strong opioid. 
• Parenteral administration of opioids required. 
• Predominantly incident pain. 
• Clearly defined history of intolerance to morphine or oxycodone. 
• Pregnancy. 
 
2.3.6 Sample Size Calculation 
The primary outcome of the study was the proportion of patients demonstrating a good 
response to their first-line opioid i.e. achieve stable dose (Time Point B).  A 15% difference 
in response rate between morphine and oxycodone would be considered to be clinically 
relevant.  The sample size was therefore calculated to detect this size of difference with 80% 
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power and significance level 5% and gave 100 patients in each arm therefore 200 patients in 
total were required for this study. 
 
2.3.7 Study Treatment and Procedures 
2.3.7.1 Randomisation 
Randomisation was computer-generated and performed by the Imperial Cancer Research 
Clinical Trials and Statistics Unit.   
2.3.7.2 Dose Titration and Breakthrough Analgesia 
Patients were titrated on regular immediate release oral morphine or oxycodone every four 
hours, with additional doses of the same immediate release opioid available for breakthrough 
pain.  The four hourly doses were increased by approximately 30-50% every 24-48 hours 
guided by used of breakthrough analgesia, until pain control was achieved with acceptable or 
no adverse reactions (Time Point B).   Once patients were on a stable dose of opioid they 
were converted to slow-release preparations.   
2.3.7.3 Opioid Switching 
Opioid switching was considered in all patients who experienced dose limiting adverse 
reactions despite dose modification and maximal treatment with adjuncts.  Patients were 
discontinued from their first-line opioid and switched to the alternative arm of the study 
(Time Point C).  The second-line opioid was started at “equipotent” dose, using the 
conversion ration of morphine:oxycodone, 2:1.  The second-line opioid was then further 
titrated as before and converted to slow release oral preparations when adequate pain control 
was achieved (Time Point D). 
2.3.7.4 Adjuvant Medication 
Co-analgesics, including anti-neuropathic agents, were allowed in keeping with local 
symptom control guidelines.  Use of co-analgesics was recorded. 
2.3.7.5 Adverse Reactions and Pharmacovigilance 
Common, well known opioid adverse reactions such as nausea, vomiting and constipation 
were treated as per local symptom control guidelines.  If adverse reactions were not resolved 
by maximal standard management or slow titration/dose reduction patients were switched to 
the alternative arm of the study.  Adverse events and adverse reactions were recorded as per 
protocol and GCP 84 . 
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2.3.8 Monitoring During Treatment 
During the titration phase(s) patients were monitored on a daily basis, with dosing 
requirements, pain and toxicity scores collected.  Patients were thereafter followed-up on a 
monthly basis. 
 
2.3.9 Study End Points and Withdrawal 
End-points for the study were as follows: 
• Subject had reached one year post recruitment. 
• Non-response to both morphine and oxycodone.  
• Conversion of opioid to parenteral formulations on clinical grounds or when unable to 
take oral opioids. If the randomised opioid was temporarily delivered parenterally on 
clinical grounds then the patient was “paused” on the study rather than withdrawn.  
The subject was then restarted on the study protocol on reinstatement of the 
randomised oral opioid.  The maximum duration of “pausing” allowed was 30 days 
after which time the patient was withdrawn. 
• Renal impairment of >1.5 upper limit of normal. 
• Subject stopped taking strong opioid on clinical grounds. 
• Patient choice. 
• Other. 
 
2.3.10 Study Assessments 
Table 3.4 describes the assessment and sample collection schedule of the study.  Examples of 
the questionnaires are available in the Appendix A. 
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Table 3.4  Morphine versus Oxycodone RCT Assessment and Sample Collection Schedule 
  Time point 
Assessment  A Titration B C Titration D E F 
Form/Questionnaire 
        
Demographics X X 
      
Modified Brief Pain Inventory X 
 
X X 
 
X X X 
Toxicity Score X 
 
X X 
 
X X X 
Opioid history & concurrent medication  X 
 
X X 
 
X X X 
Source of referral X 
       
Titration diary* 
 
X 
  
X 
   
Constipation on Opioids Assessment  X X** X X X** X X X 
Urine Metabonomics Assessment X 
 
X X 
 
X X X 
Criteria and Reasons for Switching  
   
X 
   
X 
Adverse events X X X X X X X X 
Samples 
        
Blood 
        
Haematology (1x 3ml EDTA tube) X 
 
X X 
 
X X X 
Biochemistry (1x 4.5ml Lithium heparin tube) X 
 
X X 
 
X X X 
Immunology (1x 3ml EDTA tube) X 
 
X X 
 
X X X 
Metabolites (2x 4.5ml Lithium heparin tube) X 
 
X X 
 
X X X 
Gene expression (2x PAXGene tubes) X 
 
X X 
 
X X X 
Genetic (3x 3ml EDTA tube) X 
       
Urine 
        
Urine (10mls) X 
 
X X 
 
X X X 
*Titration diaries were recorded daily until a stable dose was achieved 
**Constipation on opioid assessment was performed once a week for 4 weeks after initiation of morphine or 
oxycodone 
 
For all study participants serum Creatinine level measurements were used to calculate an 
estimated Glomerular Filtration Rate according to sex and race using the abbreviated MDRD 
equation (http://www.renal.org/eGFRcalc/) 
 
𝑒𝐺𝐹𝑅 = 186 ×  (𝑠𝑒𝑟𝑢𝑚 𝐶𝑟𝑒𝑎𝑡𝑖𝑛𝑖𝑛𝑒 ÷ 88.4)−1.154 × (𝐴𝑔𝑒)−0.203  × (0.742 𝑖𝑓 𝑓𝑒𝑚𝑎𝑙𝑒)  × (1.210 if  Black) 
 
2.3.11 Evaluation of Outcome 
2.3.11.1 Primary Outcome  
The primary outcome of the study was to compare the response rate of morphine and 
oxycodone when used as first-line strong opioids in moderate to severe cancer pain. 
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2.3.11.2 Secondary Outcome: 
Secondary outcomes included 
• A comparison of analgesic efficacy. 
• A comparison of toxicity profiles.  
• Genetic association study. 
• Gene expression study. 
 
2.3.12 Data Collection and Management 
Collection of accurate clinical trial data is an essential to GCP.  Source data is not only vital 
for reporting and analysis but is also integral to the various verification processes of quality 
control, audit or inspection. The use of computers is increasing in many aspects of clinical 
trial data management.  The GCP Inspectors Working Group has recently published a 
reflection paper on expectations for electronic source data and data transcribed to electronic 
data collection tools in clinical trials 85.  This paper included recommendations from the 
Clinical Data Interchange Standards Consortium Electronic Source Data Interchange Group 
(CDISC) 86.   The CDISC publication set out 12 user requirements for source data, which the 
reflection paper refined into five topics.   The requirements were based on in Directive 
2001/20/EC5 87 and Commission Directive 2005/28/EC6 88, and in the Note for Guidance on 
GCP CPMP/ICH/135/95 84.   
 
2.3.13 Transition to the InForm Integrated Trial Management System 
The department of Palliative Medicine has previously used Microsoft Excel for data 
collection and storage.  The paper Case Report Forms were manually completed by the 
research team and then the data transcribed onto to the Excel database by two clinicians to 
ensure the greatest accuracy.  The Excel database was password protected and stored on an 
NHS server with regular back-up procedures.  A log was kept to record data entry and any 
changes made. 
 
To update the trial data management facilities and more efficiently and effectively meet all 
the requirements of GCP a Clinical Trial Data Management System was developed.  A 
number of different data management solutions are currently available.   We elected to work 
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with Imperial College and use the Phase Forward InForm Integrated Trial Management 
System (ITMS).  I was an integral part of the team working with the Imperial Clinical Trials 
Management Facility that developed the InForm ITMS for the Morphine versus Oxycodone 
RCT.  The development of the InForm system was performed in keeping with the five 
domains required by GCP: creation and modification of systems, creation modification and 
transfer of data, copying, control and storage 85.  
 
Any system used to generate, capture, transfer, manipulate or store data should accurately 
represent the protocol, indeed the InForm ITMS was specifically designed from the 
requirements of the protocol. Optional free text fields were included so additional 
information could be recorded where appropriate.  Figure 3.2 describes the development 
process, for which detailed records were kept at all stages.  The system was vigorously tested 
internally by Imperial, before release for two rounds of User Acceptance Testing lead by 
myself on behalf of the Palliative Care Research Team.  
 
2.3.14 Validation of InForm Integrated Trial Management System 
The Inform system was rigorously tested during development.  As a further validation step 
the InForm system was compared to the previous Excel database.  Data from 60 variables 
(including discrete and continuous numerical scales, categorical and free text data) in time 
point A was downloaded from the InForm system for the first 100 patients entered using the 
report function.  Another Excel sheet was constructed with the same variables from the 
original database using cut and paste. 
 
It was immediately apparent that the InForm system allowed some variation of the format of 
patient identification numbers as there were entries for both RCT052 and RCT52.  RCT52 
was retained for further analysis, and RCT052 discarded.  This observation will be fed back 
to the Imperial Clinical Trials Management Facility.  
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Figure 3.2  InForm ITMS Development Workflow
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The two worksheets were labelled Sheet 1 and Sheet 2 for InForm and Excel data 
respectively.  The following formula in equation 3.1 was used in Sheet 3 to compare 
the two worksheets.   
 
Equation 3:1  Formula used in validation of InForm Integrated Trial Management System 
 
=IF(EXACT(Sheet1!A2,Sheet2!A2),0,Sheet1!A2&"/"&Sheet2!A2) 
 
Where the entries in Sheet 1 and Sheet 2 were identical a 0 appeared in the 
corresponding field in Sheet 3.  Where there was a difference the two entries appeared 
separated by a forwards slash. 
 
The entries for 60 variables were compared for 100 patients, therefore 6000 fields in 
total.  201 differences were detected between the two worksheets, including 162 
errors in one or other worksheet.  There were 39 fields where although the two 
worksheets differed there was no clear error, for example where two blood samples 
were taken on the same day and different samples were entered.   
 
Of the 162 differences that were classified as errors after source data verification, 97 
appeared in the Excel worksheet, compared to 65 in InForm, 1.62% compared to 
1.08% of the respective fields.  It must be noted that if the same error was made in 
both worksheets then the error will not be detected by this method.  When the blood 
results (38 continuous numerical scale variables) were compared between worksheets 
62 errors were detected in Excel and 50 in InForm. These errors could be classified 
into four groups shown in Table 3.5. 
 
Table 3.5  A Comparison InForm and Excel Errors in Data Transcription of Blood Results 
Error Excel InForm Total 
Error, within normal range 42 4 46 
Error, outside of normal range 6 1 7 
Unable to enter as field not large enough NA 4 4 
Missing data, results in CRF but not transcribed 14 41 55 
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Although there was more missing data in the InForm system, there were fewer errors 
both within and without the normal ranges.  InForm has the normal ranges built into 
the system and issues automatic edit queries when values entered fall outside the 
range, so it could be expected that there would be less errors outside the normal range 
with InForm, as was the case.   
 
When the categorical variables were compared one major error in the InForm data 
was highlighted in that the randomised opioid was incorrect.  For categorical 
variables, the options are given either as tick boxes (as for randomised opioid) or 
drop-down lists.  It could be argued that typing the name of the entry is less open to 
error that ticking a box.  However if we look at all the 7 categorical variables 
compared there were 21 errors detected in total: 15 in Excel and 6 in InForm, so on 
the whole the InForm system appears better.  Table 3.6 lists the common reasons for 
error. 
 
Table 3.6  Common Reasons for Error in Data Transcription 
Reason for error 
Typographical error 
Missing data, results in CRF but not transcribed 
Data entry field skipped therefore entered out of sequence. 
Wrong unit conversion e.g. from stone to kg 
Bloods from wrong date entered 
Bloods from wrong time point entered 
More than one answer for NRS written on paper CRF 
InForm field did not allow enough space for value when abnormally large (e.g. AP and Total Bilirubin) 
Wrong ICD-10 code for diagnosis (Subdivisions of sarcoma diagnosis) 
No identifiable reason 
 
This validation process has shown that the Inform system appears to have improved 
the data management procedures for the trial.  However it has also identified some 
areas that require refinement, for example ensuring that enough space is allowed in 
the data entry fields to allow for the abnormal blood results which could be expected 
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in the cancer population.  It has also highlighted some areas for training, for example 
with the ICD-10 coding for diagnosis. 
 
2.3.15 Statistical Analysis 
2.3.15.1 Primary Outcome Measure 
Response rates of morphine and oxycodone were compared using the chi squared test.  
Intention to treat and per protocol groups were analysed. 
 
2.3.15.2 Secondary Outcomes 
Pain 
The mean difference in mBPI scores from baseline to Time Point B (first-line clinical 
response), and Time Point C to Time Point D (second-line clinical response) were 
calculated and compared using paired t-tests (SPSS version 17.0).   
 
Toxicity 
The toxicity profiles of morphine and oxycodone were compared using: 
• Reasons for opioid switching from morphine and oxycodone. 
• Comparison of toxicity scores when considered stable on first-line and when 
switching (Mann-Whitney U test, SPSS version 17.0). 
• Adverse event reporting data for adverse events thought to be probably or 
possibly related to the drug. 
 
Opioid Dosing and Conversion 
Dose conversion ratios were calculated for a subgroup of pain controlled switchers by 
dividing the pre-switch final titration dose of first-line trial medication (Time Point C) 
by the corresponding post-switch final titration dose of the second-line trial 
medication (Time Point D).    
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Timing of Trial Periods 
Kaplan Maier curves were created and Mantel-Cox analysis performed (SPSS version 
17.0) to compare the following between populations randomised first to morphine and 
oxycodone: 
• Time to first switch. 
• Length of time on study. 
• Survival. 
 
Immunology  
Differences in immune cell populations between time points were compared using 
paired t-tests (SPSS version 17.0) 
 
Principal Component Analysis  
Principal Component Analysis was carried out to determine the underlying factors 
behind overall response to morphine and oxycodone 89.  Pain and adverse reaction 
scores from B and C were combined as in Chapter 5 (Prospective Morphine Study) to 
reflect “best response” to the drug.  Unlike the Prospective Morphine Study PCA the 
adverse reactions in this PCA are determined on a 0 -10 NRS rather than a 4-point 
Likert scale.   
 
Modelling of Opioid Response Phenotypes 
The response Components generated by PCA were used as dependant variables in 
multivariate regression analysis (SPSS version 17.0). 
 
Genetics and Gene Expression 
Please see Chapter 4 which details both the laboratory techniques and analytical 
strategy. 
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3 Methods: Laboratory 
3.1 Genetic Analysis 
3.1.1 Candidate Gene SNP Selection  
Genomic sequences for candidate genes were downloaded from CHIP Bioinformatics 
Tools (http://snpper.chip.org) and the National Centre for Biotechnology Information 
(NCBI) online databases (http://www.ncbi.nlm.nih.gov).  Validated SNPs distributed 
across the genomic region of interest were identified from information from both of 
these sources in order to construct SNP haploblocks and haplotypes. 
 
SNPs were chosen based upon potential functional significance.  The location within 
the gene was also considered, with SNPs within the promoter given the most priority 
followed by exonic, intron/exon boundaries, 3’UTR and finally intronic SNPs.  Non-
synonymous SNPs were considered more important than synonymous SNPs.  SNPs 
were also prioritised by the published minor allele frequency (MAF) from European 
Caucasians.  Taking into account the relatively small sample size in this study, only 
SNPs with a MAF > 0.1 were selected. 
 
Potential SNPs were identified in the Hapmap project (http://www.hapmap.org/) and 
in order to review LD plots and haplotype blocks data dumps were visualised on 
Haploview (http://www.broad.mit.edu/haploview).  The Haploview tagger function 
was utilised to maximise information with a minimum number of SNPs selected.  In 
cases where this process excluded non-synonymous exonic SNPs these were 
substituted for the identified SNP of lesser priority.  Where non-synonymous exonic 
SNPs in candidate genes were identified in CHIP Bioinformatics Tools or the NCBI 
database and were not covered by Hapmap these were also selected. 
 
3.1.2 DNA Extraction 
DNA was extracted from fresh blood by two-stage procedure adapted from Miller’s 
salting out technique 90.   
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3.1.3 DNA Quantification 
The concentration of DNA was measured using a Pico-Green dsDNA quantification 
kit (Molecular Probes, Oregon, USA).  Picogreen is a fluorochrome which selectively 
binds to dsDNA, which is then measured using a Lambda Fluoro 320+ fluorometer.  
From 2010 DNA yield was assessed by UV absorbance using a Nanodrop 
Spectrophotometer (Thermo Fisher Scientific).   
 
3.1.4 Single Specific Primer – Polymerase Chain Reaction 
Genotyping of SNPs within candidate genes was performed with Single Specific 
Primer-Polymerase Chain Reaction (SSP-PCR). Conditions were programmed to 
allow amplification only when there is exact matching of primer and genomic DNA to 
allow precise typing 91. 
 
Primer mixes were created to contain 1ml sterile water, 15µl cresol red (Sigma-
Aldrich Ltd, Poole, UK) and varying concentrations of primer as determined by 
primer titration.   PCR reaction mixes contained: buffer (67mM tris base pH 8.8; 
16.6mM Ammonium sulphate; 2mM Magnesium chloride; 0.01% v/v Tween 20, 
Bioline Ltd, London, UK); 200mM of each dATP, dTTP, dGTP, and dCTP (Bioline 
Ltd, London, UK); 0.32 units of Taq polymerase (Biotaq TM, Bioline Ltd, London, 
UK) and 0.01-0.1 µg DNA. Five µl of primer mix was added to 8µl PCR reaction 
mixture, and this 13µl reaction was dispensed under 10µl of mineral oil and amplified 
in a PCR machine (PTC-200 machine, MJ Research, Waltham MA, USA).  
 
Cycling parameters were set as follows: 1 min at 96ºC, followed by 5 cycles of: 96 ºC 
for 25 sec, 70 ºC for 45 sec, and 72 ºC for 45 sec, followed by 21 cycles of 96 ºC for 
25 sec, 65 ºC for 50 sec, and 72 ºC for 45 sec, followed by 4 cycles of 96 ºC for 25 
sec, 55 ºC for 60 sec, and 72 ºC for 120 sec. 
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3.1.5 Primer Design and Titration 
Specific and consensus primers were designed for each SNP.  Allele specific primers 
were designed to differ only in the 3’ region where the SNP was located.  Primers 
were designed with the following qualities when possible: length 19-21 nucleotides; 
salt adjusted melting point (Tm) 59-61oC; GC content 45-55%.  The primer 
specifications were estimated using an online “oligonucleotide properties calculator” 
(http://www.basic.northwestern.edu/biotools/oligocalc.html).  A consensus primer 
was designed to give a product size of 250-300 or 600-900 base pairs. The specificity 
for both specific and consensus primer sequences was tested using the NCBI basic 
local alignment search tool (BLAST) (http://www.ncbi.nlm.nih.gov/blast/Blast.cgi).   
In addition putative primer dimers and secondary structures were identified using Fast 
PCR v2.5.   
 
Primers were titrated to identify the optimal relative concentrations in order to 
minimize the presence of false positives and false negatives. 
 
3.1.6 Visualisation of PCR Products and Genotype Determination 
10μl of Orange G loading buffer (0.5 g/L Orange G [Sigma Ltd, Poole, UK]) was 
added to each PCR product.  PCR products were then electrophoresed for 
approximately 20 min at 200 volts/cm2 in 0.5% TBE buffer (Sigma Ltd, Poole, UK) 
on 1.5% agarose gels (Bioline Ltd, London, UK) stained with SYBR Safe 
(Invitrogen).  PCR products were visualized with a UV illuminator and photographed.  
An allele was identified by the presence of a specific allele band of the expected size 
together with a control band (Figure 4.1). 
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Figure 4.1 Example of TRPV4 SNP Genotyping. 
 
 R1A  R1G  R2A  R2G  R3A R3G R4T  R4G  R5G R5A  R6C  R6T R7T  R7G    
 
    +    -     +      -     +    +     -     +     -     +     +     -      -     + 
 
          AA                  AA                AG                GG                GA                CC                GG 
 
3.1.7 Statistical Analysis 
3.1.7.1 Genotype Data 
Genotype frequency was determined by counting the number of homozygotes for the 
major allele (XX), heterozygotes (XY) and homozygotes for the minor allele (YY). 
 
Allele frequency represents the proportion of loci that an allele occupies within the 
population.  The allelic frequency of X was calculated as: 2(XX) + XY / 2.  The allele 
carriage of X was calculated as XX+XY / XX+XY+YY.  Genotype frequencies were 
checked to see if they obeyed Hardy-Weinberg equilibrium (HWE) since frequencies 
which do not fit this model often indicate errors in genotyping 92.  An in-house 
Microsoft Excel macro (a gift from Dr P Pantelidis) was used to perform automatic 
calculation of the chi-square and significance values for HWE. 
 
3.1.7.2 Haplotype Analysis 
Pairwise LD, haplotypes and haploblocks were determined using Haploview 
(Haploview version 4.1, Broad Institute, Cambridge, USA). Haplotypes and 
haploblocks were also constructed using the statistical haplotype reconstruction 
package PHASE (PHASE Version 2.1.1, University of Chicago).  LD was presented 
as R2.  There are two commonly used values used to express LD: D’ and R2.  D’ has a 
range of 0.0 to 1.0. For D’ a value of 0.0 means independence, whereas a value of 1.0 
implies that all copies of the rare allele occur exclusively with one of the two possible 
Control band 
Allele band 
 Genotype 
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alleles at the other marker.  In comparison for R2, a value of 0.0 also means 
independence however R2=1.0 is much more stringent in that it demands identical 
frequencies for all alleles. 
 
3.1.7.3 Modelling 
PCA was used to define morphine (or oxycodone) response phenotypes (SPSS 
version 17.0, IBM Corporation, New York, USA)89.   
 
Regression analysis was performed using SPSS version 17.0 (SPSS, IBM 
Corporation, New York, USA). Univariate linear regression was used to identify 
associations with the Component scores using allele carriage (dominant model) and 
genotype (additive model) information.    
 
Genetic associations which were significant P < 0.05 or marginal P > 0.05 to P < 0.1 
were used to inform multivariate regression analysis together with clinical variables 
as opioid response is likely to be multi-factorial.  A stepwise backwards methodology 
was used 93.  Separate analyses were performed for dominant and additive models.  
Associations found using regression were further tested using ANOVA or t-tests as 
appropriate. 
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3.2 Gene Expression 
3.2.1 Isolation of Peripheral Blood Mononuclear Cells from Whole Blood  
Peripheral blood mononuclear cells (PBMC) were separated according to Sigma-
Aldrich leukocyte separation procedure No. 1119 based on a gradient density 
centrifugation method.  Briefly, a double gradient was formed by layering 3mls of 
HISTOPLAQUE -1077 onto an equal volume of HISTOPLAQUE -1119 in a 15ml 
Falcon tube. 6mls of whole blood (EDTA) was then layered onto the upper 
HISTOPLAQUE -1077.  The tube was then centrifuged at 2000rpm for 30 min at 
room temperature.  After centrifugation two distinct opaque layers could be 
visualised: granulocytes at the 1077/1119 interface and mononuclear cells at the 
plasma/1077 interface. The mononuclear and granulocyte layers were aspirated into 
separate tubes and the remaining fluid discarded.  Cells were then washed by the 
addition of 10mls cell culture medium and centrifuged for 10 mins at 1500rpm.  The 
supernatant was removed, and the wash repeated.  Following washing the cells were 
resuspended in RNA later (Qiagen, Germany) and frozen at -30°C. 
 
3.2.2 Isolation of Peripheral Blood Mononuclear Cells from Whole Blood (Royal 
Free Hospital, UCL) 
PBMCs used in the cell stimulation experiments were isolated from whole venous 
blood of healthy donors using Lymphoprep (Ficoll) and centrifugation.  The cells 
were then counted and resuspended. These procedures were performed by the team at 
the Royal Free Hospital.   
 
3.2.3 Cell culture, Reagents and Activation of PBMCs 
Healthy human donor PBMCs stored in liquid nitrogen were defrosted in a 37oC 
water bath, cultivated at 37oC and 5% CO2 in RPMI 1640 medium enriched with heat-
inactivated 10% fetal calf serum (FCS, Biowest), 1% penicillin/ streptomycin and 1% 
L-glutamine (Sigma UK). For activation experiments, cells were transferred to 24 
well tissue culture plates. 
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For polyclonal activation, staphylococcal enterotoxin B (SEB; 1mg/ml), anti-CD3 
monoclonal anti-body (OKT3; 30ng/ml), human IL-4 (R&D systems 5ng/ml), human 
IL-2 (Chiron; 600 units/ml); Ionomycin (500ng/ml) and PMA (50ng/ml) were used 
either alone or in combination. Activating agents were made up in supplemented 
RPMI 1640 as above and cells were exposed to stimulation for 24 hours.  
 
After activation, supernatants were taken to determine extra-cellular cytokine 
production by ELISA. 
 
3.2.4 Isolation of Total RNA from PBMCs 
A RNeasy Minikit was used to extract total RNA from PBMC (Qiagen, Germany).  
 
3.2.5 Reverse Transcriptase - Polymerase Chain Reaction 
To identify µ-opioid receptor mRNA within white cells by Reverse Transcriptase 
PCR (RT-PCR), two controls were used: firstly total RNA from human whole brain 
(Clontech, Takara Bio, USA) as a positive control for µ-opioid receptor mRNA 94 and 
then primers for the ubiquitously expressed GAPDH mRNA were used as an internal 
positive control for the reactions. 
 
3.2.5.1 Primer Design 
Primer pairs were designed to span adjacent exons, any product band resultant from 
DNA contamination could therefore be identified easily by size.  Primers were 
designed with a number of key qualities as detailed in Section 4.1.5.  Primer pairs 
from previous publications including a nested set of primers were also tested for 
comparison. 
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3.2.5.2 Preparation of RNA for RT-PCR 
Amplification Grade Deoxyribonuclease I (Sigma, Missouri, USA) was used to 
eliminate any contaminating DNA from the total RNA samples according to the 
manufacturer’s protocol.  Briefly, 1μl of 10x Reaction Buffer and 1μl of 
Amplification Grade DNase I was added to 8μl of RNA in an RNase-free PCR tube.  
After gentle mixing the samples were incubated at room temperature for 15 min, after 
which 1μl of Stop Solution (50mM EDTA) was added to inactivate the DNase I.  
Next the samples were denatured by heating to 70ºC for 10 min and then placed 
directly on ice.   
 
3.2.5.3 First Strand cDNA Synthesis 
A Protoscript M-MuLV First Strand cDNA Synthesis Kit (New England BioLabs Inc. 
USA) was used as per manufacturer’s instructions.  Briefly, total RNA (10pg-1µg) 
was mixed with 2μl of anchored oligo-dT primer and made up to a total volume of 8μl 
with nuclease-free water.  The RNA was then denatured at 70ºC for 5 min before 
being placed promptly on ice.  10μl of M-MuLV Reaction Mix and 2μl of M-MuLV 
Enzyme Mix were then added to each sample.  The samples were incubated at 42°C 
for 1 hour then 80°C for 5 min to inactive the enzyme.  The cDNA products were 
stored at -20°C prior to further use. 
 
3.2.5.4 PCR using HotStarTaq Master Mix 
PCR was performed using HotStarTaq Master Mix (Qiagen, Germany) according to 
the manufacturer’s protocol.  After vortexing, 25μl of HotStarTaq Master Mix was 
added to each PCR tube, followed by 2.5μl of each primer, 5μl of cDNA and the 
volume made up to 50μl with RNase-free water (15μl).  Amplification was performed 
in a PCR machine (PTC-200 machine, MJ Research, Waltham MA, USA).  Cycling 
parameters were set as: 15 min at 95ºC, followed by 40 cycles of: 94ºC for 45 sec, 
60ºC for 45 sec, and 72ºC for 1 min, followed by a final extension step of 10 min at 
72ºC. 
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3.2.5.5 Visualisation of RT-PCR Products 
10μl of Orange G loading buffer (0.5 g/L orange G [Sigma Ltd, Poole, UK]) was 
added to each PCR product.  PCR products were then electrophoresed for 
approximately 90 min, at 100 volts/cm2 in 0.5% TBE buffer (Sigma Ltd, Poole, UK) 
on 1.5% agarose gels (Bioline Ltd, London, UK) stained with SYBR Safe (Invitrogen, 
Life Technologies, California, USA).  PCR products were visualised with a UV 
illuminator and photographed.  Specific products were identified by the presence of a 
specific band of the expected size as compared to Hyperladder IV DNA markers run 
contemporaneously (Bioline, London, UK). 
 
3.2.6 Isolation of Total RNA from Whole Blood 
The PAXgene Blood RNA System was used for the collection, stabilization, storage 
and subsequent isolation and purification of total RNA from whole blood according to 
manufacturer’s protocols (PreAnalytix, Qiagen/ BD Company, Switzerland).  The 
system consists of a blood collection tube (PAXgene Blood RNATube) and nucleic 
acid purification kit (PAXgene Blood RNA Kit). 
 
Whole blood was collected into PAXgene Blood RNA Tubes and incubated at room 
temperature for at least two hours to ensure complete lysis of blood cells prior to 
freezing at -20ºC.  PAXgenes tubes were subsequently stored at -80ºC and defrosted 
overnight prior to total RNA extraction. 
 
To extract the total RNA the Manual Purification of Total RNA PAXgene from 
Human Whole Blood Collected in PAXgene Blood RNA Tubes was followed. The 
procedure is summarised briefly here.   
 
PAXgene tubes were centrifuged for 10 min at 3000-5000 x g.  The resultant 
supernatant was removed by decanting, and 4ml of RNase-free water added to the 
pellet.  The tube was then resealed with a fresh BD Hemogard closure and vortexed 
until the pellet was visibly dissolved.  The PAXgene tubes were then centrifuged for 
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10 min at 3000-5000 x g and the supernatant again removed by decanting. 350μl of 
resuspension buffer was then added to the pellet, and the tube vortexed until the pellet 
was completely re-suspended. 
 
The sample was then pipetted into a 1.5ml microcentrifuge tube and 300μl of binding 
buffer and 40μl of proteinase K added, followed by vortexing for five sec.  The 
sample was then incubated for 10 min at 55ºC using a shaker-incubator at 400-
1400rpm. 
 
The lysate was pipetted directly into a PAXgene Shredder spin column which was 
then placed into a 2ml processing tube, and centrifuged at maximum speed for three 
min.  Without disturbing the pellet, the supernatant of the flow through fraction was 
carefully transferred into a fresh microcentrifuge tube.  350μl of ethanol was added to 
the supernatant which was mixed by vortexing, before brief centrifugation to collect 
any drops from inside the lid at the bottom of the tube. 
 
700μl of the sample was pipetted into a PAXgene spin column placed into a 2ml 
processing tube, and centrifuged at 8000-20,000 x g for one min.  The spin column 
was then placed in a new 2ml processing tube, and the old processing tube containing 
the flow-through discarded.  The remainder of the sample was then added to the same 
spin column and centrifuged at 8000-20,000 x g for one min.  The spin column was 
then placed in a new 2ml processing tube, and again the old processing tube 
containing the flow-through discarded.  The spin column was then washed with 350μl 
of wash buffer 1, centrifuged and the flow-through discarded as above. 
 
10μl of DNase I stock solution was added to 70μl of DNA digestion buffer in a 1.5ml 
microcentrifuge tube and mixed by gentle flicking.  80μl of DNase I incubation mix 
was pipetted directly onto the spin column membrane and incubated at room 
temperature for 15 min. 
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The spin column was then washed twice, first with 350μl of wash buffer 1, then with 
500μl of wash buffer 2.  For each wash the spin column was centrifuged at 8000-
20,000 x g for one min then placed in a new 2ml processing tube, and the old 
processing tube containing the flow-through was discarded. 
 
A final wash was then completed with 500𝜇𝑙 of wash buffer 2, which was centrifuged 
at 8000-20,000 x g for three min.  The spin column was then placed in a new 2ml 
processing tube, and centrifuged again at 8000-20,000 x g for one min. 
 
To elute the total RNA the spin column was then placed in a new 1.5ml 
microcentrifuge tube and 40μl of elution buffer placed directly onto the spin column 
membrane and centrifuged for one min at 8000-20,000 x g.  The process was repeated 
with another 40μl of elution buffer. 
 
The elutate was then incubated at 65ºC for five min before chilling immediately on 
ice.  Total RNA was stored at -20ºC. 
 
3.2.6.1 Total RNA Quantification 
Total RNA yield was assessed by UV absorbance using a Nanodrop 
Spectrophotometer (Thermo Fisher Scientific). 
 
3.2.6.2 Total RNA Quality Assessment 
The total RNA size distribution was assessed using an Agilent 2100 Bioanalyser, a 
RNA 6000 Nanokit, and mRNA Nano Series II assay (all Agilent Technologies, 
California, USA). 
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3.2.7 Gene Expression Profiling with the Ambion WT Expression Kit 
3.2.7.1 RNA Sample Preparation 
RNA samples were prepared using the Ambion WT Expression Kit (Ambion, Texas, 
USA).  A control RNA sample derived from HeLa cells included in the kit was used 
to verify that the reagents were working as expected.  A set of poly-A RNA controls 
(Affymetrix, California, USA) was added to each sample to provide exogenous 
positive controls to monitor the target labelling process.  To minimise sample-to-
sample variation a detailed procedural plan was followed including the 
standardisation of the amount of input RNA used and workflow stopping points 
(Figure 4.2). 
 
3.2.7.2 Synthesis of First-strand cDNA 
The primers contained a T7 promoter sequence which primed the total RNA for 
reverse-transcription producing cDNA containing a T7 promoter sequence. 
 
The First-Strand Master Mix was prepared using 4μl of First-Strand Buffer Mix and 
1μl First Strand Enzyme Mix for each sample.  In PCR tubes, 5μl of First Strand 
Master Mix, 2μl of Poly-A Spike Control and 400ng of total RNA was made to 3μl 
with RNase free water.  The samples were incubated for 1 hour at 25ºC, 1 hour at 
42ºC and then for at least 2 min at 4ºC in a thermal cycler with a heated lid.  After the 
incubation, the tubes were centrifuged briefly to collect the first-strand cDNA at the 
bottom of the tube, and placed immediately on ice. 
 
3.2.7.3 Synthesis of Second-strand cDNA 
The Second-Strand Master Mix was prepared on ice.  For each reaction: 32.5μl of 
RNase free water, 12.5μl Second-Strand Buffer Mix and 5μl Second-Strand Enzyme 
Mix was added.   50μl of Second-Strand Master Mix was added to each first-strand 
synthesis cDNA sample and mixed by gentle vortexing.  The samples were then 
incubated for 1 hour at 16 ºC, 10 min at 65 ºC and 4 ºC for at least 2 min.  
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Figure 4.2  Workflow 
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3.2.7.4 Synthesis of cRNA by In Vitro Transcription 
Antisense cRNA was synthesized and amplified by in vitro transcription (IVT) of the 
second-strand cDNA template using T7 RNA polymerase.  The IVT Master Mix was 
prepared at room temperature by adding 24μl IVT Buffer Mix and 6μl IVT Enzyme 
Mix for each sample.  30μl of IVT Master Mix was added to each Second-Strand 
cDNA sample and mixed with gentle vortexing.  The samples were then incubated for 
16 hours at 40ºC with a heated lid.  After incubation the samples were centrifuged 
briefly to collect the reaction at the bottom of the tube. 
 
3.2.7.5 Purification of cRNA 
To help stabilise the cRNA, salts, inorganic phosphates, enzymes and excess 
nucleotides were removed in the process of purification.  A cRNA Binding Mix 
including 10μl of Nucleic Acid Binding Beads and 50μl of Nucleic Acid Binding 
Buffer Concentrate per sample was prepared.  60μl of cRNA Binding Mix was added 
to each sample, and mixed by pipetting up and down three times before transfer to a 
well of a U-Bottom plate.  60μl of 100% isopropanol was then added to each sample 
and mixed by pipetting up and down three times.  The plate was then shaken gently 
for 2 min on a plate shaker to mix thoroughly and allow the cRNA to bind to the 
Nucleic Acid Binding Beads.  The plate was then transferred to a magnetic stand for 5 
min to capture the Nucleic Acid Binding Beads.  The beads form pellets against the 
magnets.  The supernatant was carefully aspirated from around the bead and 
discarded. 
 
The Nucleic Acid Binding Beads were then washed twice with Nucleic Acid Wash 
Solution, each wash using 100μl of wash per sample and shaking at moderate speed 
for 1 min before transferring to the magnetic stand and discard of the supernatant.  
After the second wash the plate was again shaken, this time at maximum speed to 
evaporate any residual ethanol from the beads. 
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40μl of preheated Elution solution (55-55ºC) was then added to each sample to elute 
the purified cRNA from the Nucleic Acid Binding Beads.   The sample plate was left 
to incubate at room temperature for 2 min before being vigorously shaken for 3 min, 
or until the beads were fully dispersed.  The plate was then moved to the magnetic 
stand to capture the Nucleic Acid Binding Beads.  The supernatant containing the 
cRNA was then collected and transferred into a nuclease free multi-well plate and 
then placed on ice. 
 
3.2.7.6 Assessment of cRNA Yield and Size Distribution 
The cRNA yield and size distribution was assessed using the same methods employed 
for total RNA (Section 4.2.5.7 and 4.2.5.8). 
 
3.2.7.7 Synthesis of 2nd-cycle cDNA 
Sense-strand cDNA was synthesised by reverse transcription of cRNA using random 
primers.  Ten μl of cRNA in a total volume of 22μl (455ng/μl) was required for 
cDNA synthesis.  As some of the cRNA samples were too dilute to achieve this 
concentration, all the cRNA samples were concentrated by vacuum centrifugation. 
 
On ice, 22μl (10µg) of cRNA was combined with 2μl of the random primers. The 
tubes were mixed thoroughly by gentle vortexing and centrifuged briefly to collect the 
reaction at the bottom of the tube.  The samples were then denatured by incubation 
(with a heated lid) for 5 min at 70ºC, 5 min at 25 ºC and then 2 min at 4 ºC. 
 
The 2nd-cycle Master Mix was prepared on ice in a nuclease-free tube.  For each 
sample: 8μl of 2nd-cycle Buffer Mix and 8μl of 2nd-cycle Enzyme Mix were added.  
The Master Mix was mixed thoroughly by gentle vortexing and centrifuged briefly to 
collect the liquid at the bottom of the tube.  16μl of 2nd-cycle Master Mix was then 
added to each cRNA/random primer sample, mixed by gentle vortexing and the 
centrifuged briefly to collect at the bottom of the tube.  The reactions were incubated 
in a thermal cycler, covered with a heated lid for 10 min at 25ºC, 90 min at 42ºC, 10 
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min at 70ºC and then for at least 2 min at 4ºC.  After incubation the tubes were 
centrifuged briefly and samples placed on ice. 
 
3.2.7.8 Hydrolysis using RNase H 
The cRNA was then degraded using RNase H to leave single-stranded cDNA. For 
this, 2μl of RNase H was added to the 2nd-cycle cDNA and mixed by pipetting up and 
down three times.  The reactions were then again mixed by gentle vortexing and 
centrifuged briefly before transferring to the thermal cycler.  The samples were then 
incubated (with a heated lid) for 45 min at 37ºC, 5 min at 95ºC and then for at least 2 
min at 4ºC.  After incubation the samples were centrifuged briefly and put on ice. 
 
3.2.7.9 Purification of 2nd-cycle cDNA 
18μl of nuclease-free water was added to each sample to give a volume of 60μl.  A 
cDNA Binding Mix including 10μl of Nucleic Acid Binding Beads and 50μl of 
Nucleic Acid Binding Buffer Concentrate per sample was prepared.  60μl cDNA 
Binding Mix was added to each sample, and mixed by pipetting up and down three 
times before being transferred to a well of a U-Bottom plate.  120μl of 100% ethanol 
was then added to each sample and mixed by pipetting up and down three times.  The 
plate was then shaken gently for 2 min on a plate shaker to mix thoroughly and allow 
the cDNA to bind to the Nucleic Acid Binding Beads.  The plate was then transferred 
to a magnetic stand for 5 min to capture the Nucleic Acid Binding Beads.  The beads 
formed pellets against the magnets, allowing the transparent supernatant to be 
carefully aspirated and discarded. 
 
The Nucleic Acid Binding Beads were then washed twice with Nucleic Acid Wash 
Solution, each wash using 100μl of wash per sample, the plate being shaken at 
moderate speed for 1 min then transferred to the magnetic stand for 5 min and 
supernatant discarded.  After the second wash the plate was again shaken, this time at 
maximum speed to evaporate any residual ethanol from the beads. 
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30μl of preheated Elution solution (55-55ºC) was then added to each sample to elute 
the purified cDNA from the Nucleic Acid Binding Beads.   The samples were left to 
incubate for 2 min without shaking before the plate was vigorously shaken for 3 min 
and the beads fully dispersed.  The plate was then moved to the magnetic stand to 
capture the Nucleic Acid Binding Beads.  The supernatant was then collected and 
transferred to a nuclease free multiwell plate.  cDNA yield was determined by UV 
absorbance with a Nanodrop Spectrophotometer (Thermo Fisher Scientific) and 
samples were frozen at -20 ºC until required. 
 
3.2.8 Terminal Labelling and Hybridization  
3.2.8.1 Fragmentation of Single-Stranded DNA  
The GeneChip WT Terminal Labelling Kit (Affymetrix, California, USA) was used 
as per protocol.  The fragmentation reaction was set up in 0.2ml strip tubes.  For each 
sample, 5.5µg of single-stranded DNA was diluted in RNase-free water up to a 
volume of 31.2μl.  
 
A fragmentation master mix was prepared including: 10μl RNase-free water, 4.8μl of 
10X cDNA Fragmentation Buffer, UDG, 1.0μl of 10 U/μl, and 1.0μl of APE 1, 
1,000U/μl for each sample. 16.8μl of the fragmentation master mix was added to the 
samples to make a total volume of 48μl.  The tubes were gently vortexed and then 
centrifuged.  Reactions were incubated at: 37°C for 60 min, 93°C for 2 min and 4°C 
for a minimum of 2 min.  Following incubation the tubes were flick-mixed and spun 
down. 45μl of the sample was transferred to a new 0.2ml strip tube for labelling. 
 
A labelling master mix was prepared using the 12μl 5X TdT Buffer, 2μl TdT and 1μl 
DNA Labelling reagent (5mM).  15μl of the labelling master mix was aliquoted into 
each 45μl sample of fragmented single-stranded DNA.  Tubes were then flick-mixed 
and spun down.  The reactions were then incubated at: 37°C for 60 min, 70°C for 10 
min and 4°C for a minimum of 2 min.  
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3.2.9 Target Hybridization for Gene 1.1 ST Array Plates Processed on the 
GeneTitan Instrument  
3.2.9.1 Preparation of the Hybridization Cocktail Master Mix  
The GeneChip Hybridization Control Kit (Affymetrix, California, USA) was thawed 
at room temperature, vortexed and centrifuged briefly (~5 sec) to collect liquid at the 
bottom of the tube and then kept on ice.  
 
The hybridization mix was made in three steps.  Firstly the WT Hybridization Mix 
was prepared in the order specified by the Affymetrix protocol and mixed well. The 
5X WT Hyb Add 1 solution was very viscous, so slow pipetting was used to ensure 
the addition of the correct volume.  Secondly 39.2μl of the master mix was aliquoted 
into 1.5ml tubes and 32.8μl of the fragmented and labelled single-stranded DNA 
target added to make a volume of 72μl.  Finally 48μl of 2.5X WT Hyb Add 6 was 
added to each tube resulting in a final total volume of 120μl.  The tubes were vortexed 
and then centrifuged briefly to collect the liquid at the bottom of the tubes. 
 
The hybridization cocktails with target were denatured with target at 99ºC for 5 min, 
followed by incubation at 45ºC for 5 min.  After denaturing the samples were spun in 
a centrifuge (1 min at 5,000 RPM at room temperature) to remove any insoluble 
material from the hybridization mixture. 90μl of the supernatant was then placed into 
the appropriate well of the hybridization tray as specified by the Affymetrix protocol.  
 
3.2.9.2 Hybridization Setup  
The GeneTitan was set up according to manufacturer’s instructions.  The volumes of 
buffer and rinse were checked to ensure the minimum amount required to process one 
array plate: rinse > 450ml, wash A > 1040ml, and wash B > 450ml. 
 
First to provide static neutralization, the Zerostat 3 anti-static gun was used on the 
wells of three stain trays and four stain tray covers (Affymetrix, California, USA).  
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The gun was held within 12" (30.5 cm) of the tray at several points, and trigger 
squeezed slowly for about two sec.  
 
105μl of stains 1, 2 and 3 were aliquoted into 24 wells of stain trays 1, 2 and 3 
respectively then static neutralized stain trays placed on top of each. 150μl of the 
Array Holding Buffer was then aliquoted into the scan tray which was also then 
covered.  The trays were then loaded into the GeneTitan.  
 
3.2.10 Data analysis 
Data was analysed with Partek Genomics Suite (Partek, Missouri, USA).  After data 
normalisation principal Components analysis was used to visualise variation patterns 
in overall expression profiles. 
 
In this exploratory analysis samples were grouped according to Time Point, diagnosis, 
WCC, CD4:8 Ratio, concomitant medication (antibiotics and steroids) and recent 
chemotherapy (2 weeks).   
 
Samples were compared between groups at Time Point A.  Samples from the same 
individual at different time points were also compared. 
 
Fold change comparison across each group together with Student’s t-test was 
performed for each sequence to detect differentially expressed genes. 
 
To correct for multiple comparisons a p-value of 0.05 (false discovery rate) and 
minimum absolute fold change ≥ ± 2 was used. 
 
Dr Maxim Freydin (Molecular Genetics and Genomics Section, NHLI, Imperial 
College, London) kindly performed unsupervised hierarchical clustering analysis in a 
set of the most variable genes followed by gene expression network analysis using 
Weighted Gene Co-expressing Network Analysis package in the R statistical 
environment. Gene ontology was used to discern patterns in molecular function or 
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biological processes within these modules.  Molecular function describes activities 
such as binding or catalytic activities that occur at the molecular level. A biological 
process is a series (i.e. more than one) of events accomplished by one or more ordered 
molecular functions (http://www.geneontology.org
  
).  
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4 Results: Prospective Morphine Study, Clinical and Genetic 
Findings 
4.1 Introduction 
It is well recognised that there is wide variation between patients in their clinical 
response to morphine in the treatment of cancer-related pain 95.   A good response is 
defined by effective pain relief, achieved with acceptable or no adverse reactions.  
Conversely non-response is defined by inadequate pain relief despite appropriate dose 
titration, intolerable adverse reactions or a combination of the two.   
 
A variety of physiological, environmental and psychosocial factors may influence an 
individual’s response to a drug including: age, liver and renal function, co-
morbidities, diet, concomitant medication, psychological factors and genetic makeup. 
The genetic component to morphine response has so far been studied using the 
candidate gene approach 61, 69, 70, 96, 97 and more recently a small Genome Wide 
Association study 59, 60. Candidate genes have included those that may influence the 
pharmacokinetic and pharmacodynamic profiles of morphine (and other opioids) and 
genes that may define individual pain susceptibility.  
 
The goal of personalised medicine is to be able to predict which drug and at which 
dose an individual will best respond to gain maximal benefit.  As yet there are no 
known clinical factors that can predict an individual’s overall response to morphine 
and the study of genetics although promising has not provided the answers. 
There is no accepted standard on how to define morphine response phenotypes.  
Different groups have examined different elements of morphine response for 
example: analgesia 98, 24 hour dosing requirements 61 and particular adverse reactions 
42.  Analgesia has been assessed by change of pain intensity measured on a NRS after 
treatment 98, percentage of patients reporting severe pain (NRS ≥ 7) 69, 70 and adequate 
pain control defined as average pain ≤ 4 61. Our group has published genetic 
associations with severity of adverse reactions, specifically drowsiness and confusion 
42.  The inconsistency of phenotype studied has contributed to the lack of replication 
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of genetic findings.  The traditional morphine response phenotypes studied so far, 
often categorical in nature have largely been determined by clinical observation and 
reasoning.  A more mathematical approach to revealing the underlying elements 
behind morphine response is PCA.  In PCA any clinical preconceptions about 
morphine response for example the labels “responder” or “non-responder” are 
abandoned.   Instead a series of possibly correlated variables, in this case the pain and 
adverse reaction scores, are transformed into a much smaller number of principal 
Components that best describe the variation within the data set. 
 
This Chapter describes how PCA may be used to define major morphine response 
phenotypes.   Predictive models of each of these phenotypes or Components were 
built using clinical variables alone then incorporating genetic information from the 
new candidate genes that I have studied. 
 
This Chapter aims to: 
• Use PCA to define the major morphine response phenotypes from the 
Prospective Morphine Study 
• Build predictive models of morphine response Components from clinical 
variables 
• Present genetic data for Caucasian subgroup for six new candidate genes: 
CCKBR, TRPV4, TNF, IL6, IL8 and IL10 
• Build predictive models of morphine response Component from clinical and 
new genetic variables.
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4.2 Clinical Overview of Prospective Morphine Study 
Two hundred and ninety eight patients were recruited to the study from 2003 – 2007.   
Recruitment was completed before I joined the research team and the clinical results have 
been described in detail in previous theses 15, 39, 99.  Table 5.1 describes the demographic data 
for the 298 patients.   There was no difference in age, gender, ethnicity or cancer diagnosis 
between morphine responders and non-responders.  Morphine responders were those who 
subjectively achieved analgesia with acceptable or no adverse reactions.  Non-responders 
were those with inadequate pain relief despite adequate dose titration, intolerable adverse 
reactions or a combination of the two.  The majority of patients were Caucasian (88.6%).  
Table 5.2 details the common concomitant medications and Table 5.3 details the blood 
results. 
 
Table 5.1 Prospective Morphine Study: Patient Characteristics  
  Total Morphine 
responders 
Morphine non-
responders 
n=298 n=205 (68.8%) n=93 (31.2%) 
Age (years) mean ±SD 57.8±13.1 56.8±13.4 60.2±12.1 
  range 19-89 19-85 35-89 
        Gender n (%) Male 142 (47.7) 96 (46.8) 46 (49.5) 
 Female 156 (52.3) 109 (53.2) 47 (50.5) 
   )     Ethnicity n (%) Caucasian 264 (88.6) 183 (89.3) 81 (87.1) 
 Other 34 (11.4) 22 (10.7) 12 (12.9) 
        Diagnosis n (%) Breast 59 (19.6) 42 (20.2) 17 (18.3) 
 Urogenital 41 (13.6) 26 (12.5) 15 (16.1) 
 Lung 38 (12.6) 23 (11.1) 15 (16.1) 
 Sarcoma 35 (11.6) 29 (13.9) 6 (6.5) 
 Gynaecological 28 (9.3) 22 (10.6) 6 (6.5) 
 Upper GI 24 (8) 16 (7.7) 8 (8.6) 
 Head and Neck 22 (7.3) 15 (7.2) 7 (7.5) 
 Lower GI 19 (6.3) 11 (5.3) 8 (8.6) 
 Haematological 15 (5) 13 (6.3) 2 (2.2) 
  Other 20 (6.6) 11 (5.3) 9 (9.6) 
Survival (days)* Median (range) 106.5 (3 –3024) 112 (3-3024) 95 (3-2408) 
Time on morphine 
(days)** Median (range) 79.5 (1-4393) 103 (1-4393) 30 (1-1350) 
*Survival is time from study entry until death (days). As from time of writing 18 participants were still alive 
and 13 lost to long-term follow-up. 
**Time on morphine is date started to opioid until date of entry to study. 
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Table 5.2 Prospective Morphine Study: Table of Common Concomitant Medications  
  Total (n=298) 
Morphine  responders 
(n=205) 
Morphine non-responders 
(n=205) 
Drug name/classification n % n % n % 
Laxative 202 67.8 134 65.4 68 73.1 
Proton Pump Inhibitor 193 64.8 140 68.3 53 57.0 
Antiemetic 135 45.3 95 46.3 40 43.0 
Paracetamol 122 40.9 75 36.6 47 50.5 
Steroid 114 38.3 85 41.5 29 31.2 
NSAID 107 35.9 71 34.6 36 38.7 
Antibiotic 81 27.2 61 29.8 20 21.5 
Anticoagulant 63 21.1 44 21.5 19 20.4 
Anticonvulsant 61 20.5 39 19.0 22 23.7 
Benzodiazepine 53 17.8 38 18.5 15 16.1 
Tricyclic antidepressant 47 15.8 34 16.6 13 14.0 
SSRI or SNRI antidepressant 37 12.4 25 12.2 12 12.9 
H2 Antagonist 31 10.4 13 6.3 6 6.5 
Hormone therapy 31 10.4 13 6.3 9 9.7 
Diuretic 30 10.1 18 8.8 12 12.9 
Aspirin 26 8.7 16 7.8 10 10.8 
Bronchodilator 26 8.7 20 9.8 6 6.5 
β Blocker 21 7.0 7 3.4 14 15.1 
Antidiabetic 18 6.0 7 3.4 11 11.8 
ACE Inhibitor 13 4.4 6 2.9 7 7.5 
Statin 13 4.4 5 2.4 8 8.6 
Chemotherapy in last 4 weeks 146 48.8 104 50.7 42 45.2 
Number of additional drugs* 6 (1 – 17) 6 (1 – 16) 6 (1 - 17) 
*Number of additional drugs is given as median (range) 
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Table 5.3 Prospective Morphine Study: Haematological and Biochemical Parameters. 
  Total (n=298) 
Morphine responders 
(n=205) 
Morphine non-responders 
(n=93) 
Haemoglobin (g/dL) 11.2 (7.5, 17.1) 11.2 (8.1, 16.7) 11.1 (7.5, 17.1) 
WBC (x109/L) 8.6 (0.1, 68.1) 8.5 (0.1, 37.6) 8.9 (0.8, 68.1) 
Platelets (x109/L) 304 (4, 942) 294 (4, 795) 339 (70, 942) 
Sodium (mmol/L) 136 (120, 143) 136 (123, 143) 136 (120, 143) 
Urea (mmol/L) 4.6 (0.5, 20.7) 4.6 (0.5, 20.7) 4.5 (1.3, 13) 
Creatinine (µmol/L) 72 (34, 170) 72 (34, 170) 75 (43, 152) 
Albumin (g/L) 29 (11, 48) 29 (11, 43) 30 (14, 48) 
Corrected calcium (mmol/L) 2.23 (1.52, 3.36) 2.22 (1.52, 2.94) 2.24 (1.81, 3.36) 
Data are presented as median (range)  
 
Two hundred and five (69%) patients had a good response to morphine compared to 93 
(31%) who did not respond well because of either uncontrolled pain and/or adverse reactions 
and were switched to the second-line opioid, oxycodone (Figure 5.1).  Table 5.4 lists the 
reasons for switching opioids.  There was a wide range of known opioid related adverse 
reactions reported, frequently more than one at the same time. 
 
Figure 5.1 Prospective Morphine Study: Reason for Opioid Switch in Morphine Non-responders (n=93). 
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Table 5.4  Prospective Morphine Study: Reasons for Opioid Switching 
 
Morphine non-responders 
Reason for opioid switch n % 
Uncontrolled pain 42 46 
Adverse reactions 
  
  Nausea 26 28 
  Vomiting 8 9 
  Constipation 9 10 
  Drowsiness 59 63 
  Confusion/hallucinations 35 38 
  Nightmares 14 15 
  Pruritus 10 11 
  Myoclonus 13 14 
  Other adverse reaction 8 9 
      
There was no difference in 24 hour morphine dose between morphine responders and non-
responders.  The median 24 hour morphine dose was 100mg (range 10 - 1060mg) and 90mg 
(range 15 – 1280mg) for responders and non-responders respectively. 
 
 
4.3 Principal Component Analysis 
PCA was conducted for 16 clinical response variables: five pain descriptors and 11 adverse 
reactions using SPSS version 17.0 (Table 5.5).   Percentage relief was transformed to 100 
minus percentage relief to make the direction of response in keeping with the other pain 
scores i.e. a high score would reflect more pain or less relief. 
 
The regression method was used to calculate Component scores 93.  Rotation was carried out 
using the oblique method (direct oblimin) as morphine response Components may 
conceivably be related.  All Components with eigenvalues >1 were retained. 
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Table 5.5 Prospective Morphine Study: Variables Included in the Principal Component Analysis 
Adverse reactions Pain indices 
Nausea* Worst pain* 
Vomiting* Least pain* 
Constipation Average pain* 
Diarrhoea Pain right now* 
Drowsiness* 100 – (Percentage relief)* 
Confusion*   
Bad dreams*   
Dry mouth   
Itch   
Myoclonus   
Poor concentration   
Adverse reactions were measured on a 4-point Likert scale (0-3) 
Pain indices from the Modified Brief Pain Inventory, (NRS 0-10) 
*Variables retained for final PCA 
 
From the preliminary PCA, several variables were excluded for not correlating >0.3 with any 
other variable: constipation, diarrhoea, dry mouth, itch, myoclonus and poor concentration.  
Diarrhoea, dry mouth, myoclonus and poor concentration also had individual Kaiser-Meyer-
Olkin (KMO) values less than 0.5 or borderline (0.396, 0.485 and 0.433 respectively) 
indicating inadequate sampling adequacy for analysis 89.  Five pain and five adverse reaction 
variables were retained in the final analysis. The sample size was adequate to perform PCA, 
with overall KMO value 0.795 and Bartlett’s test of sphericity <0.005 
 
The final PCA identified three Components with eigenvalues > 1 detailed in Table 5.6.  The 
pattern and structure matrices containing the factor loadings are shown if Tables 5.7 and 5.8 
respectively.  The variables that cluster in the same Component suggests that Component 1 
represents analgesic response to morphine, Component 2 represents the upper GI adverse 
reactions of nausea and vomiting and Component 3 represents central adverse reactions to 
morphine.  The grouping of and separation between Components is demonstrated in Figure 
5.2.  Table 5.9 shows that the correlation between Components is low and therefore each 
Component may be analysed independently. 
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 Table 5.6  Prospective Morphine Study: PCA Total Variance Explained by the Main Components 
Component 
Initial Eigenvalues Extraction Sums of Squared Loadings 
Rotation Sums 
of Squared 
Loadings 
Total 
% of 
Variance 
Cumulative 
% Total 
% of 
Variance 
Cumulative 
% Total 
1 3.87 38.701 38.701 3.87 38.701 38.701 3.671 
2 1.785 17.848 56.549 1.785 17.848 56.549 1.804 
3 1.204 12.044 68.592 1.204 12.044 68.592 2.188 
4 0.784 7.842 76.434   
 
  
 5 0.577 5.769 82.203   
 
  
 6 0.471 4.711 86.914   
 
  
 7 0.46 4.604 91.517   
 
  
 8 0.359 3.593 95.111   
 
  
 9 0.306 3.055 98.166   
 
  
 n=298 
        
 
Figure 5.2  Prospective Morphine Study: PCA Component Plot in Rotated Space 
Three Components of morphine response generated by PCA : Component 1 analgesic response (red), 
Component 2 GI adverse reactions (yellow), Component 3 central adverse reactions (blue). 100 minus % relief  
=  @100relief  (n=298). 
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Table 5.7  Prospective Morphine Study: PCA Pattern Matrix  
  Component 
  1 2 3 
Average pain 0.889     
Pain now 0.876     
Least pain 0.848     
100 - % relief 0.785     
Worst pain 0.743     
Vomiting   0.91   
Nausea   0.894   
Confusion     0.825 
Bad dreams     0.724 
Drowsiness     0.698 
n=298 
 
 
Table 5.8  Prospective Morphine Study: PCA Structure Matrix   
  Component 
  1 2 3 
Average pain 0.905     
Pain now 0.862     
Least pain 0.824     
Worst pain 0.786     
100 - % relief 0.782     
Vomiting   0.905   
Nausea   0.903   
Confusion     0.831 
Bad dreams     0.721 
Drowsiness     0.702 
n=298 
Rotation Method: Oblimin with Kaiser Normalization. 
 
 
 
Table 5.9  Prospective Morphine Study: Component Correlation Matrix 
Component 1 2 3 
1 1 0.112 0.31 
2 0.112 1 0.242 
3 0.31 0.242 1 
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Figure 5.3  Prospective Morphine Study: Correlation between Analgesic Response and mBPI 
scores. 
a)                                                             b) 
   
c)                                                             d)                                          
   
e)  
 
 
Component scores were transformed for further analysis as they were not normally 
distributed.  Figure 5.3 demonstrates how log10 Component 1 scores are correlated 
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with the various Numerical Pain Rating scores of the mBPI: a) worst pain, b) least 
pain, c) average pain, d) pain right now and e) 100 minus percentage relief.  
 
4.3.1 Principal Component Analysis: Caucasian Subgroup 
Of the total study population 268 (88.6%) were Caucasian, and of these 228 had 
complete genotyping information.  The Caucasian subgroup was isolated for the 
genetic analysis as small but significant differences in allele frequencies in individual 
ethnic groups in a mixed population can lead to false-positive and -negative results 
100.  PCA of the subgroup of 228 produced the same three Components (Figure 5.4). 
 
Figure 5.4  Prospective Morphine Study (Caucasians): PCA Component Plot in Rotated Space 
 
The 3 Components of morphine response generated by PCA : Component 1 analgesic response (red), 
Component 2 GI adverse reactions (yellow), Component 3 central adverse reactions (blue) (n=228) 
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4.3.2 Multivariate Linear Regression Modelling 
Multivariate stepwise regression was used to model possible clinical factors involved 
in morphine response reflected by the three Component scores in the Caucasian 
subgroup to link with further genetic analysis.  A significance level of P < 0.1 in 
univariate analysis was used to select factors to be included.   Factors with a 
significance level of P < 0.05, and 95% confidence interval that did not cross zero 
were included in the final model.   
 
Clinical variables tested for inclusion into the models included: age (years), gender, 
tumour diagnosis, daily dose of morphine (mg), time on morphine (days), time to 
death (days), common concomitant medications (Table 5.2) and biochemical and 
haematological indices (Table 5.3). 
 
4.3.3 Component 1: Analgesic Response 
Clinical variables (P < 0.1) selected for inclusion into the model included: diagnosis 
of gynaecological malignancy, haemoglobin (g/dL), chemotherapy in the last 4 
weeks, number of additional medications, and four classes of concomitant medication: 
antiemetics, β-blockers, bronchodilators and diuretics 
 
Three independent predictive factors were retained in the final model which overall 
explained 8.7% of variability in analgesic response to morphine (Table 5.10).  The 
factors were: use of an antiemetic or β-blockers, and the total number of additional 
medications taken.  The use of more types of concomitant medication and β blockers 
were associated with poorer analgesic control.   Conversely the use of antiemetics was 
associated with better analgesic control. 
 
Table 5.10  Prospective Morphine Study: Clinical Factors Predictive of Analgesic Response 
  Unstandardized Coefficients 
95.0% Confidence 
Interval for B 
Standardized 
Coefficients 
P value 
  B Std. Error 
Lower 
Bound 
Upper 
Bound Beta 
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(Constant) 0.17 0.04 0.09 0.25   <0.005 
Antiemetic drugs -0.13 0.04 -0.20 -0.06 -.25 <0.005 
β-blockers 0.12 0.06 0.00 0.25 .13 0.05 
Number of concomitant 
medications 0.02 0.01 0.01 0.03 .21 <0.005 
Dependent Variable: Log10 Component 3 
R2 = 0.09, ANOVA F-ratio = 6.87 
4.3.4 Component 2: Upper Gastrointestinal Adverse Reactions 
Clinical variables (P < 0.1)  selected by simple regression for inclusion into the model 
included: diagnosis of sarcoma and upper GI malignancy, corrected calcium 
(mmol/L), chemotherapy in the last 4 weeks, number of additional medications and 
three groups of concomitant medication: antiemetics, antidiabetics, and SSRI or SNRI 
antidepressants. 
Three variables were retained in the final models: diagnosis of sarcoma and two types 
of concomitant medication: antiemetic and antidiabetic drugs (Table 5.11).  Together 
these factors accounted for 9.9% of variability in upper GI adverse reactions to 
morphine.  Use of antiemetic and antidiabetic medications were both associated with 
higher log10 Component 2 scores and therefore worse symptoms scores for nausea and 
vomiting. 
 
Table 5.11  Prospective Morphine Study: Clinical Factors Predictive of Upper Gastrointestinal 
Adverse Reactions to Morphine. 
  Unstandardized Coefficients 
95.0% Confidence 
Interval for B 
Standardized 
Coefficients 
P value 
  B Std. Error 
Lower 
Bound 
Upper 
Bound Beta 
(Constant) 0.22 0.02 0.18 0.25 
 
<0.005 
Antiemetic 0.10 0.02 0.05 0.15 .26 <0.005 
Antidiabetic 0.11 0.05 0.00 0.22 .13 0.04 
Sarcoma -0.09 0.04 -0.07 -0.02 -.15 0.02 
Dependent Variable: Log10 Component 2 
R2 = 0.12, ANOVA F-ratio = 10.20 
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4.3.5 Component 3: Central Adverse Reactions 
Clinical variables (P < 0.1) selected by simple regression for inclusion into the model 
included: diagnosis of gynaecological malignancy, time on morphine (days), time to 
death (days), white cell count (x109/L), platelet count (x109/L), serum creatinine 
(µmol/L), number of additional medications and five groups of concomitant 
medications: β blockers, antidiabetics, ACE inhibitors, statins and laxatives. 
All of the above variables were excluded from the modelling processes as the 95% 
confidence intervals crossed zero therefore no meaningful model could be generated 
from the available clinical information. 
 
4.4 Genetics 
Inter-individual response to opioids may be influenced by variation in the genes 
influencing the pharmacokinetics or pharmacodynamics of morphine or individual 
susceptibility or perception of pain.  The group has developed assays to test for SNPs 
in a number of candidate genes (Table 5.13), to which I have added a further six new 
candidate genes (Table 5.14).  
 
Several interesting associations between variant alleles of SNPs and response to 
morphine in cancer pain have been found by our group and others and these are 
discussed in detail in Chapter 8 41, 42, 61.   
 
4.5 Candidate Genes 
4.5.1 CCKBR 
Cholecystokinin (CCK) acts as both a neuropeptide and GI hormone.  The seven-
transmembrane domain G protein coupled receptors are widely distributed throughout 
the CNS and GI tract. Type B receptors (CCKBR) are found principally in the CNS.  
Stimulation of the receptor activates phopholipase C with subsequent production of IP 
and elevation of intracellular calcium concentration. 
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In the CNS the CCK system is involved in the modulation of pain and development of 
neuropathic pain by opposing the opioid system 101.  Studies have shown that 
administration of CCK attenuates morphine-induced analgesia, and conversely that 
CCKBR antagonists enhance morphine-induced analgesia 102.  Pre-treatment with 
CCKBR antisense oligonucleotides increases morphine-induced analgesia 102.  CCK2 
knock-out mice have altered pain sensitivity and do not  
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Table 5.12  Royal Marsden Palliative Medicine Research Department Pain Plate Summary 
        SNPs tested in pain plate  
Gene Description Position Length 
(aa) 
Length 
(bp) 
Total 
SNPs 
identified 
Exons Introns Promoter Exon Intron/other Total 
OPRM1 µ-opioid receptor 1 6q25.2 463 79865 375 4 3 0 2 5 7 
OPRK1 κ-opioid receptor 1 8q11.23 381 25919 168 4 3 1 2 8 11 
OPRD1 δ-opioid receptor 1 1p35.2 373 51555 257 3 2 0 2 5 7 
TRPV1 
Transient receptor 
potential cation channel 
V1 
17p13.3 840 43964 308 17 16 1 4 3 8 
ADORA1 Adenosine A1 receptor 1q32.1 327 76752 299 6 5 1 1 7 9 
ADRA2A α-2a-adrenergic receptor 10.25.2 451 3650 80 1 0 3 3 1 7 
ALOX12 Arachidonate 12-lipoxygenase 17p13.1 664 14649 141 14 13 2 3 0 5 
ARRB2 β-arrestin 17p13.2 410 11007 181 15 14 1 1 2 4 
ABCB1 P-glycoprotein 7q21.12 1281 209617 852 29 28 0 3 0 3 
COMT Catechol-O-methyl transferase 22q11.21 272 28235 493 6 5 1 3 9 13 
CSEN Kv channel interacting protein 3 2q11.1 257 88754 139 9 8 0 0 5 5 
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        SNPs tested in pain plate  
Gene Description Position Length 
(aa) 
Length 
(bp) 
Total 
SNPs 
identified 
Exons Introns Promoter Exon Intron/other Total 
BDNF Brain-derived neurotrophic  factor 11p14.1 248 4232 52 1 0 0 0 2 2 
GRIN1 N-methyl-D-aspartate receptor   1 9q34.3 902 30366 137 18 18 2 1 1 4 
GRIN2A N-methyl-D-aspartate receptor 2A 16p13.2 1465 421190 1959 14 13 1 3 6 10 
MC1R Melanocortin 1 receptor 16q24.3 318 2360 135 1 0 2 2 0 4 
GCH1 GTP cyclohydrolase 1 14q22.2 251 60817 209 6 5 1 0 3 4 
UGT2B7 
UDP 
glucuronosyltransferase 2 
family, polypeptide B7 
4q13.2 530 16513 278 6 5 0 2 0 2 
HNF1A Hepatic nuclear factor 1α 12q24.31 632 23765 327 10 9 0 5 6 11 
DCOH Dimerization Cofactor of 
HNF1α 10q22.1 105 5275 165 4 3 0 0 3 3 
STAT6 Signal transducer and activator of transcription 6 12q13.3 848 14895 250 22 21 0 0 7 7 
OCT1 Octamer-binding transcription factor 1 
1q24.1-
q24.2 744 195176 1064 17 16 0 0 4 4 
Details of primer design are available from the theses of Dr Joy Ross 39, Dr Dag Rutter 15, Dr Sophy Gretton 60 and Dr Joanne Droney 59. 
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Table 5.13  New Candidate Genes Added to Royal Marsden Palliative Medicine Research Department Pain Plate 
 SNPs tested  
Gene Description Position Length 
(aa) 
Length 
(bp) 
Total 
SNPs 
identified 
Exons Introns Promoter Exon Intron/other Total 
CCKBR Cholecystokinin B Receptor 11p13.4 448 12391 235 5 4 1 4 6 11 
TRPV4 
Transient receptor 
potential cation channel 
V4 
12q24.11 838 50319 268 15 14 2 1 3 6 
TNF Tumour Necrosis Factor α 6p21.3 234 2762 59 4 3 5 0 0 5 
IL6 Interleukin 6 7p15.3 213 4855 235 5 4 1 0 1 2 
IL8 Interleukin 8 4p13.1 100 3158 143 4 3 1 0 0 1 
IL10 Interleukin 10 1q32.1 179 4892 213 5 4 3 0 0 3 
Gene information from http://snpper.chip.org.    
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display neuropathic pain behaviours after chronic constriction injury.  They also have altered 
opioid system expression profiles and response to morphine 103, 104. 
 
CCKBR can be selectively blocked by synthetic antagonists.  A single amino acid, valine-
319, in the transmembrane domain ligand binding pocket has been shown to be critical to 
determining binding affinity and functional activity of these antagonists 105.  Recently a small 
RCT of L-365,260, a CCKBR receptor antagonist was performed in 40 patients taking 
morphine for chronic neuropathic pain.  L-365,260 failed to demonstrate any additional 
benefit to morphine in these patients with resistant pain, however it was well tolerated and 
further investigation is warranted 106, 107. 
 
CCKBR is located on chromosome 11 (11p13.4), spans 12391 base pairs and includes 5 
exons and 4 introns (http://snpper.chip.org).  There are 235 known SNPs in CCKBR, and no 
published genetic associations. 
 
4.5.2 TRPV4 
TRPV4 is a calcium permeable cation channel of the transient receptor potential vanilloid 
family.  In normal circumstances TRPV4 does not appear to have a major role in mechanical 
transduction.  In animal models of inflammatory and neuropathic pain however it appears to 
be a key mediator of nociceptor hyperexcitability and mechanical hyperalgesia 108.  In an 
animal model of paclitaxel-induced painful peripheral neuropathy, spinal administration of 
antisense deoxyoligonucleotides to TRPV4 decreased expression of the gene and abolished 
mechanical hyperalgesia and attenuated hypotonic hyperalgesia 109.  In addition paclitaxel-
induced mechanical hyperalgesia was strongly reduced in TRPV4 knock-out mice 110.  
 
The human TRPV4 gene is located on Chromosome 12 (12q24.11).  It is 50,319 base pairs in 
length composed of 15 exons and 14 introns, with 268 known SNPs (http://snpper.chip.org). 
Mutations in TRPV4 have been associated with subtypes of skeletal dysplasia and 
neuromuscular disorders such as subtypes of spinal muscular atrophy and hereditary motor 
and sensory neuropathy 111. 
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4.5.3 Cytokines 
Cytokines are a heterogeneous group of small soluble glycoproteins or polypeptides secreted 
by immune and non-immune cells.  They are vital to cell-to-cell communication in the co-
ordination of the immune system.  Cytokines exhibits both pleuripotency and redundancy and 
may promote growth, activation and differentiation of cells.  Cytokines may be broadly 
classified as pro-inflammatory (TNFα, IL-6, IL-8) or anti-inflammatory (IL-10, IL-4, TGFβ).  
The overall effects depend on the concentration, target cells and balance of mediators in the 
microenvironment.   
 
In animal models, administration of pro-inflammatory cytokines induces pain behavior and 
administration of anti-inflammatory cytokines produces analgesia 112, 113.  In humans an 
imbalance between serum pro-inflammatory and anti-inflammatory cytokines has been 
observed in several painful conditions such as painful peripheral neuropathy, fibromyalgia 
and chronic regional pain syndrome 114-116. 
 
In malignancy, cytokines may be aberrantly produced by the tumour or the immune response 
against it.  These tumour induced mediators may be one mechanism that contributes to cancer 
related anorexia, cachexia and fatigue 117.  Pro-inflammatory cytokines may also play a 
pivotal role in cancer related pain.  In animal models, spinal administration of morphine 
stimulates the release of pro-inflammatory cytokines by glial cells in the CNS.  These pro-
inflammatory cytokines inhibit acute opioid analgesia and contribute to the induction of 
opioid tolerance after repeated administration 118, 119.  In clinical cancer pain studies, SNPs in 
cytokine gene promoters (IL8, IL6 and TNF) have been associated with pain severity and 
morphine dose 69, 70.   Polymorphism in the promoter regions of cytokine (and other) genes 
may either interrupt or generate additional transcription factor sites thereby altering 
expression profiles 120.  An exaggerated level of pro-inflammatory cytokine expression could 
be hypothesised to augment or maintain pain states. 
 
4.5.3.1 Tumour Necrosis Factor α 
Tumour necrosis factor (TNFα) is the archetypal pro-inflammatory cytokine.  TNFα has been 
implicated in many cancer-related symptoms such as fatigue, cachexia and pain 117.   
The human TNF gene is located on Chromosome 6 (6p21.3).  It is 2762 base pairs in length 
composed of 4 exons and 3 introns, and has 56 known SNPs (http://snpper.chip.org).   
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Genetic polymorphism in the promoter region may influence protein expression.  Several 
functional SNPs in the TNF promoter have been described, although their actual functional 
significance remains controversial 120, 121.  The variant A allele at position -308 (rs1800629) 
has been extensively studied, and it has been associated with variety of inflammatory and 
infective disorders 122, 123.  There is some evidence of an association with higher expression 
levels of TNFα 124.   The rs1800629A allele has also recently been associated with increased 
pain severity and poorer opioid response on follow-up in one study of 140 lung cancer 
patients receiving supportive care 70.    
 
4.5.3.2 Interleukin 6 
Interleukin 6 (IL-6) is a pro-inflammatory cytokine with an important role in the 
pathophysiology of inflammatory pain 125 .  IL6 knock-out mice show reduced opioid 
responses, with diminished analgesia to restraint stress and morphine administration.  The 
development of tolerance to morphine induced analgesia is also more rapid in these mice 126.  
A functional SNP in the IL6 promoter rs1800795 (-174G/C) has been associated with 
morphine equivalent daily dose in lung cancer pain, the variant C allele linked to higher doses 
70.  The human IL6 gene is located on Chromosome 7 (7p15.3).  It is 4855 base pairs in length 
and composed of 5 exons and 4 introns. 235 SNPs have been identified 
(http://snpper.chip.org). 
 
4.5.3.3 Interleukin 8 
Interleukin 8 (IL-8) is a pro-inflammatory chemokine secreted by macrophages, endothelium 
and epithelial cells and acts as a chemo attractant to recruit neutrophils to sites of injury and 
inflammation.  A functional SNP in the IL8 promoter, rs4073 has previously been associated 
with severe pain in one study of 156 Caucasian pancreatic cancer patients 127  The human IL8 
gene is located on Chromosome 4 (4q13.).  It is 3158 base pairs in length and composed of 4 
exons and 3 introns, with 143 SNPs identified (http://snpper.chip.org).    
 
4.5.3.4 Interleukin 10 
Interleukin 10 (IL-10) is an anti-inflammatory cytokine, with anti-nociceptive properties. 
There is evidence to suggest that certain IL10 promoter SNPs are functional and are 
associated with variable patterns of expression after stimulation 128, 129.   
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The human IL10 gene is located on Chromosome 1 (1q32.1).  It is 4892 base pairs in length 
and composed of 5 exons and 4 introns. 213 SNPs in IL10 have been identified 
(http://snpper.chip.org). 
 
4.5.4 Genotyping 
Primers were designed, titrated and tested for 11 SNPs in CCKBR, one SNP in IL8 and six 
SNPs in TRPV4.  Tables 5.14, 5.15 and 5.16 detail the properties and specific and consensus 
sequences of the primers designed for the selected SNPs in each gene respectively.  For TNF, 
IL6 and IL10 primers were already available within the department and used with kind 
permission from Dr Sato and Dr Pantelidis, details for these primers may be found in 
Appendix B. Caucasian genotype and allele frequencies and allele carriage are detailed in the 
following tables: CCKBR (Table 5.17), TRPV4 (Table 5.20), TNF (Table 5.22), IL6 (Table 
5.24), IL8 (Table 5.26) IL10 (Table 5.27).  MAF are compared to published data 
(http://snpper.chip.org).   All genotype frequencies were in HWE. 
 
4.5.5 Haplotyping 
Three haploblocks were identified across CCKBR (Figure 5.5, Tables 5.18-19).  The LD plots 
suggest that much larger haploblock encompassing blocks 1 and 2 may be possible, however 
the strict criteria of extending the LD spine only when D’ > 0.8 did not support this 
(Haploview version 4.2, Broad Institute, Cambridge, USA).  One haploblock was identified 
across TRPV4, producing four haplotypes (Figure 5.6, Table 5.21).  One haploblock was 
identified in TNF, contributing to three haplotypes (Figure 5.7, Table 5.23).  Four haplotypes 
were identified in IL6 (Table 5.25).  Three IL10 SNPs were identified for testing.  Rs1800871 
and rs1800872 were in perfect LD and hereafter results will be reported for rs1800871 only.  
Four haplotypes were identified in IL10 (Table 5.28). 
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Table 5.14  CCKBR Primer Sequences and Properties 
 Gene Entrez SNP 
ID  
Region SNP Primer Sense/ 
Antisense 
Primer Sequence Vol 
(ml)2 
Tm GC (%) 
content 
Primer 
Length 
Product 
Length 
CCKBR rs906895 Promoter T/C T S GTC AGT GCT TGC CAC CAC T 5/5 60 58 19 
 
   
 C S GTC AGT GCT TGC CAC CAC C 5/5 62 63 19 
 
   
 cons AS TTG GAG ACC AGG TCT GCG T 
 
60 58 19 374 
            
 
rs1805000 Exon 1 C/T C S GCA GCA GTG TGG GCA ACC 10/10 61 67 18 
 
   
 T S AGC AGC AGT GTG GGC AAC T 10/10 60 58 19 
 
   
 cons AS GCT TTC CAG AGT GCT CCC T 
 
60 58 19 516 
            
 
rs11040819 Intron 1 C/T C S CAA CGA GCT CCA CAC TAC CTC 3/3 60 55 20 
 
   
 T S CAA CGA GCT CCA CAC TAC CTT 3/3 61 52 21 
 
   
 cons AS GCT TTC CAG AGT GCT CCC T 
 
60 58 19 367 
            
 
rs2929183 Intron 1 A/G A AS CCA TGA ATT CAA ACT TTG AGC TTT 15/15 58 33 24 
 
   
 G AS CAT GAA TTC AAA CTT TGA GCT TC 15/15 58 35 23 
 
   
 cons S CCG ACA CAA TTC CTA CTT CAC 
 
60 48 21 392 
            
 
rs2941029 Intron 1 T/C T AS GAG AGT TGG ATA TTA ACC CCC TTG T 7.5/7.5 59 39 23 
 
   
 C AS GAG AGT TGG ATA TTA ACC CCC TTG C 7.5/7.5 61 43 23 
 
   
 cons S AAT GGC AGA GAA GTA TGA GTG C 
 
60 45 22 501 
            
 
rs11040825 Intron 1 T/C T AS GAG AGG TTA TGA TTT CAG ATG CA 5/5 59 39 23 
 
   
 C AS GAG AGG TTA TGA TTT CAG ATG CG 5/5 61 43 23 
 
   
 cons S GGG ACA TCA GCT GGA TGA ATG 
 
61 52 21 428 
            
 
rs35816985 Exon 2 A/C A AS GAG GAA ATA TGC TCA TCA TCG T 5/5 58 41 22 
 
   
 C AS GAG GAA ATA TGC TCA TCA TCG G 5/5 60 45 22 
 
   
 cons S CTC GTG CCT GCA GTG GTC 
 
61 67 18 449 
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Entrez SNP 
ID  
Region Nucleotide Primer Sense/ 
Antisense 
Primer Sequence Vol 
(ml)2 
Tm GC (%) 
content 
Primer 
Length 
Product 
Length 
CCKBR rs1805002 Exon 2 G/A G S GCA CAT TCA TCT TTG GCA CCG 5/5 61 52 21 
 continued 
  
 A S GCA CAT TCA TCT TTG GCA CCA 5/5 60 48 21 
 
   
 cons AS CTC GTG CCT GCA GTG GTC 
 
61 67 18 305 
            
 
rs1805004 Exon 3 A/G A AS CAA GCT CAC CAG GTC TGG T 5/5 60 58 19 
 
   
 G AS CAA GCT CAC CAG GTC TGG C 5/5 62 63 19 
 
   
 cons S AGG CGG TTT CCT ACC TCA TG 
 
60 55 20 447 
            
 
rs12364575 Intron 3 C/G C AS GGA GTT GGC GTG GTA ATT CTG 5/5 61 52 21 
 
   
 G AS GGA GTT GGC GTG GTA ATT CTC 5/5 61 52 21 
 
   
 cons S GAC CAC TGC AGG CAC GAG 
 
61 67 18 292 
            
 
rs1042047 3’UTR A/C A AS CAG TGC TGA TTG GGA AGG GT 5/5 60 55 20 
 
   
 C AS AGT GCT GAT TGG GAA GGG G 5/5 60 58 19 
 
   
 cons S CAT GGA CTA ACC CCA ACG CA 
 
60 55 20 321 
              
  
 
Table 5.15  IL8 Primers Sequences and Properties 
Gene Entrez SNP 
ID  
Region SNP Primer Sense/ 
Antisense 
Primer Sequence Vol 
(ml)2 
Tm GC (%) 
content 
Primer 
Length 
Product 
Length 
IL8 rs4073 Promoter T/A T AS CTC CAC AAT TTG GTG AAT TAT CAA A 10/10 59 32 25 
 
    
A AS CTC CAC AAT TTG GTG AAT TAT CAA T 10/10 59 32 25 
 
    
cons S GCC CTC CTA TTC CTC AAT GC 
 
60 55 20 616 
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Table 5.16  TRPV4 Primer Sequences and Properties 
  
Entrez SNP 
ID  
Region SNP Primer Sense/ 
Antisense 
Primer Sequence Vol 
(ml)2 
Tm 
 (ºC) 
GC (%) 
content 
Primer 
Length 
(bp) 
Product 
Length 
(bp) 
TRPV4 rs10850836 Promoter G/A G S TGG GTG AAG CTG GAA GCG 4/4 58 61 18 
 
   
 A S ACT GGG TGA AGC TGG AAG CA 4/4 60 55 20 
 
   
 cons AS GGC TGA GGC AAG AGA AAC G 
 
60 19 19 413 
            
 
rs10850830 Promoter G/A G S CAA GCA TGG TGG TAG GCG 7.5/5 58 61 18 
 
   
 A S CCA AGC ATG GTG GTA GGC A 7.5/5 60 58 19 
 
   
 cons AS GAC AAT TTC CTC CGA GGC GT 
 
60 55 20 309 
            
 
rs10744892 Intron A/G A S GTG GTA GTG GCA TGT TTC TGT AA 5/5 61 43 23 
 
   
 G S GGT AGT GGC ATG TTT CTG TAG 5/5 60 48 21 
 
   
 cons AS CAC TGT GAG CAG GCA TGG T 
 
60 58 19 348 
            
 
rs3825394 Exon 4  G/T G S GGC GAG TTA ATG AAC TCC CG 5/5 60 55 20 
 
   
 T S GGG CGA GTT AAT GAA CTC CCT 5/5 61 52 21 
 
   
 cons AS CAC TGG ACA GAT GAG GAA ACA 
 
60 48 21 282 
            
 
rs10735104 Intron G/A G S GTA GAT TAT TGG TGG GAA GTG G 7.5/5 60 45 22 
 
   
 A S GGT AGA TTA TTG GTG GGA AGT GA 7.5/5 61 43 23 
 
   
 cons AS GAA CAG AAG CAT GTG TGT CCT 
 
60 48 21 300 
            
 
rs1861810 Intron T/G T S GGG CAT TTG CTC CCT GTT CT 5/5 60 55 20 
 
   
 G S GGC ATT TGC TCC CTG TTC G 5/5 60 58 19 
 
   
 cons AS TGG TGG CAG AAA TGA GAC AAC 
 
60 48 21 238 
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Table 5.17  Prospective Morphine Study: Genotype and Allele Frequencies and Allele Carriage for CCKBR SNPs. 
Gene Location Name Position Allele major/minor Genotype 
frequency 
Allele 
frequency 
Allele 
carriage 
Published MAF HWpval 
CCKBR Promoter rs906895 6236824 T/C tt 0.25 t 0.49 t 0.74 0.46 1.00 
     tc 0.50 c 0.50 c 0.75        cc 0.25                     Exon 1 rs1805000 6237843 C/T cc 1.00 c 1.00 c 1.00 no freq data                Intron 1* rs 11040819 6237976 C/T cc 0.63 c 0.78 c 0.93 0.23 0.09 
     ct 0.30 t 0.22 t 0.37        tt 0.07                     Intron 1 rs2929183 6239384 A/G aa 0.51 a 0.70 a 0.89 0.28 0.31 
 
    ag 0.39 g 0.29 g 0.48   
     gg 0.10                     Intron 1 rs2941029 6241793 T/C tt 0.25 t 0.49 t 0.74 0.47 0.70 
     tc 0.49 c 0.50 c 0.73        cc 0.26                     Intron 1 rs11040825 6243605 T/C tt 0.62 t 0.77 t 0.93 0.18 0.25 
     tc 0.32 c 0.22 c 0.38        cc 0.06                     Exon 2 rs35816985 6247553 A/C aa 1.00 a 1.00 c 1.00 0.00                Exon 2 rs1805002 6247696 G/A gg 0.88 g 0.93 g 0.99 0.02 0.89 
     ga 0.11 a 0.06 a 0.12        aa 0.00                     Exon 3 rs1805004 6248134 A/G aa 1.00 a 1.00 a 1.00 no freq data                Intron 3* rs12364575 6248235 C/G cc 0.45 c 0.68 c 0.91 0.22 0.26 
     cg 0.46 g 0.31 g 0.54        gg 0.08                     3'UTR rs1042047 6249758 A/C aa 0.36 a 0.61 a 0.86 0.35 0.35 
     ac 0.50 c 0.39 c 0.64        cc 0.14       
Published allele frequencies from HapMap CEU. *denotes intron/exon boundary. 
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Figure 5.5  Prospective Morphine Study: LD plot: CCKBR Haploblocks  
  
 
Haploview version 4.2 (Broad Institute, Cambridge, USA). 
 
 
 
Table 5.18 Prospective Morphine Study: CCKBR Haploblocks  
 Haploblock 1 Haploblock 2 Haploblock 3  
 SNP rs906895  rs11040819  rs2929183  rs2941029 rs11040825 rs1805002 rs12364575 rs1042047 
position 6236824 6237976 6239384 6241793 6243605 6247696 6248235 6249758 
1 T C A - - - - - 
2 C C A - - - - - 
3 C T G - - - - - 
4 C C G - - - - - 
5 T C G - - - - - 
6 T T A - - - - - 
1 - - - T T - - - 
2 - - - C T - - - 
3 - - - C C - - - 
4 - - - T C - - - 
1 - - - - - G C - 
2 - - - - - G G - 
3 - - - - - A C - 
4 - - - - - A G - 
Data shown for Caucasian population  (n=228) 
          
 
 
 
  
R2 
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       Table 5.19  Prospective Morphine Study: CCKBR Haploblock Frequency and Carriage  
  Haploblock 1 Haploblock 2 Haploblock 3 
SNP Haploblock 
frequency  
Haploblock 
carriage   
Haploblock 
frequency  
Haploblock 
carriage   
Haploblock 
frequency  
Haploblock 
carriage   position 
1 0.46 0.93 - - - - 
2 0.23 0.46 - - - - 
3 0.21 0.41 - - - - 
4 0.07 0.14 - - - - 
5 0.02 0.04 - - - - 
6 0.01 0.03 - - - - 
1 - - 0.48 0.96 - - 
2 - - 0.30 0.59 - - 
3 - - 0.21 0.42 - - 
4 - - 0.01 0.03 - - 
1 - - - - 0.64 0.83 
2 - - - - 0.30 0.55 
3 - - - - 0.05 0.09 
4 - - - - 0.01 0.03 
Data shown for Caucasian population (n=228) 
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Table 5.20  Prospective Morphine Study: Genotype and Allele Frequencies and Allele Carriage for TRPV4 SNPs 
Gene Location Name Position Allele major/minor Genotype 
frequency 
Allele 
frequency 
Allele 
carriage 
Published MAF HWpval 
TRPV4 Promoter rs10850836 108761770 G/A gg 0.26 g 0.49 g 0.71        ga 0.44 a 0.51 a 0.74 0.41 0.08      aa 0.29                     Promoter rs10850830 108756282 G/A gg 0.03 g 0.50 g 0.73        ga 0.45 a 0.50 a 0.72 0.44 0.11      aa 0.27                     Intron 1 rs10744892 108741887 A/G aa 0.52 a 0.71 a 0.90        ag 0.38 g 0.29 g 0.48 0.50 0.23      gg 0.10                     Exon 4 rs3825394 108725221 G/T gg 0.30 g 0.55 g 0.81        gt 0.51 t 0.45 t 0.70 0.50 0.70      tt 0.19                     Intron 12 rs10735104 108712348 C/T gg 0.26 g 0.50 g 0.74        ga 0.48 a 0.50 a 0.74 0.44 0.56      aa 0.26                     Intron 13 rs1861810 108709305 G/T gg 0.34 g 0.57 g 0.81        tg 0.47 t 0.43 t 0.66 0.42 0.51      tt 0.19                    
Published minor allele frequencies from HapMap CEU 
Data shown for Caucasian population (n=228) 
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Figure 5.6  Prospective Morphine Study: LD plot: TRPV4 haploblocks.  
   
Haploview version 4.2 (Broad Institute, Cambridge, USA) 
 
 
Table 5.21  Prospective Morphine Study: TRPV4 Haploblock Frequency and Carriage 
    Haploblock 1        
SNP rs10850836 rs10850830 rs10744892 rs3825394 rs10735104 rs1861810 
Haploblock 
frequency  
Haploblock 
carriage    108761770 108756282 108741887 108725221 108712348 108709305 
1 - - A T - - 0.44 0.69 
2 - - G G - - 0.28 0.47 
3 - - A G - - 0.27 0.49 
4 - - G T - - 0.01 0.02 
Data shown for Caucasian population (n=228) 
 
 
R2 
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 Table 5.22   Prospective Morphine Study: Genotype and Allele Frequencies and Allele Carriage for TNF SNPs 
 Gene Location Name Position Allele major/minor Genotype 
frequency 
Allele 
frequency 
Allele 
carriage 
Published MAF HWpval 
TNF Promoter rs1799964 31650287 T/C tt 0.57 t 0.77 t 0.97 0.21 0.08 
 
    tc 0.40 c 0.23 c 0.43   
 
    cc 0.03       
              Promoter rs1800630 31650455 C/A cc 0.70 c 0.84 c 0.98 0.18 0.33 
 
    ca 0.29 a 0.16 a 0.30   
 
    aa 0.02       
              Promoter rs1799724 31650461 C/T cc 0.84 c 0.92 c 1.00 0.07 0.64 
 
    ct 0.15 t 0.08 t 0.16   
 
    tt 0.00       
              Promoter rs1800629 31651010 G/A gg 0.66 g 0.80 g 0.94 0.22 0.10 
 
    ga 0.28 a 0.20 a 0.34   
 
    aa 0.06       
              Promoter rs361525 31651050 G/A gg 0.89 g 0.94 g 1.00 0.074* 0.85 
     ga 0.11 a 0.06 a 0.11    
    aa 0.00       
Published allele frequencies from HapMap CEU, *CEU GENO PANEL 
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Figure 5.7  Prospective Morphine Study: LD plot:  TNF haploblocks.  
 
  
Haploview version 4.2 (Broad Institute, Cambridge, USA). 
 
 
Table 5.23  Prospective Morphine Study: TNF Haploblock Frequency and Carriage 
  Haploblock 1           
 SNP rs1799964 rs1800630 rs1799724 rs1800629 rs361525 Haploblock 
frequency  
Haploblock 
carriage    position 31650287 31650455 31650461 31651010 31651050 
 1 T C - - - 0.77 0.97 
 2 C A - - - 0.16 0.30 
 3 C C - - - 0.07 0.15 
 Data shown for total Caucasian population (n=228) 
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Table 5.24 Prospective Morphine Study: Genotype and Allele Frequencies and Allele Carriage for IL6 SNPs 
Gene Location Name Position Allele 
major/minor 
Genotype frequency Allele frequency Allele carriage Published 
MAF 
HW   
P value 
IL6 Promoter rs1800795 22733170 C/G gg 0.33 g 0.56 g 0.80   
     cg 0.46 c 0.44 c 0.68 0.46 0.33 
     cc 0.21       
              Intron 4  rs2069845 22736674 A/G aa 0.32 a 0.55 a 0.79  0.34 
     ag 0.46 g 0.45 g 0.67 0.47  
     gg 0.22       
              
 
Table 5.25 Prospective Morphine Study:  IL6 Haplotype Frequency and Carriage 
  Haplotype     
SNP rs1800795  rs2069845 Haplotype 
frequency  
Haplotype 
carriage   position 22733170 22736674 
1 G A 0.53 0.76 
2 C G 0.42 0.66 
3 G G 0.03 0.06 
4 C A 0.02 0.04 
Data shown for total Caucasian population (n=228) 
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Table 5.26  Prospective Morphine Study: Genotype and Allele Frequencies and Allele Carriage for IL8 SNP 
Gene Location Name Position Allele 
major/minor 
Genotype frequency Allele frequency Allele carriage Published 
MAF 
HW   
P value 
IL8 Promoter rs4073 74824888 T/A tt 0.30 t 0.51 t 0.73 
  
 
    
ta 0.44 a 0.49 a 0.70 0.40 0.05 
 
    
aa 0.27 
      
Published allele frequencies from CEU GENO PANEL 
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Table 5.27  Prospective Morphine Study: Genotype and Allele Frequencies and Allele Carriage for IL10 SNPs 
Gene Location Name Position Allele major/minor Genotype 
frequency 
Allele 
frequency 
Allele 
carriage 
Published MAF HWpval 
IL10 Promoter rs1800896 205013520 G/A gg 0.28 g 0.52 g 0.78 0.48 0.67 
 
    ga 0.49 a 0.48 a 0.73   
 
    aa 0.23       
              Promoter rs1800871 205013257 C/T cc 0.59 c 0.77 c 0.97 0.17 0.81 
 
    ct 0.36 t 0.23 t 0.42   
 
    tt 0.05       
              Promoter rs1800872 205013030 C/A cc 0.59 c 0.77 c 0.97 0.21 0.81 
 
    ca 0.36 a 0.23 a 0.42   
 
    aa 0.05       
             Published allele frequencies from HapMap CEU 
 
 
 Table 5.28  Prospective Morphine Study: IL10 Haplotypes Frequency and Carriage 
  Haplotype      
SNP rs1800896 rs1800871 rs1800872 Haplotype 
frequency  
Haplotype 
carriage   position 205013520 205013257 205013030 
1 G C C 0.51 0.74 
2 A C C 0.26 0.43 
3 A T A 0.22 0.41 
4 G T A 0.01 0.02 
Data shown for Caucasian population (n=228) 
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4.5.6 Genetic Analysis  
Two hundred and twenty-eight Caucasian subjects had complete genotyping information 
across all SNPs.  This subgroup was used for all genetic association studies. 
Univariate regression analysis was used to test for potential associations between the three 
morphine response PCA Component scores (analgesic response, upper GI adverse reactions, 
and central adverse reactions) and each SNP (allele carriage and genotype).  
Multivariate stepwise regression was used to model possible clinical and genetic factors 
involved in morphine response as represented by the three PCA Component scores.  Separate 
models for allele carriage and genotype information were constructed.  A significance level 
of P < 0.1 in univariate analysis was used to select factors to be included in multivariate 
regression.   Factors with a significance level of P < 0.05 and 95% confidence interval that 
did not cross zero were included in the final model. Significant SNPs thus identified were 
then subjected to either ANOVA or t-testing. 
 
4.5.7 Component 1: Analgesic Response 
4.5.7.1 Univariate Analysis 
Tables 5.29-36 presents the regression coefficients from univariate analysis for analgesic 
response (log10 Component 1 scores) and allele carriage for the six genes tested. Where a 
SNP demonstrated an association P < 0.1, the regression coefficients for genotype are also 
presented. 
One SNP in the promoter region of IL10, rs1800896 showed an association with analgesic 
response. Carriers of the variant A allele (genotype AA or GA) had a worse analgesic 
response i.e. higher pain scores (P=0.042, R2=0.014, Table 5.35).  There was however no 
clear gene dose effect (P=0.052, R2=0.017, Table 5.36) and no association with any of the 
haplotypes. 
There were no significant association between the SNPs or haploblocks of CCKBR, TRPV4, 
TNF, IL6 or IL8 and analgesic response (Tables 5.29-34). 
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Table 5.29  Prospective Morphine Study: Log10 Component 1 and CCKBR SNPs Univariate Linear Regression Analysis. 
 
  Allele No allele Unstandardized Coefficients 
Standardized 
Coefficients 
t P value   CCKBR Allele n  % Mean SEM n  % Mean SEM B Std. Error Beta 
rs906895 c 174 76.3 0.224 0.020 54 23.7 0.281 0.030 -0.057 0.039 -.097 -1.451 NS 
 t 167 73.2 0.240 0.019 61 26.8 0.232 0.033 0.008 0.038 .015 0.222 NS 
               rs11040819 c 212 93.0 0.243 0.017 16 7.0 0.168 0.067 0.076 0.065 .078 1.167 NS 
 t 87 38.2 0.265 0.029 141 61.8 0.221 0.020 0.044 0.034 .087 1.292 NS 
               rs2929183 a 204 89.5 0.236 0.018 24 10.5 0.254 0.042 -0.018 0.054 -.022 -0.328 NS 
 g 113 49.6 0.251 0.025 115 50.4 0.224 0.023 0.027 0.033 .054 0.803 NS 
               rs2941029 t 165 72.4 0.244 0.020 63 27.6 0.222 0.033 0.023 0.037 .041 0.603 NS 
 c 171 75.0 0.222 0.020 57 25.0 0.286 0.030 -0.064 0.038 -.112 -1.671 0.096 
               rs11040825 t 214 93.9 0.246 0.017 14 6.1 0.113 0.074 0.133 0.068 .130 1.942 0.053 
 c 87 38.2 0.206 0.028 141 61.8 0.257 0.021 -0.052 0.034 -.101 -1.504 NS 
               rs1805002 g 227 99.6 0.238 0.017 1 0.4 - - 0.054 0.251 .015 0.217 NS 
 a 28 12.3 0.225 0.046 200 87.7 0.240 0.018 -0.014 0.051 -.019 -0.279 NS 
               rs12364575 c 209 91.7 0.238 0.017 19 8.3 0.239 0.059 -0.001 0.061 -.001 -0.013 NS 
 g 124 54.4 0.237 0.024 104 45.6 0.239 0.022 -0.002 0.034 -.004 -0.054 NS 
               rs1042047 a 196 86.0 0.234 0.018 32 14.0 0.261 0.042 -0.027 0.048 -.038 -0.567 NS 
 c 146 64.0 0.257 0.021 82 36.0 0.204 0.028 0.053 0.035 .102 1.519 NS 
Dependent variable: Log10 Component 1 
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Table 5.30  Prospective Morphine Study: Log10 Component 1 and CCKBR Genotype Univariate Linear Regression Analysis 
    Genotype 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t P value  CCKBR   n  % Mean SEM B Std. Error Beta 
rs906895 cc 61 26.8 0.232 0.033      
 ct 113 49.6 0.220 0.025      
 tt 54 23.7 0.281 0.030 -0.024 0.024 -.067 -1.005 NS 
           rs 11040819 cc 141 61.8 0.221 0.020      
 ct 71 31.1 0.287 0.031      
 tt 16 7.0 0.168 0.067 -0.014 0.027 -.035 -0.522 NS 
           rs2929183 aa 115 50.4 0.224 0.023      
 ag 89 39.0 0.251 0.029      
 gg 24 10.5 0.254 0.042 -0.019 0.025 -.050 -0.747 NS 
           rs2941029 tt 57 25.0 0.286 0.030      
 tc 108 47.4 0.222 0.025      
 cc 63 27.6 0.222 0.033 -0.031 0.023 -.092 -1.368 NS 
           rs11040825 tt 139 61.0 0.261 0.021      
 tc 74 32.5 0.223 0.030      
 cc 15 6.6 0.095 0.071 0.063 0.027 .155 2.335 0.020 
           rs1805002 gg 200 87.7 0.240 0.018      
 ga 27 11.8 0.227 0.047      
 aa 1 0.4 - - 0.015 0.049 .021 0.306 NS 
           rs12364575 cc 104 45.6 0.239 0.022      
 cg 105 46.1 0.237 0.027      
 gg 19 8.3 0.239 0.059 0.001 0.027 .002 0.037 NS 
           rs1042047 aa 82 36.0 0.204 0.028      
 ac 114 50.0 0.255 0.024      
 cc 32 14.0 0.261 0.042 -0.034 0.025 -.092 -1.374 NS 
 Dependent variable: Log10 Component 1  
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Table 5.31  Prospective Morphine Study: Log10 Component 1 and TRPV4 SNPs Univariate Linear Regression Analysis. 
    Allele No allele Unstandardized Coefficients 
Standardized 
Coefficients 
t P value  TRPV4 Allele n  % Mean SEM n  % Mean SEM B Std. Error Beta 
rs10850836 g 159 69.7 0.234 0.020 69 30.3 0.247 0.030 -0.013 0.036 -.023 -0.349 NS 
 a 168 73.7 0.234 0.020 60 26.3 0.248 0.032 -0.014 0.039 -.024 -0.358 NS 
                     
rs10850830 g 169 74.1 0.237 0.019 59 25.9 0.241 0.033 -0.005 0.038 -.009 -0.127 NS 
 a 163 71.5 0.228 0.020 65 28.5 0.263 0.030 -0.035 0.037 -.064 -0.957 NS 
                     
rs10744892 a 206 90.4 0.234 0.018 22 9.6 0.275 0.047 -0.041 0.056 -.050 -0.738 NS 
 g 110 48.2 0.244 0.022 118 51.8 0.232 0.025 0.012 0.034 .025 0.364 NS 
                     
rs3825394 g 184 80.7 0.237 0.018 44 19.3 0.240 0.042 -0.003 0.043 -.004 -0.064 NS 
 t 159 69.7 0.232 0.021 69 30.3 0.252 0.028 -0.020 0.036 -.038 -0.564 NS 
                     
rs10735104 g 169 74.1 0.238 0.020 59 25.9 0.239 0.028 -0.001 0.038 -.002 -0.033 NS 
 a 169 74.1 0.224 0.020 59 25.9 0.279 0.032 -0.055 0.038 -.097 -1.444 NS 
                     
rs1861810 g 185 81.1 0.230 0.019 43 18.9 0.271 0.038 -0.041 0.043 -.064 -0.960 NS 
 t 150 65.8 0.230 0.021 78 34.2 0.252 0.028 -0.022 0.035 -.042 -0.620 NS 
 Dependent variable: Log10 Component 1 
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Table 5.32  Prospective Morphine Study: Log10 Component 1 and TRPV4 SNP Univariate Linear Regression Analysis. 
  Allele No allele 
Unstandardized 
Coefficients 
Standardized 
Coefficients t P value 
TRPV4 Allele n % Mean SEM n % Mean SEM B Std. Error Beta 
rs1799964 T 220 96.5 0.235 0.017 8 3.5 0.318 0.087 -0.084 0.090 -.062 -0.930 NS 
 C 99 43.4 0.223 0.024 129 56.6 0.250 0.023 -0.027 0.034 -.054 -0.799 NS 
               rs1800630 C 224 98.2 0.235 0.017 4 1.8 0.388 0.018 -0.153 0.126 -.081 -1.215 NS 
 A 69 30.3 0.245 0.028 159 69.7 0.235 0.021 0.011 0.036 .020 0.296 NS 
               rs1799724 T 36 15.8 0.259 0.042 192 84.2 0.234 0.018 0.025 0.047 .035 0.521 NS 
 C 228 100.0 0.238 0.017 - - - - - - - - - 
               rs1800629 G 213 93.4 0.238 0.017 15 6.6 0.238 0.104 0.000 0.074 .000 -0.005 NS 
 A 76 33.3 0.252 0.032 152 66.7 0.231 0.019 0.020 0.036 .038 0.569 NS 
               rs361525 G 227 99.6 0.237 0.017 1 0.4 - - -0.291 0.250 -.078 -1.165 NS 
 A 26 11.4 0.162 0.053 202 88.6 0.248 0.018 -0.085 0.052 -.110 -1.644 NS 
 Dependent variable: Log10 Component 1.  NS Not significant 
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Table 5.33  Prospective Morphine Study: Log10 Component 1 and IL6 SNP Univariate Linear Regression Analysis. 
    Allele No allele 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t P value  IL6 Allele n  % Mean SEM n  % Mean SEM B Std. Error Beta 
rs1800795 g 181 79.4 0.239 0.018 47 20.6 0.237 0.043 0.002 0.041 .003 0.038 NS 
 c 153 67.1 0.237 0.021 75 32.9 0.242 0.028 -0.005 0.036 -.010 -0.153 NS 
               rs2069845 a 179 78.5 0.235 0.018 49 21.5 0.250 0.042 -0.016 0.040 -.026 -0.389 NS 
 g 157 68.9 0.237 0.021 71 31.1 0.242 0.029 -0.006 0.036 -.012 -0.176 NS 
 Dependent variable: Log10 Component 1. NS Not significant 
 
 
Table 5.34  Prospective Morphine Study:  Log10 Component 1 and IL8 SNP Univariate Linear Regression Analysis. 
    Allele No allele 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t P value  IL8 Allele n  % Mean SEM n  % Mean SEM B Std. Error Beta 
rs4073 t 165 72.4 0.243 0.020 63 27.6 0.226 0.031 0.017 0.038 .030 0.442 NS 
 a 162 71.1 0.232 0.019 66 28.9 0.254 0.034 -0.019 0.037 -.035 -0.522 NS 
 Dependent variable: Log10 Component 1. NS Not significant 
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Table 5.35  Prospective Morphine Study: Log10 Component 1 and IL10 SNPs Univariate Linear Regression Analysis 
    Allele No allele 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t P value  IL10 Allele n  % Mean SEM n  % Mean SEM B Std. Error Beta 
rs1800896 g 171 75.0 0.227 0.020 56 24.6 0.272 0.032 -0.044 0.039 -.076 -1.136  
 a 164 71.9 0.260 0.019 64 28.1 0.184 0.035 0.075 0.037 .136 2.041 0.042 
               rs1800871 c 216 94.7 0.236 0.017 12 5.3 0.287 0.057 -0.052 0.077 -.045 -0.672 NS 
 t 94 41.2 0.264 0.025 134 58.8 0.220 0.022 0.042 0.034 .083 1.243 NS 
               rs1800872 c 216 94.7 0.236 0.017 12 5.3 0.287 0.057 -0.052 0.077 -.045 -0.672 NS 
 a 94 41.2 0.264 0.025 134 58.8 0.220 0.022 0.042 0.034 .083 1.243 NS 
Dependent variable: Log10 Component 1. NS Not significant 
 
 
Table 5.36  Prospective Morphine Study: Log10 Component 1 and IL10 Genotype Univariate Linear Regression Analysis 
    Genotype 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t P value  IL10   n  % Mean SEM B 
Std. 
Error Beta 
rs1800896 gg 64 28.1 0.184 0.035      
 ga 108 47.4 0.253 0.023      
 aa 56 24.6 0.272 0.032 -0.045 0.023 -.130 -1.953 0.052 
           rs1800871 cc 134 58.8 0.220 0.022      
 ct 82 36.0 0.259 0.027      
 tt 12 5.3 0.287 0.057 -0.036 0.028 -.086 -1.286 NS 
 Dependent variable: Log10 Component 1.  NS Not significant 
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4.5.7.2 Multivariate Analysis 
Multivariate linear regression analysis was used to construct a model to predict analgesic 
response to morphine from clinical and genetic factors, P < 0.1 on univariate analysis.  In 
addition to IL10 rs1800896 there were two SNPs in CCKBR which met the criteria for 
inclusion, rs2941029C (P=0.096) and rs11040825T (P=0.053) shown in Table 5.29. 
The use of an antiemetic drug, and number of additional concomitant medications remained 
independent predictors of analgesic response.  No genetic associations were retained when 
allele carriage was used for the genetic part of the modelling (Table 5.37).    One SNP, 
rs11040825 in CCKBR, was however retained as an independent predictor of analgesic 
response when genotype was modelled, together with use of a β blocker, antiemetic and 
number of additional medications (Table 5.38). 
 
Table 5.37  Prospective Morphine Study: Genetic (Allele Carriage) and Clinical Factors Predictive of 
Analgesic Response to Morphine. 
  Unstandardized Coefficients 
95.0% Confidence 
Interval for B 
Standardized 
Coefficients 
P value 
  B Std. Error 
Lower 
Bound 
Upper 
Bound Beta 
(Constant) 0.16 0.04 0.08 0.24  <0.005 
Antiemetic drugs -0.12 0.03 -0.19 -0.05 -0.24 <0.005 
Number of additional drugs 0.02 0.01 0.01 0.03 0.22 <0.005 
Dependent Variable: Log10 Component 1 
R2 = 0.07, ANOVA F-ratio = 8.24 
 
Table 5.38  Prospective Morphine Study: Genetic (Genotype) and Clinical Factors Predictive of Analgesic 
Response to Morphine. 
  Unstandardized Coefficients 
95.0% Confidence 
Interval for B 
Standardized 
Coefficients 
P value 
  B Std. Error 
Lower 
Bound 
Upper 
Bound Beta 
(Constant) 0.07 0.06 -0.05 0.18  0.24 
CCKBR rs11040825 0.06 0.03 0.01 0.11 0.15 0.02 
Antiemetic drugs -0.12 0.03 -0.19 -0.05 -0.24 <0.005 
Beta blockers 0.13 0.06 0.00 0.25 0.13 0.05 
Number of additional drugs 0.02 0.01 0.01 0.03 0.21 <0.005 
Dependent Variable: Log10 Component 1 
R2 = 0.19, ANOVA F-ratio = 6.68 
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4.5.7.3 ANOVA 
There was a significant linear trend F (1,220) = 6.113, P<0.05, indicating that there was a 
gene dose effect with the number of CCKBR rs11040825 variant T alleles and increasing 
pain. 
 
4.5.8 Component 2: Upper Gastrointestinal Adverse Reactions 
4.5.8.1 Univariate Analysis 
One SNP in the IL10 promoter rs1800896 was weakly associated with nausea and vomiting. 
Carriers of the variant A allele had higher PCA Component 2 scores, therefore worse upper 
GI symptoms (R2=0.019, P=0.038).  There was no gene dose effect.  IL10 haplotype 2 which 
contains the rs1800896A allele was similarly associated with nausea and vomiting (R2=0.022, 
P=0.027). 
There were no association observed between SNPs or haploblocks of CCKBR, TRPV4, TNF, 
IL6, IL8 and the upper GI adverse reactions of nausea and vomiting. 
 
4.5.8.2 Multivariate Analysis 
Two SNPs in addition to IL10 rs1800896A were included in the log10 Component 2, upper GI 
adverse reactions multivariate regression analysis as they attained P < 0.1 on univariate 
analysis: TNF rs1799724T (P=0.084) and CCKBR rs12364575C (P =0.095). 
After controlling for other variables, three factors were retained as independent predictors of 
nausea and vomiting: use of antiemetic drugs, diagnosis of sarcoma and IL10 rs1800896A 
(Table 5.39).  Use of an antiemetic and carriage of the A allele of IL10 rs1800896 were 
associated with higher scores and therefore worst symptoms. 
There was however no significant difference between the two groups (IL10 rs1800896 
GA/AA vs IL10 rs1800896 GG) when mean log10 Component 2 scores were compared in a t-
test. 
No additional associations with genotype were found to inform a genotype model. 
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Table 5.39  Prospective Morphine Study: Genetic (Allele Carriage) and Clinical Factors Predictive of 
Upper Gastrointestinal Adverse Reactions to Morphine. 
  Unstandardized Coefficients 
95.0% Confidence 
Interval for B 
Standardized 
Coefficients 
P value 
  B Std. Error 
Lower 
Bound 
Upper 
Bound Beta 
(Constant) 0.17 0.03 0.12 0.22  <0.005 
IL10 rs1800896A 0.06 0.03 0.01 0.12 .15 0.02 
Antiemetic drugs 0.11 0.02 0.07 0.16 .30 <0.005 
Sarcoma -0.09 0.04 -0.16 -0.02 -.15 0.02 
Multivariate stepwise (backwards) regression. 
Dependent Variable: Log10 Component 2 
R2 = 0.13, ANOVA F-ratio = 10.85 
 
4.5.9 Component 3: Central Adverse Reactions 
4.5.9.1 Univariate Analysis 
On univariate analysis there were weak associations with two SNPs: TRPV4 rs1861810T and 
CCKBR rs1042047A, R2=0.048, P =0.018 and R2=0.021, P =0.03 respectively.  Both variant 
alleles were associated with higher central adverse reaction scores (log10 Component 3) and 
therefore worse symptoms.  Two TRPV4 haploblocks were also associated with central 
adverse reactions: haploblocks 1 and 4.  Both of the haploblocks contain the rs3825394 T 
allele and have the same R2=0.023, P =0.024.  TRPV4 rs1861810T and TRPV4 rs3825394T 
are not on the same haploblock.  
4.5.9.2 Multivariate Analysis 
In addition to the above, two other SNPs met criteria for inclusion into the modelling process: 
TNF rs361525A and TRPV4 rs3825394T as they attained P values less than 0.1.   
Although no meaningful model could be produced using clinical variables alone (Section 
5.5.3), the addition of genetic factors summarised by allele carriage (but not genotype) 
allowed a model to be generated (Table 5.40).  Three independent predictive factors for 
central adverse reactions were identified: the use of antidiabetic medications, TRPV4 
rs3825394T and CCKBR rs1042047A.  Together these variables accounted for approximately 
8% of variation in central adverse reactions.  Carriage of the variant allele T at TRPV4 
rs3825394 was protective of central adverse reactions, whereas carriage of the common allele 
A at CCKBR rs1042047 was associated with higher scores and therefore worse symptoms.  
The use of antidiabetic drugs and therefore diabetes indirectly was associated with more 
central adverse reactions. 
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Table 5.40  Prospective Morphine Study: Genetic (Allele Carriage) and Clinical Factors Predictive of 
Central Adverse Reactions to Morphine. 
  Unstandardized Coefficients 
95.0% Confidence 
Interval for B 
Standardized 
Coefficients 
P value 
  B Std. Error 
Lower 
Bound 
Upper 
Bound Beta 
(Constant) 0.20 0.04 -0.12 0.28   <0.005 
TRPV4 rs3825394T -0.07 0.03 -0.13 -0.01 -0.15 0.02 
CCKBR rs1042047A 0.11 0.04 0.03 0.18 0.17 0.01 
Antidiabetic drugs 0.19 0.06 0.07 0.31 0.20 <0.005 
Multivariate stepwise (backwards) regression. 
Dependent Variable: Log10 Component 3 
R2 = 0.08, ANOVA F-ratio = 6.31 
 
On average participants experienced more morphine related central side effects if they were 
carriers of the CCKBR rs1042047A allele (mean = 0.26, SE=0.16) compared to non-carriers 
(mean=0.17, SE=0.03) (t=2.18, P=0.03). There was only a trend towards significance for 
carriage of TRPV4 rs3825394T (P=0.057). 
 
4.6 Discussion 
The Prospective Morphine Study was specifically designed to collect detailed information 
about each patient including demographic, clinical, biochemical and haematological variables 
to allow in-depth analysis of individual factors contributing to overall morphine response. 
 
Pain scores were collected using the modified Brief Pain Inventory, which is a validated tool 
and is commonly used by studies in this area 61, 130, 131. The mBPI consists of five pain 
indices: worst pain, least pain, pain on average, pain right now and percentage relief.  
Average pain has been most used in other genetic association studies exploring opioid 
response 61, 131.  In a recent study to indentify variables to include in an international pain 
classification system, average pain, worst pain and pain relief were chosen on the basis of 
expert opinion 132.  Interestingly when PCA was used in validation studies of the BPI then 
pain intensity scores loaded highly onto the same Component, with two other Components 
identified, activity related interference and mood-related interference 130.  This current study 
included all five mBPI indices in combination with adverse reaction scores to mathematically 
define response phenotypes using PCA. 
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PCA provides a novel means of deconstructing morphine response by revealing simple 
underlying linear structures beneath a complex datasets.  The three Components uncovered: 
analgesic response, upper GI adverse reactions and central adverse reactions are in keeping 
with clinical observations.  The three Components were the same in the total population of 
mixed ethnicity and in the Caucasian subgroup alone.   In clinical practice any one or 
combination of these Components may be observed.  Other important and or distressing 
adverse reactions such as itch and myoclonus were found not to be key principal 
Components, perhaps because their incidence was low and scores did not contribute much 
variability in the dataset as a whole. 
 
4.6.1 Models of Morphine Response 
Models using clinical variables alone and then in combination with genetic information were 
constructed for the three morphine response Components: analgesic response, upper GI 
adverse reactions, and central adverse reactions.   
 
4.6.1.1 Component 1: Analgesic Response 
In the clinical model three factors were retained as independent predictors or analgesic 
response (log10 Component 1 scores): use of an antiemetic, β blocker and number of 
additional medications, however only 9% of variation could be explained by these factors.   
 
The use of an anti-emetic was associated with lower scores and therefore better analgesia.  
This may be because that the troubling potential adverse reaction of nausea/vomiting was 
controlled by the antiemetics thereby allowing adequate morphine dose titration.   
 
The number of additional medications and use of β blockers was associated with higher 
scores and therefore worse analgesic responses.  Cancer patients are often on a large number 
of concomitant medications, especially when they have cancer-related pain as shown in this 
study.  Many drugs increase the likelihood of opioid adverse reactions through a variety of 
mechanisms both pharmacokinetic and pharmacodynamic.  The number of concomitant 
medications may be influenced by the complexity of pain and the number of additional 
adjuvant analgesics required or the presence of adverse reactions requiring treatment which 
may also limit titration.   
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Βeta-blockers as the name suggests are antagonists of β-adrenergic receptors. It has been 
suggested that there is cross-talk and even oligodimerisation between β-adrenergic and 
classical opioid receptors 53, 133. Interactions between the adrenergic and opioid systems in the 
development of morphine dependence and tolerance have previously been shown in animal 
studies 134, 135. It is therefore plausible that drugs which block β-adrenergic receptors may 
impact on elements of morphine response.  
 
When genetic factors were added to the model the amount of variability in analgesic response 
explained increased to 19%.  A CCKBR SNP, rs11040825, was found to be an independent 
predictor of analgesic response.  The CCK system opposes the opioid system within the CNS, 
so alterations to the function of the main B type receptor could easily be hypothesized to alter 
the analgesic efficacy of morphine.  rs11040825 is an intronic SNP and therefore unlikely to 
be functional in itself, however it may be linked to an as yet unknown functional element 
elsewhere in the gene.   
 
There was no evidence to support the previously reported associations with IL8 rs4073 and 
TNF rs1800629 and pain severity in this study 69, 70.  However our study examined a cohort 
with mixed cancer diagnoses whereas previous work was restricted to lung cancer patients 
and measured pain scores from different times in their cancer journeys. 
 
4.6.1.2 Component 2: Upper Gastrointestinal Adverse Reactions 
The second Component of morphine response is difficult to interpret as there are many 
factors which influence the symptoms of nausea and vomiting in the cancer population. 
Common causes of nausea and vomiting apart from adverse reactions to morphine in this 
cohort would include: mechanical compression of the GI tract by the cancer itself, 
biochemical disturbances for example hypercalcaemia, raised intracranial pressure from brain 
metastasis, infective processes, adverse reactions from drugs other than morphine such as 
chemotherapy and antibiotics and psychological issues.  Often there may be several 
contributing factors and it is therefore hard to confidently diagnose the underlying aetiology.  
Participants were asked to rate any nausea and vomiting they experienced as a side effect 
from morphine, however this may be difficult to entangle in a patient with complex medical 
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problems and co-administration of antiemetics.  The nausea and vomiting phenotype 
therefore in a clinical study such as this are therefore softer than that which could be derived 
in a normal volunteer study.  
 
In the clinical model three factors were retained as independent predictors of morphine 
related nausea and vomiting: use of an antiemetic, use of an antidiabetic drug and diagnosis 
of sarcoma.  In a recent large European study exploring clinical factor associated with nausea 
and vomiting in cancer patients receiving opioid multivariate analysis agreed that use of 
antiemetics were associated with more nausea and vomiting 96.  This is probably because 
antiemetics tend to be prescribed only when the symptom appears and then the effectiveness 
is variable.  It is unclear why certain tumour groups would be associated with differences in 
nausea and vomiting than others, it may reflect types of anti-cancer treatment or anatomical 
position of the tumour.   
 
When genetic factors were also included in the modelling the amount of variability improved 
only very slightly from 12 to 13%.  Carriage of the variant A allele (genotype AA or GA) of 
IL10 rs1800896 replaced use of an antidiabetic drug.  IL10 rs1800896 lies at position -1082 
in the promoter region of IL10 and there is evidence to suggest that it is functional.  The 
variant A allele is associated to decreased expression of IL-10 after stimulation 128, 129.  IL-10 
is a major anti-inflammatory cytokine, therefore it could be expected that a reduction in IL-10 
would shift the balance towards a pro-inflammatory and pro-nociceptive environment.  A role 
for IL-10 however in upper GI adverse reactions is less clear. 
 
4.6.1.3 Component 3: Central Adverse Reactions 
Clinical factors alone did not allow a model of morphine related drowsiness, confusion and 
hallucinations to be generated.  The addition of genetic factors however resulted in a model 
that explained 8% of the variability observed including the use of antidiabetic drugs and two 
SNPs: TRPV4 rs3825394T and CCKBR rs1042047A.  The use of antidiabetic drugs and 
therefore indirectly diabetes was associated with more central adverse reactions. The variant 
A allele at CCKBR rs1042047 was predictive of increased central adverse reactions.  
rs1042047 is located in the 3’UTR region of CCKBR and may therefore influence mRNA 
stability, localisation and translational efficiency. The variant T allele at TRPV4 rs3825394 
appeared to be protective of central adverse reaction. The SNP rs3825394 is located in exon 
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four of the TRPV4 gene, and although the variant does not result in an amino acid change it 
may be in LD with a true marker SNP which may in turn alter function of the resultant 
protein.  It is unclear why variation in TRPV4 would be associated with less central adverse 
reactions to morphine.   
 
4.6.2 Limitations of the Prospective Morphine Study 
This study is limited by the heterogeneous patient population, which included a variety of 
cancer diagnoses, at many different stages and mixed pain types.  It was also carried out at a 
single time point so factors such as pain intensity at initiation of morphine therapy are not 
accounted for. The use of multivariate regression analysis was intended to correct for as 
many confounding factors as possible, however other factors such as personality traits and 
anxiety and depression were not measured.   
 
Pain and opioid response are complex traits, the genetic bases of which are multi-factorial. Of 
the SNPs in the six genes tested no strong genetic associations were observed with outcomes 
of morphine response, and indeed of the weak associations identified none would stand up to 
the rigors of correction for multiple testing. The genetic associations observed here are 
therefore discussed as a hypothesis generating exercise.  The use of PCA however has the 
advantage of reducing the number of analyses that would be necessary if all the pain and 
adverse reaction scores were considered separately.  Although the sample size of 228 used in 
this study is average for cancer-related pain genetic studies, it is underpowered to detect the 
subtle genetic influences that may be important in complex traits.  The genetic analysis was 
limited to Caucasian subjects only.  Further work would be needed to explore the genetic 
basis of opioid response in other ethnicities.  SNPs in the six candidate genes I added to the 
RMH Palliative Medicine Research Departmental Pain Plate have also been analysed as part 
of the Morphine versus Oxycodone RCT in Cancer-related Pain, the results of which are 
described in Chapter 7.   
 
4.7 Conclusion 
There is no consensus in how best to measure morphine response, and therefore no accepted 
phenotype on which to base pharmacogenomic studies.  Inter-individual variation is wide in 
both terms of analgesia and adverse reactions.   
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The cautious use of Component scores from PCA provides a novel method for defining and 
then examining the main aspects of morphine response.   
 
Three independent Components of morphine response were identified: analgesic response, 
upper GI and central adverse reactions.   All are clinically relevant and the groupings likely to 
reflect common mechanisms.  This is supported by the observation that different clinical 
factors and SNPs from different candidate genes were associated with variability in the 
different Components. 
 
The current genetic analysis is not corrected for multiple testing and if this was performed 
none of the associations found would remain significant.  The replication of these findings in 
much larger studies is now needed. 
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5 Results: Morphine versus Oxycodone Randomised Controlled Trial for 
Cancer-related Pain, Clinical Findings 
 
5.1 Introduction 
This thesis presents the results from the Morphine versus Oxycodone RCT for Cancer-related 
Pain in full for baseline characteristics and first-line opioid response, and preliminary results 
for the rest of the study.  The data were frozen on the 24th of August 2011 when all 200 
participants had reached the primary outcome of response/non-response to first-line opioid 
and five participants were still undergoing monthly follow-up. 
 
5.2 Baseline Characteristics 
Two hundred patients with moderate to severe cancer-related pain requiring treatment with a 
strong opioid were recruited from two sites of the same cancer centre, 116 from site A and 84 
from site B.  One hundred participants were randomised to each of the trial medications: 
morphine and oxycodone.  Tables 6.1 and 6.2 present the demographics and baseline blood 
results for the total population and by randomised opioid.   
 
Baseline pain characteristics are shown in Table 6.3, outlining type of pain and scores from 
the mBPI.  Clinical assessment showed patients had a variety of pain types including somatic, 
somatic (bony), visceral and neuropathic, with mixed pain easily identifiable in a quarter of 
participants.  Patients were allowed to be taking a weak opioid with or without a strong 
opioid on an as required basis, or a regular strong opioid for less than 24 hours to be included 
in the study.  Table 6.4 describes the use of weak and strong opioid analgesia at time of 
screening.  The most common weak opioids in use were codeine and tramadol.  Ten 
participants (five percent) had already been started on a regular strong opioid within 24 hours 
at the time of recruitment but not stabilised to effective dose, and 95 (47 percent) had been 
receiving a strong opioid on an as required basis already.  Substantially more patients had 
been exposed to morphine before entering the trial compared to oxycodone, both regularly 
and on an as required basis.   
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Table 6.1  Morphine versus Oxycodone RCT: Demographics 
 Total Morphine Oxycodone 
n=200 n=100 n=100 
Age (years) mean  ± SD 59.1 ± 12.2 59.2 ± 11.6 58.9 ± 13.2 
 range 20 – 83 26 – 83 20 – 83 
Body mass 
index (kg/m2) 
mean  ± SD 25.6  ± 5.2 25.6  ± 5.2 25.6  ± 5.1 
range 16.1 – 46.6 17.8 – 46.6 16.1- 42.9 
        
Gender n, % Male 88 44% 50 50% 38 38% 
 Female 112 56% 50 50% 62 62% 
        
        
Ethnicity n, 
% Caucasian 177 88.5% 89 89% 88 88.9% 
 Non-Caucasian 22 11% 11 11% 11 11.1% 
        
Diagnosis n, 
% Breast 32 16% 14 14% 18 18% 
 Digestive organs       
   Lower GI 27 13.5% 11 11% 16 16% 
   Upper GI 12 6% 10 10% 2 2% 
   Pancreas and hepatobiliary 14 7% 10 10% 4 4% 
 Sarcoma 19 9.5% 11 11% 8 8% 
 Lung 18 9% 5 5% 13 13% 
 Gynaecological 16 8% 7 7% 9 9% 
 Genitourinary       
   Urinary tract 15 7.5% 12 12% 3 3% 
   Prostate 10 5% 2 2% 8 8% 
 Haematological 13 6.5% 6 6% 7 7% 
 Malignant melanoma 9 4.5% 4 4% 6 6% 
 Head and neck 5 2.5% 2 2% 3 3% 
 Other 9 4.5% 6 6% 3 3% 
        
Survival 
(days)* mean  ± SD 187.36  ±  234.92 151.59 ± 191.71 228.28  ±  271.78 
n=152 median (range) 91.5 (3-1160) 85 (3-1092) 106 (3-1160) 
Days from study entry to death are presented in those participants who had died at the time of censoring n=152.  Further 
survival data can be seen in Kaplan Meier Curve, Figure 6.14. 
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Table 6.2  Morphine versus Oxycodone RCT: Baseline Blood Results  
  Total Morphine Oxycodone 
n=200 n=100 n=100 
       
Haematology Haemoglobin (g/dL) 11.5 ± 1.8 11.4 ± 1.8 11.6 ± 1.8 
 White blood cells (x109/L) 9.6 ± 7.2 9.9 ± 8.1 9.2 ± 6.2 
 Platelets (x109/L) 290 ± 144 298 ± 153 283 ± 135 
 Neutrophils (x109/L) 7.4 ± 6.7 7.9 ± 7.9 6.9 ± 5.4 
 Lymphocytes  (x109/L) 1.2 ± 0.7 1.2 ± 0.7 1.2 ± 0.7 
 Monocytes  (x109/L) 0.7 ± 0.4 0.8 ± 0.5 0.7 ± 0.4 
 Eosinophils  (x109/L) 0.174 ± 0.354 0.157 ± 0.307 0.190 ± 0.396 
 Basophils  (x109/L) 0.041 ± 0.042 0.042 ± 0.046 0.040 ± 0.037 
     
     
Biochemistry Sodium (mmol/L) 135 ± 4 135 ± 4 135 ± 3 
 Potassium (mmol/L) 4.0 ± 0.5 4.0 ± 0.5 3.9 ± 0.4 
 Urea (mmol/L) 5.4 ± 2.4 5.5 ± 2.7 5.3 ± 2.1 
 Creatinine (µmol/L) 76 ± 23 77 ± 24 76 ± 23 
 eGFR (ml/min/1.73m2) 92 ± 31.7 93 ± 31.0 91 ± 32.6 
 Alanine transaminase (mmol/L) 49 ± 76 53 ± 79 46 ± 73 
 Alkaline 140hosphatise (mmol/L) 201 ± 206 206 ± 216 196 ± 197 
 Gamma GT (mmol/L) 210 ± 317 250 ± 359 171 ± 265 
 Total Bilirubin (µmol/L) 13 ± 10 14 ± 10 13 ± 10 
 Total protein (g/L) 67 ± 9 66 ± 10 68 ± 8 
 Albumin (g/L) 32 ± 7 31 ± 7 33 ± 7 
 Corrected calcium (mmol/L) 2.31 ± 0.20 2.33 ± 0.21 2.30 ± 0.20 
     
  n=152 n=79 n=73 
Immunology CD3+ lymphocytes 784 ± 534 820 ± 575 746 ± 486 
 CD3+ percentage 73.0 ± 12.9 71.6 ± 13.6 74.5 ± 12.1 
 CD19+ lymphocytes 135 ± 148 147 ± 165 122 ± 127 
 CD19+ percentage 12.4 ± 9.8 13.2 ± 11.0 11.6 ± 8.4 
 CD4+ lymphocytes 501 ± 389 509 ± 288 491 ± 392 
 CD4+ percentage 45.7 ± 14.2 44.1 ± 13.2 47.4 ± 15.0 
 CD8+ lymphocytes 274 ± 213 299 ± 246 247 ± 168 
 CD8+ percentage 26.6 ± 11.3 26.7 ± 11.6 26.4 ± 11.1 
 Absolute lymphocyte count 1015 ± 625 1073 ± 670 953 ± 571 
 NK cells 96 ± 64 106 ± 70 85 ± 55 
 NK percentage 10.7 ± 8.3 11.0 ± 8.5 10.4 ± 8.1 
 CD4:CD8 Ratio 2.4 ± 2.2 2.2 ± 2.1 2.5 ± 2.4 
     
     
Data are presented as mean ± SD 
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Table 6.3  Morphine versus Oxycodone RCT: Baseline Pain Characteristics 
Baseline (Time Point A) Pain Summary Total 
Randomisation arm 
Morphine Oxycodone 
Clinical pain type,  n, % Neuropathic 24 12.7% 12 12.6% 12 12.9% 
(n=189) Somatic 76 40.2% 42 44.2% 34 36.6% 
 Somatic (bony) 78 41.3% 32 33.7% 46 49.5% 
 Visceral 59 31.2% 34 35.8% 25 26.9% 
        
No. types of pain,  n, % 1 142 75.1% 72 75.8% 70 75.3% 
(n=189) 2 43 22.8% 21 22.1% 22 23.7% 
 3 3 1.6% 2 2.1% 1 1.1% 
        
S-LANNS > 12, n,%  19 9.5% 8 8% 11 11% 
        
MPBI,  mean ± SD Worst pain 7.49 ± 1.83 7.64 ± 1.74 7.34 ± 1.92 
 Least pain 2.37 ± 2.18 2.31 ± 2.18 2.42 ± 2.19 
 Average pain 5.26 ± 1.94 5.26 ± 1.69 5.26 ± 2.17 
 Pain right now 3.82 ± 2.55 3.69 ± 2.49 3.94 ± 2.62 
 Percentage relief 50.00 ± 29.32 53.79 ± 27.61 46.33 ± 30.57 
        
 
 
 
 
Table 6.4  Morphine versus Oxycodone RCT: Previous Use of Opioid Analgesia at Baseline  
Previous opioid use   Randomisation arm 
Total  Morphine Oxycodone 
Strong opioid      
Regular strong opioid (<24 hours) 10 5 5 
 Morphine 9 5 4 
 Oxycodone 1 0 1 
Breakthrough strong opioid 95 52 43 
 Morphine 91 51 40 
 Oxycodone 4 1 3 
       
Weak opioid*  190 95  95 
 Codeine 92 47 45 
 Tramadol 92 47 45 
 Dihydrocodeine 8 3 5 
 Dextropropoxyphene 1 0 1 
 Buprenorphine (≤ 20μg/hour) 3 0 3 
      
*Includes combination preparations with paracetamol.  At recruitment 10 participants were not on a weak 
opioid and 5 were on two different weak opioids. 
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Patient rated adverse reactions from previous opioid analgesia (including both weak and 
strong opioids) are presented in Table 6.5.  Median baseline opioid adverse reaction scores 
were generally low, as would be expected in a population with minimal (< 24 hours) 
exposure to regular strong opioids and incomplete dose titration.  The range however for all 
items on the toxicity questionnaire at baseline was high.  
 
Table 6.5  Morphine versus Oxycodone RCT: Baseline Adverse Reaction Scores 
Baseline opioid adverse reaction scores Total 
Randomisation arm 
Morphine Oxycodone 
Adverse reaction  Nausea 0 (0-10) 0 (0-10) 0 (0-10) 
Median  (range) Vomiting 0 (0-10) 0 (0-10) 0 (0-8) 
 Constipation 0 (0-10) 1 (0-10) 0 (0-10) 
 Diarrhoea 0 (0-10) 0 (0-10) 0 (0-8) 
 Drowsiness 1 (0-10) 1 (0-10) 2 (0-10) 
 Confusion/disorientation/ 
hallucinations 0 (0-9) 0 (0-9) 0 (0-6) 
  Nightmares 0 (0-9) 0 (0-8) 0 (0-9) 
  
 
 
The concomitant non-opioid analgesia that was continued from baseline as well of details of 
other concomitant medications are detailed in Table 6.6.  The median number of concomitant 
non-opioid medications at baseline was five for each group and ranged from zero to fourteen.  
Concomitant medications increase the potential for confounding for example co-analgesics 
potentiating pain relief and/or other drugs effecting adverse reactions either by causing their 
own or preventing opioid induced adverse reactions from appearing. 
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Table 6.6  Morphine versus Oxycodone RCT: Baseline Concomitant Medications 
Concomitant medication    Randomisation arm 
Total Morphine Oxycodone 
Other analgesic agents      
Paracetamol 107 53 54 
Non steroidal anti-inflammatory agent* 70 30 40 
Anticonvulsant 12 7 5 
Antidepressant 27 15 12 
 TCA / TCA related 16 11 5 
 SSRI 12 5 7 
 Other antidepressant 1 1 0 
Steroid 49 26 23 
       
Other medication      
Hypnotic anxiolytic 26 15 11 
Antiemetic 76 32 44 
 Antiemetic (antipsychotic) 14 6 8 
 Antiemetic (5-HT3 blocker) 4 3 1 
 Antiemetic (antihistamine) 12 5 7 
 Antiemetic (prokinetic) 61 25 36 
Laxative 98 46 52 
 Laxative softener 82 38 44 
 Laxative stimulant 52 27 25 
Antibiotics 49 25 24 
 Penicillin and cephalosporins 28 13 15 
 Other antibiotics 36 18 18 
Anticoagulant 35 19 16 
Diuretic 20 10 10 
β-blocker 21 9 12 
ACE Inhibitor/Angiotensin II receptor antagonist 26 13 13 
Antidiabetic 8 4 4 
Bronchodilator 10 5 5 
Proton pump inhibitor/ H2 antagonists 106 48 58 
       
*Includes aspirin 
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5.3 Primary Outcome 
5.3.1 Intention-to-treat Population 
The clinical response rate of oral morphine was compared to that of oral oxycodone using the 
chi squared test in all patients who had received greater than one dose of the randomised drug 
(intention-to-treat population). “Clinical response” was subjective and defined by reports of 
satisfactory analgesic response +/- tolerable side effects, rather than by set criteria relating to 
NRS values. Ninety eight out of 100 participants who were randomised to morphine received 
the drug whereas all 100 patients randomised to oxycodone received it. Figure 6.1 shows the 
patient flow through the trial.  
 
Sixty two percent (61/98) of patients with moderate to severe cancer pain responded to oral 
morphine as first-line strong opioid compared to 67% (67/100) subjects randomised to oral 
oxycodone. The observed 5% difference in response rates between the two drugs when used 
first-line was not significant (χ2 = 0.490, P=0.484).   
 
Twenty-four patients failed to respond to oral morphine first-line and twenty-one were 
switched early to oral oxycodone.  Of these 52% (11/21) responded to second-line oral 
oxycodone treatment.  Thirteen patients failed to respond to oral oxycodone first-line and 
twelve were switched early to oral morphine.  Of these 8/12 (67%) responded to second-line 
oral morphine treatment.  When overall response to each drug, first- or second-line, is 
considered, there was no significant difference between the two drugs (χ2 = 0.08, P=0.78).  
 
A small number of individuals who responded initially to the allocated strong opioid required 
switching after an interval (late switchers). Including late switchers, at the point the trial data 
were frozen, twenty-nine patients had switched from oral morphine to oral oxycodone.  Of 
these 59% (17/29) responded to oxycodone as second-line treatment.  Sixteen patients had 
failed to respond to oral oxycodone (early or late) and were switched to oral morphine.  Of 
these 11/16 (69%) responded to second-line morphine treatment.  When overall response to 
each drug is considered, first- or second-line (early or late switchers), there was no significant 
difference between the two drugs (χ2 = 0.10, P=0.75). In total 114 patient received morphine 
and 129 patients received oxycodone in the study. 
  145 
 
When randomised to morphine first-line, 73% (72/98) of patients achieved a good response to 
either first- or second-line opioid.  Similarly, when randomised to oxycodone first-line, 75% 
(75/100) of patients achieved a good response to first- or second-line opioid.  There was no 
difference in overall opioid response rates whether morphine or oxycodone was used first-
line (χ2 = 0.061, P=0.806).   
 
5.3.2 Per-protocol Population 
The per-protocol population were those patients who reached the first time point of either 
“response” (Time Point B) or “non-response” (Time Point C), n=165.  Due to high number of 
patient withdrawals within the titration phase, the study loses power making it difficult to 
draw any conclusions.  There were more drop-outs in the oxycodone group compared the 
morphine group, with twenty and thirteen withdrawals respectively.  
 
Seventy-two percent (61/85) of patients responded to oral morphine as first-line strong opioid 
compared to 84% (67/80) subjects randomised to oral oxycodone.  The observed difference in 
response rates in the per-protocol population did not reach significance (χ2 = 3.40, P=0.07).   
 
Per-protocol, in those patients who were switched early from oral morphine to oral 
oxycodone 69% (11/16) responded to oxycodone second-line treatment.  Whereas in patients 
who failed to respond to oxycodone first-line and were switched to morphine 80% (8/10) in 
the per-protocol population responded to second-line oral morphine.  When overall response 
to each drug, first- or second-line, is considered in the per protocol population, there was no 
significant difference between the two drugs (χ2 = 2.00, P=0.21).  
 
When randomised to morphine first-line, 85% (72/85) of patients in the per-protocol 
population achieved a good response to either first- or second-line opioid.  Similarly, when 
randomised to oxycodone first-line, 94% (75/80) of patients achieved a good response to 
first- or second-line opioid.  There was no significant difference in overall opioid response 
rates in the per protocol population whether morphine or oxycodone was used first-line (χ2 = 
3.47, P=0.06).   
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Figure 6.1 Morphine versus Oxycodone RCT Participant Flow Diagram 
 
  
Randomised (n=200) 
TITRATION PHASE (n=13) 
Lost to follow-up (n=0) 
Discontinued oral morphine (n=10) 
• Adverse reaction n=1 
• Renal impairment n=3 
• Parenteral opioid n=3 
• Pain improved n=1 
• Other n=2 (patient choice: fentanyl 
patch, 1fractured NOF) 
Discontinued trial (n=3) 
• Clinical deterioration n=1 
• Death n=2 
 
 
Allocated to morphine 
(n=100) 
• Received allocated 
intervention (n=98) 
• Did not receive 
allocated 
intervention n=2 
(previous AR, 
insurance issue) 
 
Allocated to oxycodone 
(n=100) 
• Received allocated 
intervention (n=100) 
• Did not receive 
allocated 
intervention (n=0) 
 
Analysed (n=85) 
 
• Morphine responders 
(n=61) 
 
• Morphine non-
responders (n=24) 
 
• Excluded from 
analysis (n=0) 
Analysed (n=80) 
 
• Oxycodone 
responders (n=67) 
 
• Oxycodone non-
responders (n=13) 
 
• Excluded from 
analysis (n=0) 
Assessed for eligibility (n=719) 
TITRATION PHASE (n=20) 
Lost to follow-up (n=0) 
Discontinued oral oxycodone (n=16) 
• Adverse reaction n=6 
• Renal impairment n=1 
• Parenteral opioid n=4 
• Pain improved n=2 
• Other n=3 (2 reluctant to take regular 
strong opioid, 1 physician 
recommendation) 
Discontinued trial (n=4) 
• Trial too burdensome n=1  
• Clinical deterioration n=1 
• Other n=2 (1 new non-cancer pain, 1 
negative press). 
 
 
RESPONDER MONTHLY REVIEW (n=61) 
Lost to follow-up (n=0)  
Discontinued oral morphine (n=35) 
• Renal impairment n=1 
• Parenteral opioid n=10 
• Pain improved n=13 
• Other n=2 (1 physician choice, 1 
pregnancy) 
• Late opioid switch n=9, see below 
Discontinued trial (n=22) 
• Clinical deterioration n=7 
• Trial too burdensome n=3 
• No reason given n=1 
• Death n=11 
Completed one year (n=3) Active (n=1) 
 
 
 
RESPONDER MONTHLY REVIEW (n=67) 
Lost to follow-up (n=0)  
Discontinued oral oxycodone (n=35) 
• Renal impairment n=3 
• Parenteral opioid n=19 
• Pain improved n=7 
• Other n=2 (1 physician choice, 1 patient 
choice - fentanyl patch) 
• Late opioid switch n=4, see below 
Discontinued trial (n=23) 
• Clinical deterioration n=5 
• Trial too burdensome n=3 
• Move to Thailand n=1 
• Death n=14 
Completed one year (n=7) Active (n=2) 
 
 
 
Excluded (n=519) 
• Not meeting inclusion criteria (n=188) 
• Declined to participate (n=159) 
• Other reasons (n=172) 
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Analysed (n=13) 
 
• 2nd line morphine 
responders (n=11) 
 
• 2nd line morphine 
non-responders (n=2) 
 
• Excluded from 
analysis (n=0) 
Analysed (n=23) 
 
• 2nd line oxycodone 
responders (n=17) 
 
• 2nd line oxycodone 
non-responders 
(n=6+ late n=4) 
 
• Excluded from 
analysis (n=0) 
Allocated to 2nd line 
morphine (n=17) 
• Early n=13, late n=4 
 
• Received allocated 
intervention (n=16) 
• Did not receive 
allocated 
intervention n= 1, 
converted to 
parenteral opioid 
 
TITRATION PHASE (n=3) 
 
Lost to follow-up (n=0) 
 
Discontinued oral morphine (n=3) 
• Parenteral opioid n=2 
• Other n=1 (patient choice: fentanyl 
patch) 
 
Discontinued trial (n=0) 
 
 
 
RESPONDER MONTHLY REVIEW (n=11) 
 
Lost to follow-up (n=0)  
 
Discontinued oral morphine (n=7) 
• Parenteral opioid n=4 
• Death n=2 
• Pain improved n=1 
 
Discontinued trial (n=2) 
• Clinical deterioration n=2 
 
Completed one year (n=2) Active (n=0) 
 
 
 
TITRATION PHASE (n=6) 
 
Lost to follow-up (n=0) 
 
Discontinued oral oxycodone (n=5) 
• Parenteral opioid n=4 
• Pain improved n=1 
 
Discontinued trial (n=1) 
• Death n=1 
 
 
 
RESPONDER MONTHLY REVIEW (n=17) 
Lost to follow-up (n=0) 
  
Discontinued oral oxycodone (n=13) 
• Renal impairment n=1 
• Parenteral opioid n=2 
• Death n=3 
• Pain improved n=3 
• Late opioid switch n=4 
 
Discontinued trial (n=0) 
 
Completed one year (n=2) Active (n=2) 
 
 
 
Allocated to 2nd line 
oxycodone (n=33) 
• Early n=24, late n=9 
 
• Received allocated 
intervention  (n=29) 
• Did not receive 
allocated 
intervention n=4 (3 
trial too burdensome, 
1 parenteral opioid) 
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5.4 Secondary Outcomes 
5.4.1 Pain 
The mean difference in mBPI scores from baseline to Time Point B (first-line clinical 
response, Table 6.7), and Time Point C to Time Point D (second-line clinical response, Table 
6.8) were calculated and compared using paired t-tests.  As would be expected both morphine 
and oxycodone significantly reduced or improved all pain indices in opioid responders.  
There was no difference between the two drugs.  
 
Table 6.7  Morphine versus Oxycodone RCT: Mean Difference in mBPI Scores from Baseline to First-line 
Opioid Clinical Response. 
Time Point A to B 
(first-line) 
Morphine Oxycodone 
Mean 
difference 
95% Confidence 
Interval P value 
Mean 
difference 
95% Confidence 
Interval P value 
Worst pain 3.80 (3.09, 4.51) <0.005 3.26 (2.46, 4.05) <0.005 
Least pain 1.67 (1.15, 2.20) <0.005 1.55 (1.10, 1.99) <0.005 
Average pain 3.62 (3.07, 4.16) <0.005 3.03 (2.47, 3.59) <0.005 
Pain right now 2.49 (1.77, 3.21) <0.005 2.21 (1.63, 2.79) <0.005 
Percentage relief -25.82 (-34.04, -17.60) <0.005 -30.78 (-39.03, -22.53) <0.005 
 
 
Table 6.8  Morphine versus Oxycodone RCT: Mean Difference in mBPI Scores from Opioid Switch to 
Second-line Opioid Clinical Response (Time Point C to D) 
Time Point C to D 
(second-line) 
Morphine Oxycodone 
Mean 
difference 
95% Confidence 
Interval P value 
Mean 
difference 
95% Confidence 
Interval P value 
Worst pain 3.63 (1.10, 6.15) 0.01 3.23 (0.95, 5.51) 0.01 
Least pain 1.63 (0.15, 3.10) 0.04 2.08 (0.65, 3.50) 0.01 
Average pain 2.88 (0.71, 5.04) 0.02 2.54 (0.47, 4.61) 0.02 
Pain right now 2.50 (0.66, 4.34) 0.01 3.31 (1.70, 4.91) <0.005 
Percentage relief -22.50 (-50.67, 5.67) 0.10 -26.15 (-46.13, -6.18) 0.01 
              
 
Table 6.9 shows the mean difference (95% Confidence Interval) from baseline (Time Point 
A) to opioid switching (Time Point C).  For morphine there was no difference in any of the 
pain indices measured, however for oxycodone the average pain and percentage relief had 
both improved.   
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Table 6.9  Morphine versus Oxycodone RCT: Mean Difference in mBPI Scores from Baseline to Switch 
in First-line Opioid Non-responders (Time Point A to C) 
Time Point A to C 
Morphine Oxycodone 
Mean 
difference 
95% Confidence 
Interval P value 
Mean 
difference 
95% Confidence 
Interval P value 
Worst pain 0.68 (-0.19, 1.54) NS 1.50 (-0.43, 3.43) NS 
Least pain 0.11 (-0.88, 1.10) NS 1.17 (-1.08, 3.41) NS 
Average pain 0.50 (-0.44, 1.44) NS 2.17 (0.09, 4.24) 0.04 
Pain right now -0.64 (-1.94, 0.65) NS 2.00 (-0.20, 4.20) NS 
Percentage relief -5.38 (-5.38, -20.07) NS -29.17 (-55.77, -2.56) 0.03 
 NS Not significant             
 
 
Figures 6.2 and 6.3 show scatter plots for first-line titration phase MBPI scores over time.  
Morphine responders are shown in green, oxycodone responders in blue and non-responders 
in red. The median time to reach the “clinical response” time point (Time Point B) was seven 
days for both morphine and oxycodone.  Scores for both responders and non-responders are 
shown.  In general pain scores decreased over time with opioid titration. 
 
5.4.2 Adverse Reactions 
Tables 6.10 – 6.12 describe the adverse reactions reported in the toxicity questionnaires.  At 
Time Points B and D, first-line or second-line opioid response, the median adverse reaction 
scores were mostly zero.  The median drowsiness score was one out of ten for oxycodone at 
Time Point B and three out of ten for morphine at Time Point D.  Of note however is the 
large range of patient rated side effect scores classified as clinically “tolerable” at the 
response time points. 
There was no difference between morphine and oxycodone reported adverse reactions at 
opioid response or switching time points (Mann-Whitney U test).  Figures 6.4 and 6.5 show 
the individual adverse reaction scores over time for the first-line titration phase of morphine 
and oxycodone respectively.   
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Figure 6.2  Morphine versus Oxycodone RCT: First-line Morphine Titration Phase mBPI Scores. 
 
 
First-line morphine mBPI titration phase scores: worst pain, least pain, average pain, pain right now and 
percentage relief are show in simple scatter plots over time (days).  Morphine responders are show in green and 
non-responders in red.   
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Figure 6.3  Morphine versus Oxycodone RCT: First-line Oxycodone Titration Phase mBPI Scores 
 
 
First-line oxycodone mBPI titration phase scores: worst pain, least pain, average pain, pain right now and 
percentage relief are show in simple scatter plots over time (days).  Oxycodone responders are show in blue and 
non-responders in red.   
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Table 6.10  Morphine versus Oxycodone RCT: Adverse Reaction Scores at First-line Opioid Clinical 
Response (Time Point B) 
Time Point B 
Morphine Oxycodone 
n Median Range n Median Range 
Nausea 61 0.0 (0-10) 67 0.0 (0-8) 
Vomiting 61 0.0 (0-7) 67 0.0 (0-8) 
Constipation 56 0.0 (0-10) 66 0.0 (0-9) 
Diarrhoea 61 0.0 (0-6) 67 0.0 (0-7) 
Drowsiness 61 0.0 (0-9) 67 1.0 (0-9) 
Confusion/hallucinations/disorientation 61 0.0 (0-5) 67 0.0 (0-9) 
Nightmares 60 0.0 (0-5) 67 0.0 (0-9) 
       
 
Table 6.11  Morphine versus Oxycodone RCT: Adverse Reaction Scores at Second-line Opioid Clinical 
Response (Time Point D) 
Time Point D 
Morphine Oxycodone 
n Median Range n Median Range 
Nausea 16 0.0 (0-3) 10 0.0 (0-9) 
Vomiting 16 0.0 (0-1) 10 0.0 (0-0) 
Constipation 16 0.0 (0-10) 10 1.0 (0-10) 
Diarrhoea 16 0.0 (0-1) 10 0.0 (0-5) 
Drowsiness 15 3.0 (0-8) 10 0.0 (0-8) 
Confusion/hallucination/disorientation 16 0.0 (0-9) 10 0.0 (0-4) 
Nightmares 16 0.0 (0-6) 10 0.0 (0-3) 
       
 
At the point of opioid switching for non-response (Time Point C, Table 6.12), drowsiness had 
the highest median score for both drugs followed by nausea, confusion/drowsiness/ 
hallucinations and constipation in keeping with the “reasons for switch”. 
 
Table 6.12  Morphine versus Oxycodone RCT: Adverse Reaction Scores at First-line Opioid Switch 
(Time Point C) 
Time Point C 
Morphine Oxycodone 
n Median Range n Median Range 
Nausea 28 2.5 (0-10) 12 5.0 (0-9) 
Vomiting 28 0.0 (0-10) 12 0.0 (0-10) 
Constipation 28 2.5 (0-10) 12 0.0 (0-8) 
Diarrhoea 28 0.0 (0-8) 12 0.0 (0-6) 
Drowsiness 28 7.0 (0-10) 11 6.0 (0-9) 
Confusion/hallucination/disorientation 28 2.5 (0-10) 12 2.5 (0-7) 
Nightmares 27 0.0 (0-9) 12 0.0 (0-9) 
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Figure 6.4 Morphine versus Oxycodone RCT: First-line Morphine Titration Phase Adverse Reactions. 
 Morphine responders are show in green and non-responders in red.   
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Figure 6.5  Morphine versus Oxycodone RCT: First-line Oxycodone Titration Phase Adverse Reactions 
 Oxycodone responders are show in blue and non-responders in red
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5.4.3 Opioid Dosing and Conversion 
The starting dose of the randomised opioids and the following daily dose titration according to 
response was overseen by clinical members of the Palliative Medicine team.  When switching 
between the two opioids, morphine and oxycodone the standard conversion ratio of 2:1 
employed within the RMH was used in both directions.   
Figure 6.6 shows a) the mean daily dose of opioid and b) the mean equivalent daily dose of 
morphine, calculated by using the standard 2:1 conversion ratio from morphine to oxycodone, 
during the titration phase days one to eight.  Table 5.13 describes the variation in doses observed 
at the protocol time-points, first and second-line opioid response (B and D) and non-response 
(switching, C and F).   
There was wide variation seen in dose requirements for both drugs, with average doses not in 
keeping with the expected analgesic equivalence ratio of 2:1.  If the conversion ratio was simply 
2:1 the lines in Figure 5.6B, mean equivalent daily dose of morphine, could be expected to be 
aligned and this is not the case.  
 
Table 6.13  Morphine versus Oxycodone RCT: Total Daily Opioid Doses at Time Points 
Time 
Point 
Morphine first-line Oxycodone first-line 
n Mean SD Median Range n Mean SD Median Range 
B 61 77.05 43.43 60 15-240 66 61.69 39.44 60 8-180 
C 32 79.97 68.28 60 30-360 17 80.88 55.88 90 15-240 
 Oxycodone second-line Morphine second-line 
D 17 55.88 31.09 50 15-130 11 173.64 69.90 180 60-300 
F 6 108.00 130.87 50 18-360 2 75.00 63.64 75 30-120 
Doses are given in mg  
 
 
To determine a dose conversion ratio between two drugs a conventional cross-over trial design 
would be more appropriate as a subgroup of responders to both drugs could be identified and the 
doses of each drug compared.  Here where the only participants to cross-over or switch between 
the drugs are those who have failed to respond to the first-line opioid either because of 
uncontrolled pain, intolerable side-effects or both only tentative estimates can be made.   
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Figure 6.6  Morphine versus Oxycodone RCT: Comparison of Mean Morphine and Oxycodone Titration Doses Over Time. 
 
A) shows mean (95% C.I.) oxycodone and morphine doses over 24 hours (regular and breakthrough doses included).  B) shows the same mean (95% C.I.) data, 
with the oxycodone dose converted to morphine “equivalent” daily daily using the standard 2:1 conversion ratio, morphine:oxycodone.   
 
 
A B 
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A subgroup of opioid switchers: those whose pain was controlled at switching were chosen in 
which to estimate dose conversion ratios as they were deemed more comparable to second-line 
opioid responders.   Second-line dose requirements for those who switch because of uncontrolled 
pain with or without intolerable adverse reactions are likely to be different, however due to the 
small numbers in each these scenarios the conversion factors are not considered here.  Dose 
conversion ratios for the pain controlled switchers were calculated by dividing the pre-switch 
final titration dose of first-line trial medication (Time Point C) by the corresponding post-switch 
final titration dose of the second-line trial medication (Time Point D).    
 
Figures 6.7 shows pre- and post- switch opioid doses for individual patients switching for all 
causes, and then secondary to adverse reactions alone i.e. in those whose pain was ultimately 
controlled on both drugs.  Table 6.14 describes the doses in the selected pain controlled 
subgroup.  Again there was wide inter-individual variation in dose requirements, however on 
average there appeared to be differences in the conversion ratios dependant on directionality of 
the switch.   
 
Table 6.14  Morphine versus Oxycodone RCT: Total Daily Opioid Doses for Participant Switching due to 
Adverse Reactions . 
Time 
Point 
Morphine first-line Oxycodone first-line 
n Mean  SD Median Range n Mean SD Median Range 
C 19 72.58 52.75 60 30-260 12 70.42 61.48 60 15-240 
                 
  Oxycodone second-line Morphine second-line 
D 7 62.14 37.62 60 20-130 7 175.71 82.03 180 60-300 
  
 
For participants randomised to morphine first-line in this group, the median pre-switch dose of 
morphine was 60mg (range 30-260mg) and the median post-switch dose of oxycodone was 
60mg (range 20-130mg).  The median (range) dose conversion ratio for these subjects was 1.3 
(0.4-4.0), therefore oral morphine doses could be converted to oxycodone on a 4:3 basis.  
When randomised to oxycodone the median dose of oxycodone in pain controlled switchers was 
60mg (range 15-240mg) and the median post-switch dose of morphine was 180mg (range 60-
300mg).  The median dose conversion ratio for these subjects was 0.5 (0.3-1.5), therefore the 
oral oxycodone dose was converted to morphine on a 1:2 basis. 
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Figure 6.7  Morphine versus Oxycodone RCT: Pre- and Post-switch Daily Dose Comparison for Total Switching Populations and Switching Secondary 
to Adverse Reactions Only (Pain Controlled) 
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5.4.4 Reasons for Opioid Switching 
Adverse reactions were the most common overall reason for first-line opioid switching for both 
morphine and oxycodone, followed by both pain and adverse reactions together and then 
uncontrolled pain (Table 6.15). 
Table 6.15  Morphine versus Oxycodone RCT: Reason for First-line Opioid Switch (Time Point C) 
First-line opioid switch                     
Time Point C 
All Morphine Oxycodone 
n % n % n % 
Pain 4 8 3 9.1 1 5.9 
Adverse reactions 32 64 20 60.6 12 70.6 
Pain and adverse reactions 14 28 10 30.3 4 23.5 
Total 50   33   17  
              
 
The most common adverse reaction contributing to first-line opioid switching was drowsiness 
followed by nausea and confusion/hallucinations/disorientation (Table 6.16). 
Table 6.16  Morphine versus Oxycodone RCT: Adverse Reactions Contributing to First-line Opioid Switch 
(Time Point C). 
Time Point C All (n=50) Morphine (n=33) Oxycodone (n=17) 
n % n % n % 
Drowsiness 34 68 24 72.7 10 58.8 
Nausea 16 32 11 33.3 5 29.4 
Confusions/hallucinations 
/disorientation 
13 26 8 24.2 5 29.4 
Vomiting 7 14 6 18.2 1 5.9 
Constipation 7 14 6 18.2 1 5.9 
Nightmares 5 10 4 12.1 1 5.9 
Other 4 8 4 12.1 0 .0 
Dry mouth 3 6 2 6.1 1 5.9 
Myoclonus 2 4 1 3.0 1 5.9 
Itch 1 2 1 3.0 0 .0 
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There were fewer second-line opioid non-responders which makes interpretation more difficult.  
Tables 6.17 and 6.18 detail the reasons for second-line opioid switch and adverse reaction scores 
contributing to second-line opioid switch respectively.  Of note nausea was the most common 
adverse reaction or event contributing to second-line opioid switching followed by drowsiness 
and confusion/hallucinations/disorientation.   
 
Table 6.17  Morphine versus Oxycodone RCT: Reason for Second-line Opioid Switch (Time Point F) 
Second-line opioid switch                     
Time Point F All Morphine Oxycodone 
n % n % n % 
Pain   3 25.0 1 50.0 2 20.0 
Adverse reactions 6 50.0 0 0.0 6 60.0 
Pain and adverse reactions 3 25.0 1 50.0 2 20.0 
Total 12   2  10   
  
 
Table 6.18  Morphine versus Oxycodone RCT: Adverse Reactions Contributing to Second-line Opioid Switch 
(Time Point F). 
Second Switch            
Time Point F 
All Morphine Oxycodone 
n % n % n % 
Nausea 7 53.8 1 33.3 6 60.0 
Drowsiness 5 38.5 1 33.3 4 40.0 
Constipation 3 23.1 1 33.3 0 0.0 
Confusion/hallucinations 
/disorientation 
3 23.1 1 33.3 2 20.0 
Vomiting 2 15.4 1 33.3 1 10.0 
Nightmares 2 15.4 1 33.3 1 10.0 
Dry mouth 1 7.7 1 33.3 0 0.0 
Itch 1 7.7 0 0.0 1 10.0 
Myoclonus 0 0 0 0.0 0 0.0 
              
 
There were seven participants who did not respond to either first- or second-line strong opioids. 
The circumstances around opioid switching time points and clinical follow-up for these patients 
are described in Table 6.19.  Of note five of these patients returned to their “failed” first-line 
opioid of either morphine or oxycodone having not responded to their second-line opioid.
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 Table 6.19  Morphine versus Oxycodone RCT: Description of First- and Second-line Opioid Non-responders 
      First-line switch (Time Point C) Second-line switch (Time Point C)   
Age Sex Diagnosis 
Opioid, 24 hr 
dose (mg) 
Reason for switch 
(score) 
Opioid, 24 hr 
dose (mg) 
Reason for switch 
(score) Clinical follow-up 
48 F  Breast 
cancer 
Morphine Drowsiness (10) Oxycodone  Pain (40% relief) Patient choice to switch back to morphine as gave better 
pain control.   Still on morphine in 2009 (withdrawn 
2006)  
  60mg , day 3   30mg,  day 3 Nausea (6) 
35 F  Renal Cell 
Carcinoma 
Morphine  Pain (60% relief) Oxycodone  Drowsiness Brain metastases diagnosed shortly after time point F 
which could explain drowsiness and nausea, noted "may 
be able to tolerate opioids better then we previously 
thought".  Started back on PRN oxycodone - unknown 
result. 
    30mg, day14 Drowsiness (6) 18mg, day 7 Nausea 
64 M  Sarcoma Morphine Pain (60% relief) Oxycodone Pain (20% relief) Switched to methadone and pain improved with fewer 
side effects.   SLANSS≥12 360mg, day 6 Drowsiness (9) 360mg, day7 Nausea (8) 
     Hallucinations (9)   Drowsiness (8) 
         Hallucinations (8) 
76 F Oesophageal 
cancer 
Oxycodone  Pain (10% relief) Morphine Nausea (5) Switched back to co-codamol.  Pain improved over time 
with anti-cancer treatment.   90mg, day 4 Nausea (6) 120mg, day 4 Vomiting (5) 
        Constipation (5) 
        Drowsiness (4) 
        Hallucinations (7) 
        Nightmares (7) 
          Dry mouth 
67 M  Prostate 
cancer 
Morphine Drowsiness (7) Oxycodone  Nausea Continued on PRN oxycodone however restarted 
regularly later in month with good pain control.  Nausea 
had resolved and no other symptoms reported 
  30mg, day 6 Nausea (8) Dose  Vomiting  
    Vomiting (8) not recorded, Constipation 
    Constipation (8) day 3   
40* F  Fibromatosis Morphine  Drowsiness (6) Oxycodone  Nausea (8) Switched first to fentanyl but experienced no pain relief 
from this. Went back to morphine as better for pain 
despite side effects 
   60mg, day 7 Hallucinations (7) 60mg, day7 Drowsiness (5) 
     Nightmares (8)   Nightmares (5) 
     Constipation (9)   Itch 
     Dry mouth, headache     
     Urinary hesitancy     
67* F Lung cancer Oxycodone  Drowsiness (9) Morphine  Pain Switched back to oxycodone as patient felt it was better 
than morphine for pain.    15mg, day 2   30mg, day 12   
*Non-Caucasian (both Turkish). Sex, M=male, F=female 
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5.4.5 Timing of Opioid Response and Switching  
5.4.5.1 Opioid Response 
The median time for a clinical opioid response to be achieved and recorded as Time Point B was 
7 days for both morphine and oxycodone.  Table 6.20 describes the median (range) length of 
time in days to the various time points.  
 
5.4.5.2 Opioid Switching 
There were two distinct types of opioid switching populations: early switchers where 
uncontrolled pain and/or intolerable adverse reactions dictate early opioid switching and late 
switchers where there is an initial response to the first-line opioid but subsequently the response 
is lost necessitating a late opioid switch.  Table 6.20 shows the median and range of time to 
opioid switching in non-responders.  Early switching occurred after a median of 7 days after 
starting the trial opioid for both morphine and oxycodone, with similar ranges.   
 
Late switching occurred over a much greater time range for both opioids, the median time to late 
switch for early morphine responders (n=9) was 30 days (range 6-129) and for early oxycodone 
responders (n=4) was 125 days (range 35-169).  Excluding the seemingly early day 6 “late 
switch” for one early morphine responder the median time to late switch was 33.5 days (range 
21-129).  This individual reached Time Point B on day 4 with good pain control and no adverse 
reactions, but developed severe drowsiness together with uncontrolled pain and was switched on 
day 6. 
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Table 6.20  Morphine versus Oxycodone RCT: Comparison of Time to First- and Second-line Opioid 
Switches According to Opioid 
  
All Morphine Oxycodone 
  
Days to first-line opioid response, Time Point A to B 7.0 (2-31) 7.0 (2-20) 7.0 (2-31) 
    Days to first-line opioid response (subsequent late switch)     7.0 (2-11)  7.5 (4-30) 
Days to first opioid switch,  Time Point A-C (all) 7.0 (1-169) 7.0 (2-129) 7.0 (1-169) 
    Days to early opioid switch     6.0 (2-21)  7.0 (1-20) 
    Days to late opioid switch (initial response)     30.0 (6-129) 125.0  (35-169) 
Days to second-line opioid response, Time Point C-D (all) 7.0 (2-26) 7.0 (2-26) 7.5 (3-20) 
    Days from early opioid switch     6.0 (2-26)  8.5 (3-20) 
    Days from late opioid switch     10.5 (6-15) 6.0  (4-8) 
Total days in study 33.0 (0-365) 30.0 (0-365) 35.5 (1-365) 
Data presented as median (range).   
 
 
Figure 6.8 shows the Kaplan Maier curves showing time to first opioid switch for both opioids, 
comparison of the distributions over time using log-rank (Mantel-Cox) analysis showed that 
there was no difference between the two opioids (P=0.36).  Fifty percent of non-responders had 
switched opioid by day 7 in both groups.  A late separation of the curves appears to occur around 
day 30 by which point approximately 80% of patients who opioid switch have already done so. 
 
5.4.6 Early and Late Opioid Switching 
Failure of opioid response in early switching and loss of response in late- switching may be 
driven by different mechanisms and therefore the two groups may represent different 
populations.  Consequently pain and adverse reaction scores were split between early and late 
switchers and subsequent response to second-line opioid are detailed in Tables 6.21 and 6.22 for 
morphine and Tables 6.23 and 6.24 for oxycodone.   There were nine late switchers on morphine 
and four on oxycodone.  In the morphine group the main reason for late switching was given as 
intolerable adverse reactions in four patients, uncontrolled pain and intolerable adverse reactions 
in four patients and uncontrolled pain in the remaining patient. Whereas in the oxycodone group 
three patients had intolerable adverse reactions and one patient had both uncontrolled pain and 
intolerable adverse reactions.   
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Figure 6.8  Morphine versus Oxycodone RCT: Kaplan Meier Curve: Time to Opioid Switch in First-line 
Opioid Non-responders  
 
 
Pain and side effect scores at the point of switching (Time Point C) were similar for both early 
and late opioid switchers.  For patients switching from morphine to oxycodone the only 
difference in mBPI scores was “pain right now” where late switchers scored higher with a mean 
of 6.00 compared to 5.55 in early switchers, P=0.04 (t-test).  In those who responded to 
oxycodone second-line, drowsiness was scored higher by early switchers, with a median score of 
three out of ten compared to zero in late switchers, P=0.02 (Mann-Whitney U).  There was no 
difference between pain and adverse reaction scores between early or late switchers in those 
randomised to oxycodone first-line. 
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Figures 6.9 - 11 show that most, but not all, pain and adverse reaction indices may be improved 
after a successful opioid switch whether early or late.  The balance of what is deemed to be 
acceptable in terms of pain relief and adverse reactions to opioid are variable between 
individuals.  For example a degree of drowsiness may be acceptable in exchange for good pain 
control for some people, whereas any other may accept higher pain scores for less drowsiness. 
 
5.4.7 Predictive Modelling of Opioid Response from Early Titration Diary Scores. 
The time taken from the initiation of regular strong opioid to the “clinical response” Time Point 
B was very variable ranging from 2 to 31 days.   In some cases there was an interval period when 
a good response was achieved earlier but the formal Time Point required by the protocol was 
only recorded when the participant next attended the cancer centre.  In other cases, especially 
where there was a delicate balance between analgesia and adverse reactions or inter-current 
illness a slow titration was necessary in order to appropriately assess overall response.   
Achieving pain and symptom control as quickly and efficiently as possible is a priority in 
Palliative Medicine.  Given that there are no reliable clinical predictors of analgesic response to 
use before starting a strong opioid, it was questioned whether overall opioid response can be 
predicted based on early titration scores.  Markers to suggest an earlier opioid switch could avoid 
protracted titration periods with uncontrolled pain and burdensome adverse reactions. 
Binary logistic regression modelling was performed to predict overall opioid response (Time 
Point B) in the per protocol population, using pain and adverse reaction scores from the day three 
and day seven titration diaries.  As before variables P < 0.1 on univariate analysis were included 
into the multivariate modelling. 
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Table 6.21  Morphine versus Oxycodone RCT: Pain Scores for Early and Late Morphine Switchers and 
Subsequent Response to Oxycodone 
Morphine  
Time Point C Time Point D 
n Mean SD n Mean SD 
Early switch         
 Worst pain 22 6.95 2.46 11 3.27 2.97 
 Least pain 22 2.18 2.26 11 0.55 0.82 
 Average pain 21 4.52 2.36 11 2.27 2.49 
 Pain right now 22 3.55 2.60 11 1.00 1.18 
 Percentage relief 20 57.00 25.57 11 82.73 13.48 
Late switch         
 Worst pain 6 8.17 0.75 4 7.00 3.83 
 Least pain 5 2.60 1.67 4 1.25 1.50 
 Average pain 5 6.20 1.30 4 3.25 2.63 
 Pain right now 6 6.00 1.26 4 2.50 1.29 
 Percentage relief 6 55.00 15.17 4 67.50 26.30 
                
 
Table 6.22  Morphine versus Oxycodone RCT: Adverse Reaction Scores for Early and Late Morphine 
Switchers and Response to Oxycodone 
Morphine 
Time Point C Time Point D 
n Median Range n Median Range 
Early switch         
 Nausea 22 5.0 0-10 11 0.0 0-3 
 Vomiting 22 0.0 0-10 11 0.0 0-0 
 Constipation 22 3.0 0-10 11 0.0 0-10 
 Diarrhoea 22 0.0 0-8 11 0.0 0-1 
 Drowsiness 22 7.0 3-10 10 3.0 0-8 
 Confusion/hallucinations/ disorientation 22 2.5 0-9 11 0.0 0-9 
 Nightmares 21 0.0 0-9 11 0.0 0-6 
Late switch       
 Nausea 6 1.0 0-6 5 0.0 0-2 
 Vomiting 6 0.0 0-2 5 0.0 0-1 
 Constipation 6 0.5 0-8 5 0.0 0-1 
 Diarrhoea 6 0.0 0-2 5 0.0 0-0 
 Drowsiness 6 8.5 2-10 5 0.0 0-3 
 Confusion/hallucinations/ disorientation 6 3.5 0-10 5 0.0 0-0 
 Nightmares 6 0.0 0-5 5 0.0 0-0 
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Figure 6.9  Morphine versus Oxycodone RCT: Individual Pain and Adverse Reaction Scores for Early 
Switchers from Morphine to Oxycodone 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.10  Morphine versus Oxycodone RCT: Individual Pain and Adverse Reaction Scores for Late 
Switchers from Morphine to Oxycodone 
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Table 6.23  Morphine versus Oxycodone RCT: Pain Scores for Early and Late Oxycodone Switchers and 
Subsequent Response to Morphine 
Oxycodone 
Time Point C Time Point D 
n Mean SD n Mean SD 
Early switch         
 Worst pain 10 6.00 2.00 8 3.63 2.62 
 Least pain 10 1.50 1.43 8 0.63 0.74 
 Average pain 10 3.50 1.84 8 1.88 1.46 
 Pain right now 10 2.40 1.78 8 1.00 1.07 
 Percentage relief 10 54.00 35.02 8 78.75 21.67 
Late switch (early response)         
 Worst pain 3 7.33 4.62 3 5.67 2.52 
 Least pain 3 3.00 2.65 3 2.00 1.73 
 Average pain 3 4.67 3.21 3 3.67 3.06 
 Pain right now 3 4.67 4.04 3 3.67 4.04 
 Percentage relief 3 66.67 25.17 3 66.67 40.41 
                
 
Table 6.24  Morphine versus Oxycodone RCT: Adverse Reaction Scores for Early and Late Oxycodone 
Switchers and Subsequent Response to Morphine 
Oxycodone 
Time Point C Time Point D 
n Median Range n Median Range 
Early switch       
 Nausea 10 4.0 0-6 7 0.0 0-9 
 Vomiting 10 0.0 0-7 7 0.0 0-0 
 Constipation 10 0.0 0-4 7 0.0 0-6 
 Diarrhoea 10 0.0 0-6 7 0.0 0-5 
 Drowsiness 10 6.0 0-9 7 0.0 0-7 
 Confusion/hallucinations/ disorientation 10 2.5 0-7 7 0.0 0-4 
 Nightmares 10 0.0 0-9 7 0.0 0-3 
Late switch (early response)       
 Nausea 3 6.0 2-9 3 0.0 0-6 
 Vomiting 3 0.0 0-10 3 0.0 0-0 
 Constipation 3 7.0 0-8 3 5.0 0-10 
 Diarrhoea 3 0.0 0-0 3 0.0 0-0 
 Drowsiness 2 8.5 8-9 3 0.0 0-8 
 Confusion/hallucinations/ disorientation 3 0.0 0-6 3 0.0 0-0 
 Nightmares 3 0.0 0-0 3 0.0 0-0 
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Figure 6.11  Morphine versus Oxycodone RCT: Individual Pain and Adverse Reaction Scores for Early 
Switchers from Oxycodone to Morphine 
 
Figure 6.12  Morphine versus Oxycodone RCT: Individual Pain and Adverse Reaction Scores for Late 
Switchers from Oxycodone to Morphine 
Average pain
Pre-switch Post-switch
0
1
2
3
4
5
6
7
8
9
10
A
ve
ra
ge
 p
ai
n
Relief
Pre-switch Post-switch
0
10
20
30
40
50
60
70
80
90
100
Pe
rc
en
ta
ge
 re
lie
f
Nausea
Pre-switch Post-switch
0
1
2
3
4
5
6
7
8
9
10
N
au
se
a
Drowsiness
Pre-switch Post-switch
0
1
2
3
4
5
6
7
8
9
10
D
ro
w
sin
es
s
Average pain
Pre-switch Post-switch
0
1
2
3
4
5
6
7
8
9
10
A
ve
ra
ge
 p
ai
n
Relief
Pre-switch Post-switch
0
25
50
75
100
Pe
rc
en
ta
ge
 re
lie
f
Nausea
Pre-switch Post-switch
0
1
2
3
4
5
6
7
8
9
10
N
au
se
a
Drowsiness
Pre-switch Post-switch
0
1
2
3
4
5
6
7
8
9
D
ro
w
sin
es
s
  170 
5.4.7.1 Opioid Response 
5.4.7.1.1 Day Three Opioid Titration 
At day three, pain and adverse reaction scores were available for 124 participants.  On univariate 
analysis three adverse reactions (nausea, vomiting and drowsiness) and four mBPI scores (least 
pain, average pain, pain right now and percentage relief) met criteria for inclusion to the 
multivariate modelling as P < 0.1. 
The day three model (Table 6.25) retained one factor that was predictive of first-line opioid non-
response: vomiting.  The model correctly predicted 96/99 of responders (97% sensitivity) and 
9/25 of first-line switchers (36% specificity).  Overall vomiting was stated as one of the main 
reasons contributing to switching opioids in approximately a third of cases. 
 
Table 6.25  Morphine versus Oxycodone RCT: Titration-phase Day Three Scores Predictive of a Good 
Overall Response to Opioid  
Day 3 
B 
Standard 
Error Wald P value 
Odds 
Ratio 
95% C.I.for Odds 
Ratio 
Lower Upper 
Constant 1.79 0.27 43.65 0.00 5.97     
Vomiting -0.48 0.13 12.95 0.00 0.62 0.47 0.80 
Multivariate logistic stepwise regression (backwards Wald method). n=124 
Dependant variable =  Clinical opioid response (Time Point B) / switching (Time Point C) 
R2 =0.124  (Cox and Snell),  .195 (Nagelkerke).  Model χ2 = 22.31, P < 0.001 
 
 
5.4.7.1.2 Day Seven Opioid Titration 
Fifty-eight participants from the per-protocol population had pain and adverse reaction scores 
available for day seven of opioid titration.  Five adverse reaction scores: nausea, vomiting, 
drowsiness, confusion/hallucinations/disorientation and nightmares, and all five indices of the 
MBPI met criteria for inclusion into the modelling process. 
The day seven model (Table 6.26) for overall opioid response retained three independent 
predictors: drowsiness, nightmares and percentage relief.  It correctly predicted 42/45 of 
responders (93% sensitivity) and 9/13 of non-responders (69% specificity) in those participants 
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still titrating at day seven.  Drowsiness was the most common contributing factor to opioid 
switching overall occurring in 68% of cases (Table 6.16). 
 
Table 6.26  Morphine versus Oxycodone RCT: Titration-phase Day Seven Scores Predictive of a Good 
Overall Response to Opioid 
Day 7 
B 
Standard 
Error Wald P value 
Odds 
Ratio 
95% C.I.for Odds 
Ratio 
Lower Upper 
Constant -1.31 1.33 0.96 0.33 0.27     
Drowsiness -0.60 0.21 8.52 0.00 0.55 0.36 0.82 
Nightmares -0.40 0.20 4.10 0.04 0.67 0.45 0.99 
Percentage relief 0.08 0.03 7.93 0.00 1.09 1.03 1.15 
Multivariate logistic stepwise regression (backwards Wald method). n=58 
Dependant variable =  Clinical opioid response (Time Point B) / switching (Time Point C) 
R2 =0.433  (Cox and Snell),  .661 (Nagelkerke).  Model χ2 = 32.91, P < 0.001 
 
 
5.4.7.2 Morphine  
5.4.7.2.1 Day Three Morphine Titration 
Pain and adverse reaction scores from day three titration were available for 68 participants 
randomised to morphine population.  On univariate analysis the scores of two adverse reactions: 
vomiting and drowsiness, and all indices of the mBPI except worst pain met criteria for inclusion 
into the multivariate modelling process. 
In the early day three model for morphine response (Table 6.27) one factor was retained as a 
predictor of overall morphine response: vomiting.  Similar to the overall opioid model, higher 
vomiting scores were associated with lower odds of morphine response.  The model successfully 
predicted 48/50 of morphine responders at day three (96% sensitivity), but only 8/18 of early 
switchers (44% specificity).  
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Table 6.27  Morphine versus Oxycodone RCT: Titration-phase Day Three Scores Predictive of a Good 
Overall Response to Morphine  
Day 3 
B 
Standard 
Error Wald P value 
Odds 
Ratio 
95% C.I.for Odds 
Ratio 
Lower Upper 
Constant 1.56 0.35 20.06 0.00 4.77     
Vomiting -0.48 0.16 9.46 0.00 0.62 0.46 0.84 
Multivariate logistic stepwise regression (backwards Wald method). n=68 
Dependant variable =  Clinical opioid response (Time Point B) / switching (Time Point C) 
R2 =0.175 (Cox and Snell),  .253 (Nagelkerke).  Model χ2 = 12.96, P < 0.001 
 
 
5.4.7.2.2 Day Seven Morphine Titration 
Information from pain and adverse reaction scores was available for 28 patients on first-line 
morphine at day seven.  Nausea, drowsiness, confusion/hallucinations/disorientation, nightmares, 
least pain, average pain, pain right now and percentage relief all met criteria on univariate 
analysis for inclusion into the modelling process. 
Nightmares were the only predictor retained in the final model (Table 6.28) of overall morphine 
response at day seven.  Higher scores for nightmares were associated with decreased odds of 
morphine response.  The model correctly predicted 20/21 morphine responders (95% sensitivity) 
and 3/7 of first-line early switchers (43% specificity). 
 
Table 6.28  Morphine versus Oxycodone RCT: Titration-phase Day Seven Scores Predictive of a Good 
Overall Response to Morphine  
Day 7 
B 
Standard 
Error Wald P value 
Odds 
Ratio 
95% C.I.for Odds 
Ratio 
Lower Upper 
Constant 1.89 0.61 9.49 0.00 6.64   
Nightmares -0.56 0.24 5.44 0.02 0.57 0.35 0.91 
Multivariate logistic stepwise regression (backwards Wald method). n=28 
Dependant variable =  Clinical opioid response (Time Point B) / switching (Time Point C) 
R2 =0.247  (Cox and Snell),  .365 (Nagelkerke).  Model χ2 = 7.93, P = 0.005 
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5.4.7.3 Oxycodone 
5.4.7.3.1 Day Three Oxycodone Titration 
Pain and adverse reaction scores were available for 56 participants randomised to oxycodone in 
the per protocol population at day three.  On univariate analysis the scores of one adverse 
reaction: drowsiness, and two indices of the mBPI: worst pain, average pain met criteria for 
inclusion into the multivariate modelling.  Interestingly vomiting was not selected. 
The final model (Table 6.29) retained one predictor of overall oxycodone response at day three: 
drowsiness.  Higher drowsiness scores were associated with lower odds for oxycodone response. 
The model successfully predicted 49/49 of responders (100% sensitivity), however 0/7 first-line 
switchers (0% specificity).  Drowsiness was the most common reason stated for opioid switching 
from oxycodone (Table 6.16). 
 
Table 6.29  Morphine versus Oxycodone RCT: Titration-phase Day Three Scores Predictive of a Good 
Overall Response to Oxycodone 
Day 3 
B 
Standard 
Error Wald P value 
Odds 
Ratio 
95% C.I.for Odds 
Ratio 
Lower Upper 
Constant 2.75 0.65 17.75 0.00 15.70     
Drowsiness -0.29 0.14 4.34 0.04 0.75 0.57 0.98 
Multivariate logistic stepwise regression (backwards Wald method). n=56 
Dependant variable =  Clinical opioid response (Time Point B) / switching (Time Point C) 
R2 =0.075  (Cox and Snell),  .143 (Nagelkerke).  Model χ2 = 4.39, P = 0.036 
 
 
5.4.7.3.2 Day Seven Oxycodone Titration 
At day seven, pain and adverse reaction scores were available for 32 patients on first-line 
oxycodone.  Confusion/hallucinations/disorientation, worst pain and percentage relief scores all 
met criteria on univariate analysis for inclusion into the modelling process. 
The final model for oxycodone response from day seven scores shown in Table 6.30 retained one 
predictor: confusion/hallucination/disorientation.  Higher scores were associated with non-
response.  The model successfully predicted 25/26 of oxycodone responders (96% sensitivity) 
and 2/6 oxycodone first-line non-responders (33% specificity).  Confusion/hallucinations and 
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disorientation was the second most common reason for switching from oxycodone behind 
drowsiness (Table 6.16). 
 
Table 6.30  Morphine versus Oxycodone RCT: Titration-phase Day Seven Scores Predictive of a Good 
Overall Response to Oxycodone 
Day 7 
B 
Standard 
Error Wald P value 
Odds 
Ratio 
95% C.I.for Odds 
Ratio 
Lower Upper 
Constant 2.05 0.61 11.28 0.00 7.79   
Confusion etc -0.38 0.19 4.18 0.04 0.68 0.47 0.98 
Multivariate logistic stepwise regression (backwards Wald method). n=32 
Dependant variable =  Clinical opioid response (Time Point B) / switching (Time Point C) 
R2 =0.126  (Cox and Snell),  .203 (Nagelkerke).  Model χ2 = 4.30, P = 0.038 
 
 
5.4.8 Adverse Events and Withdrawals 
Titration phase adverse event recorded in the daily Toxicity Questionnaires (Appendix A) are 
presented in Section 6.4.2.  The safety data presented here encompass the adverse events not 
listed in the Toxicity Questionnaire during the initial or subsequent titration phases and all 
adverse events occurring in the monthly follow-up up to one year.   
 
Each adverse event was assessed for: 
• Severity (mild, moderate or severe) 
• Causality (possibly or probably related to study drug, or unrelated) 
• Expectedness (expected, not expected) 
• Seriousness (yes/no, seriousness defined as resulting in hospitalisation/prolongation of 
hospitalisation, life-threatening event, persistent/significant incapacity, congenital 
abnormality or significant medical other). 
 
Most of the patients entered into the Morphine versus Oxycodone RCT had advanced metastatic 
cancer with a limited prognosis. It was expected that complications due to disease progression, 
planned anti-cancer therapy or known co-morbidities would cause hospital admission, prolonged 
hospitalisation or even death and be classified as serious adverse events (SAEs).  Unexpected 
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SAEs were expeditedly reported to the Sponsor, however expected SAEs were excluded from 
expedited reporting by the trial Protocol and included in the Annual Reports.   
 
The below tables summarize the trial safety data up to the 24th August 2011, when five patients 
were still active on the study (Tables 6.31-36).   The adverse events were re-coded 
retrospectively into the MedDRA terminology, according to System Organ Class and Preferred 
Term in keeping with current recommendations 136.  Data are presented according as total 
adverse events and number of participants reporting ≥ 1 adverse event, as individuals may have 
several episodes of the same adverse event. 
 
Of the 200 patients recruited, 198 received more than one dose of the investigational medicinal 
product and were included in safety population.  In the safety population 98 were randomised to 
morphine and one hundred to oxycodone.  Including switching 114 participants received 
morphine and 129 participants received oxycodone.  There were nine reportable SAEs shown in 
Table 6.31 and 13 suspected serious adverse reactions (SSAR) shown in Table 6.32.  There were 
no suspected unexpected serious adverse reactions (SUSAR). 
 
In total there were 973 adverse events listed in Table 6.33 organised by MedDRA System Organ 
Class and Preferred Term.  Of the total number of adverse events, 135 were possibly or probably 
related to strong opioid.  Seventy-two were possibly or probably related to morphine and 81 were 
possibly or probably related to oxycodone (Table 6.34).   
One hundred and eighty three participants had greater than or equal to one adverse event, Table 
6.35 summarises these by MedDRA System Organ Class. Ninety seven participants receiving 
morphine had more than one adverse event.  Thirty-two percent (36/114) of participants 
receiving morphine had at least one adverse reaction.  One hundred and nine participants 
receiving oxycodone had at least one adverse event.  Thirty-six percent (46/129) of participants 
receiving oxycodone had at least one adverse reaction. Table 6.36 lists the adverse events 
occurring at least once deemed probably or possibly related to the study drug.  The most 
common of these adverse reactions for both drugs was constipation, followed by somnolence and 
nausea.
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Table 6.31  Morphine versus Oxycodone RCT: Serious Adverse Events which Required Reporting to the Sponsor as Per Protocol 
  Severity                                      Expectedness                           Relatedness                                Action                                      Outcome   
 1 = mild   1 = expected 1 = probably   1 = none  1 = recovered        
 2= moderate    2 = not expected  2 = possibly   2 = dose reduced 
temporarily 
2 = stabilized         
MedDRA Lower Level Term 3 = severe   3 = unrelated 3 = recovered with 
sequalae                
Reason for SAE 
       3 = study med 
interrupted 
 
       4 = not recovered yet     
         5 = fatal, 6 = unknown                 
Arthritis 3 2 3 1 3 Hospitalisation 
Medical device complication 3 2 3 1 3 Hospitalisation 
Adverse reaction 2 2 3 1 1 Hospitalisation 
Fall 2 2 3 1 5 Hospitalisation 
Upper GI haemorrhage 1 2 3 1 2 Hospitalisation 
Infective aneurysm 3 2 3 1 1 Hospitalisation 
Drug prescribing error 2 2 3 1 1 Significant medical other 
Acute coronary syndrome 2 2 3 1 1 Significant medical other 
Non-cardiac chest pain 2 2 3 3 1 Hospitalisation 
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Table 6.32  Morphine versus Oxycodone RCT: Summary of Suspected Serious Adverse Reactions  
  Severity                                      Expectedness                             Relatedness                                Action                                              Outcome         
 1 = mild   1 = expected 1 = probably   1 = none  1 = recovered         
 2= moderate    2 = not expected  2 = possibly   2 = dose 
reduced 
temporarily 
2 = stabilized          
MedDRA Lower Level Term 3 = severe   3 = unrelated 3 = recovered with sequalae                Reason for SAE IMP 
  
      3 = study med 
interrupted 
4 = not recovered 
yet      
        5 = fatal                    
          6 = unknown     
Confusion 2 1 2 2 1 Hospitalisation Morphine 
Drowsiness and hallucinations 2 1 2 2 2 Hospitalisation Oxycodone 
Confusion 2 1 2 2 1 Prolongation of hospitalisation Morphine 
Constipation 2 1 2 1 2 Hospitalisation Morphine 
Infection (causing opioid toxicity) 2 1 2 2 1 Hospitalisation Oxycodone 
Constipation 3 1 2 1 1 Hospitalisation Oxycodone 
Constipation 3 1 2 2 2 Hospitalisation Oxycodone 
Constipation 3 1 2 1 1 Hospitalisation Morphine 
Constipation 3 1 2 3 1 Hospitalisation Morphine 
Constipation 3 1 2 3 2 Hospitalisation Oxycodone 
Constipation 3 1 2 1 1 Hospitalisation Oxycodone 
Nausea and vomiting 2 1 2 3 1 Hospitalisation Oxycodone 
Confusion 2 1 2 3 2 Hospitalisation Oxycodone 
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Table 6.33  Morphine versus Oxycodone RCT: Total Adverse Events Reported by MedDRA System Organ 
Class and Preferred Term. 
MedDRA  
 
System Organ Class 
     Preferred Term 
Total Adverse 
Events (n=973) 
Adverse events in 
patients receiving 
morphine  
(n=419) 
Adverse events in 
patients receiving 
oxycodone 
(n=554) 
n % n % n % 
General disorders and administration site 
conditions 217 22.3 95 22.7 122 22.0 
 Pain 95 9.8 40 9.5 55 9.9 
 Fatigue 33 3.4 19 4.5 14 2.5 
 Death 30 3.1 14 3.3 16 2.9 
 Lethargy 12 1.2 5 1.2 7 1.3 
 Pyrexia 6 0.6 - - 6 1.1 
 Mobility decreased 3 0.3 2 0.5 1 0.2 
 Device occlusion 1 0.1 - - 1 0.2 
 Feeling abnormal 1 0.1 1 0.2 - - 
 Hot flush 1 0.1 1 0.2 - - 
 Influenza like illness 1 0.1 - - 1 0.2 
 Medical device complication 1 0.1 - - 1 0.2 
 Multi-organ failure 1 0.1 - - 1 0.2 
Gastrointestinal disorders 214 22.0 113 27.0 101 18.2 
 Vomiting 55 5.7 27 6.4 28 5.1 
 Nausea 45 4.6 25 6.0 20 3.6 
 Constipation  43 4.4 25 6.0 18 3.2 
 Diarrhoea 19 2.0 10 2.4 9 1.6 
 Mouth ulceration 9 0.9 6 1.4 3 0.5 
 Dysphagia 7 0.7 1 0.2 6 1.1 
 Intestinal obstruction 7 0.7 4 1.0 3 0.5 
 Dry mouth 5 0.5 2 0.5 3 0.5 
 Upper GI haemorrhage 5 0.5 2 0.5 3 0.5 
 Dyspepsia 4 0.4 1 0.2 3 0.5 
 Hiccups 4 0.4 2 0.5 2 0.4 
 Haemorrhoids 2 0.2 2 0.5 - - 
 Lower GI haemorrhage 2 0.2 2 0.5 - - 
 Acute abdomen  1 0.1 1 0.2 - - 
 Anal fissure 1 0.1 1 0.2 - - 
 Gastric ulcer perforation 1 0.1 1 0.2 - - 
 Oesophagitis 1 0.1 - - 1 0.2 
 Pancreatitis 1 0.1 - - 1 0.2 
 Steatorrhoea 1 0.1 1 0.2 - - 
 Toothache 1 0.1 - - 1 0.2 
Infections and infestations 96 9.9 33 7.9 63 11.4 
 Lower respiratory tract infection 29 3.0 8 1.9 21 3.8 
 Urinary tract infection 14 1.4 5 1.2 9 1.6 
 Oral candidiasis 8 0.8 2 0.5 6 1.1 
 Infection  6 0.6 1 0.2 5 0.9 
 Skin infection 6 0.6 3 0.7 3 0.5 
 Herpes virus infection 5 0.5 1 0.2 4 0.7 
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MedDRA  
 
System Organ Class 
     Preferred Term 
Total Adverse 
Events (n=973) 
Adverse events in 
patients receiving 
morphine  
(n=419) 
Adverse events in 
patients receiving 
oxycodone 
(n=554) 
n % n % n % 
 Conjunctivitis infective 4 0.4 2 0.5 2 0.4 
 Neutropenic sepsis 4 0.4 3 0.7 1 0.2 
 Biliary tract infection 3 0.3 3 0.7 - - 
 Cellulitis 3 0.3 1 0.2 2 0.4 
 Gastroenteritis 3 0.3 - - 3 0.5 
 Pneumonia 2 0.2 2 0.5 - - 
 Abdominal sepsis 1 0.1 1 0.2 - - 
 Anal infection 1 0.1 - - 1 0.2 
 Device related infection 1 0.1 - - 1 0.2 
 Hepatic infection 1 0.1 - - 1 0.2 
 Infective aneurysm 1 0.1 1 0.2 - - 
 Influenza   1 0.1 - - 1 0.2 
 Pharyngitis 1 0.1 - - 1 0.2 
 Respiratory tract infection viral 1 0.1 - - 1 0.2 
 Viral infection 1 0.1 - - 1 0.2 
Nervous system disorders 87 8.9 41 9.8 46 8.3 
 Somnolence 28 2.9 15 3.6 13 2.3 
 Spinal cord compression 11 1.1 5 1.2 6 1.1 
 Paraesthesia 8 0.8 4 1.0 4 0.7 
 Muscular weakness 7 0.7 4 1.0 3 0.5 
 Dizziness 6 0.6 2 0.5 4 0.7 
 Dyspepsia 4 0.4 1 0.2 3 0.5 
 Neuropathy peripheral  4 0.4 1 0.2 3 0.5 
 Agitation 2 0.2 - - 2 0.4 
 Cerebrovascular accident 2 0.2 1 0.2 1 0.2 
 Encephalopathy 2 0.2 2 0.5 - - 
 Memory impairment 2 0.2 1 0.2 1 0.2 
 Migraine 2 0.2 - - 2 0.4 
 Myoclonus 2 0.2 2 0.5 - - 
 Nerve root compression 2 0.2 - - 2 0.4 
 Tremor 2 0.2 1 0.2 1 0.2 
 Convulsion 1 0.1 1 0.2 - - 
 Diplopia 1 0.1 1 0.2 - - 
 Dysarthria 1 0.1 - - 1 0.2 
 Hypoaesthesia oral 1 0.1 1 0.2 - - 
 Peroneal nerve palsy 1 0.1 - - 1 0.2 
 Slow speech 1 0.1 - - 1 0.2 
Blood and lymphatic system disorders 43 4.4 11 2.6 32 5.8 
 Anaemia 33 3.4 8 1.9 25 4.5 
 Neutropenia   6 0.6 3 0.7 3 0.5 
 Thrombocytopenia 3 0.3 - - 3 0.5 
 Pancytopenia 1 0.1 - - 1 0.2 
Psychiatric disorders 43 4.4 16 3.8 27 4.9 
 Confusional state 11 1.1 3 0.7 8 1.4 
 Depressed mood 9 0.9 5 1.2 4 0.7 
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MedDRA  
 
System Organ Class 
     Preferred Term 
Total Adverse 
Events (n=973) 
Adverse events in 
patients receiving 
morphine  
(n=419) 
Adverse events in 
patients receiving 
oxycodone 
(n=554) 
n % n % n % 
 Hallucination 8 0.8 4 1.0 4 0.7 
 Abnormal dreams 4 0.4 1 0.2 3 0.5 
 Anxiety 4 0.4 2 0.5 2 0.4 
 Nightmare 2 0.2 - - 2 0.4 
 Alcohol withdrawal syndrome 1 0.1 - - 1 0.2 
 Depression 1 0.1 - - 1 0.2 
 Mental disorder 1 0.1 - - 1 0.2 
 Panic attack 1 0.1 1 0.2 - - 
 Suicidal ideation 1 0.1 - - 1 0.2 
Respiratory, thoracic and mediastinal disorders 41 4.2 18 4.3 23 4.2 
 Dyspnoea 24 2.5 13 3.1 11 2.0 
 Epistaxis 4 0.4 - - 4 0.7 
 Pleural effusion 4 0.4 2 0.5 2 0.4 
 Haemoptysis 3 0.3 2 0.5 1 0.2 
 Acute interstitial pneumonitis 1 0.1 - - 1 0.2 
 Acute respiratory failure 1 0.1 - - 1 0.2 
 Cough 1 0.1 - - 1 0.2 
 Haemothorax 1 0.1 1 0.2 - - 
 Nasal congestion 1 0.1 - - 1 0.2 
 Wheezing 1 0.1 - - 1 0.2 
Injury, poisoning and procedural complications 36 3.7 12 2.9 24 4.3 
 Fall 23 2.4 9 2.1 14 2.5 
 Medication error 3 0.3 - - 3 0.5 
 Incorrect dose administered 2 0.2 - - 2 0.4 
 Anaesthetic complication cardiac 1 0.1 - - 1 0.2 
 
Circumstance or information capable of leading to 
medication error 1 0.1 - - 1 0.2 
 Drug prescribing error 1 0.1 1 0.2 - - 
 Gastroenteritis radiation 1 0.1 - - 1 0.2 
 Iatrogenic pneumothorax 1 0.1 1 0.2 - - 
 Laceration 1 0.1 - - 1 0.2 
 Postoperative ileus 1 0.1 1 0.2 - - 
 Wound dihiscence 1 0.1 - - 1 0.2 
Metabolism and nutritional disorders 33 3.4 17 4.1 16 2.9 
 Decreased appetite 17 1.7 8 1.9 9 1.6 
 Abnormal loss of weight 11 1.1 7 1.7 4 0.7 
 Dehydration 3 0.3 1 0.2 2 0.4 
 Hypokalaemia 1 0.1 - - 1 0.2 
 Hyponatraemia 1 0.1 1 0.2 - - 
Renal and urinary disorders 33 3.4 13 3.1 20 3.6 
 Renal impairment 10 1.0 3 0.7 7 1.3 
 Urinary retention 5 0.5 2 0.5 3 0.5 
 Haematuria 4 0.4 1 0.2 3 0.5 
 Hydronephrosis 3 0.3 1 0.2 2 0.4 
 Urinary incontinence 3 0.3 2 0.5 1 0.2 
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MedDRA  
 
System Organ Class 
     Preferred Term 
Total Adverse 
Events (n=973) 
Adverse events in 
patients receiving 
morphine  
(n=419) 
Adverse events in 
patients receiving 
oxycodone 
(n=554) 
n % n % n % 
 Dysuria 2 0.2 1 0.2 1 0.2 
 Cystitis 1 0.1 1 0.2 - - 
 Nocturia 1 0.1 - - 1 0.2 
 Pollakiuria 1 0.1 - - 1 0.2 
 Prostatism 1 0.1 - - 1 0.2 
 Renal failure acute 1 0.1 1 0.2 - - 
 Urinary hesitation 1 0.1 1 0.2 - - 
Skin and subcutaneous tissue disorder 25 2.6 5 1.2 20 3.6 
 Rash 10 1.0 2 0.5 8 1.4 
 Hyperhidrosis 6 0.6 1 0.2 5 0.9 
 Pruritus 5 0.5 2 0.5 3 0.5 
 Palmar-plantar erthrodysaesthesia syndrome 2 0.2 - - 2 0.4 
 Skin nodule 2 0.2 - - 2 0.4 
Neoplasms benign, malignant and unspecified 20 2.1 8 1.9 12 2.2 
 Hypercalcaemia of malignancy 9 0.9 2 0.5 7 1.3 
 Malignant ascites 9 0.9 5 1.2 4 0.7 
 Infected neoplasm 1 0.1 1 0.2 - - 
 Tumour lysis syndrome 1 0.1 - - 1 0.2 
Musculoskeletal and connective tissue disorders 17 1.7 7 1.7 10 1.8 
 Fracture 4 0.4 - - 4 0.7 
 Pathological fracture 3 0.3 1 0.2 2 0.4 
 Joint range of motion decreased 2 0.2 1 0.2 1 0.2 
 Muscle spasm 2 0.2 1 0.2 1 0.2 
 Osteoarthritis 2 0.2 1 0.2 1 0.2 
 Arthralgia 1 0.1 1 0.2 - - 
 Joint stiffness 1 0.1 1 0.2 - - 
 Sinovial cyst 1 0.1 1 0.2 - - 
 Tenosynovitis 1 0.1 -  1 0.2 
Surgical and medical procedures 15 1.5 5 1.2 10 1.8 
 Mucositis management 5 0.5 2 0.5 3 0.5 
 Tumour excision 2 0.2 - - 2 0.4 
 Bile duct stent insertion 1 0.1 - - 1 0.2 
 Breast prosthesis removal 1 0.1 - - 1 0.2 
 Colostomy 1 0.1 1 0.2 - - 
 Ileostomy 1 0.1 1 0.2 - - 
 Interscapulothoracic amputation 1 0.1 1 0.2 - - 
 Oesophageal dilation disorders 1 0.1 - - 1 0.2 
 Orthopaedic procedure 1 0.1 - - 1 0.2 
 Spinal decompression 1 0.1 - - 1 0.2 
Vascular disorders 15 1.5 7 1.7 8 1.4 
 Deep vein thrombosis 4 0.4 1 0.2 3 0.5 
 Hypotension 3 0.3 3 0.7 - - 
 Cerebrovascular accident 2 0.2 1 0.2 1 0.2 
 Hypertension 2 0.2 1 0.2 1 0.2 
 Peripheral ischaemia 2 0.2 1 0.2 1 0.2 
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MedDRA  
 
System Organ Class 
     Preferred Term 
Total Adverse 
Events (n=973) 
Adverse events in 
patients receiving 
morphine  
(n=419) 
Adverse events in 
patients receiving 
oxycodone 
(n=554) 
n % n % n % 
 Haemorrhoidal haemorrhage 1 0.1 - - 1 0.2 
 Lymphoedema 1 0.1 - - 1 0.2 
Cardiac disorders 9 0.9 4 1.0 5 0.9 
 Arrythmia 2 0.2 1 0.2 1 0.2 
 Atrial fibrillation 2 0.2 - - 2 0.4 
 Tachycardia 2 0.2 - - 2 0.4 
 Acute coronary syndrome 1 0.1 1 0.2 - - 
 Palpitations 1 0.1 1 0.2 - - 
 Syncope 1 0.1 1 0.2 - - 
Endocrine disorders 6 0.6 3 0.7 3 0.5 
 Hypoglycaemia 3 0.3 2 0.5 1 0.2 
 Goitre 1 0.1 - - 1 0.2 
 Hyperthyroidism 1 0.1 - - 1 0.2 
 Hypothyroidism 1 0.1 1 0.2 - - 
Hepatobiliary disorders 6 0.6 2 0.5 4 0.7 
 Jaundice 3 0.3 1 0.2 2 0.4 
 Bile duct obstruction 1 0.1 - - 1 0.2 
 Cholecystitis acute 1 0.1 1 0.2 - - 
 Hepatic encephalopathy 1 0.1 - - 1 0.2 
Investigations 5 0.5 3 0.7 2 0.4 
 Liver function test abnormal 3 0.3 1 0.2 2 0.4 
 Oxygen saturation decreased 2 0.2 2 0.5 - - 
Eye disorders 4 0.4 2 0.5 2 0.4 
 Visual impairment 2 0.2 - - 2 0.4 
 Blepharospasm 1 0.1 1 0.2 - - 
 Lacrimation increased 1 0.1 1 0.2 - - 
Reproductive system and breast disorders 4 0.4 1 0.2 3 0.5 
 Vaginal haemorrhage 3 0.3 1 0.2 2 0.4 
 Vulvovaginal discomfort 1 0.1 - - 1 0.2 
Immune system disorders 3 0.3 2 0.5 1 0.2 
 Rheumatoid arthritis 3 0.3 2 0.5 1 0.2 
Pregnancy, puerperium and perinatal conditions 1 0.1 1 0.2 - - 
 Pregnancy 1 0.1 1 0.2 - - 
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Table 6.34  Morphine versus Oxycodone RCT: Total Number of Possible or Probable Adverse Reactions. 
MedDRA  Adverse events 
related to opioid 
(n=153) 
Adverse related to 
morphine (n=72) 
Adverse events 
related to 
oxycodone (n=81) System Organ Classification 
  Preferred Term n % n % n % 
General disorders and administration site 
conditions 5 3.3 4 5.6 1 1.2 
 Pain 1 0.7 1 1.4 - - 
 Lethargy 1 0.7 - - 1 1.2 
 Mobility decreased 2 1.3 2 2.8 - - 
 Feeling abnormal 1 0.7 1 1.4 - - 
Gastrointestinal disorders 76 49.7 36 50.0 40 49.4 
 Vomiting 13 8.5 4 5.6 9 11.1 
 Nausea 16 10.5 6 8.3 10 12.3 
 Constipation  42 27.5 24 33.3 18 22.2 
 Dry mouth 5 3.3 2 2.8 3 3.7 
Nervous system disorders 37 24.2 19 26.4 18 22.2 
 Somnolence 25 16.3 13 18.1 12 14.8 
 Paraesthesia 1 0.7 - - 1 1.2 
 Dizziness 5 3.3 2 2.8 3 3.7 
 Memory impairment 2 1.3 1 1.4 1 1.2 
 Myoclonus 2 1.3 2 2.8 - - 
 Diplopia 1 0.7 1 1.4 - - 
 Slow speech 1 0.7 - - 1 1.2 
 Psychiatric disorders 22 14.4 7 9.7 15 18.5 
 Confusional state 9 5.9 2 2.8 7 8.6 
 Hallucination 7 4.6 4 5.6 3 3.7 
 Abnormal dreams 4 2.6 1 1.4 3 3.7 
 Nightmare 2 1.3 - - 2 2.5 
Injury, poisoning and procedural complications 3 2.0 3 4.2 - - 
 Fall 3 2.0 3 4.2 - - 
Metabolism and nutritional disorders 1 0.7 - - 1 1.2 
 Decreased appetite 1 0.7 - - 1 1.2 
Renal and urinary disorders 1 0.7 1 1.4 - - 
 Urinary hesitation 1 0.7 1 1.4 - - 
Skin and subcutaneous tissue disorder 7 4.6 2 2.8 5 6.2 
 Hyperhidrosis 2 1.3 - - 2 2.5 
 Pruritus 5 3.3 2 2.8 3 3.7 
Eye disorders 1 0.7 - - 1 1.2 
 Visual impairment 1 0.7 - - 1 1.2 
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Table 6.35  Morphine versus Oxycodone RCT: Number of Participants Reporting an Adverse Event at least once  
MedDRA Overall safety population 
(n=198) 
Morphine  
(n=114*) 
Oxycodone  
(n=129*) 
System Organ Class n % n % n % 
General disorders and administration site conditions 107 54.0 49 43.0 64 49.6 
Gastrointestinal disorders 97 49.0 50 43.9 52 40.3 
Infections and infestations 63 31.8 22 19.3 41 31.8 
Nervous system disorders 60 30.3 30 26.3 34 26.4 
Psychiatric disorders 35 17.7 15 13.2 21 16.3 
Injury, poisoning and procedural complications 30 15.2 11 9.6 20 15.5 
Renal and urinary disorders 30 15.2 13 11.4 17 13.2 
Respiratory, thoracic and mediastinal disorders 30 15.2 15 13.2 17 13.2 
Blood and lymphatic system disorders 29 14.6 9 7.9 20 15.5 
Metabolism and nutritional disorders 26 13.1 13 11.4 14 10.9 
Skin and subcutaneous tissue disorder 17 8.6 5 4.4 14 10.9 
Musculoskeletal and connective tissue disorders 15 7.6 6 5.3 9 7.0 
Neoplasms benign, malignant and unspecified 14 7.1 6 5.3 8 6.2 
Surgical and medical procedures 14 7.1 5 4.4 9 7.0 
Vascular disorders 14 7.1 6 5.3 8 6.2 
Cardiac disorders 9 4.5 4 3.5 5 3.9 
Endocrine disorders 6 3.0 3 2.6 3 2.3 
Hepatobiliary disorders 5 2.5 2 1.8 3 2.3 
Investigations 5 2.5 3 2.6 2 1.6 
Eye disorders 4 2.0 2 1.8 2 1.6 
Reproductive system and breast disorders 4 2.0 1 0.9 3 2.3 
Immune system disorders 2 1.0 1 0.9 1 0.8 
Pregnancy, puerperium and perinatal conditions 1 0.5 1 0.9 - - 
The safety population represents patients receiving greater than or equal to one dose of the first-line investigational medicinal product, n=198 (morphine = 98, oxycodone=100).  
*Including opioid switching 114 patients received morphine and 129 patients received oxycodone.  **Includes adverse events possibly or probably related to opioid (adverse 
reactions). 
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Table 6.36  Morphine versus Oxycodone RCT: Number of Participants Reporting an Opioid Related Adverse 
Event at least once 
MedDRA  
Overall safety 
population Morphine Oxycodone 
  
Patients with 
IMP opioid 
related AE (n) 
% total 
safety 
population 
Patients with 
morphine 
related AE (n) 
% patients 
receiving 
morphine 
Patients 
with 
oxycodone 
related AE 
(n) 
% patients 
receiving 
oxycodone 
System Organ Class 
  Preferred Term 
Gastrointestinal disorders 46 23.2 21 18.4 28 21.7 
 Constipation  34 17.2 20 17.5 16 12.4 
 Nausea 14 7.1 6 5.3 10 7.8 
 Vomiting 12 6.1 4 3.5 9 7.0 
 Dry mouth 5 2.5 2 1.8 3 2.3 
Nervous system disorders 33 16.7 17 14.9 17 13.2 
 Somnolence 24 12.1 13 11.4 12 9.3 
 Dizziness 5 2.5 2 1.8 3 2.3 
 Memory impairment 2 1.0 1 0.9 1 0.8 
 Myoclonus 2 1.0 2 1.8 - - 
 Paraesthesia 1 0.5 - - 1 0.8 
 Slow speech 1 0.5 - - 1 0.8 
 Diplopia 1 0.5 1 0.9 - - 
Psychiatric disorders 21 10.6 7 6.1 15 11.6 
 Confusional state 9 4.5 2 1.8 7 5.4 
 Hallucination 6 3.0 4 3.5 3 2.3 
 Abnormal dreams 4 2.0 1 0.9 3 2.3 
 Nightmare 2 1.0 - - 2 1.6 
General disorders and 
administration site conditions 5 2.5 4 3.5 1 0.8 
 Mobility decreased 2 1.0 2 1.8 - - 
 Feeling abnormal 1 0.5 - - - - 
 Lethargy 1 0.5 - - 1 0.8 
 Pain 1 0.5 1 0.9 - - 
Skin and subcutaneous tissue 
disorder 5 2.5 2 1.8 4 3.1 
 Pruritus 4 2.0 - - 3 2.3 
 Hyperhidrosis 2 1.0 - - 2 1.6 
Injury, poisoning and procedural 
complications 3 1.5 3 2.6 - - 
 Fall 3 1.5 3 2.6 - - 
Renal and urinary disorders 1 0.5 1 0.9 - - 
 Urinary hesitation 1 0.5 1 0.9 - - 
Metabolism and nutritional 
disorders 1 0.5 - - 1 0.8 
 Decreased appetite 1 0.5 - - 1 0.8 
Eye disorders 1 0.5 - - 1 0.8 
 Visual impairment 1 0.5 - - 1 0.8 
The safety population represents patients receiving greater than or equal to one dose of the first-line investigational medicinal product 
(IMP), n=198 (morphine = 98, oxycodone=100).  *Including opioid switching 114 patients received morphine and 129 patients received 
oxycodone.  **Includes adverse events (AE) possibly or probably related to opioid (adverse reactions). 
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5.4.8.1 Reasons for Study End-point or Withdrawal 
At the time the study data was locked for this analysis there were five participants still active on 
the trial.  Table 6.37 describes the reasons for reaching study end-point/withdrawal for the other 
195 participants.  Fourteen completed the one year follow-up period per protocol, and twelve did 
not respond or lost response to the second-line opioid.  Eight other participants withdrew because 
of an adverse event, one on morphine and seven on oxycodone.  The most common reason for 
withdrawal was the conversion from oral to parenteral opioid as the participant was unable to 
take oral medication for whatever reason at 24.5%.  Death was the next common reason at16.5 % 
followed by improvement of pain with anti-cancer treatment allowing strong opioid to be 
discontinued at 13.5%.  Eleven participants requested to be withdrawn from the study as they 
found it too burdensome.   
  
  187 
 
Table 6.37  Morphine versus Oxycodone RCT: Reasons for Reaching Study End-point 
  Total population (n = 200) Morphine (n=100) Oxycodone (n=100) 
Reason for reaching study end-point n % n % n % 
              
Non response to 2nd line opioid (Time Point F) 12 6.0 10 10.0 2 2.0 
              
Completed 1 year 14 7.0 5 5.0 9 9.1 
              
Converted to parenteral opioids/unable to take oral 49 24.5 20 20.0 29 29.3 
Patient died 33 16.5 17 17.0 16 16.2 
Pain improved, stopped opioid 27 13.5 17 17.0 10 10.1 
Too unwell to continue 16 8.0 8 8.0 8 8.1 
Too burdensome 11 5.5 7 7.0 4 4.0 
Renal impairment of  >1.5X upper limit of normal 9 4.5 5 5.0 4 4.0 
Adverse event/adverse reaction 8 4.0 1 1.0 7 7.1 
              
Other             
    Physician recommendation 3 1.5 1 1.0 2 2.0 
    Declined Tablets, requested patch 3 1.5 1 1.0 2 2.0 
    New non cancer-related pain  2 1.0 1 1.0 1 1.0 
    Reluctance to take strong opioid analgesia 2 1.0 - - 2 2.0 
    Pregnancy 1 0.5 1 1.0 - - 
    Moved abroad 1 0.5 - - 1 1.0 
    Insurance issue 1 0.5 1 1.0 - - 
    Previous reaction to randomised opioid 1 0.5 1 1.0 - - 
    Concern re Northwick Park study 1 0.5 - - 1 1.0 
    Patient request to withdraw, no reason given 1 0.5 1 1.0 - - 
              
Active patient 5 2.5 3 3.0 2 2.0 
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5.4.8.2 Trial Duration 
The maximum trial duration was 365 days (one year).  The median trial duration for all 
participants was 33 days, which was similar in both morphine and oxycodone subgroups 
(Mantel-Cox, P=0.42).  Data for subjects still active in the study were censored.  Figure 6.13 
shows the length of time on study for participants by first-line randomised opioid.  
 
Figure 6.13 Morphine versus Oxycodone RCT:  Kaplan Meier Curve: Length of Time on Trial by First-
line Opioid 
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5.4.8.3 Participant Survival 
The study was censored five days after the final participant achieved the primary outcome 
time point first-line opioid response/non-response.  At this juncture, five participants 
remained active on the study.  Survival from participant entry to the study was calculated 
from medical records.  One hundred and fifty two participants had died, 42 participants were 
still alive and 6 had been lost to long-term hospital follow-up. 
 
Figure 6.14 shows the Kaplan Meier Curve for survival after study entry, with censored data 
indicated. Mantel-Cox analysis showed that there was no significant difference in survival 
between the two groups (P=0.06). 
 
Figure 6.14  Morphine versus Oxycodone RCT: Kaplan Meier Curve: Survival of Participants by 
Randomised Opioid 
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5.4.9 Immunology 
It has been suggested that exogenous opioids may detrimentally affect the function of the 
immune system by influencing cell number and function 137.  The mechanism of action being 
either/or a combination of direct action via white cell surface opioid receptors or via the 
hypothalamic-pituitary-adrenal axis.   It has also been hypothesised that the 
immunosuppressive qualities may vary between different strong opioids 80. 
 
Blood samples for white cell differential and lymphocyte subsets were collected at the 
various study time points.  Although immune cell function could not be determined in this 
manner an overview of cell numbers and ratios could be seen.  The mean and standard 
deviation of the various immune cell subsets in the total trial population over time are 
presented in Table 6.38, in the patients randomised to morphine first-line in Table 6.39 and in 
patients randomised to oxycodone first-line in Table 6.40. 
 
There was no difference seen between any of the lymphocyte subsets tested between baseline 
and Time Point B for the trial population as a whole or for each opioid separately.   
The only difference between baseline and Time Point C was CD4+ percentage in the total 
trial population, where the mean percentage was greater at Time Point C (P=0.027, paired t-
test).  There was no difference seen when morphine and oxycodone groups were considered 
separately, and no difference seen in either CD8+ percentage of CD4:CD8 ratio.  The high 
degree of variability for each of the immunological indices measured should be noted.  There 
are several possible confounding factors unaccounted for in this analysis such as age, 
infection, chemotherapy, steroids and tumour type. 
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Table 6.38  Morphine versus Oxycodone RCT: Haematological and Immunological Results for Total 
Trial Population 
 
Total Time Point A Time Point B Time Point C Time Point D 
 n=178-196 n=102-116 n=36-43 n=22-24 
Haemoglobin (g/dL) 11.53 ± 1.83 11.34 ± 1.64 11.38 ± 1.70 11.37 ± 1.48 
White blood cells (x109/L) 9.56 ± 7.20 10.04 ± 8.13 8.79 ± 7.12 8.55 ± 6.38 
Platelets (x109/L) 290.45 ± 143.90 279.01 ± 158.36 277.56 ±  127.46 265.00 ± 117.90 
Neutrophils (x109/L) 7.42 ± 6.73 8.05 ± 7.80 6.52 ± 7.00 6.35 ± 4.94 
Lymphocytes  (x109/L) 1.24 ± 0.73 1.15 ± 0.65 1.15 ± 0.58 1.02 ± 0.67 
Monocytes  (x109/L) 0.73 ± 0.44 0.72 ± 0.48 0.67 ± 0.34 0.80 ± 0.54 
Eosinophils  (x109/L) 0.17 ± 0.35 0.15 ± 0.17 0.14 ± 0.15 0.35 ± 1.15 
Basophils  (x109/L) 0.04 ± 0.04 0.04 ± 0.04 0.04 ± 0.04 0.03 ± 0.03 
         
 n=152 n=93 n=28 n=17 
CD3+ lymphocytes 784.35 ± 5.33.87 810.47 ± 536.57 806.14 ± 470.19 657.00 ± 481.35 
CD3+ percentage 72.9 ± 12.94 73.80 ± 12.41 72.88 ± 11.21 71.40 ± 13.74 
CD19+ lymphocytes 135.03 ± 148.20 124.74 ± 128.79 132.21 ± 113.55 97.24 ± 68.10 
CD19+ percentage 12.42 ± 9.84 11.77 ± 9.59 12.75 ± 10.46 13.60 ± 12.20 
CD4+ lymphocytes 500.72 ± 388.61 524.04 ± 430.41 520.39 ± 327.71 446.94 ± 359.93 
CD4+ percentage 45.69 ± 14.16 46.29 ± 14.88 47.21* ± 11.97 48.34 ± 11.28 
CD8+ lymphocytes 274.11 ± 213.26 274.91 ± 182.33 263.11 ± 156.79 208.76 ± 169.74 
CD8+ percentage 26.58 ± 11.33 26.73 ± 10.55 24.39 ± 7.78 23.14 ± 8.04 
Absolute lymphocyte count 1015.20 ± 624.98 1032.69 ± 605.99 1040.68 ± 550.44 836.82 ± 541.11 
NK cells 96.03 ± 63.76 97.45 ± 71.31 102.32 ± 62.69 82.59 ± 41.71 
NK percentage 10.70 ± 8.28 10.68 ± 7.31 10.60 ± 6.02 11.46 ± 6.79 
CD4:CD8 Ratio 2.36 ± 2.24 2.41 ± 2.45 2.14 ± 1.15 2.37 ± 1.05 
mean ±SD  *P<0.05                 
A range for n is given for the haematological indices as not all tests were performed routinely on each sample. 
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Table 6.39  Morphine versus Oxycodone RCT: Haematological and Immunological Results for 
Participants Receiving Morphine First-line 
 
Morphine first-line   Morphine Oxycodone Time Point A Time Point B Time Point C Time Point D 
  n=89-97 n=44-51 n=25-29 n=13-15 
Haemoglobin (g/dL) 11.43 ± 1.84 11.47 ± 1.60 11.49 ± 1.70 11.32 ± 1.65 
White blood cells (x109/L) 9.92 ± 8.13 10.13 ± 8.21 9.56 ± 7.97 7.49 ± 3.91 
Platelets (x109/L) 297.84 ± 153.03 293.96 ± 143.66 287.93 ± 126.64 260.20 ± 121.49 
Neutrophils (x109/L) 7.93 ± 7.89 8.34 ± 8.11 7.42 ± 8.11 5.69 ± 3.41 
Lymphocytes  (x109/L) 1.24 ± 0.75 1.24 ± 0.72 1.22 ± 0.65 1.01 ± 0.83 
Monocytes  (x109/L) 0.77 ± 0.52 0.69 ± 0.42 0.66 ± 0.35 0.65 ± 0.51 
Eosinophils  (x109/L) 0.16 ± 0.31 0.15 ± 0.20 0.15 ± 0.17 0.13 ± 0.29 
Basophils  (x109/L) 0.04 ± 0.05 0.02 ± 0.02 0.04 ± 0.04 0.03 ± 0.03 
         
 n=79 n=42 n=17 n=10 
CD3+ lymphocytes 819.58 ± 575.23 795.55 ± 452.05 879.06 ± 522.83 705.70 ± 614.98 
CD3+ percentage 71.57 ± 13.62 74.42 ± 13.28 71.96 ± 10.31 67.56 ± 17.00 
CD19+ lymphocytes 146.95 ± 165.04 119.10 ± 138.93 163.76 ± 123.90 114.60 ± 72.61 
CD19+ percentage 13.20 ± 11.00 11.76 ± 10.98 14.51 ± 11.56 16.67 ± 14.89 
CD4+ lymphocytes 509.29 ± 387.95 497.50 ± 306.47 555.41 ± 370.07 485.20 ± 462.91 
CD4+ percentage 44.08 ± 13.19 46.94 ± 13.54 44.98 ± 11.86 45.65 ± 13.33 
CD8+ lymphocytes 298.97 ± 246.17 286.33 ± 192.32 295.71 ± 164.89 223.30 ± 213.35 
CD8+ percentage 26.70 ± 11.64 26.86 ± 10.69 25.42 ± 8.40 21.78 ± 9.61 
Absolute lymphocyte count 1072.59 ± 669.66 1011.95 ± 521.43 1149.53 ± 619.23 905.80 ± 680.48 
NK cells 106.08 ± 70.00 97.26 ± 73.79 106.71 ± 72.35 85.50 ± 44.69 
NK percentage 10.97 ± 8.47 9.98 ± 6.72 10.22 ± 6.66 12.35 ± 8.38 
CD4:CD8 Ratio 2.24 ± 2.12 2.33 ± 1.95 2.08 ± 1.29 2.49 ± 1.28 
mean  ±  SD               
A range for n is given for the haematological indices as not all tests were performed routinely on each sample. 
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Table 6.40  Morphine versus Oxycodone RCT: Haematological and Immunological Results for 
Participants Receiving Oxycodone First-line 
 
Oxycodone first-line   
Oxycodone Morphine 
Time Point A Time Point B Time Point C Time Point D 
  n=89-99 n=58-65 n=11-14 n=9 
Haemoglobin (g/dL) 11.62 ± 1.83 11.25 ± 1.67 11.14 ± 1.74 11.44 ± 1.23 
White blood cells (x109/L) 9.21 ± 6.18 9.97 ±  8.13 7.21 ± 4.80 10.31 ± 9.20 
Platelets (x109/L) 283.27 ± 134.85 267.28 ± 169.17 256.07 ± 131.16 273.00 ± 118.41 
Neutrophils (x109/L) 6.92 ± 5.37 7.81 ± 7.60 4.33 ± 1.77 7.46 ± 6.89 
Lymphocytes  (x109/L) 1.24 ± 0.71 1.08 ± 0.59 1.00 ± 0.36 1.04 ± 0.25 
Monocytes  (x109/L) 0.68 ± 0.36 0.75 ± 0.53 0.68 ± 0.33 1.06 ± 0.51 
Eosinophils  (x109/L) 0.19 ± 0.40 0.15 ± 0.14 0.14 ± 0.12 0.69 ± 1.81 
Basophils  (x109/L) 0.04 ± 0.04 0.05 ± 0.04 0.04 ± 0.03 0.03 ± 0.03 
         
 n=73 n=51 n=11 n=7 
CD3+ lymphocytes 746.22 ± 486.26 822.76 ± 601.54 693.45 ± 369.51 587.43 ± 202.37 
CD3+ percentage 74.51 ± 12.07 73.29 ± 11.75 74.29 ± 12.87 76.89 ± 3.19 
CD19+ lymphocytes 122.14 ± 126.39 129.39 ± 121.00 83.45 ± 77.11 72.43 ± 56.90 
CD19+ percentage 11.57 ± 8.40 11.79 ± 8.39 10.03 ± 8.24 9.21 ± 5.12 
CD4+ lymphocytes 491.45 ± 391.80 545.90 ± 512.62 466.27 ± 256.00 392.29 ± 134.56 
CD4+ percentage 47.43 ± 15.04 45.75 ± 16.01 50.65 ± 11.85 52.17 ± 6.62 
CD8+ lymphocytes 247.21 ± 168.28 265.51 ± 175.03 212.73 ± 135.20 188.00 ± 87.75 
CD8+ percentage 26.44 ± 11.06 26.62 ± 10.55 22.78 ± 6.78 25.09 ± 5.13 
Absolute lymphocyte count 953.08 ± 570.81 1049.76 ± 672.36 872.45 ± 391.50 738.29 ± 258.75 
NK cells 85.16 ± 54.64 97.61 ± 69.94 95.55 ± 46.40 78.43 ± 40.12 
NK percentage 10.42 ± 8,13 11.25 ± 7.78 11.17 ± 5.14 10.20 ± 3.78 
CD4:CD8 Ratio 2.48 ± 2.38 2.47 ± 2.81 2.23 ± 0.95 2.20 ± 0.67 
mean  ±  SD           
A range for n is given for the haematological indices as not all tests were performed routinely on each sample. 
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5.4.10 Principal Component Analysis 
PCA was conducted on 16 clinical response variables: five pain descriptors and ten adverse 
reactions using SPSS version 17.0 (Table 6.41).   Percentage relief was transformed to 100 
minus percentage relief to make the direction of response in keeping with the other pain 
scores i.e. a high score would reflect more pain or less relief. 
 
Table 6.41 Morphine versus Oxycodone RCT: Variables included in the Principal Component Analysis 
Adverse reactions Pain indices 
Nausea* Worst pain* 
Vomiting* Least pain* 
Constipation Average pain* 
Diarrhoea Pain right now* 
Drowsiness* 100 – (Percentage relief)* 
Confusion*   
Nightmares*   
Dry mouth   
Itch   
Myoclonus   
Adverse reactions measured on a an 11 point NRS (0-10) 
Pain indices from the Modified Brief Pain Inventory, (NRS 0-10) 
*Variables retained for final PCA 
 
 
The regression method was used to calculate Component scores 93.  Rotation was carried out 
using the oblique method (direct oblimin) as opioid response Components may possibly be 
related.  All Components with eigenvalues >1 were retained. 
 
5.4.11 Morphine versus Oxycodone RCT: Opioid Response Principal Component Analysis 
From the preliminary morphine PCA, several variables were excluded for not correlating 
>0.3 with any other variable: constipation, diarrhoea, dry mouth, itch and myoclonus.  
Diarrhoea, itch and myoclonus also had individual KMO values less than 0.5 or borderline 
indicating inadequate sampling adequacy for analysis at 0.472, 0.389 and 0.453  respectively 
89.  Five pain and five adverse reaction variables were retained in the final analysis. The 
sample size was adequate to perform PCA, with overall KMO value 0.751 and Bartlett’s test 
of sphericity <0.005 
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The final opioid PCA identified three Components with eigenvalues > 1, detailed in Table 
6.42.  The pattern and structure matrices containing the factor loadings are shown in Table 
6.43.  The variables that cluster in the same Component suggests that Component 1 
represents opioid analgesic response, Component 2 represents opioid central adverse 
reactions and Component 3 represents the GI adverse reactions of nausea and vomiting.  This 
is very similar to the Components of morphine response described from the Prospective 
Morphine Study (Chapter 5).  The grouping of Components is demonstrated in Figure 6.15.  
Table 6.44 shows that correlation between the Components is low and therefore they may be 
analysed independently. 
 
Table 6.42  Morphine versus Oxycodone RCT: PCA Table of the Total Variance Explained by the Main 
Components of Opioid Response. 
Component 
Initial Eigenvalues Extraction Sums of Squared Loadings 
Rotation Sums 
of Squared 
Loadings 
Total 
% of 
Variance 
Cumulative 
% Total 
% of 
Variance 
Cumulative 
% Total 
1 4.177 41.766 41.766 4.177 41.766 41.766 3.868 
2 1.872 18.719 60.485 1.872 18.719 60.485 2.332 
3 1.223 12.227 72.713 1.223 12.227 72.713 2.141 
4 .652 6.518 79.231       
5 .542 5.422 84.653       
6 .478 4.781 89.433       
7 .351 3.511 92.944       
8 .300 2.995 95.940       
9 .236 2.359 98.298       
10 .170 1.702 100.000        
 n=146 
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Table 6.43 Morphine versus Oxycodone RCT:  PCA Opioid Response Pattern and Structure Matrices 
Opioid Response Pattern Matrix  Opioid Response Structure Matrix 
  Component    Component 
  1 2 3    1 2 3 
Average pain .876      Average pain .899     
Least pain .859      Least pain .856     
Pain now .847      Pain now .825     
Worst pain .810      Worst pain .809     
100-% relief .807      100-% relief .809     
Vomiting   .921    Nausea   .908   
Nausea   .910    Vomiting   .907   
Drowsiness        Drowsiness .416 .545 .523 
Confusion etc     .880  Confusion etc     .879 
Nightmares     .867  Nightmares     .859 
 n=146 
 
Rotation Method: Oblimin with Kaiser Normalisation 
n=146 
 
Figure 6.15 Morphine versus Oxycodone RCT:  PCA Opioid Response Component Plot in Rotated Space  
 
 
Three Components of morphine response generated by PCA : Component 1 analgesic response (red), 
Component 2 central adverse reactions (blue), Component 3 GI adverse reactions (yellow) (n=146) 
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Table 6.44  Morphine versus Oxycodone RCT:  Opioid Response Component Correlation Matrix. 
Component 1 2 3 
1 1.00 0.27 0.23 
2 0.27 1.00 0.28 
3 0.23 0.28 1.00 
  
 
 
5.4.12 Morphine versus Oxycodone RCT: Morphine Response Principal Component 
Analysis 
From the preliminary morphine PCA, several variables were excluded for not correlating 
(>0.3) with any other variable: constipation, dry mouth and myoclonus.  Diarrhoea, itch and 
myoclonus also had individual KMO values less than 0.5 or borderline indicating inadequate 
sampling adequacy for analysis at 0.376, 0.298 and 0.236 respectively 89.  Five pain and five 
adverse reaction variables were retained in the final analysis.  The sample size was adequate 
to perform PCA, with overall KMO value 0.787 and Bartlett’s test of sphericity <0.005. 
 
The final morphine PCA identified three Components with eigenvalues > 1, shown in Table 
6.45.  The pattern and structure matrices containing the factor loadings are shown if Table 
6.46.  The variables that cluster in the same Component suggests that Component 1 
represents analgesic response to morphine, Component 2 represents central adverse reactions 
to morphine and Component 3 represents the GI adverse reactions of nausea and vomiting.  
This is very similar to the Components derived from the Prospective Morphine Study 
(Chapter 5) however Components 2 and 3 are reversed.  The grouping of Components is 
demonstrated in Figure 6.16.  Table 6.47 shows that correlation the between the Components 
is low and therefore they may be analysed independently. 
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Table 6.45  Morphine versus Oxycodone RCT: PCA Table of the Total Variance Explained by the Main 
Components of Morphine Response 
Component 
Initial Eigenvalues Extraction Sums of Squared Loadings 
Rotation Sums 
of Squared 
Loadings 
Total 
% of 
Variance 
Cumulative 
% Total 
% of 
Variance 
Cumulative 
% Total 
1 4.676 46.763 46.763 4.676 46.763 46.763 4.213 
2 1.896 18.956 65.720 1.896 18.956 65.720 2.538 
3 1.156 11.556 77.276 1.156 11.556 77.276 2.721 
4 .545 5.454 82.730     
5 .509 5.090 87.820     
6 .382 3.821 91.641     
7 .273 2.729 94.370     
8 .242 2.424 96.793     
9 .185 1.847 98.641     
10 .136 1.359 100.000     
 n=72 
 
 
 
Table 6.46  Morphine versus Oxycodone RCT:  PCA Morphine Pattern and Structure Matrices 
Morphine Pattern Matrix  Morphine Structure Matrix 
  Component    Component 
  1 2 3    1 2 3 
Average pain .891      Average pain .918     
Pain now .869      Least pain .852   -.412 
Worst pain .847      100 - % relief .851     
100 - % relief .838      Pain now .842     
Least pain .818      Worst pain .806     
Nightmares   .952    Confusion etc   .937   
Confusion etc   .943    Nightmares   .933   
Drowsiness        Vomiting     -.930 
Vomiting     -.951  Nausea     -.907 
Nausea     -.901  Drowsiness .535 .579 -.588 
 n=72 
 
Rotation Method: Oblimin with Kaiser Normalisation 
n=72 
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Figure 6.16  Morphine versus Oxycodone RCT:  PCA Morphine Response Component Plot in Rotated 
Space 
 
Three Components of morphine response generated by PCA : Component 1 analgesic response (red), 
Component 2 central adverse reactions (blue), Component 3 GI adverse reactions (yellow) (n=72) 
 
 
Table 6.47   Morphine versus Oxycodone RCT:  Morphine Response Component Correlation Matrix. 
Component 1 2 3 
1 1.00 .26 -.35 
2 .26 1.000 -.36 
3 -.35 -.36 1.00 
  
 
 
5.4.13 Morphine versus Oxycodone RCT:  Oxycodone Response Principal Component 
Analysis 
Several variables were also excluded from the preliminary oxycodone PCA for not 
correlating >0.3 with any other variable: constipation, diarrhoea and dry mouth.  Diarrhoea, 
dry mouth, itch and myoclonus also had individual KMO values less than 0.5 or borderline 
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indicating inadequate sampling adequacy for analysis at 0.439, 0.485, 0.463 and 0.488 
respectively 89.  Therefore the same five pain and five adverse reaction variables were 
retained in the final analysis as for morphine.  The sample size was adequate to perform PCA, 
with overall KMO value 0.692 and Bartlett’s test of sphericity <0.005 
The final oxycodone PCA identified three Components with eigenvalues > 1, shown in Table 
6.48.  The pattern and structure matrices containing the factor loadings are shown if Table 
6.49.  The variables that cluster in the same Component suggest that Component 1 represents 
analgesic response to oxycodone, similar to that of morphine. Component 2 represents the GI 
adverse reactions of nausea and vomiting, and in addition drowsiness.  Finally Component 3 
represents the central adverse reactions of confusion, hallucinations, disorientation and 
nightmares.  The grouping of and separation between Components is demonstrated in Figure 
6.17.  Table 6.50 shows correlation between Components is low and therefore may be 
analysed independently. 
 
Table 6.48  Morphine versus Oxycodone RCT:  PCA Table of the Total Variance Explained by the Main 
Components of Oxycodone Response. 
Component 
Initial Eigenvalues Extraction Sums of Squared Loadings 
Rotation Sums 
of Squared 
Loadings 
Total 
% of 
Variance 
Cumulative 
% Total 
% of 
Variance 
Cumulative 
% Total 
1 3.596 35.957 35.957 3.596 35.957 35.957 3.455 
2 1.883 18.833 54.790 1.883 18.833 54.790 1.954 
3 1.345 13.448 68.237 1.345 13.448 68.237 1.749 
4 .952 9.519 77.757       
5 .634 6.341 84.098       
6 .510 5.102 89.200       
7 .440 4.396 93.597       
8 .284 2.837 96.434       
9 .235 2.353 98.787       
10 .121 1.213 100.000         
 n=74 
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Table 6.49  Morphine versus Oxycodone RCT:  PCA Oxycodone Pattern and Structure Matrices (n=75). 
Oxycodone Pattern Matrix  Oxycodone Structure Matrix 
  Component    Component 
  1 2 3    1 2 3 
Least pain .898      Least pain .871     
Pain now .824      Average pain .859   .444 
Average pain .819      Pain now .807     
100-Pain relief .786      Worst pain .790   .496 
Worst pain .737      100-Pain relief .779     
Nausea   .918    Nausea   .904   
Vomiting   .856    Vomiting   .847   
Drowsiness   .485    Drowsiness   .547   
Nightmares     .774  Nightmares     .761 
Confusion etc     .735  Confusion etc     .745 
  n=74 
 
Rotation Method: Oblimin with Kaiser Normalisation 
 n=74 
 
Figure 6.17  Morphine versus Oxycodone RCT: PCA Oxycodone Response Component Plot in Rotated 
Space 
 
Three Components of morphine response generated by PCA : Component 1 analgesic response (red), 
Component 2 GI adverse reactions and drowsiness (yellow), Component 3 central adverse reactions of 
confusion, hallucinations, disorientation and nightmares (blue) (n=74) 
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Table 6.50 Morphine versus Oxycodone RCT:  Oxycodone Response Component Correlation Matrix. 
Component 1 2 3 
1 1.00 .12 .15 
2 .12 1.00 .15 
3 .15 .15 1.00 
  
 
 
5.4.14 Opioid Response Multivariate Linear Regression Modelling 
Multivariate stepwise regression was used to model possible clinical factors involved in 
opioid response reflected by the three Component scores.  A significance level of P < 0.1 in 
univariate analysis was used to select factors to be included.   Factors with a significance 
level of P < 0.05, and 95% confidence interval that did not cross zero were included in the 
final model.   
 
Clinical variables tested for inclusion into the models included: age (years), gender, tumour 
diagnosis, daily dose of opioid (mg), survival (days), biochemical and haematological indices 
(see list in Table 6.2) and common concomitant medications (see list in Table 6.6). 
 
5.4.14.1 Opioid Response Component 1: Analgesic Response 
Clinical variables selected for inclusion into the model included: diagnosis of lung or 
pancreas and hepatobiliary malignancy, ALT (mmol/L), daily dose of opioid (mg), and two 
classes of concomitant medication: antidepressants and ACE inhibitor/angiotensin II receptor 
antagonists. 
One predictive factor was retained in the final model which overall explained 4.9% of 
variability in analgesic response to opioid (Table 6.51).  The concomitant use of an 
antidepressant was associated with higher Component 1 scores and therefore worse pain 
control. 
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Table 6.51  Morphine versus Oxycodone RCT: Clinical Factors Predictive of Opioid Analgesic Response  
  Unstandardized Coefficients 
95.0% Confidence 
Interval for B 
Standardized 
Coefficients 
P value 
  B Std. Error 
Lower 
Bound 
Upper 
Bound Beta 
(Constant) 0.44 0.01 0.42 0.47  <0.005 
Antidepressant 0.09 0.03 0.02 0.15 .22 0.01 
Dependent Variable: Log10 Component 1 
R2 =0.049, ANOVA F-ratio = 6.94 
 
 
5.4.14.2 Opioid Response Component 2: Upper Gastrointestinal Adverse Reactions 
Clinical variables selected for inclusion into the model included: diagnosis of upper GI or 
urinary tract malignancy, and three classes of concomitant medication: steroids, antiemetics 
and ACE inhibitor/angiotensin II receptor antagonists.  Serum corrected Calcium, and recent 
chemotherapy were not associated with log10 Component 2 scores. 
Five predictive factors were retained in the final model which overall explained 20.5% of 
variability in upper GI adverse reactions to opioid (Table 6.52).  Diagnosis of upper GI and 
urinary tract malignancy together with use of ACE inhibitors/ angiotensin II receptor 
antagonists were associated with higher Component 2 scores and therefore worse nausea and 
vomiting.  The concomitant use of steroids however was associated lower Component 2 
scores indicating less nausea and vomiting. 
 
Table 6.52  Morphine versus Oxycodone RCT: Clinical Factors Predictive of Opioid Upper 
Gastrointestinal Adverse Reactions 
  Unstandardized Coefficients 
95.0% Confidence 
Interval for B 
Standardized 
Coefficients 
P value 
  B Std. Error 
Lower 
Bound 
Upper 
Bound Beta 
(Constant) 0.43 0.01 0.40 0.46  <0.005 
Urinary tract cancer 0.09 0.03 0.02 0.15 .21 0.01 
Upper GI cancer 0.12 0.04 0.04 0.20 .23 <0.005 
Steroid -0.05 0.02 -0.10 -0.01 -.20 0.02 
Antiemetic 0.05 0.02 0.01 0.08 .19 0.02 
ACE inhibitor/ Angiotensin 
II  receptor antagonist 
0.07 0.02 0.02 0.12 .23 <0.005 
Dependent Variable: Log10 Component 2 
R2 =0.205, ANOVA F-ratio = 6.71 
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5.4.14.3 Opioid Response Component 3: Central Adverse Reactions 
Clinical variables selected for inclusion into the model included: diagnosis of gynaecological 
malignancy, daily dose of opioid (mg), chemotherapy ≤ 4 weeks, haemoglobin (g/dL), 
albumin (g/L) and concomitant use of paracetamol.  Serum Sodium and corrected Calcium 
were not associated with log10 Component 3 scores 
Chemotherapy ≤ 4 weeks, serum albumin and concomitant use of paracetamol were retained 
as independent predictive factors in the final model which overall explained 15.7% of 
variability in central adverse reactions to opioid (Table 6.53).  All the factors were associated 
with lower log10 Component 3 scores and therefore less central adverse reactions. 
 
Table 6.53  Morphine versus Oxycodone RCT: Clinical Factors Predictive of Opioid Central Adverse 
Reactions  
  Unstandardized Coefficients 
95.0% Confidence 
Interval for B 
Standardized 
Coefficients 
P value 
  B Std. Error 
Lower 
Bound 
Upper 
Bound Beta 
(Constant) 0.71 0.06 0.59 0.82  <0.005 
Chemotherapy ≤ 4 weeks -0.05 0.02 -0.09 -0.01 -.23 0.01 
Albumin (g/L) -0.01 0.00 -0.01 0.00 -.30 <0.005 
Paracetamol -0.05 0.02 -0.09 -0.01 -.24 0.01 
Dependent Variable: Log10 Component 3 
R2 =0.157, ANOVA F-ratio = 7.317 
 
 
5.4.15 Morphine Response 
5.4.15.1 Morphine Response Component 1: Analgesic Response 
Clinical variables selected for inclusion into the model included: diagnosis of lung 
malignancy, daily dose of opioid (mg), chemotherapy ≤ 4 weeks, serum ALT (mmol/L), 
Alkaline Phosphatase (mmol/L) and Total Bilirubin (µmol/L) and two classes of concomitant 
medication: non-steroidal anti-inflammatory agents and ACE inhibitor/angiotensin II receptor 
antagonists. 
One predictive factor was retained in the final model which overall explained 13.7% of 
variability in analgesic response to morphine (Table 6.54).  The concomitant use of an ACE 
inhibitor/angiotensin II receptor antagonist was associated with higher Component 1 scores 
and therefore a worse analgesic response. 
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Table 6.54  Morphine versus Oxycodone RCT: Clinical Factors Predictive of Morphine Analgesic 
Response  
  Unstandardized Coefficients 
95.0% Confidence 
Interval for B 
Standardized 
Coefficients 
P value 
  B Std. Error 
Lower 
Bound 
Upper 
Bound Beta 
(Constant) 0.43 0.02 0.40 0.47  <0.005 
ACE inhibitor/ Angiotensin 
II  receptor antagonist 
0.13 0.04 0.05 0.22 .37 <0.005 
Dependent Variable: Log10 Component 1 
R2 =0.137, ANOVA F-ratio = 10.278 
 
 
5.4.15.2 Morphine Response Component 2: Central Adverse Reactions 
Clinical variables selected for inclusion into the model included: diagnosis of urinary tract 
malignancy, total Bilirubin (µmol/L), Haemoglobin (g/dL) and two classes of concomitant 
medication: paracetamol and anticoagulants. 
Three predictive factors were retained in the final model which overall explained 27.2 % of 
variability in central adverse reactions to morphine (Table 6.55).  Diagnosis of a urinary tract 
malignancy and higher serum total Bilirubin were associated with higher Component 2 scores 
and therefore worse central adverse reactions.  Concomitant use of paracetamol was 
associated with lower central adverse reactions. 
 
Table 6.55 Morphine versus Oxycodone RCT: Clinical Factors Predictive of Morphine Central Adverse 
Reactions  
  Unstandardized Coefficients 
95.0% Confidence 
Interval for B 
Standardized 
Coefficients 
P value 
  B Std. Error 
Lower 
Bound 
Upper 
Bound Beta 
(Constant) 0.42 0.03 0.36 0.48  <0.005 
Urinary tract cancer 0.13 0.04 0.04 0.21 .37 <0.005 
Total Bilirubin (µmol/L) 0.01 0.00 0.00 0.01 .34 0.01 
Paracetamol -0.07 0.03 -0.12 -0.01 -.30 0.02 
Dependent Variable: Log10 Component 2 
R2 =0.272, ANOVA F-ratio = 6.487 
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5.4.15.3 Morphine Response Component 3: Upper Gastrointestinal Adverse Reactions 
Clinical variables selected for inclusion into the model included: diagnosis of lung, prostate 
and urinary tract malignancy, serum Creatinine (mmol/L), Haemoglobin (g/dL), number of 
additional medications and two classes of concomitant medications: tricyclic related 
antidepressants and ACE inhibitor/angiotensin II receptor antagonists . 
Diagnosis of lung cancer, Haemoglobin (g/dL) and use of a tricyclic related antidepressant 
were all retained in the final model as independent predictors of upper GI adverse reactions to 
morphine and together explained 28.2 % of variability (Table 6.56).  Diagnosis of lung 
cancer and use of a tricyclic related antidepressant were associated with lower Component 3 
scores and therefore less nausea and vomiting. 
 
Table 6.56  Morphine versus Oxycodone RCT: Clinical Factors Predictive of Morphine Upper 
Gastrointestinal Adverse Reactions  
  Unstandardized Coefficients 
95.0% Confidence 
Interval for B 
Standardized 
Coefficients 
P value 
  B Std. Error 
Lower 
Bound 
Upper 
Bound Beta 
(Constant) 0.05 0.19 -0.33 0.43  0.78 
Lung cancer -0.30 0.10 -0.50 -0.10 -.36 <0.005 
Haemoglobin (g/dL) 0.04 0.02 0.01 0.07 .29 0.02 
Tricyclic related  
antidepressant  
-0.22 0.08 -0.37 -0.06 -.34 0.01 
Dependent Variable: Log10 Component 3 
R2 =0.282, ANOVA F-ratio = 6.732 
  
 
5.4.16 Oxycodone Response Multivariate Regression 
5.4.16.1 Oxycodone Response Component 1: Analgesic Response 
Clinical variables selected for inclusion into the model included: diagnosis of prostate cancer, 
Haemoglobin (g/dL) and two classes of concomitant medications: antidepressants and 
anticoagulants. 
One independent predictive factor was retained in the final model: use of an anticoagulant 
which was associated with higher Component 1 scores and therefore worse pain (Table 6.57). 
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Table 6.57  Morphine versus Oxycodone RCT: Clinical Factors Predictive of Oxycodone Analgesic 
Response 
  Unstandardized Coefficients 
95.0% Confidence 
Interval for B 
Standardized 
Coefficients 
P value 
  B Std. Error 
Lower 
Bound 
Upper 
Bound Beta 
(Constant) 0.43 0.02 0.40 0.47  <0.005 
Anticoagulant 0.12 0.04 0.04 0.20 .35 <0.005 
Dependent Variable: Log10 Component 1 
R2 =0.124, ANOVA F-ratio = 9.477 
 
 
5.4.16.2 Oxycodone Response Component 2: Upper Gastrointestinal Adverse Reactions 
Clinical variables selected for inclusion into the model included: diagnosis of upper GI 
malignancy, age (years), survival (days) and recent chemotherapy, within four weeks. 
One independent predictive factor was retained in the final model: chemotherapy with four 
weeks which explained 10.6% of variability (Table 6.58).  Chemotherapy within the last four 
weeks was associated with lower Component 2 scores and therefore less nausea and 
vomiting. 
 
Table 6.58 Morphine versus Oxycodone RCT: Clinical Factors Predictive of Oxycodone Upper 
Gastrointestinal Adverse Reactions  
  Unstandardized Coefficients 
95.0% Confidence 
Interval for B 
Standardized 
Coefficients 
P value 
  B Std. Error 
Lower 
Bound 
Upper 
Bound Beta 
(Constant) 0.49 0.02 0.46 0.53  <0.005 
Chemotherapy ≤ 4 weeks -0.08 0.03 -0.13 -0.02 -.33 0.01 
Dependent Variable: Log10 Component 2 
R2 =0.106, ANOVA F-ratio = 7.954 
 
 
5.4.16.3 Oxycodone Response Component 3: Central Adverse Reactions 
Clinical variables selected for inclusion into the model included: diagnosis of upper 
gynaecological malignancy, serum sodium (mmol/L) and albumin (g/L), and use of an SSRI 
antidepressant. 
The final model retained three independent clinical predictors of central adverse reactions to 
oxycodone which together explained 25.8% of variability (Table 6.59).  Increasing serum 
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albumin (g/L) was associated with less central adverse reactions whereas use of an SSRI 
antidepressant or diagnoses of a gynaecological malignancy were associated with higher 
Component 3 scores and therefore more severe central adverse reactions.  
 
Table 6.59  Morphine versus Oxycodone RCT: Clinical Factors Predictive of Oxycodone Central Adverse 
Reactions  
  Unstandardized Coefficients 
95.0% Confidence 
Interval for B 
Standardized 
Coefficients 
P value 
  B Std. Error 
Lower 
Bound 
Upper 
Bound Beta 
(Constant) 0.65 0.08 0.49 0.82  <0.005 
Gynaecological cancer 0.10 0.04 0.02 0.19 .27 0.02 
Albumin (g/L) -0.01 0.00 -0.01 0.00 -.30 0.01 
SSRI antidepressant 0.10 0.05 0.01 0.20 .25 0.03 
Dependent Variable: Log10 Component 3 
R2 =0.258, ANOVA F-ratio = 7.173 
 
 
5.5 Discussion 
Morphine is recommended by the WHO as the first-line strong-opioid in moderate to severe 
cancer pain 5.  This recommendation was based upon expert opinion at the time (1980’s), 
drawing on clinical experience, worldwide availability and cost, rather than any evidence of 
its superiority over the other strong opioids.  Recent systematic reviews of the use of 
morphine in cancer pain have suggested that other strong opioids such as oxycodone are 
comparable in terms of analgesia when titrated to effect however the reviews also highlighted 
the continued paucity of data in opioid naïve patients and concluded that there was a strong 
need to identify the relative role of different opioids in the treatment of cancer-related pain 
138, 139.   
 
The use of oxycodone in clinical practice for cancer-related pain has been expanding over the 
last decade.  Like morphine it is available in oral immediate- and modified-release 
preparations.  Oxycodone has different pharmacokinetic and to some extent 
pharmacodynamic properties to morphine 9, 9, 10, 140.  This pragmatic randomised trial of oral 
morphine versus oral oxycodone is the largest of its type to be performed in cancer-related 
pain.  The selective cross-over phase for non-responders to first-line opioids widens its scope 
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to provide evidence for the clinical practice of opioid switching to improve outcomes in first-
line opioid non-responders. 
 
5.5.1 Primary Outcome 
Intention-to-treat analysis shows that on a population level there is no difference between oral 
morphine and oral oxycodone response rates when used first-line for moderate to severe 
cancer-related pain.  This is consistent which the conclusions of a recent systematic review of 
use of oxycodone in the management of cancer-related pain in which no significant 
difference in pain relief or adverse effects between oxycodone and morphine was found 33.  
On an individual patient level however there were distinct differences in response to 
morphine and oxycodone. 
 
In this present study for patients who did not respond to first-line morphine or oxycodone, 
opioid switching to the alternate arm provided clinical improvement in the majority of cases.  
In the first-line morphine group 61/98 (62%) responded to morphine and a further 11/21 
(52%) responded when switched early to oxycodone, therefore 72/98 (73%) responded 
overall. In the first-line oxycodone group 67/100 (67%) responded to oxycodone and a 
further 8/12 (67%) responded when switched to morphine and therefore 75/100 (78%) 
responded overall.  There was no difference observed on overall response rate dependant on 
which opioid was administered first.  Furthermore there was an additional group of thirteen 
cases where there had been an initial response to first-line opioid which was then lost.  Late 
opioid switching in these circumstances was also successful in the majority of cases. These 
individuals provide further evidence that the therapeutic manoeuvre of opioid switching 
improves the clinical outcome in the treatment of moderate to severe cancer related pain.   
 
Observational studies suggest that opioid switching in patients who do not respond well to 
one strong opioid due to either uncontrolled pain, intolerable side effects or both is successful 
in approximately 80% of patients, increasing to 90% if a second switch is allowed 95, 141.  The 
first-line and subsequent switching response rates of oral morphine and oral oxycodone in the 
intention-to-treat population may appear lower than expected.  This is a pragmatic trial 
mirroring effectiveness in the “real world” rather than efficacy.  As would be expected in a 
cancer population seen in a tertiary referral oncology centre with a median survival of three 
months (range 3 – 1160 days) the withdrawal rate was high.  The most common reason for 
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study withdrawal was conversion to parenteral opioids, followed by death and improvement 
in pain allowing discontinuation of strong opioid.  Drop-out rates in other RCTs of morphine 
in cancer-related pain range from 5 – 79% 138.  For example in a recent RCT of controlled-
release oral morphine versus oxycodone in pancreatic cancer pain, only 17 patients of the 60 
patients randomised (28%) reached the eight week extended end-point, fourteen were lost to 
follow-up, eleven switched opioids and eighteen died 142.   
 
In the per protocol population, those patients who reached the first time point of either 
“response” (Time Point B) or “non-response” (Time Point C), there was a trend in towards a 
higher first-line response rate for oral oxycodone (84%) compared to oral morphine (72%), 
P=0.07. The morphine response rate mirrors that seen within the Prospective Morphine 
Study (69%, Chapter 5).  There were more drop-outs in the oxycodone group compared with 
the morphine group, with twenty and thirteen withdrawals respectively which makes 
interpretation difficult.  Due to the high number of patient withdrawals within the titration 
phase, the study also loses power to make any recommendations.   
 
Withdrawals were classified as discontinuation of oral opioid (where either the route of the 
opioid or the opioid itself was stopped or changed, but not switched as per protocol), and 
discontinuation of trial when the trial but not oral opioid was stopped, Figure 6.1 shows the 
reasons for withdrawal in detail.  During the first titration phase ten patients discontinued oral 
morphine, one of which was due to an adverse reaction (upper GI adverse reaction: nausea 
and vomiting), whereas sixteen patients discontinued oral oxycodone, six of which were due 
to adverse reactions (two upper GI adverse reactions, two central adverse reactions, one with 
both upper GI and central adverse reactions and one due to dry mouth, itching and hot 
flushes).  This is difficult to interpret as per protocol the presence of an intolerable adverse 
reaction would trigger opioid switching rather than withdrawal.  The withdrawals due to 
adverse reactions all happened between one and five days of starting the trial drug.   
 
Of note two of the patients randomised to oral oxycodone who withdrew in the first-titration 
phase due to adverse reactions had previously received morphine on an as required basis and 
are documented to have preferred morphine, therefore introducing the possibility of bias.  
When the 33 patients who did not respond to oxycodone first-line (either Time Point C or 
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withdrawals) are considered together however, only 27% had received as required morphine 
before randomisation which is much lower than the 49% overall. 
 
5.5.2 Secondary Outcomes 
5.5.2.1 Pain 
As expected both morphine and oxycodone significantly improved all pain scores when used 
as both first- and second-line opioids in responders.   
In PCA all pain intensity indices loaded onto the same analgesic response factor were 
therefore considered as a whole in the modelling process. 
5.5.2.2 Adverse Reactions 
Adverse reactions were assessed using a toxicity questionnaire which asked participants to 
rate various side effects “due to the opioid” in the past 24 hours on a NRS of 0-10.  Whilst a 
direct question in many cases it was very difficult for the participants (and medical staff) to 
determine the aetiology of the symptoms listed on the toxicity questionnaire as all had 
multiple potential causes in this cancer population as well as an adverse reaction to opioid.  
The results presented here therefore are at best an estimate of the adverse reaction profiles 
given “real world” limitations.  Morphine and oxycodone adverse reaction profiles were 
comparable on a population level.  Wider variability in adverse reactions was observed on an 
individual level to both drugs in terms of type of adverse reaction experienced and the 
tolerability of each.   
 
PCA identified two main adverse reaction domains: upper GI reactions and central adverse 
reactions.  It should be noted that constipation, was excluded from the PCA as it was not 
correlated with other pain or adverse reaction scores.  In addition less common adverse 
reactions (that were not routinely asked about on the toxicity questionnaire) such as dry 
mouth and itch were also excluded from the PCA due to sampling inadequacy.   
 
5.5.3 Reasons for Opioid Switching 
Opioid switching was performed on a clinical basis when after careful dose titration and 
appropriate use of adjuvants there was uncontrolled pain or intolerable adverse reactions.  
Other studies have used pre-defined criteria of opioid non-response in the protocol 141, 
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however in keeping with current clinical practice and the subjective nature on tolerability of 
pain and adverse reactions the decision was on clinical grounds in this trial.  
 
Switching for adverse reactions was more common than for uncontrolled pain.  Drowsiness 
was the most common adverse reaction contributing to opioid switching for both morphine 
and oxycodone.  This was despite careful dose titration by the Specialist Palliative Medicine 
team.  Drowsiness contributing to opioid switching was reported more commonly in the 
morphine group (72.7%) compared to the oxycodone group (58.8%).  Drowsiness is a 
common symptom in the cancer population, and even at baseline drowsiness scores ranged 
from zero to ten in both the morphine and oxycodone groups, with a median of one and two 
respectively. 
 
Seven patients both received and did not respond to morphine or oxycodone, the so called 
second-line non-responders.  These represent the “extremes” of opioid non-response and as a 
group they would benefit from further study. 
 
5.5.4 Timing of Opioid Response and Switching 
There were two circumstances where switching was deemed necessary.  Firstly early 
switching when uncontrolled pain or intolerable adverse reactions occurred soon after starting 
the drug, and secondly when there was an initial good response to the first-line opioid which 
was subsequently lost necessitating a switch.  Several factors are known to interfere with 
opioid responsiveness within the cancer journey, these include the progression of the disease 
and the type of pain, the development of opioid tolerance, and pharmacokinetic factors such 
as the accumulation of metabolites and the appearance of intractable side effects 143. 
 
Late switching occurred over a much greater time range for both opioids, the median time to 
late switch for morphine responders was 125 days (range 35-169) and for oxycodone 
responders was 30 days (range 6-129).  It is possible that the underlying mechanisms 
determining the need to switch in early and late switchers is different. The early switchers 
may indicate an innate intolerance whilst late switchers may be due to an acquired tolerance 
to the first-line opioid.  The intolerance of early switchers may be genetically determined and 
a further investigation to differentiate between the two groups is required. 
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Late switching accounted for 26% of switching overall. There were nine late switchers on 
morphine and four on oxycodone.  Intolerable adverse reactions were the main reason for late 
switching, although uncontrolled pain contributed to approximately half of cases.  The most 
common adverse reactions reported were drowsiness followed by nausea and vomiting.   
 
Variable amounts of information were available detailing the circumstances of late switching. 
Intercurrent illness associated with progressive disease was known to contribute to the 
symptomatology in four cases: including drowsiness associated with systemic infection, 
worsening renal impairment, worsening liver function tests and hypercalcaemia. Some 
adverse reactions that were tolerable initially become intolerable over time, for example the 
development of constipation. 
 
Tolerance to opioids is defined as the need to increase the dose of drug administered to 
produce the same pharmacologic effect.  In the Morphine versus Oxycodone RCT six patients 
(three morphine and three oxycodone) had a 200% increase (Time Point E) from their 
original stable dose at Time Point B during the year long follow-up phase, however due to the 
high number of drop-outs it is hard to draw any conclusions from this.  Many patients 
remained on stable doses of opioids for weeks and even many months.  All µ-opioid receptor 
agonists such as morphine and oxycodone are associated with tolerance following repeated 
usage and exhibit cross tolerance to each other, the degree of cross tolerance varies 
substantially.  Incomplete cross tolerance is a mechanism which is utilised to return analgesic 
sensitivity in highly tolerant patients by switching one strong opioid to another.  In these 
circumstances analgesia may be restored by the second strong opioid at doses substantially 
below the predicted equivalent dose 46.  This however was not observed in the 13 late 
switchers from the current study. 
In this study, of the six patients in which uncontrolled pain was one of the main reasons for 
late opioid switching five had a clear change in their pain most commonly due to disease 
progression, for example worsening neuropathic pain, worsening lymphoedema pain, and 
vertebral collapse.  
The phenomenon of opioid induced hyperalgesia is becoming increasingly well recognised in 
the clinical setting however most evidence still comes from animal studies. Although the 
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possibility of opioid induced hyperalgesia was part of the differential diagnosis in the clinical 
management of patients with uncontrolled pain on opioid treatment it was not identified in 
this study. Opioid induced hyperalgesia appears to be more common when opioids are 
administered intravenously and doses are escalated rapidly 144, 145. 
 
5.5.5 Opioid Dosing and Conversion 
It is well known that the dose conversion ratios when switching between opioids are variable 
between individuals.  A recent systematic review has summarised the evidence for dose 
conversion ratios between opioids 44. It included RCTs comparing oxycodone and morphine 
under stable analgesic conditions and studies where patients were switched from morphine to 
oxycodone because of poor pain relief and/or intolerable side effects.  Under stable analgesic 
conditions the dose conversion ratio appears dependant on directionality, the median total 
opioid consumption ratio of morphine: oxycodone was 4:3 (1.3) when morphine was 
administered first and 3:2 (1.5) when morphine was administered after oxycodone 146.  In the 
Prospective Morphine Study, opioid switchers who were stabilised on second-line oxycodone 
had a median (range) dose ratio of  morphine : oxycodone of 1.7 (0.25-12) 39.   
 
When switching between strong opioids in this study the conversion ratio of morphine to 
oxycodone, 2:1 was used.  This study not only switched from morphine to oxycodone, but 
from oxycodone to morphine.  Although the study design is limited to this purpose it appears 
that converting from morphine to oxycodone may be different to converting from oxycodone 
to morphine.  In the subgroup analysis of pain-controlled switchers in this study, dose 
conversion ratios from morphine to oxycodone ranged from 0.4 to 4.0, and similarly from 
oxycodone to morphine ranged from 0.3 to 1.5.  This study therefore supports to the evidence 
that the conversion ratio may depend on the directionality of the switch and in the settings of 
“controlled” and “uncontrolled” pain i.e. opioid rotation and opioid switching 45.  On average 
the oral morphine: oral oxycodone ratio was 4:3 (1.3:1) when morphine was administered 
first and 2:1 when oxycodone was administered first.  It must however be remembered that 
the numbers of pain controlled switchers was small, and there may be different requirements 
in patients who switch for other reasons. 
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5.5.6 Health Economics 
In this day and age health economics is becoming increasing more powerful as resources are 
stretched.  No health economic information was captured in this study however morphine is 
by far the cheaper of the two drugs compared.  For example, if we consider the cost of 
60mg/day (30mg modified release preparation twice daily), which was the median dose of 
both morphine and oxycodone responders using the latest pricing in the British National 
Formulary (Number 62, September 2011) an approximate one month supply of the 30mg 
modified release preparation would cost £8.30 for morphine and £74.81 for oxycodone.  The 
cost of the drugs is not the only factor in health economic modelling, as the latter also takes 
into consideration resource use including clinic visits, professional time and treatment of 
adverse reaction.  The median time to stable dose was the same for both drugs in the present 
study and adverse reactions were comparable, suggesting that the cost of the drugs is the 
major difference between morphine and oxycodone. 
 
5.5.7 Predictive Modelling of Response/Non-response 
The safe and efficient titration of opioid to obtain pain control is a priority.  The time period 
between baseline and opioid response (Time Point B) ranged from two to thirty-one days, 
with a median of seven days.  This however is not a true reflection of time for opioid titration 
as collection of time point data was often delayed to coincide with the participant’s next 
hospital visit. 
 
In opioid non-responders however, the time from baseline to opioid switch (Time Point C) 
ranged from two to twenty-one days with a median of seven days.  This represents a more 
accurate representation of careful opioid titration, with time for either up- and down- titration 
and trials of adjuvant agents such as anti-emetics or laxatives to assist with adverse reactions. 
The question remains whether we can predict ultimate opioid response faster to save time 
with futile dose adjustments or adjuvant treatments and switch earlier for a better outcome. 
Logistic regression modelling was performed from day three and seven pain and adverse 
reaction scores in an attempt to construct useful models of ultimate response.  The resultant 
models have high sensitivity and low specificity therefore we can reliably predict who will 
respond, however less good at identifying those who will ultimately not respond which would 
perhaps be more useful. 
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5.5.7.1 Day Three Models 
High vomiting scores on day three were predictive of opioid switching for the combined 
opioid population and the morphine subgroup, whereas drowsiness was retained in the final 
model for oxycodone.  In conclusion if vomiting is seen at day three then early opioid 
switching should be considered especially if the patient is also drowsy on oxycodone.  
Central adverse reactions were included in both day 3 and day 7 models of oxycodone non-
response underlining their importance. 
5.5.7.2 Day Seven Models 
On day seven the final model retained three independent predictors of overall opioid 
response: drowsiness, nightmares and percentage relief.  If drowsiness and nightmare scores 
are high and percentage relief scores low switching is much more likely.  For the morphine 
subgroup only one factor was retained: nightmares which were associated with non-response. 
For oxycodone confusion was retained as a predictor of non-response.  If central adverse 
reactions are still present at day 7, especially with poor pain relief then opioid switching 
should be considered.   
 
5.5.8 Adverse Events and Withdrawals 
As would be expected in a cancer population the year long follow-up period resulted in a raft 
of adverse event data being collected. Importantly there were no suspected unexpected 
serious adverse reactions and the adverse reactions recorded had all been previously reported. 
 
At the time of analysis five patients were still active, undergoing monthly follow-up.  Of 195 
patients who had reached study end point: 14 completed one year follow-up and 12 did not 
respond to second-line opioid.   Of those who were withdrawn from the trial, 49 were 
converted to parenteral opioids, 33 died, 16 were too unwell to continue the study protocol, 
and 11 found the trial too burdensome, 9 developed significant renal impairment, 8 withdrew 
secondary to an adverse event or adverse reaction and 27 patients pain improved with anti-
cancer therapy so no longer need to take strong opioid.   
 
Other reasons for trial withdrawal included: patient choice to convert to a patch rather than 
continue oral medication (3), physician recommendation (3), moving abroad (1), medical 
insurance issue (1) and pregnancy (1). Two patients withdrew because of an ongoing 
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reluctance to take strong opioids.  There remain significant barriers to the acceptance of 
strong opioid analgesics for analgesia in cancer pain.  Studies have highlighted that deep-
seated concerns remain regarding the symbolism of morphine, addiction and tolerance that 
are held by patients and influence use.  Cancer pain may be viewed as an indicator of disease 
status, with the initiation of morphine becoming a “metaphor for impending death” 147. 
 
5.5.9 Immunology 
No significant changes were seen in the immune cell populations of patients treated with 
morphine or oxycodone for cancer-related pain in this study.  There were several 
confounding factors which limit interpretation of this part of the study, including a 
heterogeneous patient group with varied malignant diagnoses, anti-cancer therapies, co-
morbidities and infections and concomitant medications.  We were able to measure cell 
populations at the various time points, however as previously discussed there was a wide 
variation in a) the duration between time points and b) the doses of opioids the patients were 
exposed to.  A limited number of samples were available for gene expression analysis which 
is discussed in Chapter 8.  
 
5.5.10 Principal Component Analysis of Opioid Response 
Similar to the results seen for the Prospective Morphine Study (Chapter 5), three Components 
of opioid response: analgesic response, upper GI adverse reactions and central adverse 
reactions were identified in the Morphine versus Oxycodone RCT.  These three Components 
were seen in the combined opioid population, and when morphine and oxycodone first-line 
subgroups were considered together.   
There were however some differences in that drowsiness separated from confusion and 
nightmares in both the combined opioid population and morphine subgroup in the Morphine 
versus Oxycodone RCT, whereas in the Prospective Morphine Study drowsiness loaded in to 
the same central adverse reaction Component as confusion and nightmares.  In the oxycodone 
Morphine versus Oxycodone RCT subgroup however drowsiness loaded with upper GI 
reactions of nausea and vomiting, although this association was comparatively weak. 
The Morphine versus Oxycodone RCT and Prospective Morphine Study differed in the way 
they measured adverse reactions.  The Prospective Morphine Study employed a 4-point 
Likert scale, whereas the Morphine versus Oxycodone RCT used an 11-point (0-10) 
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numerical rating scale.  In the Morphine versus Oxycodone RCT drowsiness was the most 
common symptom reported even at baseline in the strong opioid naïve population.  As 
previously discussed, there are many possible aetiologies in the cancer population for the 
symptoms designated as adverse reactions to opioids in the toxicity profiling. The ubiquitous 
nature of drowsiness in this population may therefore partially reflect a common experience 
of this cancer patient group rather than wholly be specific to opioid treatment. 
The Component scores generated by PCA were used for modelling purposes.  The advantage 
being that they capture the most information possible from numerous measurements 
minimising the need for multiple testing. 
 
5.5.11 Clinical Modelling of Opioid Response Phenotypes 
Models were constructed using multivariate regression to predict the three dimensions of 
first-line opioid response for combined opioid, and the smaller morphine and oxycodone 
subgroups.  The clinical models predicted some but by no means all the variability in the 
response phenotypes (4.9-28.2%).  Other factors, particularly genetic factors may contribute 
to opioid response and are discussed in Chapter 7. 
 
5.5.11.1 Analgesic Response 
One predictive factor was retained in the final model of combined opioid which overall 
explained 4.9% of variability in analgesic response to opioid.  The concomitant use of an 
antidepressant was associated with higher scores and therefore worse pain control. An 
individual’s pain experience is may be influenced by a multitude of factors from physical to 
psychosocial and spiritual issues in the concept of total pain 148.  Psychiatric morbidity is 
associated with increased pain intensity in chronic pain patients 149. Certain classes of 
antidepressants, such as tricyclic antidepressants may also be used as adjuncts in the 
treatment of neuropathic pain which is a particularly challenging to manage and only partially 
opioid responsive.  It was not known whether the antidepressants in this study were 
prescribed for low mood or neuropathic pain so this could not be examined further. 
 
When the morphine subgroup was considered separately, one predictive factor was retained 
in the final model which overall explained 13.7% of variability in analgesic response. The 
concomitant use of an ACE inhibitor/angiotensin II receptor antagonist was associated with a 
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worse analgesic response.  Equally in the oxycodone subgroup a single predictive factor was 
retained in the final model of analgesic response: use of an anticoagulant, which was 
associated with worse pain scores.  The clinical relevance of these statistically significant 
observations remains unclear.  The use of these drugs may be markers for other confounding 
factors not yet taken into consideration during the modelling. 
 
5.5.11.2 Upper Gastrointestinal Adverse Reactions 
In the combined opioid model five clinical predictive factors were retained which overall 
explained 20.5% of variability in upper GI adverse reactions to opioids.  Diagnosis of upper 
GI or urinary tract malignancy and use of ACE inhibitors/angiotensin II receptor antagonists 
or antiemetics were associated with higher log10 Component 2 scores and therefore worse 
nausea and vomiting.  The concomitant use of steroids however was associated lower 
Component 2 scores and therefore less nausea and vomiting.  Steroids are well known to have 
antiemetic properties.  The association between use of ACE inhibitors/angiotensin II receptor 
antagonists and increased nausea and vomiting with opioids is unclear.  ACE inhibitors have 
been reported to have GI side effects including nausea and vomiting of their own 
(http://bnf.org). 
 
When the morphine subgroup was considered separately, three predictive factors were 
retained in the final model as independent predictors of upper GI adverse reactions:  
diagnosis of lung cancer, haemoglobin (g/dL) and use of a tricyclic related antidepressant and 
together explained 28.2 % of variability.  Diagnosis of lung cancer and use of a tricyclic 
related antidepressant were associated with lower Component 3 scores and therefore less 
nausea and vomiting.  In the oxycodone subgroup one independent predictive factor was 
retained in the final model: chemotherapy within four weeks which explained 10.6% of 
variability.  Chemotherapy within the last four weeks was associated with lower Component 
2 scores and therefore less nausea and vomiting. One of the main adverse reactions associated 
with chemotherapy is nausea and vomiting particularly shortly after administration.  Its 
protective nature here may be a marker of performance status in that these patients are fit 
enough to undergo active anti-cancer treatment, these patients may also have different 
experiences of these symptoms to relate to when filling out the questionnaires.   
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In a recent large European study exploring clinical factor associated with nausea and 
vomiting in cancer patients receiving opioid multivariate analysis showed that lower age, 
deleterious physical status (lower BMI, lower Karnofsky performance status), female gender 
or diagnosis of gynaecological malignancy, use of opioids other than fentanyl and use of 
antiemetics were associated with more nausea and vomiting 96.  Both studies agree that use of 
an antiemetic is paradoxically associated with more nausea and vomiting.  This is probably 
because they are not prescribed routinely until the symptom appears and then the 
effectiveness is variable.  
 
5.5.11.3 Central Adverse Reactions 
In the combined opioid group, chemotherapy within the last weeks, higher serum albumin 
(g/L) and concomitant use of paracetamol were retained as independent predictive factors in 
the final model which overall explained 15.7% of variability in central adverse reactions to 
opioid.  All the factors were associated with lower scores and therefore protective of central 
adverse reactions. When central adverse reactions to morphine were considered separately 
three predictive factors were retained in the final model which overall explained 27.2 % of 
variability. Diagnosis of a urinary tract malignancy and higher serum total bilirubin (µmol/L) 
were associated with higher log10 Component 2 scores and therefore worse central adverse 
reactions whereas concomitant use of paracetamol was associated lower central adverse 
reactions. The oxycodone model of central adverse retained three independent clinical 
predictors which together explained 25.8% of variability.  Increasing serum albumin (g/L) 
was associated with less central adverse reactions whereas use of an SSRI antidepressant or 
diagnoses of a gynaecological malignancy were associated with higher Component 3 scores 
and therefore more severe central adverse reactions. 
 
Serum albumin is often used as a marker of prognosis, lower levels are associated with 
physical debility and poor outcome, clinically these patients would be expected to be more 
fatigued 150. Serum bilirubin (µmol/L) is a marker of liver function, the primary site of opioid 
metabolism so dysfunction could be expected to increase the chances of adverse reactions.  
Chemotherapy within the last four weeks may be a marker of performance status in that these 
patients are fit enough to undergo active anti-cancer treatment.  Paracetamol is often lauded 
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for its opioid sparing qualities in terms of dose; however it has not been shown to improve 
side effect profiles, including sedation in a meta-analysis of post-operative pain studies 151. 
 
5.6 Conclusion 
The main findings of this Chapter are: 
 
• When compared head-to-head in a pragmatic RCT there is no difference between the 
first-line response rates of oral morphine and oral oxycodone for the treatment of 
moderate-severe cancer-related pain in a strong opioid naïve population. 
 
• Analgesia and adverse reaction profiles of morphine and oxycodone are similar. 
 
• Opioid switching is a valid method of improving clinical outcome when response to 
first-line opioid is poor. 
 
• Switching from morphine to oxycodone and vice versa improved outcomes in the 
majority of non-responders, whether switching was early or late. 
 
• Dose conversion between morphine and oxycodone when switching should be 
cautious, conversion rations may be different dependant on the directionality of the 
switch. 
 
• Opioid response appears to have three main domains identified by PCA in two 
different studies. 
o Analgesic response 
o Upper gastrointestinal adverse reactions  
o Central adverse reactions 
 
• Morphine should remain the first-line opioid in the treatment of moderate to severe 
cancer-related pain, however alternative opioids should be available to allow 
switching in non-responders. 
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6 Results: Morphine versus Oxycodone RCT for Cancer-related Pain, 
Genetic Findings 
6.1 Introduction 
PCA in both the Prospective Morphine Study (Chapter 5) and the Morphine versus 
Oxycodone RCT (Chapter 6) identified three main components to opioid response: 1) 
analgesic response, 2) upper GI adverse reactions and 3) central adverse reactions.  In 
Chapter 5 morphine response Component scores from the Prospective Morphine Study were 
used to investigate possible clinical and genetic associations with six new candidate genes 
(CCKBR, TRPV4, TNF, IL6, IL8 and IL10). 
There was a large degree of inter-individual variability in opioid response in the Morphine 
versus Oxycodone RCT.  This Chapter investigates possible clinical and genetic associations 
with opioid, morphine and oxycodone response Component scores (Chapter 6).  SNPs from 
fifteen candidate genes are tested including the six that I added as part of this thesis and nine 
selected from Palliative Medicine Department Pain Plate: OPRM, OPRK, OPRD, STAT6, 
ARRB2, ABCB1, COMT, ADORA1 and SCL6A4. 
 
This Chapter aims to: 
• Present genetic data for Morphine versus Oxycodone RCT Caucasian subgroup for 
SNPs from fifteen genes: CCKBR, TRPV4, TNF, IL6, IL8, IL10, (OPRM, OPRK, 
OPRD, STAT6, ARRB2, ABCB1, COMT, ADORA1 and SCL6A4). 
• Build predictive models of overall opioid, morphine and oxycodone response 
components from clinical and genetic variables from the Morphine versus Oxycodone 
RCT. 
• Compare morphine response predictive models between the Prospective Morphine 
Study and the Morphine versus Oxycodone RCT. 
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6.2 Candidate genes 
6.2.1 New Candidate Genes  
The following genes contributed by this thesis to the Palliative Medicine Research 
Department Pain Plate are discussed in detail in Chapter 5.  
- Cholecystokinin B receptor 
- Transient receptor potential cation channel V4 
- Tumour necrosis factor α 
- Interleukin 6 
- Interleukin 8 
- Interleukin 10 
 
6.2.2 Palliative Medicine Research Departmental Pain Plate 
Candidate genes were selected from the Palliative Medicine Research Pain Plate on the basis 
of previous association with opioid response.  In depth information on each gene may be 
found in the theses of Dr Joy Ross 39, Dr Dag Rutter 15, Dr Sophy Gretton 60 and Dr Joanne 
Droney 59.  
 
6.2.2.1 Opioid Pharmacogenomics 
6.2.2.1.1 Opioid Receptors 
Opioid receptors are the target receptors of all strong opioids and are found throughout the 
nervous system.  There are three different types of classical opioid receptor: mu (µ), kappa 
(κ) and delta (δ).  They are all G protein coupled receptors with an extracellular N-terminus, 
seven transmembrane domains and an intracellular C-terminus.  Their genes are found on 
different chromosomes and have been cloned 152-154.  The three receptors share a high degree 
of homology with most variation found in the extracellular loops and N-terminal domains 153, 
154.  The extracellular loops are particularly important as they determine ligand binding.  
Opioid receptor subtypes generated by alternative splicing have also been classified through 
pharmacological studies 155.  The classical receptors are also thought to interact and form 
heterodimers with each other and other G protein coupled receptors 51-53, 155.   
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6.2.2.1.1.1 Mu Opioid Receptor 
Knockout studies in mice show that the µ-opioid receptor is essential for morphine induced 
analgesia 156.  Genetic variation in OPRM has been associated with variation in opioid 
response in human volunteer studies 157-159, non-cancer studies including acute post-operative 
pain 160-162, chronic non-cancer pain 62 and cancer-related pain studies.  The most studied SNP 
in OPRM is the non-synonymous exonic SNP A118G, rs1799971 which has been reported to 
be associated with pain and opioid response 61-64.  Klepstad et al reported that the variant G 
allele was associated with increased doses of morphine to achieve pain control in cancer 
patients is 61.  The common A allele has also been associated with increased analgesia from 
morphine in cancer related pain 98.  In an experimental pain study the carriage of the variant 
G allele was also associated with reduced analgesic effects of oxycodone after electrical 
nerve stimulation 163.  A recent meta-analysis of opioid pain studies however showed no 
association with increased pain and only weak associations with increased morphine dose 
requirements and nausea in homozygous carriers of the variant G allele 164.  The functional 
significance of the A118G SNP remains unclear 62.    
 
Recent work using comparative genome analysis, has resulted in the identification of several 
additional potential exons to the original four described in the human μ-opioid receptor gene 
165, therefore adding scope for multiple splice variants and further protein diversity.  Both C- 
49 and N- terminal splice variants 50, 94 have been described.   Splice variants may exhibit 
functional differences, and show different expression patterns depending on anatomical 
region 50.   
 
6.2.2.1.1.2 Kappa Opioid Receptor  
Knock-out studies in mice show that κ-opioid receptors may influence chemical visceral pain 
and thermal nociception 166. Pharmacological studies also suggest a role for κ-opioid 
receptors in mediating the dysphoric and sedative effects of opioids 167.  The human kappa 
opioid receptor gene, OPRK, is situated on chromosome 8 (8q11.23) and spans 25,919 base 
pairs.  One study has suggested association between OPRK haplotypes and increased risk of 
alcohol dependence 168.  
 
6.2.2.1.1.3 Delta Opioid Receptor 
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Combination opioid receptor knockout studies suggest that δ-opioid receptors play a role in 
modulating mechanical and inflammatory pain 169.  Delta opioid receptor knockout mice also 
do not exhibit analgesic tolerance to morphine 170.  Pharmacological studies have suggested 
that selective δ-opioid receptor agonists also decrease anxiety and reduce alcohol 
consumption and have been proposed as potential new treatments for alcoholism 171.  The 
delta-opioid receptor gene, OPRD, is located on chromosome 1 (1p35.3).   It spans 51,556 
base pairs and is composed of three exons.  Over 400 SNPs within OPRD have been 
identified.  OPRD rs1042114 and OPRD rs2234918 have been previously associated with 
alcohol dependence 168.  
 
6.2.2.1.2 STAT6 
STAT6 is an important transcription factor activated following stimulation by TH2 cytokines 
such as IL-4 172.  IL-4 has been shown to induce up-regulation of μ-opioid receptor 
expression.  A functional SNP in the binding site for STAT6 in the promoter region of OPRM 
has been shown to reduce its trans-activating potential by fifty percent 65. Genetic variation in 
STAT6 has previously been associated with IgE, eosinophil levels and atopic conditions such 
as asthma 173, 174.  Polymorphisms in STAT6 have also been implicated in overall response to 
morphine and opioid switching by our group 41.  
 
6.2.2.1.3 β-arrestin 
β-arrestin is an intercellular protein which is involved in μ-opioid receptor inactivation and 
internalisation 66.  Opioid receptor agonists differentially trigger receptor phosphorylation and 
recruitment of β-arrestin, with consequent receptor internalisation 175, 176.  This could be 
linked to variation in agonist binding and activated receptor conformations with differential 
phosphorylation of the receptor c-terminal tail 177, 178.  It has been shown that ARRB2 
knockout mice receive prolonged analgesia from morphine treatment, even at normally sub-
analgesic doses 179.  Desensitization and tolerance to morphine are not observed in these 
animals 180.  Conversely, rats in which β-arrestin is over-expressed experience little or no 
analgesia from morphine 181.  Polymorphisms in ARRB2 have been associated with overall 
response to morphine and opioid switching by our group 41. 
 
6.2.2.1.4 Multidrug Resistance gene 
The multidrug resistance gene or ATP-binding cassette subfamily B, member 1 (MDR1 or 
ABCB1) encodes p-glycoprotein.  P-glycoprotein is a membrane transporter important in 
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regulating drugs across the blood-brain barrier and actively pumps drugs out of the CNS.   
ABCB1 is polymorphic and variant alleles have been associated with morphine central side 
effects 42.   Zwisler et al studied ABCB1 polymorphisms and oxycodone analgesia and 
adverse reactions in an experimental pain study 163.  The variant alleles 3453T and 2677A 
were protective of the adverse reactions: nausea and vomiting, dizziness and itching.  There 
was no association observed between genotype and tiredness/drowsiness.  The 2677A allele 
was associated with better oxycodone analgesia in the cold pressor test 163.  Carriage of the 
3435T allele has been associated with increased pain relief from morphine in cancer related 
pain 98 and decreased morphine equivalent daily dose in mixed chronic pain population 
(n=352) 182. 
 
6.2.2.2 Pain Susceptibility Genes 
6.2.2.2.1 Catechol-O-methyltransferase 
The enzyme catechol-O-methyltransferase (COMT) metabolises catecholamines, and is 
therefore key to adrenergic/noradrengeric and dopaminergic neurotransmission. The most 
commonly studied SNP in COMT Val158Met, rs4680, results in a substitution of valine to 
methionine at amino acid position 158.  This change has significant functional consequences 
as enzyme active is reduced by three- to four-fold.  Zubieta et al first suggested that 
Val158Met polymorphism was associated with increased pain sensitivity and lower µ-opioid 
system activation in prolonged experimental pain 183.  Morphine related central side effects 
have also been associated with COMT polymorphisms by our group 42. 
 
6.2.2.3 Adenosine A1 Receptor 
There are a number of different adenosine receptors, A1, A2A, A2B and A3.  Activation of the 
A1 subtype is thought to play a role in modulation of pain transmission 184.  Like the opioid 
receptors, the adenosine A1 receptor is a seven transmembrane G-protein coupled receptor. 
Adenosine has analgesic properties when administered intrathecally 185.  Animal studies have 
suggested that A1 adenosine receptor agonists increase morphine analgesia, morphine 
tolerance and dependence whilst antagonists such as caffeine produce the opposite effects 186, 
187.  A1 adenosine receptor knock-out mice show reduced analgesia from morphine when 
administered intrathecally, but not systemically 188. In addition studies in µ-opioid receptor 
knock-out mice show reduced binding to A1 adenosine receptors in the brain, supporting a 
functional interaction between the opioid and adenosine receptor systems 189.  
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6.2.2.3.1 SLC6A4 
Serotonin (5-HT) is a neurotransmitter in both the central and peripheral nervous systems.  
SLC6A4 transporters localised in presynaptic neuronal membranes actively remove 5-HT 
from the synapse and terminate its action.  Genetic variation in the promoter region has been 
shown to influence gene expression 190.  Polymorphisms in SCL6A4 have been associated 
with anxiety traits and psychiatric disorders 191.  Variants with low expression have been 
variably associated with pain states such as chronic tension headache and fibromyalgia 192, 193 
and better analgesia with remifentanil 194.  
 
6.2.3 Primer Sequences and Properties 
Primer sequences and properties for the six new genes added to the departmental pain plate 
are shown in Chapter 5.  Information for the other primers designed by Dr Joy Ross, Dr Dag 
Rutter, Dr Sophy Gretton and Dr Joanne Droney can be found the Appendix B 15, 40, 59, 60. 
 
6.2.4 Frequencies and Haplotype Information 
Of the 177 Caucasians recruited to the Morphine versus Oxycodone RCT, genotyping was 
achieved in ninety percent.  Of the 15 candidate genes presented here I performed complete 
genotyping for 12 and 50% for the remaining three (OPRM, OPRK, OPRD, started by Dr 
Joanne Droney).  Genotype and haplotype information is detailed in this Chapter for the six 
new candidate genes: CCKBR (Tables 7.1-7.3, Figure 7.1), TRPV4 (Tables 7.4-7.5, Figure 
7.2), TNF (Tables 7.6-7.7 Figure 7.3), IL6 (Tables 7.8-7.9), IL8 (Table 7.10) and IL10 
(Tables 7.11-7.12, Figure 7.4).  This information for the remaining nine candidate genes are 
from the pre-existing Royal Marsden Palliative Medicine Research Department Pain Plate 
and can be found in Appendix C.  
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6.2.4.1 Cholecystokinin B Receptor 
Table 7.1  Morphine versus Oxycodone RCT: Genotype and Allele Frequencies and Allele Carriage for CCKBR SNPs 
Gene Location  Name Position 
Allele 
major/minor 
Genotype 
frequency 
Allele 
frequency 
Allele 
carriage 
Published 
MAF HWpval 
CCKBR Promoter rs906895  6236824 A/G tt 0.31 t 0.55 t 0.80 
  
     
tc 0.48 c 0.45 c 0.69 0.46 0.72 
     
cc 0.20 
                   
 
Intron 1 
(boundary) rs11040819  6237976 C/T cc 0.69 c 0.83 c 0.96 
  
 
 
   
ct 0.27 t 0.17 t 0.31 0.24 0.50 
 
 
   
tt 0.04 
                   
 
Intron 1 rs2929183  6239384 A/G aa 0.57 a 0.75 a 0.90 
  
 
 
   
ag 0.34 g 0.25 g 0.41 0.29 0.14 
 
 
   
gg 0.09 
                   
 
Exon 2 rs1805002 6247696 G/A gg 0.89 g 0.94 g 0.99 
  
 
 
   
ga 0.11 a 0.06 a 0.11 0.06 0.55 
 
 
   
aa 0.01 
                   
 
Intron 3 
(boundary) rs12364575 6248235 C/G cc 0.41 c 0.65 c 0.89 
  
 
 
   
cg 0.48 g 0.35 g 0.59 0.26 0.23 
 
 
   
gg 0.11 
                   
 
3'UTR rs1042047 6249758 A/C aa 0.39 a 0.63 a 0.87 
  
 
 
   
ac 0.48 c 0.37 c 0.61 0.37 0.66 
 
 
   
cc 0.13 
      
 
 
           Data shown for Caucasian subgroup, n=157 
Published minor allele frequencies from HapMap CEU 
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Figure 7.1  Morphine versus Oxycodone RCT: LD plot: CCKBR Haploblocks 
  
Haploview version 4.2, Broad Institute, Cambridge, USA. 
 
Table 7.2  Morphine versus Oxycodone RCT: CCKBR Haploblocks  
  Haploblock 1 Haploblock 2   
SNP rs906895  rs 11040819  rs2929183  rs1805002 rs12364575 rs1042047 
position 6236824 6237976 6239384 6247696 6248235 6249758 
1 T C A - - - 
2 C C A - - - 
3 C T G - - - 
4 C C G - - - 
5 T C G - - - 
6 T T A - - - 
1 - - - G C - 
2 - - - G G - 
3 - - - A G - 
4 - - - A C - 
Data shown for Caucasian subgroup, n=157 
 
Table 7.3  Morphine versus Oxycodone RCT: CCKBR Haploblock Frequency and Carriage  
  Haploblock 1 Haploblock 2 
SNP Haploblock 
frequency  
Haploblock 
carriage   
Haploblock 
frequency  
Haploblock 
carriage   position 
1 0.53 0.78 - - 
2 0.21 0.36 - - 
3 0.17 0.30 - - 
4 0.07 0.13 - - 
5 0.02 0.04 - - 
6 0.00 0.01 - - 
1 - - 0.65 0.89 
2 - - 0.29 0.50 
3 - - 0.06 0.11 
4 - - 0.00 0.01 
Data shown for Caucasian subgroup, n=157 
  
R2 
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6.2.4.2 Transient Receptor Potential Cation Channel V4 
Table 7.4  Morphine versus Oxycodone RCT: Genotype and Allele Frequencies and Allele Carriage for TRPV4 SNPs 
Gene Location  Name Position 
Allele 
major/minor 
Genotype 
frequency 
Allele 
frequency 
Allele 
carriage 
Published 
MAF HWpval 
TRPV4 Promoter rs10850836 108761770 G/A gg 0.23 g 0.49 g 0.75 
  
 
    
ga 0.53 a 0.51 a 0.77 0.41 0.51 
 
    
aa 0.25 
                   
 
Promoter rs10850830 108756282 G/A gg 0.26 g 0.51 g 0.76 
  
 
    
ga 0.50 a 0.49 a 0.74 0.44 1.00 
 
    
aa 0.24 
                   
 
Intron 1 rs10744892 108741887 A/G aa 0.25 a 0.51 a 0.76 
  
 
    
ag 0.51 g 0.49 g 0.75 0.50 0.23 
 
    
gg 0.24 
                   
 
Exon 4 rs3825394 108725221 G/T tt 0.28 t 0.53 t 0.79 
  
 
    
tg 0.51 g 0.47 g 0.72 0.50 0.70 
 
    
gg 0.21 
                   
 
Intron 12 rs10735104 108712348 C/T gg 0.25 g 0.51 g 0.76 
  
 
    
ga 0.51 a 0.49 a 0.75 0.44 0.87 
 
    
aa 0.24 
                   
 
Intron 13 rs1861810 108709305 T/G tt 0.33 t 0.56 t 0.80 0.44 
 
 
    
tg 0.47 g 0.44 g 0.67 
 
0.55 
 
    
gg 0.20 
                   Data shown for Caucasian subgroup, n=158 
Published minor allele frequencies from HapMap CEU 
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Figure 7.2  Morphine versus Oxycodone RCT: LD plot: TRPV4 Haploblock  
  
Haploview version 4.2, Broad Institute, Cambridge, USA. 
 
Table 7.5  Morphine versus Oxycodone RCT: TRPV4 Haploblock Frequency and Carriage  
      Haploblock 1         
SNP rs10850836 rs10850830 rs10744892 rs3825394 rs10735104 rs1861810 Haploblock 
frequency  
Haploblock 
carriage   position 108761770 108756282 108741887 108725221 108712348 108709305 
1 - - A T - - 0.46 0.72 
2 - - G G - - 0.27 0.46 
3 - - A G - - 0.26 0.44 
4 - - G T - - 0.00 0.01 
Data shown for Caucasian subgroup, n=158  
 
 
R2 
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6.2.4.3 Tumour necrosis factor α 
Table 7.6  Morphine versus Oxycodone RCT: Genotype and Allele frequencies and Allele Carriage for TNF SNPs 
Gene Location Name Position 
Allele 
major/minor 
Genotype 
frequency 
Allele 
frequency 
Allele 
carriage 
Published 
MAF HWpval 
TNF Promoter rs1799964 31650287 T/C tt 0.65 t 0.80 t 0.96 
  
 
 
   
tc 0.30 c 0.20 c 0.35 0.21 0.64 
 
 
   
cc 0.04 
      
 
 
           
 
Promoter rs1800630 31650455 C/A cc 0.73 c 0.86 c 0.98 
  
 
 
   
ca 0.25 a 0.14 a 0.27 0.18 0.89 
 
 
   
aa 0.02 
      
 
 
           
 
Promoter rs1799724 31650461 C/T cc 0.85 c 0.92 c 0.99 
  
 
 
   
ct 0.14 t 0.08 t 0.15 0.07 0.91 
 
 
   
tt 0.01 
      
 
 
           
 
Promoter rs1800629 31651010 G/A gg 0.67 g 0.80 g 0.94 
  
 
 
   
ga 0.27 a 0.20 a 0.33 0.22 0.05 
 
 
   
aa 0.06 
      
 
 
           
 
Promoter rs361525 31651050 G/A gg 0.92 g 0.96 g 1.00 
  
 
 
   
ga 0.08 a 0.04 a 0.08 0.07* 0.59 
 
 
   
aa 0.00 
                   Data shown for Caucasian subgroup, n=159 
Published allele frequencies from HapMap CEU, *CEU GENO PANEL 
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Figure 7.3  Morphine versus Oxycodone RCT: LD plot: TNF haplotypes.  
  
 
Haploview version 4.2, Broad Institute, Cambridge, USA. 
 
Table 7.7  Morphine versus Oxycodone RCT: TNF Haplotype Frequency and Carriage 
  Haplotype      
SNP rs1799964 rs1800630 rs1799724 rs1800629 rs361525 Haplotype 
frequency  
Haplotype 
carriage   position 31650287 31650455 31650461 31651010 31651050 
1 T C C G G 0.53 0.75 
2 T C C A G 0.19 0.32 
3 C A C G G 0.14 0.26 
4 T C T G G 0.08 0.14 
5 C C C G A 0.04 0.08 
6 C C C G G 0.01 0.03 
Data shown for Caucasian subgroup, n=159 
R2 
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6.2.4.4 Interleukin 6 
Table 7.8  Morphine versus Oxycodone RCT: Genotype and Allele Frequencies and Allele Carriage for IL6 SNPs 
Gene Location Name Position 
Allele 
major/minor 
Genotype 
frequency 
Allele 
frequency 
Allele 
carriage 
Published 
MAF HWpval 
IL6 Promoter rs1800795 22733170 C/G gg 0.35 g 0.59 g 0.83 
  
     
gc 0.48 c 0.41 c 0.65 0.46 0.99 
     
cc 0.17 
      
            
 
Intron 4  rs2069845 22736674 A/G aa 0.37 a 0.60 a 0.83 
  
     
ag 0.46 g 0.39 g 0.62 0.47 0.76 
     
gg 0.16 
                  Data shown for Caucasian subgroup, n=159 
Published minor allele frequencies from HapMap CEU 
 
Table 7.9  Morphine versus Oxycodone RCT: IL6 Haplotype Frequency and Carriage 
  Haplotype     
SNP rs1800795  rs2069845 Haploblock 
frequency  
Haploblock 
carriage   position 22733170 22736674 
1 G A 0.58 0.83 
2 C G 0.39 0.62 
3 G G 0.02 0.04 
4 C A 0.00 0.01 
Data shown for Caucasian subgroup, n=159 
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6.2.4.5 Interleukin 8 
Table 7.10  Morphine versus Oxycodone RCT: Genotype and Allele Frequencies and Allele Carriage for IL8 SNP 
Gene Location Name Position 
Allele 
major/minor 
Genotype 
frequency 
Allele 
frequency 
Allele 
carriage 
Published 
MAF HWpval 
IL8 Promoter rs4073 74824888 T/A tt 0.23 t 0.47 t 0.70 
  
     
ta 0.47 a 0.53 a 0.77 0.40 0.45 
     
aa 0.30 
      
            Data shown for Caucasian subgroup, n=158 
Published minor allele frequencies from HapMap CEU 
 
 
6.2.4.6 Interleukin 10 
Table 7.11  Morphine versus Oxycodone RCT: Genotype and Allele Frequencies and Allele Carriage for IL10 SNPs 
Gene Location Name Position 
Allele 
major/minor 
Genotype 
frequency 
Allele 
frequency 
Allele 
carriage 
Published 
MAF HWpval 
IL10 Promoter rs1800896 205013520 G/A gg 0.30 g 0.53 g 0.77 
  
 
 
   
ga 0.48 a  0.47 a  0.70 0.48 0.62 
 
 
   
aa 0.23 
      
 
 
           
 
Promoter rs1800871 205013257 C/T cc 0.57 c 0.76 c 0.95 
  
 
 
   
ct 0.38 t 0.24 t 0.43 0.17 0.58 
 
 
   
tt 0.05 
      
 
 
           
 
Promoter rs1800872 205013030 C/A cc 0.57 c 0.76 c 0.95 
  
 
 
   
ca 0.38 a 0.24 a 0.43 0.21 0.68 
     
aa 0.05 
      
            Data shown for Caucasian subgroup, n=159 
Published minor allele frequencies from HapMap CEU 
  236 
 Figure 7.4  Morphine versus Oxycodone RCT: LD plot: IL10 haplotypes  
  
Haploview version 4.2, Broad Institute, Cambridge, USA. 
 
Table 7.12  Morphine versus Oxycodone RCT: IL10 Haplotype Frequency and Carriage  
  Haplotype     
SNP rs1800896 rs1800871 rs1800872 Haplotype 
frequency  
Haplotype 
carriage   position 205013520 205013257 205013030 
1 G C C 0.53 0.77 
2 A T A 0.24 0.43 
3 A C C 0.23 0.43 
4 G T A 0.01 0.01 
Data shown for Caucasian subgroup, n=159 
   
 
  
R2 
  237 
 
6.3 Opioid Response Component Scores 
Opioid response Component scores from PCA were transformed to Normalise the data.  
Associations between log10 Component scores and genetic variation expressed as genotype 
and allele carriage for each SNP as well as haplotypes were tested using simple linear 
regression.  For each gene the most significant findings (P < 0.1) either with allele carriage or 
haplotype information were entered into multivariate regression analysis. 
 
6.3.1 Opioid Response Component 1: Analgesic Response 
6.3.1.1 Univariate Analysis 
On univariate analysis, weak associations with log10 Component 1 scores were found with 
four SNPs: CCKBR rs11040819C (R2=0.043, P=0.022), SLC6A4 rs7214991G (R2=0.041, 
P=0.025) OPRK rs963549G (R2=0.036, P=0.036) and OPRD rs533123A (R2=0.033, 
P=0.044).  The ABCB1 haplotype 3 was also weakly associated with log10 Component 1 
scores (R2=0.044, P=0.022). 
The common alleles of CCKBR rs11040819 and OPRK rs963549, and ABCB1 haplotype 3 
were associated with higher Component 1 scores and therefore worse symptoms.  Whereas 
the variant G allele of SLC6A4 rs7214991 and the common allele of OPRD rs533123 were 
associated with lower Component 1 scores and therefore a better analgesic response to 
opioid. 
 
6.3.1.2 Multivariate Analysis 
In addition to the above, ten other SNPs or haplotypes met criteria for inclusion into the 
modelling process as P < 0.1: IL6 haplotype 1, CCKBR rs906895C, rs1042047C and 
haploblock 2.2, ADORA1 rs2364571C, OPRM rs563649T and rs9479757G, OPRK 
rs1365098G and rs7824175C and OPRD rs2236857C.   
 
From the clinical multivariate regression analysis in Chapter 6, one clinical factor: use of an 
antidepressant was also included in the modelling. 
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The final model retained four factors as independent predictors of analgesic response (log10 
Component 1 scores): concomitant use of an antidepressant, CCKBR rs11040819C, OPRK 
rs1365098G and OPRD rs2236857C which together accounted for approximately 17% of 
variability (Table 7.13).  Use of an antidepressant, CCKBR rs11040819C and OPRK 
rs1365098G were associated with higher log10 Component 1 scores and therefore more pain 
and less analgesic response whereas OPRD rs2236857C was associated with lower scores 
and therefore better analgesia. 
 
Table 7.13  Morphine versus Oxycodone RCT: Genetic and Clinical Factors Predictive of Analgesic 
Response to Opioid. 
  Unstandardized Coefficients 
95.0% Confidence 
Interval for B 
Standardized 
Coefficients 
P value 
  B Std. Error 
Lower 
Bound 
Upper 
Bound Beta 
(Constant) 0.24 0.07 0.10 0.37 
 <0.005 
Antidepressant 0.08 0.03 0.02 0.15 0.22 0.01 
CCKBR rs11040819C 0.15 0.05 0.04 0.25 0.23 0.01 
OPRK rs1365098G 0.11 0.04 0.02 0.19 0.21 0.02 
OPRD1 rs2236857C -0.06 0.02 -0.11 -0.01 -0.22 0.01 
Dependent Variable: Log10 Component 1 (opioid response) 
R2 =0.169, ANOVA F-ratio = 5.862 
 
 
6.3.2 Opioid Response Component 2: Upper Gastrointestinal Adverse Reactions 
6.3.2.1 Univariate Analysis 
Weak associations with log10 Component 2 scores were found with eleven SNPs or 
haplotypes on univariate analysis: IL10 haplotype 2 (R2=0.056, P=0.008), CCKBR 
rs1805002A (R2=0.067, P=0.004), rs1042047A (R2=0.085, P=0.001) and haploblock 1.4 
(R2=0.064, P=0.005), ADORA1 haploblock 1.2 (R2=0.034, P=0.041), COMT haploblock 1.6 
(R2=0.033, P=0.047), STAT6 rs167769C (R2=0.049, P=0.013) and haplotype 7 (R2=0.047, 
P=0.047), ABCB1 rs3213619T (R2=0.086, P=0.001) and OPRD rs1042114T  (R2=0.051, 
P=0.012) and rs2234918C (R2=0.046, P=0.017).   
The variant A allele of CCKBR rs1805002, and the common C allele of STAT6 rs167769C 
together with CCKBR haploblock 1.4, ADORA1 haploblock 1.2, COMT haploblock 1.6. and 
STAT6 haplotype 7 were associated with higher log10 Component 2 scores and therefore 
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worse upper GI adverse reaction scores.  The other SNPs were associated with lower 
Component 1 scores and therefore less nausea and vomiting. 
 
6.3.2.2 Multivariate Analysis 
In addition to the above, six other SNPs or haplotypes met criteria for inclusion into the 
modelling process as P < 0.1: IL10 haplotype 3, TRPV4 rs10850836A, COMT haploblock 
1.4, ABBR2 rs1973555, OPRM rs563649T and OPRD rs533123G.   
 
Five clinical factors from the clinical multivariate regression analysis in Chapter 6 were also 
included in the modelling: diagnosis of urinary tract or upper GI malignancy and three classes 
of concomitant medication: steroid, antiemetic and ACE inhibitor/angiotensin II receptor 
antagonists. 
 
The final model retained nine factors as independent predictors of log10 Component 2 scores 
(Table 7.14).  Diagnosis of urinary tract malignancy, concomitant use of an ACE 
inhibitor/angiotensin II receptor antagonist remained as clinical factors and together with 
CCKBR rs1805002A, TRPV4 rs10850836A, COMT haploblock 1.4 and STAT6 haplotype 7 
were all associated with higher log10 Component 2 scores and therefore worse upper GI 
adverse reactions.  IL10 haplotype 2, ABCB1 rs3213619T and OPRD rs1042114T were 
associated with less nausea and vomiting.  The model explained approximately 48% of the 
variation observed in this dataset. 
 
6.3.3 Opioid Response Component 3: Central Adverse Reactions 
6.3.3.1 Univariate Analysis 
On univariate analysis, weak associations with log10 Component 3 scores were found with 
three SNPs or haploblocks: TRPV4 haploblock 1 (R2=0.066, P=0.004) and COMT haploblock 
1.3 (R2=0.035, P=0.039), and SLC6A4 rs140700C (R2=0.042, P=0.022).   TRPV4 haploblock 
1 and SLC6A4 rs140700C were associated with lower log10 Component 3 scores and 
therefore less central adverse reactions, whereas COMT haploblock 1.3 was associated with 
higher scores and therefore worse symptoms. 
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Table 7.14  Morphine versus Oxycodone RCT: Genetic and Clinical Factors Predictive of Upper 
Gastrointestinal Adverse Reactions to Opioids. 
  Unstandardized Coefficients 
95.0% Confidence 
Interval for B 
Standardized 
Coefficients 
P value 
  B Std. Error 
Lower 
Bound 
Upper 
Bound Beta 
(Constant) 0.99 0.11 0.77 1.21  <0.005 
Urinary tract malignancy 0.10 0.03 0.04 0.16 0.25 <0.005 
ACE inhibitor/ Angiotensin 
II  receptor antagonist 0.08 0.02 0.04 0.13 0.27 <0.005 
IL10 haplotype 2 -0.04 0.02 -0.08 -0.01 -0.18 0.02 
CCKBR rs1805002A 0.08 0.03 0.02 0.14 0.19 0.01 
TRPV4 rs10850836A 0.05 0.02 0.01 0.09 0.17 0.02 
COMT haploblock 1.4 0.08 0.03 0.03 0.13 0.24 <0.005 
STAT6 haplotype 7 0.10 0.03 0.04 0.16 0.23 <0.005 
ABCB1 rs3213619T -0.40 0.09 -0.57 -0.22 -0.32 <0.005 
OPRD rs1042114T -0.21 0.06 -0.33 -0.08 -0.24 <0.005 
Dependent Variable: Log10 Component 2 
R2 =0.478, ANOVA F-ratio = 10.362 
 
 
6.3.3.2 Multivariate Analysis 
In addition to the above, nine other SNPs or haploblocks from five genes met inclusion 
criteria for the modelling process at P < 0.1: TNF haplotype 2, IL10 haplotype 1, CCKBR 
rs906895T and haploblock 1.3, SLC6A4 rs7214991A, rs25528T and rs6354T and OPRD 
rs2236857T and rs2234918C.   
 
From the clinical multivariate regression analysis (Chapter 6), three clinical factors were also 
included in the modelling: chemotherapy within the last four weeks, serum albumin (g/L) and 
concomitant use of paracetamol. 
 
Concomitant use of paracetamol, chemotherapy within the last 4 weeks and three genetic 
variables: TRPV4 haplotype 1, COMT haploblock 1.3 and CCKBR rs906895T were retained 
in the final model as independent predictors of central adverse reactions to opioid (log10 
Component 3 scores). Together these factors accounted for approximately 21% of variability 
(Table 7.15).  Concomitant use of paracetamol, chemotherapy within the last four weeks and 
carriage TRPV4 haploblock 1 were protective of central adverse reactions to opioids.  
Carriage of the common T allele of CCKBR rs906895T and COMT haploblock 1.3 were 
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however associated with higher log10 Component 3 scores and therefore more severe central 
adverse reactions to opioid. 
 
Table 7.15  Morphine versus Oxycodone RCT: Genetic and Clinical Factors Predictive of Central 
Adverse Reactions to Opioid. 
  Unstandardized Coefficients 
95.0% Confidence 
Interval for B 
Standardized 
Coefficients 
P value 
  B Std. Error 
Lower 
Bound 
Upper 
Bound Beta 
(Constant) 0.48 0.03 0.43 0.54 
 <0.005 
Paracetamol -0.05 0.02 -0.08 -0.01 -0.23 0.01 
Chemotherapy ≤ 4 weeks -0.04 0.02 -0.07 0.00 -0.19 0.03 
TRPV4 haplotype 1 -0.06 0.02 -0.10 -0.02 -0.25 <0.005 
COMT haploblock 1.3 0.03 0.02 0.00 0.07 0.17 0.05 
CCKBR rs906895T 0.05 0.02 0.01 0.10 0.21 0.02 
Dependent Variable: Log10 Component 3 
R2 =0.214, ANOVA F-ratio = 6.222 
 
 
6.4 Morphine Response Component Scores 
6.4.1 Morphine Response Component 1: Analgesic Response 
6.4.1.1 Univariate Analysis 
On univariate analysis, weak associations with analgesic response (log10 Component 1 
scores) were found with ten SNPs or haploblocks in seven genes: CCKBR rs11040819C 
(R2=0.079, P=0.027), ADORA1 rs10920576T (R2=0.074, P=0.031) and haploblock 1.1 
(R2=0.062, P=0.049), SLC6A4 haplotype 3 (R2=0.069, P=0.037), STAT6 rs3024979T 
(R2=0.111, P=0.008), ABCB1 rs1202168C (R2=0.079, P=0.031), rs1128503C (R2=0.079, 
P=0.031), and rs2032582G (R2=0.079, P=0.031), OPRM rs563649T (R2=0.067, P=0.047),  
and OPRD haplotype A (R2=0.072, P=0.033). The variant T alleles of OPRM rs563649 and 
ADORA1 rs10920576 and the common C allele of CCKBR rs11040819 were associated with 
higher Component 1 scores and therefore worse pain scores.  The other identified SNPs or 
haplotypes were associated with better morphine analgesic response. 
CCKBR rs11040819 was the only SNP to exhibit a significant gene dose effect (R2=0.072, 
P=0.035). 
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6.4.1.2 Multivariate Analysis 
In addition to the above, three other SNPs met criteria for inclusion into the modelling 
process as P < 0.1: CCKBR rs2929183G, TRPV4 rs10735104A and OPRK rs10504151C. 
 
One clinical factor: use of an ACE inhibitor/angiotensin II receptor antagonist was identified 
in Chapter 6 for inclusion into the model. 
 
The final model retained one clinical factor and three SNPs as independent predictors of 
morphine analgesic response (log10 Component 1 scores): concomitant use of an ACE 
inhibitor/angiotensin II receptor antagonist and CCKBR rs11040819C, TRPV4 rs10735104A 
and ADORA1 rs10920576T.  Together these factors accounted for approximately 34% of 
variability (Table 7.16) and were all associated with increased pain and therefore less 
analgesic response.   
 
Table 7.16  Morphine versus Oxycodone RCT: Genetic and Clinical Factors Predictive of Analgesic 
Response to Morphine. 
  Unstandardized Coefficients 
95.0% Confidence 
Interval for B 
Standardized 
Coefficients 
P value 
  B Std. Error 
Lower 
Bound 
Upper 
Bound Beta 
(Constant) 0.21 0.07 0.07 0.35 
 <0.005 
ACE inhibitor/ Angiotensin 
II  receptor antagonist 
0.13 0.04 0.05 0.21 0.37 
<0.005 
CCKBR rs11040819C 0.15 0.07 0.01 0.29 0.24 0.03 
TRPV4 rs10735104A 0.07 0.03 0.01 0.14 0.24 0.03 
ADORA1 rs10920576T 0.09 0.03 0.02 0.16 0.29 0.01 
Dependent Variable: Log10 Component 1 
R2 =0.345, ANOVA F-ratio = 7.373 
 
 
6.4.2 Morphine Response Component 3: Upper Gastrointestinal Adverse Reactions 
6.4.2.1 Univariate Analysis 
Weak associations with log10 Component 3 scores were found with ten SNPs or haplotypes 
on univariate analysis: IL10 haplotype 4 (R2=0.128, P=0.005), CCKBR rs1805002A 
(R2=0.105, P=0.012) and haplotype 1.4 (R2=0.071, P=0.039), COMT haploblock 1.6 
(R2=0.165, P=0.001),  SLC6A4 rs255828G (R2=0.076, P=0.032), rs6354G (R2=0.085, 
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P=0.023), rs140700T (R2=0.073, P=0.036), STAT6 rs3024974T (R2=0.194, P<0.005), OPRM 
rs563649T (R2=0.096, P=0.018) and OPRD rs2234918C (R2=0.102, P=0.012).   
The variant C allele of OPRD rs2234918 and the common T allele of STAT6 rs3024974 were 
associated with higher log10 Component 3 scores and therefore worse upper GI adverse 
reaction scores.  The other variants were associated with lower log10 Component 3 scores and 
therefore less nausea and vomiting. 
 
6.4.2.2 Multivariate analysis 
In addition to the above, six other SNPs from three genes met criteria for inclusion into the 
modelling process at P < 0.1: CCKBR rs1042047A, TRPV4 rs10850836A, ADORA1 
rs2364571C, rs10920568G and rs10800901A and STAT6 rs167769T. 
 
Three clinical factors from the clinical multivariate regression analysis in Chapter 6 were 
included in the modelling: diagnosis of lung cancer, Haemoglobin (g/dL) and concomitant 
use of a tricyclic related antidepressant. 
 
The final model retained three factors as independent predictors of log10 Component 3 scores: 
COMT haploblock 1.6, STAT6 rs3024979T and OPRD rs2234918C (Table 7.17).  COMT 
haploblock 1.6 was associated with lower log10 Component 3 scores and therefore less upper 
GI adverse reactions, whereas the other two SNPs were associated with more nausea and 
vomiting.  The model accounted for approximately 43% of variability within the dataset. 
 
 
Table 7.17   Morphine versus Oxycodone RCT: Genetic and Clinical Factors Predictive of Upper 
Gastrointestinal Adverse Reactions to Morphine 
  Unstandardized Coefficients 
95.0% Confidence 
Interval for B 
Standardized 
Coefficients 
P value 
  B Std. Error 
Lower 
Bound 
Upper 
Bound Beta 
(Constant) -0.38 0.19 -0.76 0.00 
 0.05 
COMT haploblock 1.6 -0.46 0.11 -0.69 -0.24 -0.42 <0.005 
STAT6 rs3024979T 0.79 0.19 0.40 1.18 0.42 <0.005 
OPRD rs2234918C 0.12 0.05 0.01 0.22 0.23 0.03 
Dependent Variable: Log10 Component 3 
R2 =0.434, ANOVA F-ratio = 14.048 
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6.4.3 Morphine Response Component 2: Central Adverse Reactions 
6.4.3.1 Univariate Analysis 
Weak associations with log10 Component 2 scores were found with six SNPs or haplotypes in 
four genes: CCKBR rs11040819T (R2=0.063, P=0.049), COMT haploblock 1.6 (R2=0.082, 
P=0.025), SLC6A4 rs7214991A (R2=0.062, P=0.049), rs140700T (R2=0.077, P=0.027) and 
haplotype 1 (R2=0.130, P=0.004) and STAT6 haplotype 6 (R2=0.112, P=0.008).  SLC6A4 
rs140700 was the only SNP to exhibit a significant gene dose effect (R2=0.123, P=0.005).   
STAT6 haplotype 6, COMT haploblock 1.6 and SLC6A4 rs140700T were associated with 
higher log10 Component 3 scores and therefore more severe central adverse reactions whereas 
the other identified variants were protective against them.  
 
6.4.3.2 Multivariate Analysis 
In addition to the above, six other SNPs or haplotypes genes met the inclusion criteria for the 
modelling process at P < 0.1: CCKBR haploblock 1.4, TRPV4 rs3825394T, ARRB2 
rs4522461G, STAT6 rs3024974T, ABCB1 haplotype 1 and OPRD rs2234918C.   From the 
clinical multivariate regression analysis in Chapter 6, three clinical factors were also included 
in the modelling: diagnosis of urinary tract malignancy, serum total bilirubin (µmol/L) and 
concomitant use of paracetamol. 
 
Four variables were retained within the final model as independent predictors of central 
adverse reactions to morphine (log10 Component 2 scores).  Concomitant use of paracetamol 
and the variant T allele of TRPV4 rs382539 were associated with lower scores and therefore 
protective of central adverse reactions to morphine.  COMT haploblock 1.6 and STAT6 
haplotype 6 were however associated with more central symptoms. Together the variables in 
the model accounted for approximately 36% of variability (Table 7.18). 
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Table 7.18  Morphine versus Oxycodone RCT: Genetic and Clinical Factors Predictive of Central 
Adverse Reactions to Morphine. 
  Unstandardized Coefficients 
95.0% Confidence 
Interval for B 
Standardized 
Coefficients 
P value 
  B Std. Error 
Lower 
Bound 
Upper 
Bound Beta 
(Constant) 0.53 0.02 0.48 0.57 
 
0.00 
Paracetamol -0.06 0.02 -0.10 -0.01 -0.28 0.01 
TRPV4 rs3825394T -0.08 0.02 -0.13 -0.03 -0.34 0.00 
COMT haploblock 1.6 0.12 0.05 0.02 0.22 0.27 0.02 
STAT6 haplotype 6 0.14 0.05 0.04 0.24 0.30 0.01 
Dependent Variable: Log10 Component 2 
R2 =0.364, ANOVA F-ratio = 7.596 
 
 
6.5 Oxycodone Response Component Scores 
6.5.1 Oxycodone Response Component 1: Analgesic Response 
6.5.1.1 Univariate Analysis 
Weak associations with log10 Component 1 scores were found with eight SNPs or haplotypes 
in four genes: TNF rs1800630C (R2=0.119, P=0.007) and rs361525 (R2=0.066, P=0.045),  
CCKBR haploblock 1.4 (R2=0.106, P=0.010), haploblock 2.1 (R2=0.086, P=0.022),  
haploblock 2.4 (R2=0.081, P=0.026), OPRM rs9479757G (R2=0.072, P=0.040) and OPRK 
rs963549G (R2=0.065, P=0.050) and haploblock 1.5 (R2=0.087, P=0.023).   
TNF rs361525 and OPRK rs963549 were the only SNPs to exhibit a significant gene dose 
effect, R2=0.066, P=0.045 and R2=0.096, P=0.016 respectively. 
CCKBR haploblocks 1.4 and 2.1 and OPRK rs963549G were associated with higher log10 
Component 1 scores and therefore less analgesic response to oxycodone.  The other variants 
were associated with lower scores and therefore a better response. 
 
6.5.1.2 Multivariate Analysis 
In addition to the above, six other SNPs or haplotypes in five genes met the inclusion criteria 
for the modelling process as P < 0.1: CCKBR haploblock 1.5, COMT rs2075507G, 
rs7290221C and rs740603A, ARRB2 rs197355C and SLC6A4 haplotype 4.   
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After controlling for all other variables three factors were retained in the final model as 
independent predicators of analgesic response to oxycodone: use of an anticoagulant, TNF 
1800630C and CCKBR haploblock 1.4.  The model accounted for approximately 39% of 
variability in analgesic response to oxycodone (Table 7.19).  Concomitant use of an 
anticoagulant and carriage of CCKBR haploblock 1.4 were associated with less analgesic 
response to oxycodone whereas carriage of the common C allele at rs1800630 in the TNF 
promoter was associated with a better outcome. 
 
Table 7.19  Morphine versus Oxycodone RCT: Genetic and Clinical Factors Predictive of Analgesic 
Response to Oxycodone. 
  Unstandardized Coefficients 
95.0% Confidence 
Interval for B 
Standardized 
Coefficients 
P value 
  B Std. Error 
Lower 
Bound 
Upper 
Bound Beta 
(Constant) 0.72 0.08 0.56 0.88 
 <0.005 
Anticoagulant 0.13 0.04 0.06 0.20 0.39 <0.005 
TNF rs1800630C -0.31 0.08 -0.47 -0.15 -0.40 <0.005 
CCKBR haploblock 1.4 0.17 0.05 0.07 0.26 0.36 <0.005 
Dependent Variable: Log10 Component 1 (Oxycodone) 
R2 =0.388, ANOVA F-ratio = 12.068 
 
 
6.5.2 Oxycodone Response Component 2: Upper Gastrointestinal Adverse Reactions 
There were several weak associations with upper GI adverse reaction scores (log10 
Component 2).  Associations were found with eight SNPs or haplotypes in eight genes: IL10 
haplotype 3 (R2=0.135, P=0.004), CCKBR rs12364575G (R2=0.108, P=0.010), TRPV4 
rs3825394G (R2=0.083, P=0.024), COMT haploblock 1.4 (R2=0.066, P=0.046), SCL6A4 
haplotype 4 (R2=0.142, P=0.003), STAT6 haplotype G (R2=0.125, P=0.006), OPRM 
rs533586C (R2=0.081, P=0.028) and OPRK rs10504151C (R2=0.065, P=0.049).  
CCKBR rs12364575G, OPRM rs533586C and OPRK rs10504151C all had significant gene 
dose effects, R2=0.116, P=0.007, R2=0.080, P=0.030, and R2=0.065, P=0.049 respectively. 
Most of the identified variants were associated with higher log10 Component 2 scores and 
therefore increased upper GI adverse reaction scores. Only OPRM rs533586C was associated 
with lower scores and therefore less nausea and vomiting. 
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6.5.2.1 Multivariate Analysis 
In addition to the above, six other SNPs or haplotypes in four genes met the inclusion criteria 
for the modelling process as P < 0.1: IL10 rs1800871T, CCKBR rs1805002A, OPRK 
rs7016778A, rs7824175C and rs16918875T and OPRD rs1042114T.  From the modelling of 
clinical factors in Chapter 6, chemotherapy within the last four weeks was also included in 
the multivariate regression analysis of upper GI adverse reactions to oxycodone. 
 
The final model retained three genetic factors as independent predictors of upper GI adverse 
reactions to oxycodone which together explained approximately 28% of the variability 
observed (Table 7.20).  Carriage of the COMT haploblock 1.4 and SLC6A4 haplotype 4, and 
carriage of the variant G allele at rs12364575 in CCKBR were all associated with increased 
nausea and vomiting. 
 
 
Table 7.20  Morphine versus Oxycodone RCT: Genetic and Clinical factors Predictive of Upper 
Gastrointestinal Adverse Reactions to Oxycodone. 
  Unstandardized Coefficients 
95.0% Confidence 
Interval for B 
Standardized 
Coefficients 
P value 
  B Std. Error 
Lower 
Bound 
Upper 
Bound Beta 
(Constant) 0.41 0.02 0.37 0.45 
 <0.005 
CCKBR rs12364575G 0.06 0.03 0.01 0.11 0.26 0.03 
COMT haploblock 1.4 0.09 0.04 0.01 0.17 0.24 0.04 
SLC6A4 haplotype 4 0.32 0.10 0.12 0.52 0.36 0.00 
Dependent Variable: Log10 Component 2 
R2 =0.280, ANOVA F-ratio = 7.394 
 
 
6.5.3 Oxycodone Response Component 3: Central Adverse Reactions 
Weak associations with log10 Component 3 scores were found with two SNPs TRPV4 
rs3825394T (R2=0.067, P=0.044) and OPRD rs2236857T (R2=0.072, P=0.038). 
Both SNPs were associated with lower log10 Component 3 scores and therefore protective 
against central adverse reactions to oxycodone. 
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6.5.3.1 Multivariate Analysis 
Ten other SNPs met the inclusion criteria for the modelling process as P < 0.1: IL10 
rs1800896G, TRPV4 rs10735104G, COMT rs2075507A and G, rs7290221C and rs740603A, 
ABCB1 rs1045642C, OPRK rs786120G and rs7016778A and OPRD rs2236857C.   
 
From the clinical multivariate regression analysis in Chapter 6, three clinical factors were 
also included in the modelling: diagnosis of gynaecological malignancy, serum albumin (g/L) 
and concomitant use of an SSRI antidepressant.  The final model did not provide any 
improvement on the previous clinical model (Chapter 6, Table 6.59).  No genetic factors were 
retained as independent predictors. 
 
 
6.6 Discussion 
Pain and response to opioid analgesics are complex traits and are likely to be under the 
influence of a number of genes and environmental factors.  Previous candidate gene 
association studies have tended to examine associations at single loci only.  More recently the 
trend has become to investigate possible interactions between candidate loci and phenotypes, 
often only two SNPs at a time 195-197.  This chapter aimed to bring together the possible 
influence of clinical and genetic factors by building multivariate regression models. Genetic 
information was summarised in terms of allele carriage or haplotype depending on which 
measure had the strongest association in terms of significance level.   
 
PCA of both the Morphine Prospective Genetic Study and the Morphine versus Oxycodone 
RCT pain and adverse reaction scores identified three similar Components of response to 
opioids: analgesic response, upper GI adverse reactions and central adverse reactions.  Log10 
Component scores were used as the dependant variable in multivariate regression analysis.  
These three elements of opioid response may be caused by three separate mechanisms or 
pathways that each contribute to overall response to opioid. 
 
In Chapter 6 it was shown that clinical response to morphine and oxycodone are very similar 
at a population level, however on an individual basis there is much more variability in terms 
of analgesia and adverse reactions.  There are likely to be class specific and drug specific 
effects of the opioids.  Models were therefore been constructed for morphine response, 
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oxycodone response and combined opioid response.  There are clear differences between 
morphine and oxycodone models presented here, however interpretation must be cautious as 
the sample sizes are small.   
 
The addition of genetic factors as well as clinical factors presented in Chapter 6 improved the 
predictive value of nearly all the response phenotype models with the exception of the central 
adverse reaction model for oxycodone. The degree of variance explained in the models 
including genetic and clinical variables ranged from 17-48%, which although improved from 
5-28% still leaves more variation unaccounted for than explained.  There are many elements 
to the pain experience that were unaccounted for in this study including various 
psychological factors and more detailed clinical information. 
 
The three components are considered individually here.  Comparison is performed for 
between the models for the different drugs, and reference made to the same components 
studied in the Prospective Morphine Study in Chapter 5.  Previously published associations of 
similar symptoms are commented upon.  Table 7.21 lists the predictive factors of opioid 
response components from multivariate linear regression analysis in the combined opioid, 
morphine and oxycodone populations from the Morphine versus Oxycodone RCT for 
Cancer-related Pain. 
   
6.6.1 Analgesic Response 
6.6.1.1 Analgesic Response to Opioids 
The addition of genetic variables in the modelling process improved the predictive 
capabilities for variability in opioid analgesic response from 5% to 17%.  SNPs from three 
genes: CCKBR, OPRK and OPRD contributed to the final model.  All of these genes encode 
receptors from or that influence the endogenous opioid system, as the cholecystokinin B 
receptor is part of the opioid opposing CCK system.  Interestingly no SNPs from OPRM, the 
receptor primarily responsible for opioid analgesic was associated with analgesic response, 
even in the univariate analyses stage.  The opioid receptors however have been shown to 
form heterodimers which have different pharmacological properties than their parent 
receptors alone which may influence opioid response 52, 198, 199. 
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The  C and G alleles of CCKBR rs11040819 and OPRK rs1365098 respectively were 
associated with a poorer outcome in terms of analgesic response and the C allele of OPRD 
rs2236857 a better outcome.  All three SNPs are intronic and therefore unlikely to be of 
functional significance, unless they influence alternative mRNA splicing.  They potentially 
are more likely to be in LD with another functional SNP capable of influencing receptor 
function and therefore opioid analgesic response. 
 
6.6.1.2 Analgesic Response to Morphine  
When morphine is considered independently the analgesic response model changes 
significantly with the variance explained increasing to 34%.  Four variables were retained in 
the final model including SNPs from three genes: CCKBR, TRPV4 and ADORA1.  The same 
intronic CCKBR SNP rs11040819C was included in both the combined opioid and morphine 
analgesic response models.  
 
In the Prospective Morphine Study SNPs from CCKBR were also found to be associated with 
analgesic response.  One SNP, rs11040825, was retained in the final genotype model.  
Unfortunately rs11040825 or other SNPs from its haploblock were not tested in the RCT 
cohort due to the time considerations and further work in this area would be useful to explore. 
 
The other two SNPs associated with analgesic response to morphine TRPV4 rs10735104 and 
ADORA1 rs10920576 are also intronic. There are important interactions between the 
adenosine and opioid systems in regulating pain. Agonists of the adenosine A1 receptor has 
previously been shown to increase morphine analgesia, morphine tolerance and dependence 
in animal studies 186, 187 therefore it is entirely plausible that genetic variation in the human 
ADORA1 could impact on analgesic response to morphine.  TRPV4 although not known to 
influence the opioid system has been implicated in nociceptor hyperexcitability and 
mechanical hyperalgesia 108 and consequently may be a factor in individual pain 
susceptibility. 
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Table 7.21  Morphine versus Oxycodone RCT: Comparison of Predictive Factors of Opioid Response 
Components in the Combined Opioid, Morphine and Oxycodone Populations. 
Response Component Combined opioid Morphine Oxycodone 
Analgesic response       
Antidepressant +    
ACE inhibitor/ARB   +  
Anticoagulant     + 
OPRK rs1365098G +    
OPRD1 rs2236857C -    
CCKBR rs11040819C + +  
CCKBR haploblock 1.4     + 
ADORA1 rs10920576T   +  
TRPV4 rs10735104A   +  
TNF rs1800630C     - 
      
Upper gastrointestinal adverse reactions       
Urinary tract malignancy +    
ACE inhibitor/ARB +    
IL10 haplotype 2 -    
OPRD rs1042114T -    
OPRD rs2234918C   +  
CCKBR rs1805002A +    
CCKBR rs12364575G     + 
COMT haploblock 1.4 +   + 
COMT haploblock 1.6   -  
STAT6 haplotype 7 +    
STAT6 rs3024979T   +  
ABCB1 rs3213619T -    
TRPV4 rs10850836A +    
SLC6A4 haplotype 4     + 
        
Central adverse reactions       
Gynaecological cancer     + 
Albumin (g/L)     - 
Paracetamol - -  
SSRI antidepressant     + 
Chemotherapy ≤ 4 weeks -    
CCKBR rs906895T +    
COMT haploblock 1.3 +    
COMT haploblock 1.6   +  
TRPV4 haplotype 1 -    
TRPV4 rs3825394T   -  
STAT6 haplotype 6   +  
      
Angiotensin II  receptor antagonist (ARB)       
 Direction of association + positive, - negative   
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Although not included in the final model, the common alleles of three ABCB1 SNPs were 
associated with a better analgesic response to morphine on univariate analysis: rs1202168C, 
rs1128503C and rs2032582G (all P=0.031).  Previously rs1128503C (1236C) and 
rs2032582G (2677G) have been associated with being protective against moderate to severe 
morphine related drowsiness and confusion 42.  Although no association was found with log10 
central adverse reaction Component scores in the RCT, drowsiness and confusion often 
prohibit adequate dose titration to achieve a good analgesic response. 
 
6.6.1.3 Analgesic Response to Oxycodone 
The oxycodone analgesic response model explained 39% of the variation observed.  It 
contained three predictive variables: use of anti-coagulant, TNF rs1800630C and CCKBR 
haploblock 1.4.  Haploblock 1.4 contains the C allele of rs11040819 which was included in 
the combined opioid and morphine models. 
 
The common C allele of TNF rs1800630 was associated with better analgesic response to 
opioids.  The rare A allele of rs1800630 has previous been associated with both increased and 
decreased TNF expression 200, 201.  Another TNF promoter SNP associated with increased 
TNF expression, rs1800629A, also known as -308G/A has previously been associated with 
pain severity and opioid response in lung cancer patients 69.  Although the rs1800629 was not 
associated with analgesic response in the RCT cohort it is in LD with rs1800630.  
 
Interestingly two OPRK variants: rs963549G and haploblock 1.5 were identified on 
univariate testing to be associated with analgesic response to oxycodone. OPRK rs963549 
exhibited a significant gene dose effect.  This association however was lost on multivariate 
analysis.  Oxycodone has been suggested to act via κ-opioid receptors for improved efficacy 
on visceral pain compared to other opioids, although this remains controversial 140, 202, 203.  
rs963549 is located in the 3’UTR of the κ-opioid receptor gene. It has been suggested that 
because of its population genetic characteristics (high FST, a measure of genetic 
differentiation) rs963549 has undergone selection, and therefore might be of functional 
importance 204, 205. 
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6.6.2 Upper Gastrointestinal Adverse Reactions 
6.6.2.1 Upper Gastrointestinal Adverse Reactions to Opioids 
The multivariate model which brought together genetic and environmental factors 
contributing to upper GI reactions to opioids retained nine variables and explained 48% of 
variance observed within this phenotype.  Multiple genes were involved including variants in 
IL10, CCKBR, TRPV4, COMT, STAT6, ABCB1 and OPRD.   
 
The “vomiting centre” in the medulla oblongata receives input from four major areas: the 
chemoreceptor trigger zone (CTZ), the GI tract, the vestibular apparatus in the temporal lobe, 
and the cerebral cortex.  The emetic effects of opioid are thought to be due to multiple 
mechanisms involving the classical opioid receptors, principally stimulation of the CTZ, 
inhibition of gut motility, and stimulation of the vestibular apparatus.  At the CTZ µ-and δ-
opioid receptors are activated, and signalling to the vomiting centre occurs via dopamine D2 
receptors and serotonin (5-HT3) receptors 206. In this study the common T allele of rs1042114 
in exon 1 of OPRD was protective of opioid related nausea and vomiting.  The variant G 
allele of rs1042114 results in an amino acid change from phenylalanine to cysteine in the 
protein and may therefore affect receptor function.  rs1042114 has previously been associated 
with alcohol dependence 168. 
 
In the European Pharmacogenetic Opioid Study (EPOS) nausea and vomiting scores were 
modelled using clinical factors and SNPs from 16 candidate genes including OPRM, OPRD, 
OPRK, ARRB2, STAT6, ABCB1 and COMT which are also studied in this project 96.  Both 
studies produced complex multi-factorial models of opioid related nausea and vomiting.  Of 
the SNPs in the genes common to both studies, only three COMT SNPs were found to be 
weakly associated with intensity of nausea and vomiting in EPOS: rs165722C, rs4633T, and 
rs4680G 96.  rs4680 was genotyped in the RCT cohort but no association was found with 
log10 Component 2 scores, however another genetic variant in COMT: haploblock 1.4 was 
associated with increased nausea and vomiting.  The COMT enzyme metabolises 
catecholamines such as dopamine, an important neurotransmitter in the area postrema and 
vomiting centre. Dopamine D2 receptor antagonists such as domperidone are used as anti-
emetics.  COMT inhibitors increase dopaminergic activity and therefore nausea and vomiting 
are prominent side effects 207. SNPs in two other EPOS candidate genes: 5-HT (serotonin) 
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receptor 3B gene (HTR3B) and cholinergic receptor, muscarinic 3 gene (CHRM3) would be 
useful to examine in the Morphine versus Oxycodone RCT cohort in the future. 
 
Carriage of the common T allele of ABCB1 rs3213619 was associated with lower nausea and 
vomiting scores in the combined opioid population in univariate analysis (P=0.001) and 
retained in the final model, but was not significant in the subgroup morphine or oxycodone.  
Other ABCB1 polymorphisms have previously been associated with opioid induced nausea 
and vomiting.  In a post-operative pain study use of antiemetic for morphine related nausea 
and vomiting was decreased in patients who we homozygous for the 2677GG/ 3435CC 
diplotype (rs2032582/rs1045642) 208.   
 
Carriage of the A allele of IL10 rs1800896 was associated with increased morphine related 
nausea and vomiting scores in the Prospective Morphine Study.  Haplotype 2 of IL10, which 
contains rs1800896A, was associated with less nausea and vomiting in the RCT combined 
opioid response group, however no association was seen in the morphine cohort.  
 
The STAT6 haplotype 7 was associated with increased nausea and vomiting scores. STAT6 is 
an important transcription factor involved in cytokine induced up-regulation of µ-opioid 
receptor transcription 209.  It is plausible that changes in µ-opioid receptor expression may 
influence opioid response in terms of severity of adverse reactions.   
 
The variant A allele of CCKBR rs1805002 was associated with increased log10 Component 2 
scores and therefore more severe nausea and vomiting. This missense SNP in exon 2 
produces an amino acid change from valine to isoleucine at position 125 and so may affect 
receptor function and interaction with the opioid system. 
 
The variant A allele of the TRPV4 promoter SNP rs10850830 was included in the final model 
of opioid related nausea and vomiting scores and was predictive of more severe symptoms.  
Its position within the promoter region may affect possible transcription factor binding and 
subsequently influence expression. When modelled the G>A nucleotide change results in two 
possible transcription factor binding site gains (a member of the Twist subfamily of class B 
bHLH transcription factors and a Neurogenin and NeuroD binding site) and one loss, 
specifically the Tax/CREB complex, a cAMP-responsive element binding protein. 
(www.genomatix.de). 
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6.6.2.2 Upper Gastrointestinal Adverse Reactions to Morphine  
In comparison to the opioid model, the morphine model retained just three factors predictive 
of GI side effects: COMT haploblock 1.6, carriage of the T allele of STAT6 rs3024979 and 
carriage of the C allele of OPRD rs223491.  The variables explained approximately 43% of 
the observed variation in morphine related nausea and vomiting in this population.   
 
COMT haploblock 1.6 (AACG) is similar to haploblock 1.4 (AACA) which appears in both 
combined opioid and oxycodone models of nausea and vomiting, the difference being in 
rs740603 the final SNP of the block.  COMT haploblock 1.6 was protective of the adverse 
reactions of nausea and vomiting to morphine. 
 
rs3024979 is located in the 3’UTR of STAT6.  Carriage of the common T allele was 
associated with increased nausea and vomiting scores.  Variation in the 3’UTR may influence 
mRNA stability, localisation and translational efficiency. Variation in the expression of 
STAT6 may in turn affect expression of the µ-opioid receptor. 
 
The variant C allele of rs2234918 in exon 3 of OPRD was also associated with increased 
severity of upper GI adverse reactions to morphine.  Although this SNP does not result in an 
amino acid change in the protein, it may be in LD with an as yet unknown functional 
element.  Another OPRD SNP rs1042114 was protective of nausea and vomiting in the 
Morphine versus Oxycodone RCT combined opioid population. 
 
6.6.2.3 Upper Gastrointestinal Adverse Reactions to Oxycodone 
Upper GI reactions to oxycodone were also modelled using log10 Component 2 scores.  The 
final model retained three genetic factors: carriage of the variant G allele of CCKBR 
rs12364575G, COMT haploblock 1.4 and SLC6A4 haplotype 4 all of which were associated 
with increased symptoms.  rs12364575 is located in at the boundary of intron 3 in CCKBR so 
could feasibly influence mRNA splicing.  COMT haploblock 1.4 was also present in the 
combined opioid cohort nausea and vomiting model.  Polymorphisms in serotonin receptors 
have previously been implicated in opioid related nausea and vomiting 96.  Here genetic 
variation in the serotonin transporter gene, SLC6A4 haplotype 4, was associated with upper 
GI adverse reactions to oxycodone. 
 
  256 
6.6.3 Central Adverse Reactions 
6.6.3.1 Central Adverse Reactions to Opioids 
Twenty one percent of the variation observed in central adverse reactions to opioids was 
explained by the model including clinical and genetic factors.  Concomitant use of 
paracetamol, chemotherapy within the last four weeks and TRPV4 haplotype 1 were 
associated with less drowsiness and confusion.  COMT haploblock 1.3 and the T allele of 
CCKBR rs906895 were associated with more severe central adverse reactions. 
 
Carriage of the A allele of CCKBR rs1042047 was associated with worse drowsiness and 
confusion in the Prospective Morphine Study, however this not in the same haploblock as 
rs906895.  As previously mentioned the CCK system opposes the opioid system in the CNS 
therefore genetic variation in the gene encoding the CCK B receptor may impact on this 
balance and influence the development of central adverse reactions. 
 
Interestingly although the κ-opioid receptor has been implicated in dysphoria and the sedative 
effects of opioids in pharmacological studies, there was no association with any OPRK and 
central adverse reactions in this study. 
 
6.6.3.2 Central Adverse Reactions to Morphine  
The model for adverse reactions to morphine retained four independent predictors: 
concomitant use of paracetamol and the T allele of TRPV4 rs3825394 which were protective 
of drowsiness and confusion, and COMT haploblock 1.6 and STAT6 haplotype 6 which were 
predictive of worse symptoms. 
 
As in the Prospective Morphine Study the variant T allele of TRPV4 rs3825394 was 
protective of central adverse reactions in both in the morphine subgroup and the combined 
opioid group as part of haplotype 1.  The SNP rs3825394 is located in exon four of the 
TRPV4 gene, and although the variant does not result in an amino acid change it may be in 
LD with a true marker SNP which may in turn alter function of the transient receptor 
potential cation channel V4.  It is unclear why variation in TRPV4 would be associated with 
less central adverse reactions to opioids.  
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No single SNP in COMT was associated with central adverse reactions, however COMT 
haploblock 1.3 (AAGG) in the combined opioid population and haploblock 1.6 (AACG) in 
the morphine subgroup were associated with more drowsiness, confusion and hallucinations.  
Previously SNPs in intron 1 have been shown to be protective of central adverse reactions to 
morphine however the associations do not fit with these haploblocks 42.   
 
Previously associations between the variant alleles of two STAT6 SNPs (rs167769 and 
rs841718) and opioid switching have been published by our group 41.  Here the STAT6 
haplotype 6 was associated with more severe central adverse reactions; however this 
haplotype includes neither of the above variants.  As previously mentioned STAT6 is an 
important transcription factor for the OPRM therefore variation in STAT6 may ultimately 
influence µ-opioid receptor expression levels and therefore morphine response. 
 
6.6.3.3 Central Adverse Reactions to Oxycodone 
The addition of genetic variables did not add any improvement to the clinical model which 
included the diagnosis of gynaecological cancer, serum albumin and SSRI antidepressants 
which is discussed in Chapter 6.   
 
6.7 Conclusion 
• There are three distinct clinical phenotypes of opioid response: analgesia, upper GI 
adverse reaction and central adverse reactions which have been demonstrated by PCA 
in two separate studies by this thesis.   
 
• Opioid response phenotypes are complex traits.  Multivariate modelling identified 
separate sets of clinical and genetic predictors for each response phenotype suggesting 
divergent mechanisms behind each Component of opioid response.   
 
• When morphine and oxycodone response phenotypes were modelled separately the 
same three response phenotypes were identified, however the modelling defined 
different predictive factors for each drug.  This suggests that there are opioid class 
effects and drug specific effects behind opioid response.  
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• When compared to other work in the area there is supporting evidence for some of the 
genetic associations found with the opioid response phenotypes.   
 
• The data presented in this Chapter are exploratory only and have not been adjusted for 
multiple testing.  Further work in larger independent studies would be required to 
explore potential associations further. 
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7 Results: Gene Expression  
7.1 Introduction 
This thesis has examined the effect of inter-individual variation at the DNA level on opioid 
response in Chapters 5 and 7. DNA is transcribed to mRNA and then translated into protein 
and variations at all these levels can influence the final phenotype.  The ideal tissue from 
which to study the effects of transcriptome variability in pain and opioid response would be 
either peripheral or central nervous tissue.  As this was not possible I used total RNA 
extracted from a more accessible source: peripheral blood leukocytes (PBL) in an exploratory 
study.  There is some evidence to suggest that PBLs express classical opioid receptors 75-77 
and it has been hypothesised this may mirror that which is seen in the brain.  It was hoped 
that PBLs could act as a model for changes in expression of opioid receptor mRNA over time 
76. 
 
Multiple µ-opioid receptor subtypes from alternative splicing have been found in both animal 
studies and human studies 47-50.  These subtypes are thought to contribute to incomplete cross 
tolerance and may explain some of the different effects of the various strong opioids 46. One 
SNP in OPRM, rs563649, has been associated with differential translation of splice variants 
and altered pain response (135). Splice variants may be identified by employing techniques 
such as reverse-transcription polymerase chain reaction (RT-PCR). 
 
Opioids appear to modulate both innate and acquired immune responses, acting directly via 
opioid receptors on PBLs and indirectly via the HPA axis.  The potential immunosuppressive 
qualities of exogenous opioid administration may theoretically have an impact on incidence 
and severity of infection, cancer progression and ultimately survival.  Immunosuppression 
however in cancer patients is common and multi-factorial and it is unclear whether any 
additional immunosuppressive effects of exogenous opioids are clinically meaningful 83.  
Examining changes in PBL global gene profiles in patients receiving opioids would be one 
way that this could be explored. 
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7.2 Reverse-Transcription Polymerase Chain Reaction 
This part of the study aimed to: 
• Identify µ-opioid receptor mRNA (OPRM1) in PBL. 
• Develop the pain studies from inter-individual variation in the genome to the 
transcriptome. 
 
To attempt to identify µ-opioid receptor mRNA in PBL I used RT-PCR.  The technique had 
had mixed success in other laboratories 75, 210-212.  I designed primer pair A which spanned 
OPRM1 exons 1 and 2, and avoided potential SNPs in the nucleotide sequences.  All other 
primer sequences were sourced from previous publications (positive and negative) as 
referenced (Table 8.1).  During the optimisation process primer pair A was chosen to take 
forwards as it produced the best bands with the positive control using our methodology.   
 
 OPRM1 mRNA was not detected in quiescent peripheral blood mononuclear cells using RT-
PCR with any of the primer pairs tested.  Previous work had suggested that µ-opioid receptor 
mRNA was only detectable in immune cells after stimulation, for example by IL-4 or TNFα 
77.   I therefore collaborated with Dr Nicholas Gough, another Palliative Medicine Research 
Fellow, at University College London to maximally activate healthy human donor peripheral 
blood mononuclear cells with a series of known stimulants: SEB, OKT3, IL-4, IL-2 and 
Ionomycin/PMA.  Figure 8.1 shows that no OPRM1 mRNA was detected in maximally 
activated PBMCs.     
 
As OPRM1 mRNA was not detected using RT-PCR with several different primer pairs, this 
part of the study was not taken forwards to look for other splice variants. 
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Figure 8.1  Gel Electrophoresis Image of Products of OPRM1 mRNA 
500 
100 
500 
100 
1 2 3 4 5 6 7 
Lane 1: Frontal lobe mRNA (+ve control).  Lane 2: Unstimulated PBMC. Lanes 3-7: Stimulated 
PBMC, Lane 3: SEB, Lane 4:OKT3, Lane 5:IL4, Lane 6:IL2, Lane 7: Ionomycin/PMA.  The top row 
represents RT-PCR product for µ-opioid receptor mRNA (515bp), and the bottom row represent RT-
PCR product for GAPDH mRNA (290bp) (positive control). 
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Table 8.1 Primer pairs for OPRM1 
mRNA Primer pair Region Sense/ 
Antisense 
Primer Sequence Tm 
(ºC) 
GC (%) 
content 
Primer 
Length (bp) 
Product 
Length (bp) 
OPRM1 A exon 1 S ACG CTC CTC TCT GTC TCA G 60 58 19 
 
  
exon 2 AS ACT GGT GGC TAA GGC ATC TG 60 55 20 515 
         
 
B 75 exon 1 S ATT GCA CTG ATG CCT TGG CGT A 63 48 23 
 
  
exon 2 AS CAT GGT CAC CAG CAT ATT CAC C 62 50 22 443 
         
 
C 210 exon 2 S GTT GAT CGA TAC ATT GCA GTC  57 43 21 
 
  
exon 3 AS GGG AGT CCA GCA GAC GAT GAA 63 57 21 398 
         
 
D 210 exon 2 S ACC AAC ATC TAC ATT TTC AAC CTT 58 33 24 
 
  
exon 3 AS CAG TAC CAG GTT GGA TGA GAG 61 52 21 376 
         
 
E (nest 1)212 exon 1 S CTT GGC GTA CTC AAG TTG CT 58 50 20 
 
  
exon 3 AS AAT GTG AAT GGG AGT CCA GC 58 50 20 853 
         
 
F (nest 2)212 exon 1 S GAT CAT GGC CCT CTA CTC CA 60 55 20 
 
  
exon 2 AS GCA TTT CGG GGA GTA CGG AA 60 55 20 343 
         
 
G94 exon 1 S GTG CCC GCC CGG CCG TCA GTA 71 76 21 
 
  
exon 4 AS 
CCA CTG  GGT GTC TTG CAC AAA CTG 
GAC 71 56 27 1474 
         
         GAPDH Control   exon 1 S AGT CAG CCG CAT CTT CTT TTG C 62 50 22 
 
  
exon 4 AS CTC CTG GAA GAT GGT GAT GGG A 64 55 22 290 
          Sequences for GAPDH control primers were kindly supplied by Dr H Sato. 
 Nucleotides marked in red represent position of SNPs 
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7.3 Microarray 
I used whole transcript microarray technology in a small pilot study assess global gene 
expression in PBLs from patients recruited to the Morphine versus Oxycodone RCT.   
 
This exploratory study aimed to: 
• Explore global gene expression in PBLs of cancer patients. 
• Identify any changes to PBL gene expression profiles after successful treatment of 
cancer related pain with oxycodone, especially any immunosuppressive action. 
• Detect classical opioid receptor mRNA in PBL using a different to technique to RT-
PCR. 
 
7.3.1 Samples 
Twenty-four samples from nineteen patients were selected from the Morphine versus 
Oxycodone RCT.  Nineteen samples were from RCT Time Point A, and five paired samples 
were from Time Point B.  All paired samples were taken from patients with a diagnosis of 
either breast cancer or sarcoma who had been randomised to oxycodone first-line. 
Table 8.2 describes the characteristics of the nineteen patients.  Table 8.3 describes the 
sample pairs: two patients had breast cancer and three patients had sarcoma
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Table 8.2  Patient Characteristics of Gene Expression Study Population 
Sample 
No. 
 
Partek ID Diagnosis Gender 
Age 
(yrs)  WCC CD4:8 Antibiotic Steroid 
Chemo 
(≤ 2 weeks) 
2*/21 4*/15 Breast cancer Female 81 15.3   X X   
3 7 Lung cancer Female 69 8.7 1.2   X   
4 10 Colon cancer Female 61 12.8 0.7 X     
5*/16 13*/23 Fibrosarcoma Female 38 8.1 3.5       
6 16 Squamous cell carcinoma of bladder Female 43 9.4 1.5 X   X*** 
7 19 Colon cancer Male 69 8 5.8       
8 22 Transitional cell carcinoma Male** 62 15.2 5.6   X X*** 
9 2 Renal cell cancer Male 56 6.4 1.5 X     
10 5 Mesothelioma Female 62 7.8       X 
11 8 Sarcoma Female 47 9         
12 11 Oesophageal cancer Male** 54 7.6         
14 17 Lung cancer Male 54 15.3       X 
15 20 Head and neck cancer Male 53 5.8 2.1       
17 3 Multiple myeloma Female** 67 6.6 2.7       
18 6 Diffuse large B cell lymphoma Female 48 1.5 0.9 X     
19 9 Multiple myeloma Male 70 7.1 1 X X X 
22*/20 18*/12 Sarcoma Female 64 10.8     X   
27*/13 21*/14 Breast cancer Female** 49 7.6         
28*/1 24*/1 Sarcoma Male 41 5.9 1.5   X   
*Paired sample  (A*/B)               
**Non-Caucasian               
***Chemotherapy administered on the day of  sample 
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Table 8.3  Paired Samples in the Gene Expression Study 
  Pairs code 
Time 
point 
Sample 
No. WCC CD4 : 8 Antibiotic Steroid 
Days on 
oxycodone 
Breast cancer 
                
  B1a A 27 7.6 -       
  B1b B 13 10.4 2.6   X  30 
                  
  B2a A 2 15.3 - X X   
  B2b B 21 12.1 1.5   X  4 
                  
Sarcoma 
                
  S1a A 22 10.8 -   X   
  S1b B 20 10.1 -   X 6  
                  
  S2a A 28 5.9 1.5   X   
  S2b B 1 9.7 0.9   X  27 
                  
  S3a A 5 8.1 3.5       
  S3b B 16 4.9 3.7      14 
All paired samples were from patients randomised to oxycodone, who had not received any chemotherapy 
                  
 
 
7.3.2 RNA Size Distribution 
The integrity of the RNA sample or the proportion that is full length is an important 
component of RNA quality.  The total RNA integrity was assessed with microfluidic analysis 
using the Agilent 2100 Bioanalyzer with an RNA LabChip Kit (Agilent Technologies, 
California, USA).  The RNA Integrity Number (RIN) can be used to evaluate RNA integrity.  
RIN values range from 1 (totally degraded) to 10 (intact). 
 
Good quality total RNA was extracted from PMBC using the PAXGene kit (PreAnalytix, 
Qiagen/ BD Company, Switzerland).  The RNA quality for one sample before (RIN 8.6) and 
after (RIN 8.2) vacuum concentration is demonstrated in Figures 8.2 and 8.3.  The Peaks are 
the 18 and 28S ribosomal RNA bands. 
 
Following first and second strand cDNA synthesis from total RNA, cRNA was synthesised 
using in vitro transcription (Section 4.2.6.4).  Figure 8.4 shows a sample electropherogram of 
cRNA (2100 Bioanalyser, Agilent Technologies, California, USA). 
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Figure 8.2 Sample Electropherogram of total RNA 
 
RIN 8.6 
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Figure 8.3 Sample Electropherogram of total RNA Post-vacuum Concentration. 
 
RIN 8.2 
 
 
 
 
 
Figure 8.4  Sample Electropherogram of cRNA 
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7.3.3 Microarrays 
Second cycle cDNA was synthesized from cRNA (Section 4.2.6.7).  This was followed by 
fragmentation and labelling of cDNA in order to be run on Gene 1.1 ST Microarrays using 
the GeneTitan instrument (Sections 4.2.7-8). 
 
7.3.4 Quality Assessment of Microarrays 
7.3.4.1 Relative Log Expression Signal 
Figure 8.5 shows box plots for the relative log expression (RLE) values of all 24 samples 
which were generated in Partek Genomic Suit software (Partek, Missouri, USA).  The median 
RLE demonstrated by the middle bar in each box plot was for approximately zero for all 
samples, as it should be to reflect low biological variability. There was however substantial 
variation in all samples and Partek ID numbers 1,2,3,6 and 20 appear to have larger inter-
quartile ranges on inspection. Deviations of the median RLE from zero typically indicate a 
skewness in the raw intensities for the chip that was not properly corrected by normalization 
213.   
 
Figure.8.5  Box Plot on Relative Log Expression Signal 
 
Sample numbers correspond to Partek ID numbers 
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7.3.4.2 Labelling 
 
Figure 8.6 demonstrates the set of polyadenylated RNA spikes (Lys, Phe, Thr and Dap) 
which are useful for identifying potential problems with the target preparation phase of the 
experiment.  The rank order of the polyA spikes was consistent however the graph shows 
significant variability between the samples. 
Figure 8.6  Labelling 
 
 
 
Sample numbers correspond to Partek ID numbers 
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7.3.4.3 Hybridization 
 
Figure 8.7 demonstrates hybridization to the pre-labelled bacterial spike controls (BioB, 
BioC, BioD and Cre).  The rank order of the bacterial spikes was consistent and as expected 
213.  There was however some variability between samples for example sample 20 is an 
obvious outlier indicating a problem with hybridization. 
 
 
Figure 8.7  Hybridization 
 
 
 
Sample numbers correspond to Partek ID numbers 
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7.3.5 Principal Component Analysis 
PCA was performed in Partek Genomics Suite (Partek, Missouri, USA) to examine 
correlations among the data from different arrays.  Figure 8.8 shows the PCA map for all 
twenty-four samples tested, colour coded by time point.  The three major principal 
Components explain 34.7% of the variance for the samples.  There were three obvious 
outliers two from Time Point A (Partek ID numbers 2 and 20) and one from Time Point B 
(Partek ID number 1).  No obvious distinction in the principal Components was seen between 
samples from Time Point A and Time Point B.   
 
Figure 8.8  Principal Component Mapping for Total Sample 
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7.3.5.1 Time Point A and Cancer Diagnosis 
Figure 8.9 shows the PCA map for the nineteen patient samples from Time Point A, colour 
coded by patient cancer diagnosis.  There were twelve cancer diagnoses in total.   
 
 
Figure 8.9  Principal Component Mapping of Time Point A Samples 
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7.3.5.2 Paired Samples 
Figure 8.10 shows the PCA map highlighting the position of the paired samples (Time Point 
A and Time Point B) from breast and sarcoma patients randomised to oxycodone. 
Figure 8.10  Principal Component Mapping of Paired Samples 
 
 
 
 
Paired samples were from two breast (B) cancer patients and three sarcoma (S) patients at two time points in the 
Morphine versus Oxycodone RCT: baseline (a) and when pain controlled (b). The white coloured points are 
non-paired samples. 
 
 
 
7.3.5.3 Differentially Expressed Genes 
7.3.5.3.1 Time Point A 
 
Gene expression was compared between groups at Time Point A in Partek Genomics Suite 
(Partek, Missouri, USA) with respect to white cell count, CD4:8 Ratio, tumour diagnosis, use 
of concomitant medication (antibiotics and steroids), and recent chemotherapy in the last two 
weeks.  All 19 Time Point A samples were used.  There were no significant changes in gene 
expression when samples were grouped according to use of antibiotics, steroids or recent 
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chemotherapy in the last two weeks.  Table 8.4 shows the differentially expressed genes 
when high WCC or CD4:8 Ratio was compared to normal or low values, and when diagnosis 
of haematological malignancy (myeloma, lymphoma) was compared to non-haematological 
malignancy. The cut-off of differential expression was a twofold change.   
 
When the two Time Point A outliers identified in PCA mapping were excluded (Partek ID: 2 
and 20), as with the previous set there were no significant changes in gene expression when 
samples were grouped according to use of antibiotics, steroids or recent chemotherapy in the 
last two weeks.  In addition, the significant change seen with HUWE1 and ABLIM1 CD4:8 
Ratio in the 19 sample set were lost.  The associations with haematological malignancy and 
IF127 and SEC16A were preserved. 
 
Further analysis highlighted technical problems with the microarrays in that there was a high 
degree of variability within the control probes.  Interpretation of these results is therefore 
limited. 
 
µ-, κ-, and δ- opioid receptor mRNA was detectable however no significant change was seen 
between any of the group comparisons. 
 
7.3.5.3.2 Paired Samples 
All patients had either a diagnosis of breast cancer or sarcoma and were randomised to 
oxycodone.  Table 8.5 lists the differentially expressed genes between the Time Points, as a 
whole group and split by diagnosis. 
 
µ-, κ-, and δ- opioid receptor mRNA were detectable however no significant change was seen 
between the time points.
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Table 8.4  Differential Expressed Genes between groups in RCT Time Point A 
 
  
Gene 
Symbol Gene p-value 
Fold 
change Description of change 
WCC       
 CDH7 cadherin 7, type 2 4.30E-08 -3.540 High WCC down vs Normal or low WCC 
 APOBEC3B apolipoprotein B mRNA editing 
enzyme, catalytic polypeptide-like 
3B 
8.97E-07 -5.248 High WCC down vs Normal or low WCC 
      
CD4:8 Ratio      
 HUWE1 HECT, UBA and WWE domain 
containing 1 
3.47E-07 3.027 High CD4:8 Ratio up vs Normal or Low CD4:8 Ratio 
 ABLIM1 actin binding LIM protein 1 5.26E-07 3.814 High CD4:8 Ratio up vs Normal or Low CD4:8 Ratio 
      
Haematological 
malignancy 
     
 IFI27 interferon alpha-inducible protein 27 3.83E-08 -41.121 Non-haematological malignancy down vs 
haematological malignancy 
 SEC16A SEC homolog A (S. Cerevisiae) 1.67E-07 2.707 Non-haematological malignancy up vs haematological 
malignancy 
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Table 8.5  Differentially expression genes between RCT Time Points A and B 
 
  
Gene 
Symbol Gene p-value  
Fold 
change 
Description of change between Time 
Points 
All      
 MUC16 mucin 16, cell surface associated 1.55E-08 3.384 A up vs B 
      
Breast      
 KDR kinase insert domain receptor (a type III receptor 
tyrosine kinase) 
6.46E-08 -4.881 A down vs B 
 BDP1 B double prime 1, subunit of RNA polymerase III 
transcription initiation factor IIIB 
4.01E-07 -3.905 A down vs B 
 C12orf64 chromosome 12 open reading frame 64 7.00E-07 -2.554 A down vs B 
      
Sarcoma      
 MUC16 mucin 16, cell surface associated 5.50E-09 5.552 A up vs B 
 TPTE2P2 transmembrane phosphoinositide 3-phosphatase and 
tensin homolog 2 pseudogene 2 
8.43E-08 3.280 A up vs B 
 CACNA1G calcium channel, voltage-dependent, T type, alpha 
1G subunit 
8.82E-07 4.802 A up vs B 
 C1orf213 chromosome 1 open reading frame 213 7.97E-07 -2.318 A down vs B 
 USH2A Usher syndrome 2A (autosomal recessive, mild) 1.07E-06 -2.664 A down vs B 
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7.3.6 Hierarchical Cluster Analysis 
Cluster analysis can be performed in order to group samples with similar expression profiles 
together with the aim of making meaningful biological inferences. Clustering methods can 
either be hierarchical or non-hierarchical.  Hierarchical methods group objects into clusters 
and specifying relationships among them, resembling a phylogenetic tree.  Non-hierarchical 
methods group objects into clusters without specifying relationships between them.  
 
Unsupervised hierarchical clustering was first performed on the entire 24 sample set using the 
R programming language by Dr Maxim Freydin.  The first phase of the analysis identified a 
high degree of variability in the control probes.  The samples were then reassessed and 
outliers from the quality control and PCA mapping were excluded.   From the quality control 
indices Partek ID samples 1, 2, 3, 6, 20, 21 and 23 were excluded.  Partek ID samples 3, 21 
and 23 were also considered outliers on the PCA mapping. 
 
The analysis was repeated on the remaining seventeen samples, including fourteen from time 
point A, three from time point B (two paired samples only).  Of note a substantial degree of 
variability remained within the control probes of the final seventeen samples.  In the absence 
of time and resources to repeat the experiments, the preliminary results presented here are 
shown as an example only. 
 
1411 genes with the most variability (standard deviation above 95th percentile) were chosen 
for further cluster analysis.  Two clusters were identified, named X (smaller cluster) and Y 
(larger cluster) using Pearson correlation distance (Figure 8.11).   
 
Fishers Exact test was used to compare qualitative traits including: gender, Morphine versus 
Oxycodone RCT Time Point (A or B), recent chemotherapy, antibiotic, steroid between 
clusters.  Morphine versus Oxycodone RCT Time Point showed a significant difference 
between groups P=0.02, with all the time point B samples in cluster X. 
 
Quantitative traits including haematological, biochemical and immunological parameters as 
well as pain and adverse reaction scores were compared between clusters using the Wilcoxon 
rank sum test.  The absolute lymphocyte count and CD3+ lymphocyte absolute count were 
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significantly higher in cluster X, P=0.01 and P=0.01 respectively, whereas the B lymphocyte 
percentage was higher in cluster Y (P=0.02). 
 
 
Figure 8.11 Hierarchical cluster analysis of the expression profiles of the 1411 most variable genes 
between 17 samples. 
 
 
 
 
The three samples from time point B are marked with a B in cluster X.  Paired samples A*B* and A**B** are 
also indicated. Samples are identified as Position on Chip_Sample numbers.   
 
 
 
 
 
  
X Y 
B* B** B 
A** 
A* 
  279 
7.3.7 Network and Gene Ontology Analyses 
The same set of the 1411 most variable genes was used to perform gene expression network 
analysis using Weighted Gene Co-expressing Network Analysis package WGCNA in the R 
statistical environment. This type of analysis is based on revealing stable modules of 
correlated genes followed by an analysis of the module relationships defined as a network. 
Using this approach, seven modules of correlated genes were identified, which were 
organised in two clusters. One of these clusters was comprised of the red and turquoise 
modules; whereas the other cluster held all the other modules (brown, yellow, black, blue and 
green). Within the larger cluster, the brown and yellow modules comprised a separate clade.    
 
Gene ontology was used to define patterns in molecular function or biological processes 
within these modules.  Molecular function describes activities such as binding or catalytic 
activities that occur at the molecular level. A biological process is series (i.e. more than one) 
of events accomplished by one or more ordered molecular functions 
(http://www.geneontology.org
 
).  Table 8.6 lists the biological processes of the genes within 
the different modules.  As would be expected in this cell types many of the processes are 
related to activation or regulation of the immune system. 
Gene expression modules may be correlated with clinical, haematological, biochemical and 
immunological variables in an expression matrix in order to depict possible relationships 
(Figure 8.13).  For example the absolute lymphocyte count was positively correlated with the 
blue and green modules, P=0.002 and P=0.01 respectively and the use of a steroid was 
positively correlated with the black module P=0.004.  The potential for meaningful 
interpretation of the data presented here is however limited here due to methodological and 
technical reasons described above.   
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Table 8.6  Gene Ontology (Biological Process) of Modules  
Module Gene Oncology: Biological Process P value 
Red viral transcription 0.0049 
  negative regulation of multicellular organismal process 0.0064 
  protein K11-linked ubiquitination 0.0104 
  translation 0.0132 
  immune response 0.0138 
Turquoise regulation of immune response 0.00025 
  antigen processing and presentation 0.00291 
  response to stress 0.00326 
  protein K11-linked ubiquitination 0.00379 
  coagulation 0.00485 
Brown viral reproductive process 0.00086 
  coagulation 0.00723 
  viral reproduction 0.00751 
  positive regulation of cell killing 0.01116 
  regulation of body fluid levels 0.01674 
Yellow translational elongation 3.10E-08 
  cellular Component disassembly 4.00E-07 
  cellular Component disassembly at cellular level 6.30E-07 
  translation 1.10E-06 
  macromolecular complex subunit organization 1.30E-06 
Black cellular macromolecular complex subunit organization 0.00051 
 
translational elongation 0.00064 
 
lymphocyte co-stimulation 0.00326 
 
macromolecular complex subunit organization 0.00353 
 
antigen processing and presentation 0.00358 
Blue small GTPase mediated signal transduction 0.0013 
  translation 0.0056 
  translational elongation 0.006 
  nucleobase, nucleoside and nucleotide metabolic process 0.0075 
  viral transcription 0.0081 
Green apoptotic mitochondrial changes 0.0054 
  response to inorganic substance 0.0065 
  response to toxin 0.0073 
  epithelial cell differentiation 0.0083 
  protein activation cascade 0.0084 
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Figure 8.12  Module Expression Matrix Detailing Correlation between Modules and Clinical, Haematological, Biochemical and Immunological Variables from the 
Morphine versus Oxycodone RCT. 
 
 
 
 
Clinical data from the Morphine versus Oxycodone RCT.  Values presented are Correlation Coefficient (P value) between modules and clinical haematological, biochemical 
and immunological indices.  Abbreviations: Chemo = chemotherapy within the last 2 weeks, Relief 24 = Percentage pain relief in the past 24 hours, Abs = absolute count, Per 
= percentage, Calcium.corr = corrected Calcium. 
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7.4 Discussion 
7.4.1 Opioid Receptors 
It has previously been suggested that immune cell opioid receptors could be used to model 
nervous tissue opioid receptors 76.  The Royal Marsden Palliative Medicine Research Group 
have previously demonstrated the presence of opioid receptors on granulocytes, monocytes 
and lymphocytes with fluoroscein labelled naloxone by flow cytometry 39.   
 
There have been several studies that also provide evidence that opioid receptors are expressed 
by peripheral blood leukocytes.  Beck et al demonstrated the presence of μ-, κ-, δ-opioid 
receptors on peripheral lymphocytes, monocytes and granulocytes from HIV positive, and 
methadone treated patients as well as healthy controls using FACS analysis. This was 
supported by the detection of μ-opioid receptor mRNA from lymphocytes 75.   Vousooghi et 
al refined this to the expression of the opioid receptor splice variants: hMOR-1A and hMOR-
1O in peripheral blood lymphocytes, hMOR-1X and hMOR-1Y were not expressed 76.  
Börner et al detected µ-opioid receptor transcripts and functional receptors in T and B cell 
lines only after stimulation with IL4 or TNFα 77.  Furthermore expression levels were 
significantly lower than that observed in both the human neuroblastoma cell line SH SY5Y 
(x50) and primary cortical fetal neurons from rats (x15) 77.  Other studies have shown that 
cytokines regulate μ-opioid receptor gene expression, TNFα and IL6 up-regulate transcription 
whereas IFNγ down regulates transcription 212, 214. 
 
There however are several additional studies which provide contradictory evidence.  Madden 
et al however hypothesised that the morphine binding observed on activated lymphocytes is 
not via the μ-opioid receptor as different ligand binding properties were displayed and h-
MOR-1 mRNA could not be detected by RT-PCR 210.  Williams et al also could not identify 
any classical opioid receptors on human PBMC from healthy volunteers, by FACS analysis 
and RT-PCR although these assays were performed on quiescent cells 211. 
 
In this study µ-opioid receptor mRNA was not detected in PBMC by RT-PCR, even when 
maximally activated by cytokines and other cell stimulants.  Our assays however may not 
have been sensitive enough to detect low levels of expression.  Expression of µ-opioid 
receptor mRNA in PBMCs may be up to 50 times lower than in neuronal cell 77.   If opioid 
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receptor mRNA was detectable it would have been interesting to look for splice variants and 
link this to genotype information. OPRM, OPRD and OPRK transcripts were however 
detected in the Affymetrix WT gene expression analysis.  No differences in opioid receptor 
expression between any of the groups were observed. 
 
7.4.2 Global Gene Expression 
The Morphine versus Oxycodone RCT Protocol was amended to include the collection of 
PAXgene tubes towards the end of the trial.  Consequently there was little scope to minimize 
potentially confounding factors utilising more specific selection criteria.  The sample 
therefore consists of a heterogeneous group of patients with varied ages, cancer diagnoses, 
treatments and concomitant medications which may all influence on the activation of the 
circulating immune cells from which gene expression was investigated.   
 
The paired samples were selected from the two most common tumour types in which samples 
were available: breast cancer and sarcoma, in order to try and minimize confounding factors.  
All of these patients were randomised to oxycodone and none had received recent 
chemotherapy treatment. The paired sample size of five was however very small and the time 
between samples in each pair highly variable (between 5 and 30 days).   In addition only two 
pairs were used in the analysis as three of the samples excluded were from different pairs. 
 
Hierarchical cluster analysis was performed on a selected subset of 17 samples.  Two clusters 
were identified: X and Y which appeared to be associated with differences in lymphocyte 
counts and percentages.  This would be expected as cell differentiation within the immune 
cell population leads to different gene expression profiles.  All three of the remaining Time 
Point B samples were localized to cluster X, with the paired Time Point A samples in cluster 
Y however the significance of this remains to be seen.  Gene Ontology analysis identified 
several gene expression modules also clustered into two groups.  Many of the biological 
processes associated with the modules were related to activation or regulation of the immune 
system as would be expected. 
 
Technical difficulties were identified within the analysis including a high level of variability 
in the microarray control probes.  This degree of variability was still seen within the control 
probes in the subset of 17 samples from which outliers from the quality control procedures 
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and PCA mapping were excluded.  Due to the already small sample size and clinically 
heterogeneous nature of the remaining samples further exploration was not performed.  
Unfortunately there was not the time or the resources to repeat the experiments or obtain 
samples from a more homogenous group therefore the results presented here act purely as an 
example of the scope future studies could have. 
 
7.5 Conclusion 
The exploratory nature of this pilot study in a highly heterogeneous group makes it difficult 
to draw any definitive conclusions. The technique however is promising and it would be 
interesting to perform further studies with a more controlled experimental design to study the 
effects of opioids on cells of the immune system. 
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8 Discussion 
 
8.1 Clinical Trials in Opioid Response 
This thesis describes results from two trials in morphine response and opioid switching 
performed by the department.  The Prospective Morphine Study was the first prospective 
case-control study of the practice of opioid switching, from morphine to oxycodone.  The 
Morphine versus Oxycodone RCT is the largest trial of its type in cancer-related pain and 
compares the first-line response rates of these two commonly drugs in strong opioid naïve 
patients.  The selective cross-over design in first-line opioid non-responders examined the 
effectiveness of opioid switching not just from morphine to oxycodone but vice versa.  DNA 
was collected from participants in both studies and genetic assays developed to test 
associations with candidate genes. 
The Morphine versus Oxycodone RCT is a pragmatic trial that tests real world effectiveness 
of these drugs for cancer-related pain in the relevant population.  The inclusion criteria were 
designed specifically with minimal restrictions to reflect the spectrum of patients seen on a 
daily basis with cancer-related pain.  The study design mirrored standard clinical practice, 
with treatment decisions lead by clinical staff 215.  As such the results of this trial provide 
strong supporting evidence for the continued use of morphine first-line in the treatment of 
moderate-severe cancer related pain.  It also supports the clinical practice of opioid switching 
to improve outcomes in first-line opioid non-responders.  
 
Opioid response appears to have three main domains identified by PCA in the two different 
studies: analgesic response, upper GI adverse reactions (nausea and vomiting) and central 
adverse reactions.  Multivariate regression analyses suggested that each response phenotype 
is a complex trait with different clinical and genetic variables contributing.  Morphine and 
oxycodone exhibited similar response phenotypes, however different clinical and genetic 
factors appeared to contribute to each of them, suggesting that different mechanisms behind 
overall response to each drug. 
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8.2 Research Challenges Encountered in this Thesis 
8.2.1 Research Challenges in Palliative Medicine 
Research is essential in order to establish a good quality evidence base on which best practice 
can be established.  Palliative Medicine is no different for any other medical speciality in this 
respect, and research in this area has been highlighted as a priority at a government level in 
the End of Life Care Strategy 216.  In recognition of this, research is now a mandatory part of 
speciality training in Palliative Medicine 217. Increasing numbers of palliative care 
professionals from all disciplines are becoming more involved in research, and collaborative 
and supportive networks have been bodies have been set up, including the Junior Forum of 
the European Association of Palliative Care Research Network to promote research in this 
field 218. 
 
The practical and ethical challenges of conducting research in the palliative care population 
raises have long been debated 219.  Recruitment can be difficult due to patient frailty 
combined with “gate keeping” from well-meaning family and staff who may overly protect 
patients.  Unequal access to services and research centres also limits the potential for 
recruitment.  Study design with strict inclusion/exclusion criteria such as performance status 
and minimum prognosis may discriminate against patients in this setting.  In addition current 
recommendations in the collection of data from multiple outcomes may be prohibitively 
burdensome for some patients in this group 220.  Participant retention to completion in studies 
is also a problem as this group of patients have limited and unpredictable prognoses leading 
to high attrition rates.    
 
All of these factors were considered in the design stage of each of the studies in order to get 
the appropriate level of information to answer the research question but not overburden the 
participant.  The Palliative Medicine Research Team is well established within the RMH 
where the trials described in this thesis were undertaken.  Even so recruitment to studies was 
slow and it took years of dedication from the clinical and research teams to complete the 
studies. 
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8.2.2 Challenges in Genetic Association Studies 
Complex traits such as pain susceptibility and analgesic response are the expression of a 
complex interaction between a multitude of genetic variants and environmental factors.  This 
thesis examined 73 SNPs in fifteen candidate genes and therefore represents one of the 
studies with the largest scope in the area of opioid response.  The largest study to date, EPOS, 
included 112 SNPs in 25 genes 97.  It is likely however that many more genes are involved.   
 
Population based association studies aiming to correlate genotypes and phenotypes of 
complex traits, including pain, have had mixed success and reproducibility of results has 
remained low.  In experimental pain, twin studies have suggested that up to 60% of the 
variability in responses to painful stimuli is genetically determined, however genetic and 
environmental factors are only moderately correlated across pain modalities, suggesting 
different genes influence different types of pain.  Cancer-related pain is often of mixed 
aetiology and type and consequently genetic influences may not be as clearly identified 140. 
 
One of the major limitations of the genetic association studies presented in this thesis is the 
small sample size.  There are several factors which contribute to the required sample size in 
genetic association studies including:  the prevalence of disease/trait in the general 
population, the frequency of the susceptibility allele and its effect size, and the number of 
SNPs to be tested.  The lower the frequency of the susceptibility allele and the lower the 
effect size, the larger the sample size required.  Complex traits are likely to be influenced by 
multiple genetic variables all with small or modest effect sizes.  Any variant strongly 
associated with a disease or trait is likely to rare 221.  The number of SNPs to be tested is also 
important in order to be able to correct for multiple testing, although on balance the effect 
size of the susceptibility allele is more important 222. In general therefore large sample sizes, 
possibly of many thousands, are preferable in the study of complex traits.  The sample sizes 
in the studies described in this thesis, although similar to other studies in the field, are small 
and therefore many associations, particularly with small effect sizes may not have been 
identified. 
 
Accurate phenotyping of the disease/trait in question may reduce the sample size required to 
detect genetic associations with it.  One of the earliest genome wide association studies 
identified an association with a SNP in the complement factor H gene in advanced age-
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related macular degeneration (AMD).  It was carried out with 146 individuals of whom 96 
were cases and 50 controls 223.  Results were replicated and the association strengthened 
when the phenotype was tightened to include wet AMD with 96 cases and 130 controls (P = 
4.1 x 10-12) 224.  EPOS looked for genetic associations with the complicated phenotype of oral 
equivalent morphine dose requirements in 2294 patients taking a variety of strong opioids for 
cancer-related pain, but did not identify association with any of the 112 SNPs in 25 candidate 
genes tested in both development and validation analyses 97.  When the secondary more 
directed phenotype of nausea and vomiting scores in this cohort was however considered, 
associations with SNPs in three genes HTR3B, COMT and CHRM3 were found 96. 
 
A concerted effort was put into carefully defining the opioid response phenotypes in this 
study in orders to make the most of the limited sample sizes.  The opioid response 
phenotypes used in the studies presented in this thesis were defined by PCA, from combining 
data from opioid responders and non-responders 59. The three phenotypes: analgesic 
response, upper GI adverse reactions and central adverse reactions were found in two 
different studies, however due to the difference in scoring the adverse reactions in each study 
(4-point Likert and 11-point NRS) may not be directly comparable. 
 
The potential for interaction between genes or epistasis for complex traits is high, which 
makes matters more challenging especially as the effect of one locus may be altered or 
masked by effects at another locus.  If more than two loci are involved, the score for complex 
multi-way interactions among some or all of the contributing loci is increased and the chance 
of detecting such interactions is decreased.  Epistasis may be identified by employing 
methods such as  logistic regression in qualitative traits and multiple linear regression in 
quantitative traits such as the Component scores in this study 225.  Component scores of 
opioid response were normalised to fulfil the requirements of the analysis. 
 
The simplest way to search for interactions between genetic the loci is by an exhaustive 
search, however the number of tests required is prohibitive and raise the multiple testing 
issue.  The Bonferroni correction adjusts the significance level (α) according to the number of 
tests performed. The adjusted α is calculated as 0.05/n, where n is the number of tests 
performed.  For example in this study if the 73 SNPs were simply tested against one clinical 
phenotype only, then a positive association would be considered when a significance level (α) 
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value of less than 6.8 x 10-4 was achieved.  Bonferroni correction however is only appropriate 
if all the tests are independent and the phenomenon of LD between loci can induce 
correlation between many of the tests.  The genetic association work presented in this thesis 
does not account for multiple testing, and therefore should be considered exploratory in 
nature only. 
 
For complex diseases two- three- or even higher-level interactions might be expected which 
would require extremely large data sets and highly sophisticated analytic tools.  A number of 
techniques have been proposed to examine these interactions including regression which was 
used in this study, such as recursive partitioning approaches, multifactor dimension reduction 
and Bayesian model selection techniques 226.  All of these methods are not without limitations 
and different methods may produce different results, so validation is an important step for all 
227. 
 
In the studies presented in this thesis it was not feasible to explore all possible interactions 
between all possible SNPs. Previously it has been suggested that analysis of epistasis in 
genetic association studies should be targeted to candidate genes and candidate biological 
pathways 228.  I therefore studied the interactions between the candidate genes on the RMH 
Palliative Medicine Research Department Pain Plate specifically chosen for their possible 
role in pain perception and opioid analgesic response together with clinical factors.  The 
regression method employed here has a number of limitations.  First and foremost is that as 
the number of predictor variables used for the modelling increases, the distribution of data 
decreases introducing the potential for bias, particularly when the ratio of independent 
variables to sample size exceeds ten to one 229.  Problems also arise when the loci have low 
minor allele frequencies or where there is missing data 229.  To streamline the modelling a 
two-step approach was used, firstly by identifying a subset of more important markers by 
univariate regression analysis and secondly exploring interactions between these markers 
using multivariate regression modelling 230.  The cut-off for inclusion for the modelling was 
P < 0.1 as it is possible that some factors of only borderline significance would become more 
prominent when interactions with other factors are taken into account. This does however 
limit the model to include only those factors which meet the inclusion criteria for the first 
step.   
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Regression analysis is designed for testing epistasis between loci that have been genotyped.  
Where the genotyped loci are thought to be markers in LD with the true functional or disease 
causing loci then the epistasis between the marker loci is likely to be diluted depending on the 
magnitude of LD 225.  Another limitation is that statistical evidence of an interaction does not 
necessarily imply a biologically significant interaction, although could be informative 225.  
Caution is therefore vital when interpreting results from statistical modelling.  The models 
presented in this thesis are exploratory only and require validation in much larger 
independent studies. 
 
There have been several instances where different studies have reported associations between 
a certain polymorphism and a given disease but with the direction of association reversed.  
There have been various explanations proffered for this “flip-flop” phenomenon including 
differences in genetic background or environment, as well as the undeniable possibility of 
false-positive results.  In complex traits where multiple loci and environmental factors 
interact to produce a certain phenotype a single-locus association may therefore be 
confounded by other factors.  Flip-flop associations may also occur when there is a difference 
in LD architecture between ethnic groups or between samples from the same ethnic group 
when a marker SNP is used as a proxy for functional polymorphism 231. 
 
8.2.3 Future Research  
Future work to be taken forwards from the Morphine versus Oxycodone RCT includes 
investigating the role of opioid metabolites on response phenotypes and expanding the 
candidate gene work.  Currently our group is collaborating with a team at Bournemouth 
University to measure morphine and oxycodone metabolite in serum samples taken from the 
Morphine versus Oxycodone RCT main time points.  Previously Dr Sophy Gretton in her 
thesis examined morphine metabolites from patients in the Prospective Morphine Study 60.  
Linking with the metabolite work the group aims to examine genetic variation in the main 
metabolic enzymes of oxycodone.  It would be very interesting to examine genetic variation 
in CYP2D6, oxycodone metabolites and oxycodone response phenotypes.  Unfortunately the 
CYP2D6 work was beyond the scope of this thesis, however the department is considering 
use of the Roche Amplichip in order to elucidate the metaboliser status of individuals in the 
study.  Other genes to be considered are those identified by the EPOS study to be associated 
with nausea and vomiting  HTR3B and CHRM 96. 
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To further research into inter-individual variation to opioid response in cancer-related pain, 
study sizes need to be increased together with the use of careful and standardised phenotypic 
definition.  Multisite, possible international collaboration such as that seen with EPOS could 
be a way to achieve this.  
 
Our group is already in collaboration with teams working on experimental pain studies in 
normal volunteers in London (Professor Qasim Aziz, Wingate Institute of 
Neurogastroenterology, Barts and the London School of Medicine & Dentistry, Queen Mary 
University of London, UK) and Denmark (Professor Drewes, Laboratory for Experimental 
Pain Research, Aalborg Hospital, Aarhus University Hospital, Denmark).  Selected SNPs 
from our department pain plate have been run on samples from these experimental pain 
studies.  Associations with pain sensitivity and analgesic response are likely to be more easily 
identifiable in these more controlled environments. 
 
The London group is also interested in personality traits, in particular neuroticism in the 
experience of experimental visceral pain.  Previous work has suggested that higher levels of 
neuroticism are associated with engagement of brain regions responsible for emotional and 
cognitive appraisal during anticipation of pain and may influence maladaptive mechanism of 
coping with pain 232.  It would be interesting to look at some of these aspects in the cancer-
related pain and coping. 
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8.3 Summary of Thesis 
This thesis aimed to build on the RMH Palliative Medicine Research Departments work on 
inter-individual variation in opioid response, and switching.  Elements of opioid response 
were explored using PCA and the three independent response phenotypes identified in the 
Prospective Morphine Study were confirmed in the Morphine versus Oxycodone RCT for 
Cancer-related Pain.  Interactions between clinical and genetic factors contributing to these 
phenotypes were explored in multivariate regression analysis.  Morphine and oxycodone, two 
of the most commonly used opioids were compared. 
 
The main findings of this thesis were: 
 
• CTIMPs are important to provide high quality evidence for improved pain and 
symptom control in Palliative Medicine.  The process from inception to completion is 
a complex and lengthy process.  
 
• When compared head-to-head in a pragmatic RCT there is no difference between 
first-line response rates of oral morphine and oral oxycodone in a strong opioid naïve 
population. 
 
• Analgesia and side effect profiles of morphine and oxycodone are similar. 
 
• Morphine should remain the first-line opioid in the treatment of moderate to severe 
cancer-related pain. 
 
• Opioid switching is a valid method of improving clinical outcome when response is 
poor to first-line opioid. 
 
• Switching from morphine to oxycodone and vice versa improved outcomes in the 
majority of non-responders. 
 
• Opioid response appears to have three main domains identified by Principal 
Component Analysis in two different studies. 
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o Analgesic response 
o Upper gastrointestinal adverse reactions  
o Central adverse reactions 
 
• Each response phenotype is a complex trait with clinical and genetic variables 
contributing. 
 
• Morphine and oxycodone although have similar response phenotypes have different 
clinical and genetic factors contributing to each of them, suggesting different 
mechanisms behind them. 
 
• Further work in larger studies would be needed to develop the work on genetic 
associations to morphine and oxycodone response. 
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8.4 Closing Remarks 
In the writing of this thesis I have had the extraordinary opportunity to contribute to two 
independent CTIMPs that add to the growing knowledge base of Palliative Medicine.  I have 
been privileged to work within a team dedicated to improving patient care on all levels. 
 
This thesis provides strong supporting evidence for the continued use of morphine first-line 
in the treatment of moderate-severe cancer related pain.  It also supports the clinical practice 
of opioid switching to improve outcomes in first-line opioid non-responders, and therefore 
shows that individual response to different strong opioids is not the same.  The world-wide 
availability and accessibility of morphine has improved since the advent of the WHO 
recommendations for the treatment of cancer-related pain. This study however shows that 
more than one type of opioid should be available.  
 
Multivariate regression analyses suggested that different clinical and genetic factors were 
associated with opioid response phenotypes for each drug.  At present the clinical 
implications of such data are as yet unclear, however it may provide the stepping stone to 
further, larger studies that develop this modelling.  The ultimate goal would be to be able to 
predict response before the start of the drug, thereby tailoring individual treatment and 
expediting safe, efficient and effective pain relief. 
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Publications Arising from and Relevant to the Work Presented in this Thesis 
 
Journal Articles 
Published 
• Ethnic Considerations in Pharmacogenetic Studies. Ruth A. Branford, Panagiotis 
Pantelidis, Joy R. Ross. Journal of Clinical Oncology 2008;26(10):1766-7 
 
• EAPC Research Network: the Junior Forum. Sophy Gretton, Joanne Droney, Ruth 
Branford, Guro Birgitte Stene, Anne Kari Knudsen and Stein Kaasa. European 
Journal of Palliative Care (2009) 16;5:232-5 
 
In Press 
• Droney J, Gretton S, Sato H, Ross J, Branford R, Welsh K, Cookson W, Riley J, 
Analgesia and central side-effects: two separate dimensions of morphine response. 
Eur J Pain 
 
• The Efficacy and Cost-Effectiveness of Different Treatment Pathways for 
Neuropathic Pain: systematic review and economic modelling of post-herpetic 
neuralgia and painful diabetic neuropathy.  JA Fox-Rushby, GL Griffith, JR Ross, JL 
Peacock, P Farquhar-Smith, T Jones, TJC Phillips, RA Branford, C Bruni, D Coyle, 
JE Williams. Health Technology Assessment  
 
 
Abstracts and Poster Presentations 
• A systematic review of the clinical effectiveness of pharmacological treatments of 
diabetic painful peripheral neuropathy Ross JR, Branford RA, Bruni C, Jones T, 
Peacock JL, Griffith G, Williams JE, Farquhar-Smith P, Philips T, Fox-Rushby J. 
Abstract #2942, Poster PF153,12th World Congress on Pain, IASP, Glasgow 2008 
 
• A systematic review of the clinical effectiveness of pharmacological treatment for 
post herpetic neuralgia Williams JE, Farquhar-Smith P, Philips T, Ross JR, Branford 
RA, Peacock JL, Jones T, Griffith G, Fox-Rushby J. Poster PH275, 12th World 
Congress on Pain, IASP, Glasgow 2008 
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• InForm: A step forwards in clinical trial data management. RA Branford, A Kennett, 
JR Ross, M Thick and J Riley. Poster #P266, European Association of Palliative Care, 
Glasgow 2010 
 
• Genetic polymorphisms in interleukin-6 and -10 do not influence daily morphine dose 
or analgesic response in cancer pain.  RA Branford, H. Sato, P. Pantelidis, M Moffatt, 
J Riley and JR Ross. 6th Research Congress of the European Association of Palliative 
Care, Glasgow 2010 
 
• Genetic variation in the tumour necrosis factor-α (TNFA) promoter influences pain 
severity and morphine response in cancer patients. RA Branford, H Sato, J Droney, P 
Pantelidis, M Moffatt, J Riley and J Ross. Poster 145, 13th World Congress on Pain, 
IASP, Montreal 2010 
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Appendix A Morphine versus Oxycodone RCT Case Report Forms 
• Demographics 
• Modified Brief Pain Inventory 
• S-LANSS 
• Toxicity scores 
• Opioid history and concomitant medications 
• Opioid dosage and breakthrough medication 
• Criteria for changing to an alternate opioid 
• Source of referral 
• Clinical assessment form 
• Study end-point 
• Titration diary 
• Constipation assessment 
• Adverse event log 
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Morphine versus Oxycodone for Pain Relief 
PARTICIPANT DEMOGRAPHICS 
 
Patient Study Number: RCT_____________ 
 
Name: 
 
Hospital No: 
Diagnosis 
 
DOB: 
Sex 
 
Date: 
Height (cm): 
 
Weight (Kg): 
Postcode:  
 
NHS number: 
 
Please select one of the following that most clearly resembles your ethnic origin. 
Information on Ethnicity 
 
White     
British      1 
Irish      2 
Any other White background   3 
Please specify………………………………………………  
    
Black or Black British  
Caribbean     4 
African     5 
Any other Black background    6 
Please specify………………………………………………… 
  
Asian or Asian British –  
Indian      7 
Pakistani     8 
Bangladeshi     9 
Any other Asian background   10 
Please specify………………………………………………… 
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Mixed   
White and Black Caribbean   11 
White and Black African   12 
White and Asian    13 
Any other Mixed background   14  
    Please specify…………………………………………………. 
 
 
Chinese       15 
 
 
Jewish   
  Sephardic     16 
Ashkenazi     17 
 
Any other Ethnic Background    18 
Please specify………………………………………………….  
 
 
Is your natural hair colour red?  Yes      /        No 
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Morphine versus Oxycodone for Pain Relief 
MODIFIED BRIEF PAIN INVENTORY (Short Form) 
 
 
 
Name: ___________________      Date: ___/____/____ 
 
Time points: (please circle) 
 
A:  At time of entry to the study (baseline). 
 
B:  When the patient is stabilised on first line opioid (approx one week). 
 
C:  If patients do not respond to the first line opioid and require switching to the 
alternative arm of the study (samples must be taken before receiving their first 
dose of alternative opioid). 
 
D:  If the patient is stabilised on second line opioid (approx one week post-switch). 
 
E:  If patients’ analgesic requirements have increased by 200% of their initial stable 
dose of opioid. 
 
F:  If patients do not respond to the second opioid and fit the criteria to exit from the 
study. 
 
 
Throughout our lives, most of us have had pain from time to time (such as minor 
headaches, sprains and toothaches). Have you had pain other than these 
everyday kinds of pain today? 
 
1.  Yes    2.  No 
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On the diagram, shade in the areas where you feel pain. Put an X on the area where you 
have pain. 
 
 
 
What type of pain is the participant describing? (please circle) 
 
Somatic Body surface (usually sharper and may have a burning or pricking 
quality)or deep tissues (i.e. musculoskeletal) 
 
Somatic (bony) Dull ache within bones or tender hot spot  
 
Visceral Pain due to infiltration, compression, extension or stretching of the 
thoracic, abdominal or pelvic viscera (internal organs within a cavity).  
Visceral pain is usually not well localized and described pressure-
like/squeezing. 
 
Neuropathic Due to injury to the nervous system, usually burning or tingling. 
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3. Please rate your pain by circling the one number that best describes your pain at its 
worst in the last 24 hours. 
 
No pain 
 
 
  0 
 
  1  
 
  2  
 
  3  
 
  4  
 
  5  
 
  6  
 
  7  
 
  8  
 
  9 
 
10 
Worst pain 
imaginable   
 
4. Please rate your pain by circling the one number that best describes your pain at its 
least in the last 24 hours. 
 
No pain 
 
 
  0 
 
  1  
 
  2  
 
  3  
 
  4  
 
  5  
 
  6  
 
  7  
 
  8  
 
  9 
 
10 
Worst pain 
imaginable   
 
5. Please rate your pain by circling the one number that best describes your pain on 
average in the last 24 hours. 
 
No pain 
 
 
  0 
 
  1  
 
  2  
 
  3  
 
  4  
 
  5  
 
  6  
 
  7  
 
  8  
 
  9 
 
10 
Worst pain 
imaginable   
 
6. Please rate your pain by circling the one number that best describes how much pain 
you have right now. 
 
No pain 
 
 
  0 
 
  1  
 
  2  
 
  3  
 
  4  
 
  5  
 
  6  
 
  7  
 
  8  
 
  9 
 
10 
Worst pain 
imaginable   
 
7. In the last 24 hours, how much relief  have pain treatments or medications provided 
for your pain? Please circle the one percentage that most shows how much relief you have 
received? 
 
No relief 
 
 
0% 
 
10%  
 
20%  
 
30% 
 
40%  
 
50%  
 
60% 
 
70% 
 
80%  
 
90% 
 
100% 
 
Complete relief  
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S-LANSS 
 
1. In the area where you have pain, do you also have ‘pins and needles’, tingling or 
prickling sensations? 
 
a) NO – I don’t  get these sensations (0) 
b) YES – I get these sensations (5) 
 
 
2. Does the painful area change colour (perhaps looks mottled or more red) when 
the pain is particularly bad? 
 
a) NO – The pain does not affect the colour of my skin (0) 
b) YES – I have noticed that the pain does make my skin look different from normal (5) 
 
3. Does your pain make the affected skin abnormally sensitive to touch? Getting 
unpleasant sensations or pain when lightly stroking the skin might describe this. 
 
a) NO – The pain does not make my skin in that area abnormally sensitive to touch (0) 
b) YES – My skin in that area is particularly sensitive to touch (3) 
 
4. Does your pain come on suddenly and in bursts for no apparent reason when you 
are completely still? Words like ‘electric shocks’, jumping and bursting might 
describe this. 
 
a) NO – My pain doesn’t really feel like this (0) 
b) YES – I get these sensations often (2) 
 
5. In the area where you have pain, does your skin feel unusually hot like a burning 
pain? 
 
a) NO – I don’t have burning pain (0) 
b) YES – I get burning pain often (1) 
 
6. Gently rub
 
 the painful area with your index finger and then rub a non-painful 
area (for example, an area of skin further away or on the opposite side from the 
painful area). How does this rubbing feel in the painful area? 
a) The painful area feels no different from the non-painful area (0) 
b) I feel discomfort, like pins and needles, tingling or burning in the painful area that is different from  
 the non-painful area (5) 
 
7. Gently press
 
 on the painful area with your finger tip then gently press in the 
same way on to a non-painful area (the same non-painful area that you chose in 
the last question). How does this feel in the painful are? 
a) The painful area does not feel different from the non-painful area (0) 
b) I feel numbness or tenderness in the painful area that id different from the non-painful area (3) 
 
Scoring: a score of 12 or more suggests pain of a predominantly neuropathic nature 
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Morphine versus Oxycodone for Pain Relief 
TOXICITY SCORES 
 
Name:  __________________                                     Date:  ___/____/____ 
     
 
Current Opioid (please circle)  Morphine / Oxycodone 
 
 
Time point (please circle)  A B C D E F 
 
 
During the past 24 Hours: 
 
 
Symptom  Not  
at all 
  Worst  
imaginable 
 
Have you felt nauseous due to the opioid? 
 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
Have you vomited due to the opioid? 
 
 
0 
 
1 
 
2 
 
3 
 
4 
 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
Have you been constipated due to the opioid?  
 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
Have you had diarrhoea due to the opioid? 
 
 
0 
 
1 
 
2 
 
3 
 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
Have you felt drowsy due to the opioid? 
 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
 
10 
 
Have you felt confused, disorientated or 
experienced hallucinations due to the opioid? 
 
 
 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
6 
 
 
7 
 
 
8 
 
 
9 
 
 
10 
 
Have you had bad dreams due to the opioid? 
 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
Have you had any other notable symptoms due 
to the opioid? 
……………………………………………. 
 
0 
 
1 
 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
 
…………………………………………….. 
 
0 
 
 
1 
 
2 
 
3 
 
 
4 
 
5 
 
6 
 
7 
 
 
8 
 
9 
 
10 
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Morphine versus Oxycodone for Pain Relief 
 
OPIOID HISTORY AND CONCOMITANT MEDICATION 
 
 
Name:……………………………    Date  ….. / …… / ……. 
 
Current Opioid: (please circle)  Morphine/Oxycodone 
 
Time Point: (please circle)  A B C D E F 
 
 
Opioid History: (Baseline data collection only) 
 
Name of previous step 2 analgesia 
 
Approximate dates of administration 
(start – finish) 
  
  
  
  
 
Concomitant Medications:  
 
Drug Dose and frequency 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
Chemo:  Date and time last given ………………………………………. 
 
Blood transfusion: Date and time last given ……………………………………….. 
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Morphine versus Oxycodone for Pain Relief 
 
OPIOID DOSAGE AND BREAKTHROUGH MEDICATION 
 
 
Name:………………………………    Date: ……/……/…….. 
     
 
Time Point: (please circle) A    B C D E F 
 
 
Current Regular Opioid:  (please circle) 
 
                Morphine  /  Oxycodone 
 
 
Dose and Frequency 
Breakthrough Opioid 
 
 
 
Dose and Frequency 
Number of breakthrough doses per day 
(Average daily requirements over past 3 
days) 
 
 
 
 
• Time and Date of last dose of opioid ………………………………………………….. 
 
 
 
• Time and Date of study blood sample ………………………………………………. 
 
 
 
• Time and Date of study urine sample ……………………………………………… 
 
 
• What date did you start taking this dose of opioid ………………………………… 
(If you cannot remember the date, give an approximation in weeks and days of the length of time you have been on this 
dose). 
 
 
• Do you take anything else for your breakthrough pain?  
 
Please specify……………………………………………………………….. 
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Morphine versus Oxycodone for Pain Relief 
 
CRITERIA FOR CHANGING TO AN ALTERNATIVE OPIOID 
 
 
Name: ………………………………    Date: ……./……../…….. 
 
Current Opioid: (please circle) Morphine / Oxycodone 
 
Has the participant already switched once? (please circle) Y   /    N  
 
 
 
Please give the primary reason for changing to an alternative opioid 
 
1) Uncontrolled Pain 
 
 
2) Opioid Toxicity  
(Side effects which are intractable despite appropriate intervention 
and at a level unacceptable to the patient) 
 
- Nausea 
 
 
- Vomiting 
 
 
- Constipation 
 
 
- Drowsiness 
 
 
- Hallucinations 
 
 
- Nightmares 
 
 
- Pruritis 
 
 
- Myoclonus 
 
 
- Any other symptom 
 
Describe…………………………………………. 
 
 
 
Was patient already on medications to control this symptom?   Y/N 
If so, what (please specify medication and dose) 
 
……………………………………………………………………………………………… 
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Morphine versus Oxycodone for Pain Relief 
 
SOURCE OF REFERRAL 
 
 
 
 
Name ………………………………………… Date ……./………./……… 
 
 
Referring Team: (please circle) 
 
Medical Oncology 
 
Clinical Oncology 
 
Surgical 
 
Palliative Care 
 
 
 
Geography of Patient: (please circle) 
 
   Outpatient Clinic 
 
   Inpatient 
 
   Ward (please specify)………………………………………… 
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Morphine versus Oxycodone for Pain Relief 
CLINICAL ASSESSMENT FORM 
 
 
 
 
Name……………………………………….. Date ……/………/……… 
 
 
Current Opioid (please circle)   Morphine  /  Oxycodone 
 
 
Initial Stable Dose Of Opioid …………  Present Dose Of Opioid ………… 
 
 
1. Have there been any significant clinical events in last 4 weeks?  
 
      ……………………………………………… 
       
      ……………………………………………… 
 
2. Is there any specific evidence of disease progression?  
(blood tests/tumour markers, imaging) 
      ……………………………………………… 
    
      ……………………………………………… 
  
      ……………………………………………… 
 
3. Have there been any changes to concurrent medication? (please specify medication) 
 
      ……………………………………………… 
 
      ……………………………………………… 
 
      ……………………………………………… 
 
4. Is there any other relevant information?  
      …………………………………………….. 
 
      ……………………………………………… 
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Morphine versus Oxycodone for Pain Relief 
STUDY ENDPOINT 
 
 
Name: ………………………………. 
 
On what date did the patient reach the study endpoint? ....................... 
 
 
Why has the subject reached the study endpoint? 
 
1. Non-response to 2nd line opioid (ie reached Time Point F) 
2. Converted to parenteral opioids 
3. Unable to take oral opioids 
4. Renal impairment (>1.5 upper limit of normal) 
5. Patient requested to withdraw 
6. Patient has died 
 
7. Other …………………………………………………………………. 
 
Date of Death ................................................................ 
 
Certified Cause of Death Ia  …………………………………………. 
     Ib  …………………………………………. 
     Ic  ………………………………………… 
     II  …………………………………………. 
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Morphine versus Oxycodone for Pain Relief 
OPIOID TITRATION DIARY 
 
 
Name:………………………………    Today’s date: ……/……/……..
      
CURRENT OPIOID (please circle) Morphine / Oxycodone 
4 hourly dose 
  
mg 
Number of 4 hourly doses taken in last 24hours 
 
 
Breakthrough dose 
 
mg 
Number of breakthrough doses in last 24hours 
 
 
Total dose (mg) of morphine/oxycodone  in last 24hours 
 
mg 
 
SIDE EFFECTS:  In the past 24hours……. 
Symptom  Not  
at all 
  Worst  
imaginable 
 
Have you felt nauseous? 
 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
Have you vomited due to the opioid? 
 
 
0 
 
1 
 
2 
 
3 
 
4 
 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
Have you been constipated due to the opioid?  
 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
Have you had diarrhoea due to the opioid? 
 
 
0 
 
1 
 
2 
 
3 
 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
Have you felt drowsy due to the opioid? 
 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
 
10 
 
Have you felt confused, disorientated or 
experienced hallucinations due to the opioid? 
 
 
 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
6 
 
 
7 
 
 
8 
 
 
9 
 
 
10 
 
Have you had bad dreams due to the opioid? 
 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
Have you had any other notable symptoms? 
 
……………………………………………. 
 
0 
 
1 
 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
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PAIN SCORES IN LAST 24 HOURS 
 
1. Please rate your pain by circling the one number that best describes your  pain at its 
worst in the last 24 hours. 
 
0   1 2 3 4 5 6 7 8 9 10 
No pain          Pain as bad as 
           you can 
imagine 
 
2. Please rate your pain by circling the one number that best describes your  pain at its 
least in the last 24 hours. 
 
0   1 2 3 4 5 6 7 8 9 10 
No pain             Pain as bad as 
              you can 
imagine 
 
3. Please rate your pain by circling the one number that best describes your pain on 
the average. 
 
0    1 2 3 4 5 6 7 8 9 10 
No pain         Pain as bad as 
           you can 
imagine 
 
4. Please rate your pain by circling the one number that tells how much pain you have 
right now. 
 
0   1 2 3 4 5 6 7 8 9 10 
No pain          Pain as 
bad as           you can 
imagine 
 
5. In the last 24 hours, how much relief  have pain  treatments or medications provided 
for your pain? Please circle the one percentage that most shows how much relief you 
have received?   
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
No relief         Complete 
relief 
 
 
 
OTHER PAIN KILLERS TAKEN IN LAST 24 HOURS?  
ie paracetamol, ibuprofen, gabapentin 
……………………………………………………………………………………………… 
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Constipation Assessment 
 
Thank you for taking part in this study about bowel function. Many of these questions appear 
similar. Please answer them individually. 
 
 
 
Are you satisfied with how your bowel has functioned during the PAST WEEK?      (Please tick) 
Yes□     No□  
 
 
 
In the PAST WEEK have you been constipated? (Please tick) 
 
Not at all □  A little□  Quite a bit □  Very much □ 
 
 
 
In the PAST WEEK how has your bowel functioned OVERALL? (Please tick) 
Severe diarrhoea  □ 
Moderate diarrhoea  □ 
Mild diarrhoea   □ 
Normal    □ 
Mild constipation  □ 
Moderate constipation  □  
Severe constipation  □ 
 
 
 
In the PAST WEEK please rate how constipated you been?        
 
    
        
0 □ 1□ 2□ 3□ 4□ 5□ 6□ 7□ 8□ 9□ 10□ 
 
 
 
What does being constipated mean to you? 
__________________________________________________________________________________
__________________________________________________________________________________
________________________________________________________________ 
  
Worst 
imaginable 
Not at all 
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Everyone’s usual bowel activity is different.  
 
 
During the PAST WEEK has your bowel activity been USUAL FOR YOU, MORE CONSTIPATED 
than usual or LESS CONSTIPATED than usual? (Please tick) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
During the PAST WEEK did you open your bowels MORE or LESS FREQUENTLY than 
usual? (Please tick) 
 
 
 
 
 
 
 
 
 
During the PAST WEEK what  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A little more constipated □   
 
Quite a bit more constipated □ 
 
        
A little less constipated       □ 
 
Quite a bit less constipated   □ 
 
       
Usual for you □ 
A little less frequently  □ 
 
Quite a bit less frequently  □ 
 
        
 
A little bit more frequently □ 
 
Quite a bit more frequently □ 
 
      
Usual for you □ 
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During the PAST WEEK how many times did you open your bowels?                                     
(Please tick) 
More than once a day□  _______times in the week□   None at all □    
 
 
 
Everyone’s usual bowel activity is different. How many times a week do you USUALLY open your 
bowels? 
 ___________________________________________________________________________ 
 
 
 
During the PAST WEEK what has your STOOL CONSISTENCY been like in general?   
              
 
 
 
During the PAST WEEK have your stool been HARD (Please tick) 
 
Never □  Rarely□  Occasionally □ Nearly always □ 
 
 
 
During the PAST WEEK did you have to STRAIN to open your bowels? (Please tick) 
 
Not at all □  A little□  Quite a bit □  Very much □ 
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Laxatives taken during the past week: 
 
Laxative Name 
 
Laxative dose and 
how often taken a 
day? 
How many days 
did you take this 
medication? 
Any side-effects 
with this 
medication? 
  
 
   
  
 
   
  
 
   
  
 
   
  
 
   
  
 
   
 
Other current medications: 
Medication Name Dose and frequency 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
 
Planned change to laxative regimen:  
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During the PAST WEEK how active have you been? (Please tick) 
□  Fully active, able to carry out all activities without restriction 
 
□ Fully mobile, able to carry out light work. Unable to carry out physically 
strenuous activity 
 
□ Mobile, capable of self-care, unable to carry out any work. Up and about more 
than 50% of waking hours. 
 
□ Capable only of limited self-care, confined to bed or chair more than 50% of 
waking hours. 
 
□  Unable to carry out self care. Totally confined to bed or chair 
 
 
 
During the past week what has your food intake been like? 
 
As usual□  Less than usual□  More than usual□ 
 
During the past week what has your fibre intake been like?  
 
As usual□  Less than usual□  More than usual□ 
 
During the past week what has your fluid intake been like? 
 
As usual□  Less than usual□  More than usual□ 
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Patient Initials and Study Number: 
Date entered study: Date completed: 
Royal Marsden NHS Foundation Trust 
Adverse Event Log RCT CCR2586 
AE No Adverse event Start date 
DD/MM/YY 
Stop date 
DD/MM/YY 
Ongoing 
Tick if yes 
Once stop 
date known 
enter in 
stop date 
field 
Severity 
1=mild 
2=moderate 
3 =Severe 
Expectedness 
1 = expected 
2 = not expected 
Relationship 
to study drug 
1= probably 
2= possibly 
3=unrelated 
Action taken 
with study drug 
1=None 
2=dose reduced 
temporarily 
3=study med 
interrupted  
Outcome 
1=recovered 
2= stabilized 
3=recovered with 
sequelae 
4= not yet 
recovered 
5=fatal 
6=unknown 
Serious 
Adverse Event 
If serious 
complete SAE 
for as per SOP 
Yes/No 
 
 
 
 
 
          
           
           
           
SAE Definition: 
Hospitalisation / prolongation of hospitalisation 
Death 
Life-threatening event 
Resulting in persistent / significant incapacity 
Resulting in congenital abnormality 
Important medical event 
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Appendix B Primer Tables 
Primer sequences for the following genes are presented in this appendix: 
• TNF 
• IL6 
• IL10 
• OPRM 
• OPRK 
• OPRD 
• STAT6 
• ARRB2 
• ABCB1 
• COMT 
• ADORA1 
• SLC6A4 
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TNF 
 
  
Entrez SNP 
ID  
Region Nucleotide Primer Sense/ 
Antisense 
Primer Sequence Vol 
(mL)2 
Tm GC 
(%) 
content 
Primer 
Length 
TNF rs1799964 Promoter C/T C S  CAA AGG AGA AGC TGA GAA GAC 10/10 60 48 21 
    T S CAA AGG AGA AGC TGA GAA GAT 10/10 57 43 21 
    cons AS CCG GGA ATT CAC AGA CCC C  62 63 19 
           
 rs1800630 Promoter C/A C S CGA GTA TGG GGA CCC CCC 10/10 63 72 18 
    A S GAG TAT GGG GAC CCC CCA 10/10 57 65 17 
    cons AS CCG GGA ATT CAC AGA CCC C  62 63 19 
           
 rs1799724 Promoter C/T C AS TCA CAT GGC CCT GTC TTC G 12/12 59 58 19 
    T AS CTC ACA TGG CCC TGT CTT CA 12/12 60 55 20 
     S AAG GAT AAG GGC TCA GAG AG  58 50 20 
           
 rs1800629 Promoter G/A G S ATA GGT TTT GAG GGG CAT GG 1.5/1.5 58 50 20 
    A S ATA GGT TTT GAG GGG CAT GA 8/8 56 45 20 
    cons AS GCA TCC CCG TCT TTC TCC AC  62 63 19 
           
 rs361525 Promoter G/A G S GAA GAC CCC CCT CGG AAT CG 2/2 65 65 20 
    cons AS GCA TCC CCG TCT TTC TCC AT  61 55 20 
    A S GAA GAC CCC CCT CGG AAT CA 2.5/2.5 63 60 20 
    cons AS GCA TCC CCG TCT TTC TCC AC  63 60 20 
           
  These primers were a kind gift from Dr Panos Pantelidis 
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IL6 
 
Gene Entrez SNP 
ID  
Region SNP Primer Sense/ 
Antisense 
Primer Sequence Vol 
(mL)2 
Tm GC 
(%) 
content 
Primer 
Length 
IL6 rs1800795  Promoter G/C G S AAT GTG ACG TCC TTT AGC ATG 10/10 57 43 21 
    C S AAT GTG ACG TCC TTT AGC ATC 10/10 57 43 21 
     AS TCG TGC ATG ACT TCA GCT TTA  57 43 21 
           
  rs2069845 Intron 4 A/G A AS CTG TTG AAA GAC CAC TGA TCT 10/10 57 43 21 
    G AS CTG TTG AAA GAC CAC TGA TCC 10/10 60 48 21 
     S GAG GAA CAA GCC AGA GCT GT  60 55 20 
   
   
 
    
 These primers were a kind gift from Dr Panos Pantelidis 
 
                      
 
 
 
IL10 
 
Gene Entrez SNP 
ID  
Region SNP Primer Sense/ 
Antisense 
Primer Sequence Vol 
(mL)2 
Tm GC 
(%) 
content 
Primer 
Length 
IL10 rs1800896 Promoter  G S  GTA CTA AGG CTT CTT TGG GAG 12/12 60 48 21 
    A S GTA CTA AGG CTT CTT TGG GAA 12/12 58 43 21 
    cons AS CAA ACT GAG GCA CAG AGA TG  50 58 20 
           
 rs1800871 Promoter  C AS CAA ACT GAG GCA CAG AGA TG 12/12 58 50 20 
    T AS GCA AAC TGA GGC ACA GAG ATA 12/12 60 48 21 
    cons S GTA CTA AGG CTT CTT TGG GAA  58 43 21 
           
  These primers were a kind gift from Dr Panos Pantelidis 
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OPRM 
 
  
Entrez SNP 
ID  
Region Nucleotide Primer Sense/ 
Antisense 
Primer Sequence Vol 
(mL)2 
Tm GC 
(%) 
content 
Primer 
Length 
OPRM rs1799971*  Exon 1  A/G A S TTG TCC CAC TTA GAT GGC A 10/10 55 47 19 
    G S TGT CCC ACT TAG ATG GCG 10/10 56 56 18 
    Cons AS GTT GCC AAG GTC CAT CTC  56 56 18 
           
 rs589046* Intron 1 C/T C S ACA GAC TGA TGG TTA GCA ACC 4/2 59 48 21 
    T S CAC AGA CTG ATG GTT AGC AAC T 4/2 60 45 22 
    Cons AS CTG CCT ACC TTG CTA TGC C  59 58 19 
           
 rs563649**  Intron 1 C/T C S GAT CAT GCA GGT CTA TAA CCA AC 5/4 61 43 23 
    T S GAT CAT GCA GGT CTA TAA CCA AT 5/4 59 39 23 
    Cons  AS GCT TCT GAT TTA CAC GGT GCC  61 52 21 
           
 rs9479757* Intron 2 G/A G AS CAT ATC AGG CTG TGA ACC C 10/10 57 53 19 
    A AS AAC ATA TCA GGC TGT GAA CCT 10/10 57 43 21 
    Cons S AAT AGC CAA GCT GAT ACT GG  56 45 20 
           
 rs2075572* Intron 2 G/C G S CTC TGG TCA AGG CTA AAA ATG 20/20 57 43 21 
    C S CTC TGG TCA AGG CTA AAA ATC 20/20 57 43 21 
    Cons AS CAA TTT GCT TCC CCT CTT C  55 47 19 
           
 rs533586** Intron 3 C/T C S TGT GAG GAC AGA TGG CTC C 5/5 59 58 19 
    T S ACT GTG AGG ACA GAT GGC TCT 5/5 61 52 21 
    Cons  AS ATG ACG GAT GTA TCT GGG CC  60 55 20 
           
 These primers were designed by: Dr Joy Ross* and Dr Joanne Droney** 
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OPRK 
 
  
Entrez SNP 
ID  
Region Nucleotide Primer Sense/ 
Antisense 
Primer Sequence Vol 
(mL)2 
Tm GC (%) 
content 
Primer 
Length 
OPRK rs 10504151 Intron 2 T/C T AS CCT GAC AGT TAT GGC CAC ACA 10/10 61 52 21 
    C AS CTG ACA GTT ATG GCC ACA CG 10/10 60 55 20 
    Cons S  AGC TTC TTG GAG GAG TAA TCC  59 48 21 
           
 rs 7836120  Intron 2 A/G A S GAG TAT AAG GGA GGA TCT GCA 10/10 59 48 21 
    G S GAG TAT AAG GGA GGA TCT GCG 10/10 61 52 21 
    Cons AS TTA GAA GGA CCA AGC TCT ACG     
           
 rs 6473799  Intron 2 T/C T S ACT CAT CTC TGA CCA TGC TCA T 10/10 60 45 22 
    C S CTC ATC TCT GAC CAT GCT CAC 10/10 61 52 21 
    Cons AS AGT AAA GGA ACT CAG GCT TGT C  60 45 22 
           
 rs 1365098 Intron 2 G/T G S CAT TGT TTT GTC CAT TGA GGG G 10/10 60 45 22 
    T S CAT TGT TTT GTC CAT TGA GGG T 10/10 58 41 22 
    Cons AS TTC CTG CTG AGG AGT CAC AG  60 55 20 
           
 rs 7016778  Intron 2 T/A T AS CAT TCC CCA AGC TTT GTC TCA A 10/10 60 45 22 
    A AS CAT TCC CCA AGC TTT GTC TCA T 10/10 60 45 22 
    Cons S TAG AAG GGC AGT AGT TTC GAG  59 48 21 
           
 rs 7824175 Intron 3 G/C G S CAG TTC ACA TTC TGG ATG GAG 10/10 59 48 21 
    C S CAG TTC ACA TTC TGG ATG GAC 10/10 59 48 21 
    Cons AS GTA GAA GAG TTT CCT TGG AGG  59 48 21 
           
 rs 16918875 Exon 4 C/T C AS AGT CCA GCA GAC GAC GAA G 10/10 59 58 19 
    T AS GAG TCC AGC AGA CGA CGA AA 10/10 60 55 20 
    Cons S ATT GAG TGC TCC TTG CAG TTC  59 48 21 
           
 rs 963549 3UTR G/A G AS TCA TTG AAC TCC TCT CTT CCC 10/10 59 48 21 
    A AS GAT CAT TGA ACT CCT CTC TTC CT 10/10 61 43 23 
    Cons S ACT TCT GCA TCG CCT TAG GC  60 55 20 
            These primers were designed by Dr Sophy Gretton 
                      
 340 
 
 
 
 
OPRD 
  
Entrez SNP 
ID  
Region Nucleotide Primer Sense/ 
Antisense 
Primer Sequence Vol 
(mL)2 
Tm GC (%) 
content 
Primer 
Length 
OPRD rs 1042114 Exon 1 G/T G S GCCTACCCTAGCGCCTG 10/10 60 71 17 
    T S CGCCTACCCTAGCGCCTT 10/10 61 67 18 
    Cons AS AAGCTCACACCAACAGATGAGC  62 50 22 
           
 rs 533123 Intron 1 G/A G S GTTGGCTGACTGAGCACAG 10/10 59 58 19 
    A S TGGTTGGCTGACTGAGCACAA 10/10 61 52 21 
    Cons AS TCTGCTCTCTGAGGACTCTAA  59 48 21 
           
 rs 419335 Intron 1 A/G A AS TCCCTGCCTCTCTCTCACTTT 10/10 61 52 21 
    G AS CCTGCCTCTCTCTCACTTC 10/10 59 58 19 
    Cons S AGGCACCCTGCCTAGAGAT  59 58 19 
           
 rs 2236857 Intron 1 T/C T S TCCAACACTCAGACAGCATGT 10/10 59 48 21 
    C S TCCAACACTCAGACAGCATGC 10/10 61 52 21 
    Cons AS ACACTCAACAAGAAGCAGGAC  59 48 21 
           
 rs 2234918 Exon 3 C/T C AS TTGAGGCTGCTATTGGCGTAG 10/10 59 52 21 
    T AS TTGAGGCTGCTATTGGCGTAA 10/10 59 48 21 
    Cons S TGTTGTCTGTCTTAGCAGTCC  59 48 21 
           
 These primers were designed by Dr Sophy Gretton 
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STAT6 
 
  
Entrez SNP 
ID  
Region Nucleotide Primer Sense/ 
Antisense 
Primer Sequence Vol 
(mL)2 
Tm GC (%) 
content 
Primer 
Length 
STAT6 rs167769 Intron 1 C/T  C AS AAGGTCTTGGAGCAGAAACG 5/5 58 50 20 
 
   T AS GAAGGTCTTGGAGCAGAAACA 5/5 60 48 21 
 
   Cons S  GGCTAGAAGGCAAAGATGAG  58 50 20 
 
          
 
rs3024971  Intron 14  A/C A S CATACACCAGTCACCTCCATA 14/14 60 48 21 
 
   C S ATACACCAGTCACCTCCATC 14/14 58 50 20 
 
   Cons AS CCACAGAAGGAAGAAGAGAAG  60 48 21 
 
          
 
rs841718  Intron 16  C/T  C AS GAGTGACATCAGGATGACACG 4/1 61 52 21 
 
   T AS GAGTGACATCAGGATGACACA 2/1 60 48 21 
 
   Cons S GAAAGTCCGGACAGAGGGAT  60 55 20 
 
          
 
rs3024974  Intron 17  C/T  C S GGGGCTTAGTGCTTATCTGC 4/2 60 55 20 
 
   T S GGGGCTTAGTGCTTATCTGT 4/2 58 50 20 
 
   Cons AS AAGATTCCCTGTTCAGCCCC  60 55 20 
 
          
 
rs3024979 3' UTR A/T A AS AGAAAGCTGTGAAGATGGGCT 5/5 60 48 21 
 
   T AS AGAAAGCTGTGAAGATGGGCA 5/5 60 48 21 
 
   Cons S CTGGCTTCCTGTTCTCCCT  60 58 19 
 
       
    These primers were designed by Dr Joy Ross 
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ARRB2 
  
Entrez SNP 
ID  
Region Nucleotide Primer Sense/ 
Antisense 
Primer Sequence Vol 
(mL)2 
Tm GC 
(%) 
content 
Primer 
Length 
ARRB2 rs1973555 Promoter C/T C AS CTG CAT AAT TGA GGG TGA CAA G 5/5 58 41 22 
    T AS CTG CAT AAT TGA GGG TGA CAA A 5/5 60 45 22 
    Cons S  CTT GAG GCT GGG AAA TGG AG  60 55 20 
           
 rs3786047 Intron 1 A/G A AS GCC AAG TTA GCA GTC TCC TTT 5/5 60 48 21 
    G AS GCC AAG TTA GCA GTC TCC TTC 5/5 61 42 21 
    Cons S GAG GGT ATC AGG AAT AGG GAA T  60 45 22 
           
 rs4522461 Intron 9 T/G T AS CGA GGC TCC CCG TAT CAT TA 5/5 60 55 20 
    G AS GAG GCT CCC CGT ATC ATT C 5/5 60 58 19 
    Cons S ACA CAC TGA TGA TGG GAA CAG  60 48 21 
           
 rs1045280 Exon 11 C/T C S CAT AAC CCC ACT GCT CAG C 7.5/7.5 60 58 19 
   S280S T S CCA TAA CCC CAC TGC TCA GT 7.5/7.5 60 55 20 
    Cons AS CCT TCA TAC TTG TCA CTA AAC C  58 41 22 
           
 rs2271167 Intron 11 A/G A AS CAT ACT TGT CAC TAA ACC TGCT 5/5 58 41 22 
    G AS CAT ACT TGT CAC TAA ACC TGC C 5/5 60 45 22 
    Cons S TCC CAG CTC CAC ATT CTG TAA  60 48 21 
           
 rs2036657 3'UTR A/G A AS AGG AGC AGT GGA AAT GAA CGT 7.5/7.5 61 52 21 
    G AS AGG AGC AGT GGA AAT GAA CGC 7.5/7.5 60 48 21 
    Cons S ACG GAG GCT ATC AGC AAA TG  58 50 21 
           
 These primers were designed by Dr Joy Ross  
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ABCB1 
  
Entrez SNP 
ID  
Region Nucleotide Primer Sense/ 
Antisense 
Primer Sequence Vol 
(mL)2 
Tm GC 
(%) 
content 
Primer 
Length 
ABCB1 rs3213619 Exon1 C/T C S  AAG CCT GAG CTC ATT CGA GC 5/5 61 55 20 
    T S AAG CCT GAG CTC ATT CGA GT 5/5 58 50 20 
    Cons AS TGA TTC CAA AGG CTA GCT TGC     
           
 rs1202168 Intron 7 C/T C A CAA AAT TCC TTC TAA GCA GCA AC 7/7 60 48 21 
    T A ACA AAA TTC CTT CTA AGC AGC AAT 7/7 58 33 24 
    Cons AS TAC TCA GTG AGG CTG GAT ATG  60 48 21 
           
 rs1128503 Exon 13 C/T C A CCT GGT AGA TCT TGA AGG GC 5/5 61 55 20 
    T A TCC TGG TAG ATC TTG AAG GGT 4/4 60 48 21 
    Cons AS CAG GAG GAT CTT GGG GTT G  60 58 19 
           
 rs2032582 Exon 22 G/T/A G AS GTT TGA CTC ACC TTC CCA GC 3/4 61 55 20 
    T AS TAG TTT GAC TCA CCT TCC CAG A 3/4 60 45 22 
    A AS TAG TTT GAC TCA CCT TCC CAG T 3/4 60 45 22 
    Cons S CAG ACT CCC TCT GGA ATT CAA  60 48 21 
           
 rs1045642 Exon 27 C/T C S GTG GTG TCA CAG GAA GAG ATC 20/20 61 52 21 
    T S GTG GTG TCA CAG GAA GAG ATT 20/20 60 48 21 
    Cons AS TTC CAG TTC TCC TAT CCC AG  58 50 20 
           
 These primers were designed by Dr A Taegetmeyer 
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COMT 
  
Entrez SNP 
ID  
Region Nucleotide Primer Sense/ 
Antisense 
Primer Sequence Vol 
(mL)2 
Tm GC 
(%) 
content 
Primer 
Length 
COMT rs2097603 Promoter A/G A AS TGG GGA CAA CAG ACA GAA AAG T 10/10 60 45 22 
    
G AS GGG GAC AAC AGA CAG AAA AGC 10/10 61 52 21 
    
Cons S  ACT CCT CTG GCG GAA AGG AA 
 
60 55 20 
           
 
rs737866 Intron 1 A/G A S CAC AAA AAT 10/10 CCC TGG CTG GAA 60 48 21 
   
NF-AT KO G S ACA CAA AAA TCC CTG GCT GGA G 10/10 62 50 22 
    
Cons 
 
TGT GGA GCC CCA GAC TCA G 
 
62 63 19 
    
(C) A S ACA AAA ACC CCT GGC TGG AA 10/10 58 50 20 
    
(C) G S ACA AAA ACC CCT GGC TGG AG 10/10 60 55 20 
           
 
rs7287550 Intron 1  T/C T S GGC GGG ATA ATC GCT TGA ACT 10/10 61 52 21 
   
(cmyb KO) C  S GCG GGA TAA TCG CTT GAA CC 10/10 60 55 20 
    
Cons AS GGC TTG GCT TCC TAA CCT CG 
 
63 60 20 
 
      
 
rs7290221 Intron 1 C/G C AS ACC CAT TGA GCC AGG CAT G 10/10 60 58 19 
    
G AS ACC CAT TGA GCC AGG CAT C 10/10 60 58 19 
    
Cons S TCA CCT CTT CTC AGG TGT CAC 
 
61 52 21 
 
      
 
rs740603 Intron 1  A/G A S CAC TGA GGA TGC CCT CAC A 10/10 60 58 19 
    
G S ACT GAG GAT GCC CTC ACG 10/10 61 58 18 
    
Cons AS CTT CCA TCC GTT AGC ACC TGA 
 
61 52 21 
           
 
rs6269 Intron 2 A/G A S TGA ACC TTG CCC CTC TGC A 10/10 60 58 19 
    
G S TGA ACC TTG CCC CTC TGC G 10/10 62 63 19 
    
Cons AS ACC GTC AGA CCC TGT GAG T 
 
60 58 19 
           These primers were designed by Dr Joy Ross 
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Entrez SNP 
ID  
Region Nucleotide Primer Sense/ 
Antisense 
Primer Sequence Vol 
(mL)2 
Tm GC 
(%) 
content 
Primer 
Length 
COMT rs2239393 Exon 3 A/G A S GGA GAA GCT GTT ATC ACC CCA 10/10 61 52 21 
continued 
   
G S GAG AAG CTG TTA TCA CCC CG 10/10 60 55 20 
    
Cons AS CAC GAT CTT GCC TGT GCA G 
 
60 58 19 
   
   
     
 
rs4680 A Exon 4 A/G A S GAT GGT GGA TTT CGC TGG CA 10/10 60 55 20 
   
val/met G S ATG GTG GAT TTC GCT GGC G 10/10 60 58 19 
    
Cons AS AGG GTT CTG GGA TGA CAA GG 
 
60 55 20 
   
   
     
 
rs165728 3'UTR C/T C S GAT GCA GTG CTG GTT TCT GC 10/10 60 55 20 
    
T S GGA TGC AGT GCT GGT TTC TGT 20/20 61 52 21 
    
Cons AS ACT TGG GCT CAC TGG TCT GT 
 
60 55 20 
   
   
     These primers were designed by Dr Joy Ross 
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ADORA1 
  
Entrez SNP 
ID  
Region Nucleotide Primer Sense/ 
Antisense 
Primer Sequence Vol 
(mL)2 
Tm GC 
(%) 
content 
Primer 
Length 
ADORA1 rs2364571 Promoter C/G C  S  ACA CGG AGG GAA AGT AGA AGA C 5/5 62 50 22 
    
G S ACA CGG AGG GAA AGT AGA AGA G  5/5 62 50 22 
    
Cons AS AGT GAG GTT AAA CCT GGG AGC  61 52 21 
           
 rs10920568 Exon 5 T/G T S GGC CCT GCT GGC AAT TGC T  5/5 62 63 19 
    
G S TGC CCT GCT GGC AAT TGC G 5/5 62 63 19 
    
Cons AS AGT TCA CAG TAC AGT CCT CCA   60 48 21 
           
 rs10800901 Intron 5 G/A G S GCA CAT AGT AGG CAC TCC G  5/5 60 58 19 
    
A S TGG CAC ATA GTA GGC ACT CCA  5/5 61 52 21 
    
Cons AS CTT CCC AAC CTG GCT TAC TCA   61 52 21 
           
 rs10920576 Intron 5 C/T C  S TGC TCC AAG CTT CCA TCC C  5/5 60 58 19 
    T S CTG CTC CAA GCT TCC ATC CT  5/5 61 55 20 
    Cons AS TCA ACC AGC GGG TAT AAT GCA   60 48 21 
           
These primers were designed by Dr Sophy Gretton 
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SLC6A4 
 
  
Entrez SNP 
ID  
Region Nucleotide Primer Sense/ 
Antisense 
Primer Sequence Vol 
(mL)2 
Tm GC 
(%) 
content 
Primer 
Length 
SLC6A4 rs7214991 Promoter A/G  A S ACA ACT TCA GCC CAT TTC CCT A 5/5 60 45 22 
     G S ACA ACT TCA GCC CAT TTC CCT G 5/5 62 50 22 
    Cons AS TAC CGA CCG GCT TGG TGA T  59 58 19 
           
 rs 25528 Intron boundary 1 
T/G  T S TGA TGC TGG GGT GGT TGG TT 5/5 60 55 20 
    G S ATG CTG GGG TGG TTG GTG 5/5 58 61 18 
    Cons AS ATA AAC AGT CCA TCC CTG GC  58 50 20 
           
 rs 6354 5UTR / non coding exon 
T/G  T AS CGA CCT TGC TTG CCC TCT A 5/5 59 58 19 
    G AS  GAC CTT GCT TGC CCT CTC 5/5 58 61 18 
    Cons S ACT CGC TTC CCT TTG AGC CA  60 55 20 
           
 rs 140700 Intron 6 C/T  C S AAG ACC TTG AGA AAG GAG GGC 5/5 61 52 21 
     T S AAG ACC TTG AGA AAG GAG GGT 5/5 59 48 21 
    Cons AS AAG ATT CCT TCA ACC CAC TGG  59 48 21 
           
 rs 4583306 Intron 9 A/G  A S GTA ACA GAT CCA AGA CCC AGA 5/4 59 48 21 
     G S GTA ACA GAT CCA AGA CCC AGG 5/4 61 52 21 
    Cons AS AGT GGG TTT GCT TCC TGT GAT  59 48 21 
            These primers were designed by Dr Joanne Droney 
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Appendix C  Morphine versus Oxycodone RCT Genetic Results, 
Supplementary Tables 
 
This Appendix details information for the following genes from the Royal Marsden Hospital 
Palliative Medicine Research Department Pain Plate: 
• OPRM 
• OPRK 
• OPRD 
• STAT6 
• ARRB2 
• ABCB1 
• COMT 
• ADORA1 
• SLC6A4 
 
The tables and figures below contain information regarding the following from the Caucasian 
subgroup from the Morphine versus Oxycodone RCT: 
• Genotype and Allele Frequencies and Allele Carriage  
• Haploblock Frequency and Carriage 
• LD Plots 
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Morphine versus Oxycodone RCT: Genotype and Allele Frequencies and Allele Carriage  
OPRM 
Gene Location Name Position 
Allele 
major/minor 
Genotype 
frequency 
Allele 
frequency 
Allele 
carriage 
Published 
MAF HWpval 
ORPM Exon 1 rs1799971 154402490 A/G aa 0.68 a 0.82 a 0.97 
  
 
 
 
 
 
ag 0.29 g 0.18 g 0.32 0.16 0.95 
 
 
 
 
 
gg 0.03 
                   
 
Intron 1 rs589046 154434831 C/T cc 0.57 c 0.76 c 0.95 
  
 
 
 
 
 
ct 0.39 t 0.24 t 0.43 0.25 0.91 
 
 
 
 
 
tt 0.05 
                   
 
Intron 1 rs563649 154449660 C/T cc 0.84 c 0.91 c 0.97 
  
 
 
 
 
 
ct 0.14 t 0.09 t 0.16 0.08 0.01 
 
 
 
 
 
tt 0.03 
                   
 
Intron 2 rs9479757 154453037 G/A gg 0.90 g 0.94 g 0.99 
  
 
 
 
 
 
ga 0.10 a 0.06 a 0.11 0.08 0.48 
 
 
 
 
 
aa 0.10 
                   
 
Intron 2 rs2075572 154453697 C/G cc 0.39 c 0.62 c 0.86 
  
 
 
 
 
 
cg 0.47 g 0.38 g 0.61 0.43 0.98 
 
 
 
 
 
gg 0.14 
                   
 
Intron 3 rs533586 154455367 T/C tt 0.52 t 0.74 t 0.96 
  
 
 
   
tc 0.45 c 0.26 c 0.48 0.342* 0.06 
     
cc 0.04 
                   Data shown for Caucasian subgroup, n=155 
Published allele frequencies from Hapmap CEU or CEU GENO PANEL* 
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OPRK 
 
Gene Location Name Position 
Allele 
major/minor 
Genotype 
frequency 
Allele 
frequency 
Allele 
carriage 
Published 
MAF HWpval 
OPRK Intron 2 rs10504151 54320793 T/C tt 0.82 t 0.90 t 0.97   
     tc 0.16 c 0.10 c 0.18 0.05 0.05 
     cc 0.03       
             
 Intron 2 rs7836120 54320092 A/G aa 0.66 a 0.82 a 0.98   
     ag 0.32 g 0.18 g 0.34 0.14 0.25 
     gg 0.02       
             
 Intron 2 rs6473799 54315676 T/C tt 0.70 t 0.82 t 0.95   
     tc 0.25 c 0.18 c 0.30 0.24 0.10 
     cc 0.05       
             
 Intron 2 rs1365098 54315236 G/T gg 0.55 g 0.73 g 0.92   
     gt 0.37 t 0.27 t 0.45 0.21 0.45 
     tt 0.08       
             
 Intron 2 rs7016778 54312658 T/A tt 0.72 t 0.85 t 0.99   
     ta 0.27 a 0.15 a 0.28 0.12 0.39 
     aa 0.01       
             
 Intron 3 rs7824175 54306727 G/C gg 0.88 g 0.94 g 1.00   
     gc 0.12 c 0.06 c 0.12 0.10 0.42 
     cc 0.00       
             
 Exon 4 rs16918875 54304707 C/T cc 0.87 c 0.93 c 0.99   
     ct 0.12 t 0.07 t 0.13 0.04 0.17 
     tt 0.01       
             
 3UTR rs963549 54304377 G/A gg 0.75 g 0.86 g 0.97   
     ga 0.22 a 0.14 a 0.25 0.15 0.20 
     aa 0.03       
             Data shown for Caucasian subgroup, n=158 
Published minor allele frequencies from HapMap CEU 
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OPRD 
Gene Location Name Position 
Allele 
major/minor 
Genotype 
frequency 
Allele 
frequency 
Allele 
carriage 
Published 
MAF HWpval 
OPRD Exon 1 rs1042114 29011562 T/G tt 0.77 t 0.88 t 0.24 
  
     
tg 0.22 g 0.13 g 0.99 0.12 0.76 
     
gg 0.01                    
 
Intron 1 rs533123 29013742 A/G aa 0.65 a 0.81 a 0.98 
  
     
ag 0.33 g 0.19 g 0.35 0.19 0.21 
     
gg 0.02                    
 
Intron 1 rs2236857 29034196 T/C tt 0.60 t 0.78 t 0.97 
  
     
tc 0.37 c 0.22 c 0.40 0.27 0.26 
     
cc 0.03                    
 
Exon 3 rs2234918 29062184 T/C tt 0.31 t 0.57 t 0.83 
  
     
tc 0.53 c 0.43 c 0.69 0.40* 0.36 
     
cc 0.17 
                  Data shown for Caucasian subgroup, n=156 
Published allele frequencies from HapMap CEU or pilot 1 CEU low coverage panel* 
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STAT6 
Gene Location Name Position 
Allele 
major/minor 
Genotype 
frequency 
Allele 
frequency 
Allele 
carriage 
Published 
MAF HWpval 
STAT6 Intron 1 rs167769 57503775 C/T cc 0.40 c 0.62 c 0.83 
  
     
ct 0.43 t 0.38 t 0.60 0.33 0.23 
     
tt 0.17                    
 
Intron 14 rs3024971 57493727 A/C aa 0.79 a 0.89 a 0.98 
  
     
ac 0.19 c 0.11 c 0.21 0.08 0.48 
     
cc 0.02                    
 
Intron 16 rs841718 57492996 T/C tt 0.36 t 0.58 t 0.81 
  
     
tc 0.45 c 0.42 c 0.64 0.49 0.30 
     
cc 0.19                    
 
Intron 17 rs3024974 57492745 C/T cc 0.75 c 0.87 c 0.99 
  
     
ct 0.23 t 0.13 t 0.25 0.10 0.65 
     
tt 0.01                    
 
3'UTR rs3024979 57488293 T/A tt 0.81 t 0.89 t 0.97 
  
     
ta 0.17 a 0.11 a 0.19 0.10 0.09 
     
aa 0.03 
                  Data shown for Caucasian subgroup, n=159 
Published minor allele frequencies from HapMap CEU 
 
  
 353 
 
ARRB2  
Gene Location Name Position 
Allele 
major/minor 
Genotype 
frequency 
Allele 
frequency 
Allele 
carriage 
Published 
MAF HWpval 
ARRB2 Promoter rs1973555 4605887 C/T cc 0.48 c 0.70 c 0.92 
  
     
ct 0.44 t 0.30 t 0.52 0.26 0.58 
     
tt 0.08                    
 
Intron 1 rs3786047 4615098 G/A gg 0.47 g 0.68 g 0.88 
  
     
ga 0.41 a 0.32 a 0.53 0.31 0.44 
     
aa 0.12                    
 
Intron 9 rs4522461 4621773 T/G tt 0.56 t 0.75 t 0.95 0.221 
 
     
tg 0.39 g 0.25 g 0.44 
 
0.57 
     
gg 0.05                    
 
Exon 11 rs1045280 4622638 T/C tt 0.49 t 0.69 t 0.89 
  
     
tc 0.40 c 0.31 c 0.51 0.40 0.52 
     
cc 0.11 
                  
 
Intron 11 rs2271167 4622880 G/A gg 0.46 g 0.68 g 0.89 
  
     
ga 0.42 a 0.32 a 0.54 0.32 0.68 
     
aa 0.11                    
 
3'UTR rs2036657 4625159 A/G aa 0.46 a 0.67 a 0.89 
  
     
ag 0.43 g 0.33 g 0.54 0.31* 0.77 
     
gg 0.11                    Data shown for Caucasian subgroup, n=159 
Published allele frequencies from HapMap CEU or pilot 1 CEU low coverage panel* 
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ABCB1  
Gene Location Name Position 
Allele 
major/minor 
Genotype 
frequency 
Allele 
frequency 
Allele 
carriage 
Published 
MAF HWpval 
ABCB1 Exon 1 rs3213619 87230193 T/C tt 0.84 t 0.92 t 0.99 
  
     
tc 0.15 c 0.08 c 0.16 0.03 0.99 
     
cc 0.01                    
 
Intron 7 rs1202168 87195962 C/T cc 0.36 c 0.60 c 0.85 
  
     
ct 0.49 t 0.40 t 0.64 0.45 0.70 
     
tt 0.15                    
 
Exon 13 rs1128503 87179601 C/T cc 0.35 c 0.60 c 0.84 
  
     
ct 0.49 t 0.40 t 0.65 0.45 0.75 
     
tt 0.16                    
 
Exon 22 rs2032582 87160618 G/T/A gg 0.36 g 0.59 g 0.83 
  
     
gt 0.42 t 0.37 t 0.59 0.47 
 
     
tt 0.15 a 0.04 a 0.07 0.00 0.77 
     
ga 0.05       
     
ta 0.02       
                          
 
Exon 27 rs1045642 87138645 T/C tt 0.26 t 0.52 t 0.78 
  
     
tc 0.52 c 0.48 c 0.74 0.43 0.61 
     
cc 0.22 
                  Data shown for Caucasian subgroup, n=154 
Published minor allele frequencies from HapMap CEU 
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COMT  
Gene Location Name Position 
Allele 
major/minor 
Genotype 
frequency 
Allele 
frequency 
Allele 
carriage 
Published 
MAF HWpval 
COMT Promoter rs2075507 19928092 A/G aa 0.32 a 0.58 a 0.84   
     ag 0.52 g 0.42 g 0.68 0.40 0.36 
     gg 0.16       
             
 Intron 1 rs737866 19930109 A/G aa 0.50 a 0.72 a 0.93   
     ag 0.43 g 0.28 g 0.50 0.33 0.50 
     gg 0.07       
             
 Intron 1 rs7290221 19942680 G/C gg 0.22 g 0.51 g 0.80   
     gc 0.59 c 0.49 c 0.78 0.48* 0.05 
     cc 0.20       
             
 Intron 1 rs740603 19945177 G/A gg 0.23 g 0.53 g 0.82   
     ga 0.59 a 0.47 a 0.77 0.48 0.02 
     aa 0.18       
             
 Intron 2 rs6269 19949952 A/G aa 0.35 a 0.58 a 0.82   
     ag 0.47 g 0.42 g 0.65 0.40* 0.70 
     gg 0.18       
             
 Exon 3 rs2239393 19950428 G/A gg 0.35 g 0.59 g 0.84 0.42  
     ga 0.49 a 0.41 a 0.65  0.85 
     aa 0.16       
             
 Exon 4 rs4680 19951271 G/A aa 0.30 a 0.52 a 0.74 0.48  
    Val/Met ag 0.44 g 0.48 g 0.70  0.13 
     gg 0.26       
             
 Intron 5 rs174699 19954458 T/C tt 0.89 t 0.94 t 1.00 0.07  
     tc 0.11 c 0.06 c 0.11  0.45 
     cc 0.00       
                          Data shown for Caucasian subgroup, n=159 
Published allele frequencies from HapMap CEU or pilot 1 CEU low coverage panel* 
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ADORA1  
Gene Location Name Position 
Allele 
major/minor 
Genotype 
frequency 
Allele 
frequency 
Allele 
carriage 
Published 
MAF HWpval 
ADORA1 Promoter rs2364571 201327167 C/G cc 0.41 c 0.65 c 0.88 
  
     
cg 0.47 g 0.35 g 0.59 0.32 0.77 
     
gg 0.12                    
 
Exon 5 rs10920568 201364898 T/G tt 0.37 t 0.62 t 0.86 
  
     
tg 0.49 g 0.38 g 0.63 0.34 0.69 
     
gg 0.14                    
 
Intron 5 rs10800901 201377927 G/A gg 0.40 g 0.64 g 0.87 
  
     
ga 0.47 a 0.36 a 0.60 0.28 0.75 
     
aa 0.13                    
 
Intron 5 rs10920576 201395802 C/T cc 0.72 c 0.85 c 0.98 
  
     
ct 0.27 t 0.15 t 0.28 0.19 0.69 
     
tt 0.02                    Data shown for Caucasian subgroup, n=158 
Published allele frequencies from HapMap CEU 
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SLC6A4 
Gene Location Name Position 
Allele 
major/minor 
Genotype 
frequency 
Allele 
frequency 
Allele 
carriage 
Published 
MAF HWpval 
SLC6A4 Promoter rs7214991 28572360 A/G aa 0.33 a  0.60 a  0.86 
  
     
ag 0.53 g 0.40 g 0.67 0.35 0.21 
     
gg 0.14                    
 
Intron 
boundary 1 rs25528 28549978 T/G tt 0.62 t 0.77 t 0.92 
  
     
tg 0.31 g 0.23 g 0.38 0.18 0.10 
     
gg 0.08                    
 
5'UTR/Non 
coding exon rs6354 28549898 T/G 
tt 0.62 t 
0.78 t 0.94 
  
     
tg 0.32 g 0.22 g 0.38 0.18 0.34 
     
gg 0.06                    
 
Intron 6 rs140700 28543389 C/T cc 0.75 c 0.85 c 0.94 
  
     
ct 0.19 t 0.15 t 0.25 0.09 0.001 
     
tt 0.06                    
 
Intron 9 rs4583306 28538715 A/G aa 0.30 a 0.57 a 0.83 
  
     
ag 0.53 g 0.43 g 0.70 0.39 0.34 
     
gg 0.17 
                  Data shown for Caucasian subgroup, n=159 
Published allele frequencies from HapMap CEU 
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Haploblock Frequency and Carriage 
OPRM  
  Haploblock 1   Haploblock 2 
SNP rs 1799971 rs589046 rs563649 rs 94797571 rs 2075572 rs533586 
position 154402490 154434831 154449660 154453037 154453697 154455367 
1 A C C - - - 
2 G C C - - - 
3 A T C - - - 
4 A T T - - - 
1 - - - - C T 
2 - - - - G C 
3 - - - - G T 
Data shown for Caucasian subgroup, n=155 
 
  Haploblock 1 Haploblock 3 
SNP Haploblock 
frequency  
Haploblock 
carriage   
Haploblock 
frequency  
Haploblock 
carriage   position 
1 0.58 0.85 - - 
2 0.18 0.32 - - 
3 0.15 0.27 - - 
4 0.09 0.16 - - 
1 - - 0.62 0.86 
2 - - 0.26 0.48 
3 - - 0.12 0.21 
Data shown for Caucasian subgroup, n=155 
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OPRK 
  Haploblock 1   Haploblock 2 
SNP rs10504151 rs7836120 rs6473799 rs1365098 rs7016778 rs7824175 rs16918875 rs963549 
 54320793 54320092 54315676 54315236 54312658 54306727 54304707 54304377 
1 T A - - - - - - 
2 C G - - - - - - 
3 T G - - - - - - 
4 C A - - - - - - 
1 - - - G T G C G 
2 - - - T T G C G 
3 - - - T A G T A 
4 - - - T A G C G 
5 - - - T T C C A 
6 - - - G T G C A 
7 - - - G A G C G 
OPRK Data shown for Caucasian subgroup, n=158 
 
  Haploblock 1 Haploblock 2 
SNP Haploblock 
frequency  
Haploblock 
carriage   
Haploblock 
frequency  
Haploblock 
carriage   position 
1 0.82 0.97 - - 
2 0.10 0.18 - - 
3 0.08 0.16 - - 
4 0.00 0.01 - - 
1 - - 0.71 0.90 
2 - - 0.07 0.13 
3 - - 0.07 0.13 
4 - - 0.06 0.13 
5 - - 0.06 0.11 
6 - - 0.01 0.02 
7 - - 0.01 0.01 
 OPRK Data shown for Caucasian subgroup, n=158   
 
OPRD  
  Haploblock 1       
SNP rs1042114 rs533123 rs2236857 rs2234918 Haploblock 
frequency  
Haploblock 
carriage   position 6236824 6237976 6247696 6248235 
1 T A - - 0.81 0.97 
2 G G - - 0.12 0.22 
3 T G - - 0.07 0.13 
4 G A - - 0.01 0.01 
OPRD Data shown for Caucasian subgroup, n=156 
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STAT6  
  Haplotype     
SNP rs167769 rs3024971 rs841718 rs3024974 rs3024979 Haploblock 
frequency  
Haploblock 
carriage   position 57503775 57493727 57492996 57492745 57488293 
1 T A T C T 0.36 0.58 
2 C A C C T 0.23 0.40 
3 C A C T T 0.12 0.23 
4 C A T C A 0.11 0.19 
5 C C T C T 0.07 0.13 
6 C C C C T 0.04 0.08 
7 T A T C T 0.03 0.06 
8 T A C C T 0.01 0.02 
STAT6 Data shown for Caucasian subgroup, n=159 
 
ARRB2  
  Haplotype     
SNP rs1973555 rs3786047 rs4522461 rs1045280 rs2271167 rs2036657 Haploblock 
frequency  
Haploblock 
carriage    4605887 4615098 4621773 4622638 4622880 4625159 
1 C G T T G A 0.63 0.82 
2 T A G C A G 0.22 0.39 
3 T A T C A G 0.05 0.10 
4 C A T C A G 0.02 0.03 
5 C A G T A G 0.01 0.02 
ARRB2 Data shown for Caucasian subgroup, n=151  
 
ABCB1  
  Haplotype      
SNP rs3213619 rs1202168 rs1128503 rs2032582 rs1045642 Haploblock 
frequency  
Haploblock 
carriage   position 87230193 87195962 87179601 87160618 87138645 
1 T C C   C 0.37 0.60 
2 T T T   T 0.36 0.60 
3 T C C   T 0.14 0.26 
4 C C C   C 0.08 0.16 
5 T T T   C 0.03 0.05 
6 T C T   T 0.02 0.03 
7 T T C   T 0.01 0.01 
8 T T C   C 0.00 0.01 
ABCB1 Data shown for Caucasian subgroup, n=154 
 
The programmes Phase (PHASE Version 2.1.1, University of Chicago) and Haploview 
(Haploview version 4.1, Broad Institute, Cambridge, USA) were unable reconcile triallelic 
SNP data into meaningful haplotype data.  Haplotypes are shown here excluding rs2032582.  
A more detailed ABCB1 haplotype analysis can be found in the thesis of Dr Joy Ross who 
designed the primers utilised here 39 
 361 
 
COMT  
  Haploblock 1 Haploblock 2   
SNP rs2075507 rs737866 rs7290221 rs740603 rs6269 rs2239393 rs4680 rs174699 
 19928092 19930109 19942680 19945177 19949952 19950428 19951271 19954458 
1 G A C A - - - - 
2 A G G G - - - - 
3 A A G G - - - - 
4 A A C A - - - - 
5 G A G G - - - - 
6 A A C G - - - - 
7 A G C A - - - - 
1 - - - - A G A - 
2 - - - - G A G - 
3 - - - - A G G - 
4 - - - - A G A - 
5 - - - - G A A - 
COMT Data shown for Caucasian subgroup, n=159 
 
  Haploblock 1 Haploblock 2 
SNP Haploblock 
frequency  
Haploblock 
carriage   
Haploblock 
frequency  
Haploblock 
carriage   position 
1 0.38 0.65 - - 
2 0.27 0.47 - - 
3 0.21 0.38 - - 
4 0.07 0.14 - - 
5 0.03 0.06 - - 
6 0.02 0.04 - - 
7 0.01 0.02 - - 
1 - - 0.50 0.72 
2 - - 0.41 0.65 
3 - - 0.08 0.15 
4 - - 0.01 0.02 
5     0.00 0.01 
COMT Data shown for Caucasian subgroup, n=159 
    
 
 
ADORA1  
  Haploblock 1 Haploblock 2     
SNP rs2364571 rs10920568 rs10800901 rs10920576 Haploblock 
frequency  
Haploblock 
carriage   position 201327167 201364898 201377927 201395802 
1 C T - - 0.62 0.86 
2 G G - - 0.35 0.59 
3 C G - - 0.03 0.05 
1 - - G C 0.48 0.75 
2 - - A C 0.36 0.60 
3 - - G T 0.15 0.28 
ADORA1 Data shown for Caucasian subgroup, n=158     
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SCL6A4  
    Haploblock 1       
SNP rs7214991 rs25528 rs6354 rs140700 rs4583306 Haploblock 
frequency  
Haploblock 
carriage    28572360 28549978 28549898 28543389 28538715 
1 - T T C - 0.77 0.92 
2 - G G T - 0.15 0.25 
3 - G G C - 0.07 0.13 
4 - G T C - 0.01 0.02 
5 - T G C - 0.00 0.01 
 SCL6A4 Data shown for Caucasian subgroup, n=159 
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LD Plots 
 
LD plots show R2 values (Haploview version 4.2, Broad Institute, Cambridge, USA). a) OPRM, b) OPRK, c) 
OPRD, d) STAT6, e) ARRB2, f) ABCB1, g) COMT, h) ADORA1, i) SCL6A4. 
a) b) c) 
d) e) 
g) 
f) 
i) h) 
